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Inherited retinal diseases (IRDs) are a group of progressive disorders that lead to severe visual 
impairment or even complete blindness. IRDs display a vast heterogeneity, clinically as well as 
genetically, with over 250 genes identified in which mutations can cause one or more clinical subtypes 
of IRD. Long considered incurable diseases, intense research over the last two decades, combined with 
major technological advancements, have enabled the development of the first therapeutic approaches 
for these diseases. The approval of LuxturnaTM (voretigene neparvovec), a gene augmentation 
therapy vector for RPE65-associated IRD, by the US Food and Drug Administration and the European 
Medicines Agency, is considered a true milestone in the field, and has led to the development of similar, 
or different therapeutic strategies for many other subtypes of IRD. Despite these major achievements, 
there are still many aspects that can—and need to—be improved, including more insights into the 
relationship between genetic variation and cellular dysfunction, optimization of the vectors and 
sequences used, improving delivery methods, as well as understanding and modulating the (local) 
immune response. In addition, the extreme rarity of some genetic subtypes of IRDs poses an enormous 
challenge on the development of novel therapies, in terms of e.g., costs and regulatory affairs.
In this Special Issue of Genes, we focus our attention on molecular therapeutic approaches 
for IRD, i.e., strategies that aim to overcome the primary genetic defect, or its consequences, by 
using genetic material or small compounds to restore molecular and cellular function. The issue is 
comprised of original research articles as well as (mini-)reviews, on topics such as gene augmentation, 
RNA-based therapies, genome editing, proteostasis, small molecule approaches and delivery vectors. 
The manuscripts mainly contain preclinical research, varying from work in cellular systems to in vivo 
studies. Some reviews summarize the current stage of ongoing clinical trials, i.e., for CHM- and 
RPGR-associated IRD. We close this Special Issue with a contribution of the Foundation Fighting 
Blindness USA on the patient’s (organizations’) perspective on the current landscape, as well as a 
future perspective on the era that lies ahead of us. With this, we aim to provide a contemporary 
overview on the development and implementation of novel (personalized) therapies for IRD, and 
identify the tremendous possibilities as well as the key bottlenecks that currently exist.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
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Abstract: The Crumbs complex has prominent roles in the control of apical cell polarity, in the
coupling of cell density sensing to downstream cell signaling pathways, and in regulating junctional
structures and cell adhesion. The Crumbs complex acts as a conductor orchestrating multiple
downstream signaling pathways in epithelial and neuronal tissue development. These pathways
lead to the regulation of cell size, cell fate, cell self-renewal, proliferation, differentiation, migration,
mitosis, and apoptosis. In retinogenesis, these are all pivotal processes with important roles for the
Crumbs complex to maintain proper spatiotemporal cell processes. Loss of Crumbs function in the
retina results in loss of the stratified appearance resulting in retinal degeneration and loss of visual
function. In this review, we begin by discussing the physiology of vision. We continue by outlining
the processes of retinogenesis and how well this is recapitulated between the human fetal retina and
human embryonic stem cell (ESC) or induced pluripotent stem cell (iPSC)-derived retinal organoids.
Additionally, we discuss the functionality of in utero and preterm human fetal retina and the current
level of functionality as detected in human stem cell-derived organoids. We discuss the roles of
apical-basal cell polarity in retinogenesis with a focus on Leber congenital amaurosis which leads to
blindness shortly after birth. Finally, we discuss Crumbs homolog (CRB)-based gene augmentation.
Keywords: apical polarity; crumbs complex; fetal retina; PAR complex; retinal organoids;
retinogenesis; gene augmentation; adeno-associated virus (AAV); Leber congenital amaurosis
1. The Physiology of Vision
Vision is perhaps the most dominant sense in daily life and both non-correctable unilateral and
bilateral vision loss severely impact the quality of life [1]. Vision begins with the processing of light,
which is electromagnetic radiation that travels as waves (Figure 1A). Light waves, as with all waves,
can be characterized by their wavelength (distance between wave peaks), frequency (number of
wavelengths within a time period), and amplitude (the height of each peak or depth of each trough).
Visible light is a narrow group of wavelengths between approximately 400 nm and 760 nm which we
interpret as a spectrum of different colors (Figure 1B) [2]. Light can be reflected (bounce of a surface),
absorbed (transfer of energy to a surface), or refracted (bending of light between two mediums)
(Figure 1C).
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Figure 1. Transmission of light. (A) Light is electromagnetic radiation that travels as waves consisting of
perpendicular oscillating electric and magnetic fields. (B) Visible light is a narrow group of wavelengths
between approximately 400 nm (short wavelength) and 760 nm (long wavelength) which we interpret
as a spectrum of different colors. Wavelengths outside this range are not visible to humans. (C) Light
can be reflected, absorbed and refracted.
When light first enters the eye, it is refracted by the cornea through the pupil, whose size is
controlled by the iris. The iris, the colored part of the eye, controls the amount of light entering the eye
while the lens focuses the light through the vitreous humor and on to the proximal surface of the retina
(Figure 2A). The adult retina consists of one glial cell type, the Müller glial cells, and six major types of
neurons, the rod and cone photoreceptors, bipolar cells, amacrine cells, horizontal cells, and ganglion
cells (Figure 2B). Their cell bodies are distributed across three nuclear layers, the outer nuclear layer
(ONL), inner nuclear layer (INL), and ganglion cell layer (GCL). Two synaptic layers, the outer plexiform
layer (OPL) and inner plexiform layer (IPL), contain the axonal and dendritic processes of the cells [3].
Whereas there is one type of rod photoreceptor, there are various subtypes of cone photoreceptor,
bipolar, amacrine, horizontal, and ganglion cells that differ in their functional roles and morphology [4].
Besides Müller glial cells there are two other glial cell types that serve to maintain retinal homeostasis,
the astrocytes and resident microglia [5]. Light must be channelled through the retina and absorbed by
its three light responsive cells: the rod and cone photoreceptors and the intrinsically-photosensitive
retinal ganglion cells (ipRGCs). The mammalian retina contains various opsin proteins involved in the
photoreception synchronisation of circadian rhythms (photoentrainment). These are the cone opsins
(M/LWS, red/green opsin; SWS1, blue opsin) responsible for high visual acuity, resolution, and color
vision (photopic vision), and rod opsin (RH1, Rhodopsin) responsible for dim light vision (scotopic
vision) and ipRGCs opsin (OPN4, Melanopsin) responsible for synchronisation of the circadian rhythms
and ambient light perception [6–9]. The cones are less sensitive to light and rods are more sensitive to
light and are also used together under intermediated light conditions (mesopic vision) [10]. Most forms
of inherited retinal disease negatively affect the function of photoreceptors, resulting in progressive
loss of rod and/or cone photoreceptors. Müller glial cells mediate the channelling of light through
the retina towards the photoreceptors [11,12]. Müller glial cells can channel different wavelengths
of light to specific subsets of photoreceptors to optimise day vision [13]. The visual pigments of the
photoreceptors contain an opsin protein covalently linked to the chromophore 11-cis-retinal. Upon
the absorption of a photon 11-cis-retinal becomes isomerised to all-trans-retinal, this leads to an
activated opsin intermediate (metarhodopsin II, rods; Meta-II, cones). This active intermediate leads to
triggering of a transduction cascade resulting in hyperpolarisation of the photoreceptors, due to the
4
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closure of cyclic guanosine 3′,5′-monophosphate (cGMP)-gated channels, and a reduction in glutamate
release [14]. This electrophysiological signal is then further propagated to the inner retina and can be
propagated through many different pathways to the ganglion cells. Prototypically these signals can be
direct, from photoreceptor (PRC) to bipolar cells to ganglion cells. However, it can also be indirect
with lateral modulation of the electrophysiological signals being made by horizontal cell processes in
the OPL or by amacrine cell processes in the IPL [10,15,16]. Thus, creating radially aligned “functional
units” of photoreceptors, bipolar cells, amacrine cells, horizontal cells, and ganglion cells. The fovea
contains a specialised pathway, termed the midget pathway, which helps account for its ability to
provide high visual acuity [17–19].
The visual system, however, is not solely comprised of the eye but also the topographically
mapped ganglion cell axonal projections connecting the retina to the superior colliculus (SC) and
lateral geniculate nucleus (LGN) in the brain [20]. The ganglion cell axonal projections exit the left
and right eyes as bundles, the optic nerves, and they extend to below the hypothalamus to the optic
chiasm. The optic chiasm is the crossover point for the nasal axons of each eye which combine with
the opposing eyes temporal axons. The two optic tracts extend from the optic chiasm to the SC and
the LGN, with the optic radiations further extending from the LGN to the primary visual cortex
(Figure 2C) [21]. The SC, LGN, and pulvinar nuclei are all involved in the process of relaying and
refining visual information to the primary visual cortex [22,23]. Interestingly, despite the severe retinal
dysfunction of Leber congenital amaurosis-2 (LCA2) patients, recovery of both retinal function, but
also reorganization and maturation of synaptic connectivity in the visual pathway, is found upon
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Figure 2. Processing of light. (A) Schematic picture of the eye. The eye is comprised of the aqueous
humor, ciliary body, cornea, iris, lens, optic nerve, pupil, retina, retinal pigment epithelium, retinal
vasculature, sclera, vitreous body, and zonal fibers. When light first enters the eye, it is refracted by
the cornea through the pupil, whose size is controlled by the iris. The iris, the colored part of the eye,
controls the amount of light entering the eye while the lens focuses the light through the vitreous
humor and on to the proximal surface of the retina. (B) Schematic picture of the retina. The retina is
composed of seven cell types: amacrine cells (red), bipolar cells (blue), cones (orange), ganglion cells
(green), horizontal cells (purple), Müller glial cells (yellow), and rods (pink). When light first enters
the retina, it goes through the ganglion cell layer (GCL), then the inner plexiform layer (IPL), inner
nuclear layer (INL), outer plexiform layer (OPL), and outer nuclear layer (ONL). As light is passing
through the retina it is absorbed by its light responsive cells: rod and cone photoreceptors and the
intrinsically-photosensitive retinal ganglion cells (ipRGCs). This creates electrophysiological signals
that then are further propagated to the inner retina and can be propagated through many different cell
to cell pathways to the ganglion cells. (C) Schematic picture of the visual pathway. The axons of the
retinal ganglion cells exit the eyes as bundles, the optic nerve, and extend to the optic chiasm were
the nasal axons of each eye crossover and combine with the contralateral eyes temporal axons and
subsequently via the optic tract travel to the lateral geniculate nucleus (LGN) and superior colliculus
(SC). The LGN, SC, and pulvinar nucleus are all involved in the process of relaying and refining visual
information to the visual cortex. Visual information is relayed to the visual cortex via optic radiations
which extend from the LGN.
2. Retinogenesis
The retina, part of the central nervous system, offers an extremely accessible and relatively
immune-privileged model system for investigating the mechanisms of neural development and
vision [25]. A high conservation of the genes involved in retinal development exists across species
allowing us to gain an in-depth fundamental knowledge of these mechanisms. Retinal development is
both a pre- and postnatal process. The development of the retina begins when the anterior neural plate
subdivides into a number of domains, with the medial region specifying as the eye field (Figure 3).
The formation of the eye field is coordinated by expression of the eye field transcription factors (EFTFs),
shortly after gastrulation. There are a number of EFTFs in mammals including Pax6, Rax, Lhx2, Six3,
and Six6. The eye field consists of all the progenitors which go on to form all the neural-derived cell
types and structures of the eye [26–30]. The progenitors of the eye field begin to specialize very early
in development, hence the large number of bilateral diseases of eye morphogenesis [28]. From the eye
field, bilateral optic sulci form and evaginate from the diencephalon at human fetal embryonic day 22
6
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(E22) forming optic vesicles at E24 (Figure 3). The optic vesicles extend towards the surface ectoderm
remaining connected to the forebrain through the optic stalk, which eventually develops into the optic
nerve. The hyaloid artery, running from the optic stalk and into the retinal neuroepithelium through
the optic fissure, provides the basis for the vascularisation of the retina and developing eye. As the
optic vesicles invaginate forming the two-layered optic cups by E32, the surface ectoderm thickens
forming the lens placode and further develops into lens vesicle, sitting behind the surface ectoderm
(Figure 3). The anterior rim of the optic cup will become the iris and ciliary body, while the posterior
rim will become the pigmented and neural retina. The outer layer of the posterior optic cup remains as
a single cuboidal layer becoming the retinal pigment epithelium (RPE). The single inner layer of the
posterior optic cup proliferates and differentiates, beginning in the 7th fetal week (Fwk), developing
into the multilayered neural retina [28,31].
The processes of the newborn progenitors of the inner optic cup, the retinal neuroepithelium,
extend and attach both apically through adherens junctions (AJs) at the outer limiting membrane
(OLM), and basally through integrin- and proteoglycan-based focal adhesions at the inner limiting
membrane (ILM) [32,33]. Retinal progenitors undergo interkinetic nuclear migration in which their
nuclei move in an apical-basal manner in phase with the cell cycle, this occurs in mainly a stochastic
manner but becomes briefly directed at cell division (Figure 4A) [33–35]. Progenitors initially undergo
symmetric cell division leading to an increase in the pool of progenitors and thus thickening of the
neuroepithelium. After that the progenitors go through asymmetric divisions, and produce one
daughter cell to maintain the stem cell pool and one terminally differentiated postmitotic cell. Later in
development depletion of the retinal progenitor pool occurs through symmetric divisions leading to
two postmitotic terminally differentiated daughter cells (Figure 4B) [34,36]. Cell intrinsic and extrinsic
factors govern cell fate choice and thus tissue architecture and function. The retinal cells governed by
these factors progress from multipotent retinal progenitors to competent postmitotic precursors, which
undergo further specification before becoming the final differentiated adult cell type [4,37–39].
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Figure 3. The organization of the developing retina. Schematic picture of early retinal development.
From the blastocyst which contains the pluripotent cell mass gastrulation and neurulation occur forming
the neural plate. The eye field specifies at the medial region of the anterior neural plate and contains all
the progenitors which go on to form all the neural-derived cell types and structures of the eye. Bilateral
optic sulci develop from the eye field forming the optic vesicles which extend towards the surface
ectoderm. The optic vesicles invaginate forming the two-layered optic cups and the lens vesicle forms
and sits behind the surface ectoderm. The outer layer of the optic cup remains as a single cuboidal
layer becoming the retinal pigment epithelium. The single inner layer of the optic cup proliferates and
differentiates forming the multilayered neural retina. EF: eye field; CMZ: ciliary marginal zone.
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Figure 4. Retinogenesis. (A) Radial progenitor cells undergoing interkinetic nuclear migration during
cell cycle phases G1, S, G2, and M. The mitosis (M) phase takes place at the apical side, whereas the DNA
synthesis (S) phase takes place more basally. (B) Symmetric versus asymmetric cell division. (C) Genesis
of retinal cells born during the development of the human eye can be divided into an early phase
(ganglion cells, cone photoreceptors, horizontal cells, and amacrine cells) and an overlapping late phase
(rod photoreceptors, Müller glial cells, and bipolar cells; see Aldiri et al. 2017 [40]). FWK—fetal week.
The birth of the seven major cell types of retina occur from the early multipotent retinal progenitor
cells and happens in an orderly and overlapping manner [39]. The genesis of the major cell types group
into an early phase and a late phase. The early phase consists of the birth of the first ganglion cells, cone
photoreceptors, horizontal cells, and amacrine cells. The overlapping late phase consists of the birth of
the first rod photoreceptors, Müller glial cells and bipolar cells (Figure 4C) [39]. Recently, both Aldiri et
al. (2017) and Hoshino et al. (2017) described similar retinal time courses for the developing human
retina based on RNA-Seq analysis [40,41]. The newborn postmitotic cell types must become positioned
correctly within the retina; this occurs through migration of cells along the radial axis (apical-basal) of
the retina or by tangential migration of cells perpendicular to the radial axis of the retina. Interestingly,
only the early born cell types (ganglion cells, cone photoreceptors, horizontal cells, and amacrine cells)
exhibit tangential migration (Figure 5A) [42,43].
There are a number of modes of radial migration for newborn neurons including: glial cell-guided,
the migration of neurons along radial glial progenitors (Figure 5B); Somal translocation, the movement
of nuclei across inherited apical or basal processes (Figure 5C); Multipolar migratory mode, nuclei
movement due to multiple cell processes with no retention of apical or basal attachment to facilitate
nuclei movement (Figure 5D); No translocation, inefficient migration due to retention of the apical or
basal process and slow release of opposing process (Figure 5E). These various modes of migration
9
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are cell type-specific [44–47]. Tangential dispersion is driven by a mix of diffusible signals and/or
contact-mediated interactions that drive a local spacing rule to keep a minimum distance between
neighboring cells of the same cell type [48].
 
Figure 5. Tangential and Radial migration. (A) Tangential migration can be described in three steps:
(1) Early born cell type progenitors localize to their correct laminar position (Cones: orange, Bipolar
cells: purple, amacrine cells: red, ganglion cells: green), (2) they undergo morphological differentiation,
(3) tangential migration coincides with morphological differentiation allowing subsets of early born
cell types to move a short distance within their laminar position (see Reese et al. 1999 [43]). (B) Glial
cell-guided, apically born neurons become initially detached and subsequently attach to radial glial
progenitor cells. They then migrate along the radial glial progenitor cells to the target laminar location
where they fully integrate. (C) Somal translocation, apically born nuclei can move along there inherited
basally attached process from. Once they move to their final laminar location they fully integrate (This
process can also occur with only apically inherited processes). (D) Multipolar migratory mode, in rare
case apically born neurons can loses both apical and basal attachments but can move to their final
laminar position and integrate due to a multipolar mode. (E) No translocation, inefficient migration
due to retention of the apical or basal process and slow release of opposing process. For further details
see Icha et al. 2016 and Amini et al. 2018 [45,47].
Retinal mosaic is the term used for the distribution of a neuronal cell type orthogonal to
the apical-basal axis in a particular retinal layer. There is a highly ordered mosaic architecture
in the mammalian retina leading to the non-random distribution of its cell bodies and dendritic
10
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process. This mosaic patterning is essential for retinal functionality, tying information together in a
regularly patterned/ordered way from radially aligned “functional units” such that complete sampling
and coverage of an image is achieved. Development of mosaics may be due to a combination of
tangential dispersion (for early born cell types), programmed cell death, and lateral inhibition [45,48,49].
Interestingly, mosaic patterning can apply to a group of cells that have yet to reach their final
developmental position, suggesting a pre-orchestrated cell intrinsic process [45].
Thus, retinogenesis is a precise orchestration of spatiotemporal processes such as symmetric and
asymmetric cell division, cell fate choice (determination, competence, specification, and differentiation),
cell migration (interkinetic nuclear migration, radial migration, and tangential migration), and
maturation (integration and specialization of retinal spatiotemporal processes to provide adult
functionality). The developing retinal neuroepithelium has a large amount of plasticity to accommodate
these spatiotemporal process while maintaining its tissue integrity and architecture.
3. The Genetics of Retinal Development
As briefly highlighted in the previous section a number of genes are responsible for forming
the early eye field. In this section we will shortly expand on some of the important gene regulatory
networks (GRNs) essential for retinal development. GRNs can establish precise spatial, temporal,
and cellular context specific controlled changes in gene expression patterns through the synergistic
relationship of sets of transcription factors (TF) and their action on cis-regulatory modules (CRMs).
The CRMS typically are a collection of TF-binding sites on the same strand of DNA as they affect [50–53].
GRNs are important as they can provide us with mechanistic insight into what is need to acquire and
maintain a particular cell type identity. We will discuss the GRNs responsible for retinal progenitors
and subsequent competent postmitotic precursors and their cell type specification. Mutations in, or
misregulation of, several of these early developmental genes can lead to inherited retinal diseases.
A number of recent papers have focused on retinal development using bulk transcriptomic [40,41,54,55]
and single-cell transcriptomic approaches [54,56–61] to study human fetal retina and retinal organoids.
These works add too many of the findings from work on mammalian animal models which have
defined developmental or cell specific gene clusters and networks [62–70].
Several genes have been attributed to neuroretinal specification as well as the proliferative and
multipotent ability of retinal progenitor cells, including Vsx2 (also known as Chx10), Pax6, Lhx2, Rax,
Six3, and Six6 [71–79]. Many of the genes are also implicated in retinal abnormalities; for instance,
Pax6 mutations can lead to foveal hypoplasia, while Rax mutations can cause microphthalmia leading
to retinal dysplasia [80,81]. Two genes, Ikzf1 and Casz1, are required for the temporal regulation of
retinal progenitor cell fate, with dysregulation of these genes leading to changes in the production of
early versus late-born retinal cell types [82,83]. Interestingly, many retinal progenitor cell transcription
factors are also important in Müller glia cell specification [68]. This includes the Hippo effector Yap,
which is essential for retinal progenitor cell cycle progression. Additionally, Yap is required for Müller
glial cell reprogramming and cell cycle re-entry and is misregulated in retinal disease [84–87]. Other
factors related to retinal progenitors and Müller glial cells include Notch factors Hes1 and Hes5 as well
as Lhx2, Rax, and Sox9 [88–91].
Several retinal TFs including Otx2, Crx, Nrl, and Nr2e3 control rod and cone-specific photoreceptor
specification. Mutations in Crx can cause Leber congenital amaurosis (LCA), cone-rod dystrophy
(CRD), and Retinitis pigmentosa (RP), while Nrl and Nr2e3 mutations can cause RP and enhanced
S-cone syndrome [92–98]. Otx2 can determine both rod and cone photoreceptor cell fate, while Crx acts
with Nrl and Rorβ for terminal photoreceptor gene expression controlling the cone/rod ratio [99–102].
Activation of Nrl expression leads to the subsequent activation of the Nr2e3 rod-specific factor; both
Nrl and Nr2e3 can suppress cone cell fate genes [101,103,104]. Prdm1 (also known as Blimp1) also
promotes rod specification while repressing bipolar fate [105,106]. Thrβ2 and RXRgamma are required
for cone generation and subtype specification [107–109]. A CRM of the Thrb gene is regulated by Otx2
and Onecut1 transcription factors for the production of cones and horizontal cells, with Onecut1 found
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to be critical in specifying cone versus rod fate [110]. Recently, the Emerson Lab further confirmed that
ThrbCRM1 progenitor cells preferentially form cone photoreceptors as well as subtypes of horizontal
and ganglion cells [111].
Bipolar cells are also specified from Otx2 component postmitotic precursors in which expression
with Vsx2 leads to their cell specification [105,106]. Vsx1 and Bhlhb5 are required for bipolar cell
subtype fate [112,113]. The other interneurons, amacrine cells, and horizontal cells arise from Pax6,
Ptf1a and Foxn4 expressing retinal progenitor cells [76,114,115]. Prox1 lies further downstream of
Foxn4 and Ptf1a and specifies horizontal cell fate [116]. While, Onecut1 acts downstream of Foxn4, in
parallel with Ptf1a, but upstream of Prox1 to specify horizontal cell fate [117]. Additionally, Lim1, Isl1
and Lhx1 also specify horizontal cell fate [118–120]. Tfap2a and 2b, Barhl2, Bhlhb5, NeuroD factors,
and Isl1 act downstream of Ptf1a to specify an amacrine cell fate [113,121–124]. Lastly, Pou4f2 and Isl1
are essential in the acquisition of ganglion cell fate being downstream of retinal progenitor cell factor
Atoh7 [125,126]. Additionally, genes promoting ganglion cell specification include Neurod1, Sox4, and
Sox11 [127,128].
Nevertheless, what has been found out about CRB1 transcript expression in early retinal
development? Recently, Hu et al. found using single-cell RNA-seq that CRB1 transcripts were
particularly enriched during human retinal development in retinal progenitor and Müller glial cells
from human fetal retina [56]. In human retinal organoids, CRB1 transcripts were found to be lowly
expressed in very early organoids with moderate expression in later organoids [57]. In a study by
Clark et al. they found using single-cell RNA-seq that transcripts for Crb1 in mouse retina increased
from embryonic to postnatal stages. Interestingly, they found the opposite for Crb2 transcripts, being
more abundant early embryonically and decreasing postnatally [63]. This pattern is in agreement with
studies of human fetal retina and retinal organoids that show initial low protein levels of CRB1 and
higher levels of CRB2 in early development [129]. Redundancy of function for CRB1 and CRB2 has been
identified in the mouse retina. With knockout of either Crb1 or Crb2 in mouse Müller glial cells leading
to mild retinal morphological phenotypes, while ablation of both Crb1 and Crb2 concomitantly from
mouse Müller glial cells leads to a severe Leber congenital amaurosis phenotype [130–132]. However,
while Crb1 knockout mice are viable, Crb2 ablation causes lethality in mice and genetic variants of
the CRB2 gene cause a syndromic phenotype in humans [133,134]. CRB3 is more widely expressed
in epithelial tissues than either CRB1 or CRB2 and does not share their large extracellular domains.
Ablation of Crb3 leads to lethality shortly after birth with defects in (lung and intestinal) epithelial
tissue morphogenesis [135,136].
4. Morphological and Molecular Recapitulation of the Human Fetal Retina
Studying retinal development in animal models is useful to understand the underlying cellular
processes, but some of these processes are remarkably different in the human retina. There are
molecular and morphological similarities between mammalian retina, but subtle differences highlight
caution when applying information from other species to the human retina and its diseases, even
between non-human primate and human retina [137–140]. Additionally, limited access to human fetal
and adult cadaveric donor retina limited the studies in human retina at a tissue or single cell type
level in regards to pathobiology, signaling dynamics, and physiology. Retinal organoids derived from
human embryonic stem cells or induced pluripotent stem cells mimic the three-dimensional laminated
structure of the retina allowing us to study basic eye development, disease modelling, drug potency
assays, gene augmentation, and cell therapeutic strategies [141–146].
Multiple recent studies have directly compared human fetal retina with human stem cell-derived
retinal organoids, analyzing their morphology or transcriptome, or both [54,147–149]. Additionally,
a large body of research exists regarding the morphology and transcriptome of either human fetal
retina [8,40,41,150–160] or human stem cell-derived retinal organoids [58,141,142,161–170]. Together,
these studies provide a unique insight into human retinogenesis and allow us to have a reference point
between in vivo human retinal development and in vitro models of it. Do human stem cell-derived
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retinal organoids sufficiently recapture the cell type diversity including all sub-types, morphological
cues, synaptic wiring, and light sensitivity of the human fetal retina and subsequent adult retina?
Human retinal organoids have been found to recapitulate the main temporal and spatial cues of the
in vivo human retina producing all the retinal layers and containing the 7 major cell types [142,145,171].
The spatiotemporal birth and maturation of retinal cell types differ depending on their location within
the retina. In the human fetal retina, photoreceptors are born and remain located in the apical retina.
However, in human stem cell-derived retinal organoids, photoreceptors reside mostly apically but are
also seen in more basal positions particularly in early developmental stages, suggesting incomplete
positional cues. Interestingly, Kaewkhaw et al. (2015) were able to track basally located photoreceptors
from DD42 to DD44 with live cell imaging, finding that they translocated their soma apically [168]. The
mammalian retina matures in a centroperipheral manner with the peripheral retina organizing its adult
like lamination later than the central retina [155]. This delayed peripheral maturation is also detected
in gene expression profiles comparing these regions. Cell type expression patterns, analyzed by
immunohistochemistry, can be delayed by at least 50 days in the peripheral compared to more central
retina. Differences are also found between nasal and temporal retina [41]. Additionally, sustained
differences in gene expression profiles of peripheral and macula of the human adult retina is found,
but this has been attributed to the anatomical differences between these two regions [172]. Mammals
are known to contain a peripherally located ciliary marginal zone (CMZ), a stem cell-like niche able to
contribute postmitotic cells to the retina in addition to radial glial progenitor cells [173,174]. However,
little data is available on the CMZ of the human fetal retina, but studies on human and mouse stem
cell-derived retinal organoids have highlighted its presence [164,165].
The human retina contains a central region termed the macula in which the 1.5 mm fovea centralis
resides. The fovea, required for high visual acuity and color vision, in particular, was found to
develop and maturate much earlier than the rest of the retina [41,175]. The developing fovea, already
free of mitotic cells at Fwk 8.4, initially consists of a single row of cone photoreceptors. The rapidly
maturating foveal inner retina already consists of the main components of the midget ganglion pathway
as well as of presynaptic markers present in the OPL and IPL by Fwk 13.7 [41]. However, a small
depression called the foveal pit develops from Fwk 25 which leads to a gradual receding of all retinal
layers except for the outer nuclear layer which begins to thicken. Foveal development continues
in early childhood with elongation of cone outer segments and is considered adult-like in early- to
mid-adolescence [152,153,160,176,177]. Newborns still have underdeveloped outer segments at the
cone-rich fovea after birth. Therefore, suggesting that human newborns rely on extrafoveal vision
initially [138]. Immature cones are present from Fwk 8 and immature rods from Fwk 10. Cone S opsin
expresses from Fwk 12 while cone L and M opsin and rhodopsin express at Fwk 15 [8,151,153,155,159].
Rod photoreceptor maturation defined as the development of both inner and outer segments, occurs
quicker in the mid-peripheral human retina than the parafoveal region [150]. Full maturation of the
human retina does not occur until early adolescence. The average adult human retina contains 4.6
million cones, decreasing sharply in density outward from the fovea. However, the average number of
rods in the adult human retina, 92 million, far exceeds the number of cones. The density of rods is
highest around the optic nerve and decrease in density towards the peripheral retina and are absent
from the central fovea [156].
Retinal organoids do not yet form a separate specialized fovea. However, they do form all
of the main photoreceptor subtypes including photoreceptors with Rhodopsin, L/M-opsin and
S-opsin [146,178,179]. Retinal organoid photoreceptors form both inner and outer segments and
contain many of the prototypic morphological structures including: mitochondria, basal body,
centriole, connecting cilium, and outer segment discs. Additionally, adjacent structures, such as the
adherens junctions of the OLM, the microvilli of radial glial progenitors, and subsequently Müller glial
cells are also found [142,162,163,169–171,179]. The quality of these structures greatly varied between
studies and in particularly outer segments had very few or disorganized disk stacks. Recently, Eldred et
al. (2018) found that the DD200 retinal organoids can recreate the temporal generation of cones having
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a similar distribution, gene expression profile, and morphology as adult human retina. They also
identified a temporal switch which promotes the differentiation of S cones towards L/M cones through
thyroid hormone signaling. Going one step further they also found that the two thyroid hormone
states, T3 and T4, were modulated by different deiodinase enzymes in early or late organoids to specify
the change from S to L/M cone subtypes and found that temporal gene expression of these enzymes
correlated with data from Hoshino et al. (2017) on the human developing retina [41,146]. Interestingly,
preterm human infants that have low T3/T4 are more likely to have defects in color vision [180]. Local
modulation of thyroid signaling in retinal organoids may specify a more cone-rich, fovea-like region,
making them a step closer to the in vivo human retina. Such modulation of thyroid signaling in retinal
organoids might be achieved through optogenetically controlled protein expression. Recently, Kim et al.
were able to make more cone-rich retinal organoids by using an improved differentiation protocol [57].
5. Light Responsiveness and Synaptic Transmission of the Fetal Retina and Stem Cell-Derived
Retinal Organoids
Light responsiveness and synaptic transmission are critical milestones for a functioning retina.
As previously mentioned, the fetal retina does have both rods and cones with developing inner and
outer segments as early as Fwk 15. The fetal retina is however considered not fully mature until
post birth. The eyelids open by approximately Fwk 25, a milestone that suggests that the fine tuning
of the retina to visual stimulation can begin from this point [181]. In utero visual stimulation is
considered very limited. However, fetal responses to visual stimulus as measured by heart rate,
physical movement and brain activity have been reported. Transabdominal illumination has been
reported to increase fetal heart rate at Fwk 36 (Smyth et al. 1965: Fwk not reported, Kiuchi et al. 2000:
Fwk 36–40) and fetal movement at Fwk 26 [182,183]. Fetal heart rate increase has also been shown
during amnioscopy in which a cold light source was exposed to the amnion and fetus for 30 s at Fwk
38 [184]. An increase in fetal heart rate in response to light with increasing gestational age as analyzed
by actocardiogram is seen from Fwk 18 to 41 [185]. However, fetuses have only been reported to
reliably respond to light stimulation from Fwk 37; this is likely due to differences in abdominal and
uterine wall thicknesses, light sources used, the distance of light source, and its focus on the fetus
eyes [185–187]. Magnetoencephalography (MEG) studies have recorded visually evoked brain activity
from as early as Fwk 28 [188–191]. Functional magnetic resonance imaging (fMRI) has also been
successfully used to measure fetal response to transabdominal illumination, finding activity in the
frontal lobes but not the visual cortex from Fwk 36 [192].
Two main techniques have been utilized to measure preterm neonatal vision, the electroretinogram
(ERG) for retinal activity and visual evoked potentials (VEP) for brain activity. VEP studies suggest that
extrauterine age accelerates the development of the fetal visual system once a maturational threshold
has been reached at post Fwk 25 [193–196]. Interestingly, this coincides with the approximate age of
eyelid opening. Similarly, from as early as Fwk 31, ERG studies on preterm neonates suggest that
improvements in retinal activity are correlated with postconception age and extrauterine age [196–198].
Improvements in retinal activity can be recorded by a decrease in a- and b-wave latency with an
increase in amplitude. Preterm ERG studies cannot be used to assess if in vivo retinal activity also
has a maturational threshold because the eyelids are yet closed before Fwk 25. Other features of
preterm ERG include decreasing rod threshold with increasing postconception age, adult-like b-wave
sensitivity is reached at six months after normal birth [199,200]. Rod functional maturation occurs
peripherally and then parafoveally [201]. Preterm birth, however, has been consistently linked with
reduced rod and cone function when compared to usual term infants [202–204]. This suggests that
premature exposure of the retina to light is harmful. It is unknown if premature light exposure harms
cultured stem cell-derived retinal organoids.
As previously mentioned, human retinal organoids develop photoreceptor outer segments of
different quality between week (Wk) 16-28 [142,146,162,163,167,169–171,179,205]. Retinal as well as
brain organoids have been shown to respond to light [142,162,206]. Zhong et al. (2014) found that 2 out
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of 13 rod cells with putative outer segments in Wk 25-27 hiPSC-derived retinal organoids responded to
light as measured by perforated-patch recordings in the voltage-clamp mode. The sensitivity of these
immature human rod cells was less than found in adult non-human primate photoreceptors. Multiple
responses could not be elicited in these retinal organoids, likely due to a depletion in components
required for phototransduction [142]. Hallam et al. (2018) used a 4096 channel multielectrode
array (MEA) on which they flattened longitudinally opened Wk 21.4 (DD150) hiPSC-derived retinal
organoids ganglion side down and detected changing spike activity from pulses of white light. They
also used puffs of cGMP, which depolarizes photoreceptors leading to an unstimulated condition (Dark
Current), to show that the light responses found were driven by phototransduction in photoreceptors
and not the potential activity of ipRGCs [162]. Quadrato et al. (2017) found that eight month
hiPSC-derived brain organoids exhibited spontaneously-active neuronal networks, using high-density
silicon microelectrodes. Additionally, subpopulations of neurons were identified which were responsive
to 530 nm light in 4 out of 10 organoids. However, they were unable to attribute the responses directly
to the photosensitive cells or the downstream neuronal networks [206].
Human stem cell-derived retinal organoids can develop some synaptic maturity. Electron
microscopy data showed the presence of electron-dense ribbons surrounded by synaptic vesicles.
Immunohistochemistry markers such as PSD-95, vGlut1, PNA, Synaptophysin, and Syntaxin 3, confirm
synapses in human stem cell-derived retinal organoids. Markers such as RIBEYE (as detected by CtBP2)
and Bassoon confirm the presence of ribbon synapses. These markers roughly aligned at the outer
plexiform layer of retinal organoids. However, this varied between protocols and degeneration of the
inner retina in ageing organoids may also play a factor [148,162,167,170,171,178]. Interestingly, Dorgau
et al. (2018) showed that blocking of the extracellular matrix protein Laminin γ3 in late-stage retinal
organoids led to the disruption of ribbon synapse marker Bassoon. This may be due to the significant
disruption of Müller glial cell end feet at the inner limiting membrane [148]. Wahlin et al. (2017)
showed that both excitatory (L-aspartate, glutamate) and inhibitory (GABA, glycine) neurotransmitters
of the retina were present in Wk 43 (DD300) hiPSC-derived retinal organoids. L-aspartate was found
in the ONL, glutamate and GABA throughout the retina and glycine in the INL [170]. Hallam et al.
(2018) used puffs of GABA to highlight the emerging functional neural networks in Wk 21 (DD150)
human stem cell-derived retinal organoids [162]. Wahlin et al. (2017) used whole-cell patch clamp
recordings to elicit membrane capacitance changes as an index of voltage-dependent synaptic vesicle
release in retinal organoid photoreceptors [170]. Similarly, Deng et al. (2018) were able to show
the electrophysiological response from whole-cell patch clamp recorded rod photoreceptors from
hiPSC-derived retinal organoids [178].
Together, these data highlight the potential for producing light responsive human stem cell-derived
retinal organoids with maturating synapses that are capable of transferring information from
the photoreceptors to the inner retina. At the least, retinal organoids have “functional units” of
photoreceptors, bipolar cells, and ganglion cells. Work needs to be carried out to assess the quality
of these neural networks and how well all cell types contribute. More emphasis needs to be put
on comparing the early in vivo and in vitro retinal response to light and how that ties in with the
maturational stage. Unsurprisingly, retinal organoids represent an immature/incomplete development
stage, and thus functional responses reflect this. Improved culturing methods and better control of the
microenvironment might help in further maturation of the retinal organoids.
6. Improved Retinal Organoid Modelling
Despite ongoing issues with batch to batch variations, many of the current differentiation protocols
lead to the generation of well laminated retinal organoids that contain all the primary retinal cell
types but have putative photoreceptor segments or show in long-term cultures degeneration of the
inner retina. This may be due to the lack of correct microenvironmental cues and structural support.
Degeneration of the inner retina is likely due to the lack of access by medium components, particularly
as the retina thickens during development. Furthermore, misregulation of ECM components in
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human stem cell-derived retinal organoids may significantly affect their correct lamination [148].
Reproducibility and staging of human retinal organoids is also an important consideration particular
as we further explore their use in developmental studies and disease modelling [207]. Many teams are
focusing on new methodologies to improve the quality of retinal organoids by tweaking protocols,
using bioreactors, or microfluidic systems, [163,167,169,170]. Recently, Mellough et al. (also with slight
modification performed by Cowan et al.) showed that mechanical dissociation at the embryoid body
formation stage lead to improved formation of human retinal organoids [208,209]. The use of bioreactor
setups, instead of static culture setups, may help solve a number of these problems as they allow for
improved aeration and distribution of nutrients as well as allow for scaling up of organoid production.
Bioreactor setups report stem cell-derived retinal organoids with better lamination and enhanced
differentiation, an increased yield of photoreceptors with outer segment structures, improved cone
formation and a better recapitulation of the spatiotemporal development of in vivo retina [167]. While
the initial stages of differentiation require hypoxic conditions, improved oxygen diffusion at later stages
is essential for greater cell proliferation and ganglion cell survival. In the absence of vascularized stem
cell-derived retinal organoids, bioreactors help facilitate this mechanism. A number of teams have also
very recently come up with methods that lead to better cone and rod specification in human retinal
organoids [57,210–213].
Many of the differentiation procedures used to derive human retinal organoids lead to the
concomitant production of RPE. However, it produces RPE that is consistently not directly adjacent to
the photoreceptor segments when using a 2D to 3D differentiation protocol. It does allow however
medium that is conditioned by both the retinal organoids and RPE, which may provide some essential
diffusible factors for both structures. Production of full-length photoreceptor segments by Wahlin et al.
(2017) suggested that contact of RPE is non-essential for their development/maturation [170]. However,
correctly located RPE may provide essential structural support and may help to facilitate a number of
the physiological roles of photoreceptor segments such as phototransduction. Microfluidic systems
for retinal organoids may help to promote improved cell to cell interaction and additionally provide
tighter control of the microenvironment [214,215]. One of the future uses of human stem cell-derived
retinal organoid technology is potentially as a source of transplantable tissue and in particularly
photoreceptor cells to treat retinal diseases [171,216–218]. Integration and functionality of transplanted
photoreceptors into host retina has been shown to be much more limited than initially thought,
with predominant cytoplasmic material transfer including fluorescent reporter proteins [219–221].
Transplanted photoreceptors may not facilitate their physiological roles fully due to lack of interaction
with the host RPE. One way to enhance the photosensitivity of transplanted photoreceptors from
human stem cell-derived retinal organoids is to use optogenetically transformed photoreceptors [222].
Material transfer is found as well from conjugates formed from transplanted NTPDase2-positive
CellTracker Green labelled Müller Glial Cells [223,224]. Material transfer represents a novel route
to develop cell-based therapeutics which may be able to transfer “healthy components” to diseased
retinal cells [225].
7. The Apical CRB and PAR Complexes
Apical-basal cell polarity is pivotal for the formation and functionality of epithelial tissues being
governed by conserved canonical factors that define the apical domains. Apical polarity factors are
for example the Crumbs-homologues (CRB1 and CRB2), Protein associated with Lin Seven 1 (PALS1
also called MAGUK p55 subfamily member 5 or MPP5), Partitioning defective-6 homolog (PAR6),
atypical protein kinase C (aPKC), and PAR3. Basolateral polarity factors are for example Protein
scribble homolog (SCRIB), Discs large homolog (DLG), and Lethal giant larvae protein homolog (LGL).
However, recent work in the fruit fly Drosophila mid gut indicates that there are alternative apical
polarizing factors other than the canonical epithelia polarity factors and that this may also extend to
some types of vertebrate epithelia [226]. Additionally, there also exists planar cell polarity (PCP) in
tissue epithelia, which is orthogonal to the apical-basal axis (Figure 6A) [227]. The retinal sub-apically
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localized CRB and PAR complexes (Figure 6B) are pivotal in maintaining the spatiotemporal processes
of retinogenesis. The CRB complex has a prominent role in the control of apical-basal polarity acting
as a sensor for cell density and upon polarization leading to regulation of Adherens Junctions (AJs)
to promote maintenance of cell adhesion [228,229]. Disruption of the CRB complex leads to loss of
polarity and can lead to subsequent loss of adhesion, ectopic localization of progenitors and postmitotic
cells due to disrupted apically anchored process and coordinated cell migration, increase in cycling
progenitor cells and late-born cell types, increase in early retinal apoptosis, and disruption of lamination.
A long-term consequence of loss of retinal apical polarity is mild to severe retinal degeneration with a
concurrent loss of retinal function in line with morphological deficit [130,131,230–233]. The complex
acts in the role of conductor coordinating multiple downstream signaling pathways which have
essential roles in development, such as the Notch and Hippo pathways [228,234,235]. Thus, leading
to the regulation of cell size, cell fate determination, cell self-renewal, proliferation, differentiation,
mitosis, and apoptosis. However, how these intertwined cellular responses are mediated collectively
by the core complex remains ambiguous.
Figure 6. Schematic picture of Epithelial polarity. (A) Epithelial cell polarity consist of apical-cell
polarity and orthogonal to this axis planar cell polarity (PCP). PCP is the collective alignment of
cell polarity across the tissue plane and involves asymmetric segregation of proximal (purple) and
distal (blue) PCP components. Apical-basal polarity involves the antagonistic, functional, and spatial
segregation of apical (red) and basal (black) components. (B) In the retina the CRB and PAR complexes
are located at the sub-apical region (green), below the apical surface (red) and adjacent to the adherens
junctions (yellow). Scribbled (SCRIB), discs large (DLG), and lethal giant larvae (LGL) form a basolateral
domain (black) extending below the adherens junctions. (C) Schematic overview of the prototypic
CRB1, CRB2, and CRB3 proteins. Mutations from the three iPSC CRB1 RP patients lines recently
derived to retinal organoids are mapped to their protein location in CRB1. Adapted from Quinn et al.
2017 [144].
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The mammalian retinal CRB complex comprises of at least one of the three CRB family members,
CRB1, CRB2, and CRB3 (isoform CRB3A which has a conserved C-terminus, isoform CRB3B which
lacks the conserved C-terminus), in addition to PALS1 (also called MPP5), PATJ, MUPP1, MPP3, and
MPP4. Both CRB1 and CRB2 have a large extracellular domain with epidermal growth factor (EGF) and
laminin-globular domains. As discovered in Drosophila epithelia cells CRB1, CRB2, and CRB3A have a
single transmembrane domain juxtaposing a short intracellular C-terminus of 37 amino acids which
contains a FERM-binding motif (4.1, ezrin, radixin, moesin) and PSD-95/Discs-large/ZO-1 (PDZ)-binding
motif ERLI (Glu-Arg-Leu-Ile) [144,229,235,236]. The three prototypic CRB proteins are shown in
Figure 6C, for further details also on other isoforms details can be found in Quinn et al. 2017 [144].
Alternatively, the non-prototypic CRB3B isoform, which has a role in ciliogenesis and cell division,
contains a C-terminal PDZ-binding motif CLPI (Cys- Leu-Pro-Ile) that does not interact with the PAR
complex as found in Madin-Darby canine kidney epithelial cells (MDCK) [237,238]. The FERM motif
can bind to proteins such as EPB4.1L5 which plays a role in epithelial-to-mesenchymal transition
during gastrulation in mice and similar proteins are negative regulators of photoreceptor size in
Drosophila and zebrafish [239–243]. EPB4.1L5 oligomerization is essential for its binding to CRB and is
mediated through its FERM and FERM adjacent (FA) domains, as found in Drosophila and in MDCK
cells [244]. EPB4.1L5 controls the actomyosin cytoskeleton at both apical junctions and basal focal
adhesions, as found in the mouse kidney and during mouse development [239,245]. EPB4.1L5 is
predominantly located basolaterally in early development, repressing CRB, but is recruited by CRB
apically at later stages of differentiation. In the adult mammalian retina EPB4.1L5 has been found to
localize to the OLM [242,243]. PAR complex member aPKC can bind and phosphorylate the FA domain
of EPB4.1L5 leading to the dismantling of the EPB4.1L5 oligomer. This phosphorylation by aPKC
prevents the premature apical localization of EPB4.1L5, in turn EPB4.1L5 restrains aPKC signaling thus
antagonizing each other, leading to tightly controlled segregation of apical/basal membrane domains,
as found in Drosophila and in MDCK cells [244,246]. The 4 amino acid PDZ-binding motif ERLI of CRB
allows for interaction with adaptor proteins such as PALS1 and PAR6, as found in Drosophila and in
MDCK cells [247,248]. Binding of PALS1 to the C-terminal PDZ domain of CRB leads to recruitment of
PATJ or MUPP1 through binding of the PALS1 N-terminal L27 domain to the L27 domain of PATJ or
MUPP1, as found in Drosophila and in MDCK cells [249,250]. Additionally, PALS1 can recruit MPP3
and MPP4 to the apical complex, in the mouse retina [251,252]. PALS1 is abundantly expressed at the
OLM and tight junction of the RPE. Ablation of PALS1 in the mouse neural retina resulted in late onset
retinal degeneration suggestion redundancy of MPPs in the neural retina, whereas ablation of PALS1
in the mouse RPE and neural retina results in early onset retinal degeneration suggesting specific roles
for PALS1 in RPE [231].
Binding of PAR6 to the C-terminal PDZ binding domain of CRB leads to the recruitment of the
other PAR complex members PAR3, aPKC, and cell division control 42 (CDC42). PAR6 can interact
with PAR3 through their PDZ domains, with aPKC through their N-terminal Phox and Bem1 (PB1)
domains, and with CDC42 through their semi-CDC42- and Rac-interactive binding (CRIB) domains, as
found in Caenorhabditis elegans and mammalian tissue lysates and cos1 cells [253–256]. The activity
of aPKC is suppressed by PAR6 binding, but this suppression is partially relieved when GTP bound
CDC42 interacts with the complex, as found in Drosophila and in MDCK cells [257,258]. However, the
activity of aPKC has also been shown to be promoted by PAR6 [259]. PAR3 is both an inhibitor of
aPKC activity but also its substrate, found in mammalian tissue lysates [256]. At adherens junctions,
PAR3 can also bind to the scaffolding proteins FERM domain containing 4A (FRMD4A) and FRMD4B
(also known as GRSP-1) leading to the recruitment of cytohesin-1 (CYTH)1 and causing subsequent
activation of ARF6, this complex being essential for epithelial polarity [260]. FRMD4B and CYTH3
(also known as GRP1) also exist in a complex, found in COS1 cells [261]. Recently, in the mouse retina
a variant of FRMD4B, Frmd4bTvrm222, led to the suppression of OLM fragmentation and photoreceptor
dysplasia in Nr2e3rd7 and Nrl-/- mice. Whole exome sequencing revealed that the Frmd4bTvrm222 variant
had a substitution of serine residue 938 by proline (S938P). Transfection of COS7 cells with either
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S938P or wild-type FRMD4B and the addition of insulin, an agonist of the phosphoinositide 3-kinase
(PI3K)-AKT pathway, revealed that the FRMD4B variant does not translocate to the plasma membrane
as occurs with wildtype FRMD4B. The Frmd4bTvrm222 mice showed reduced AKT phosphorylation and
an increase in cell junction proteins, activated AKT leads to loss of apical-basal polarity. Therefore, the
interactions of the FRMD4B variant and cytohesin-3 may modulate both the PAR3 activated ARF6
pathway and/or PI3K-AKT pathway to prevent retinal dysplasia in Nr2e3rd7 and Nrl-/- mice [262].
CDC42 in addition to its role in regulating aPKC has recently been shown to regulate another kinase to
the apical domain, p21-activated kinase-1 (PAK1), as found in Drosophila and mammalian epithelial
cells [258,263]. Loss of PAK1 or aPKC leads to a moderate polarity phenotype however a dramatic loss
of epithelial polarity was detected when PAK1 as well as aPKC are inactive. Both aPKC and PAK1
act redundantly downstream of CDC42. PAK1 is expressed throughout the mouse retina [263,264].
The CRB and PAR complexes may interact additionally through direct interaction of the amino terminus
of PALS1 and the PDZ domain of PAR6, the interaction being regulated by GTP bound CDC42, as
investigated in mammalian cell lines [265]. PAR6, PAR3 and aPKC are located at the OLM in the
embryonic mouse retina while CDC42 is located throughout the retina [266–268].
8. The Localization of the Mammalian Retinal CRB Complex
The developing mammalian retina expresses both CRB1 and CRB2. In mouse retina, both CRB1
and CRB2 are expressed at the subapical region adjacent to adherens junctions of progenitor cells at
embryonic day 12.5 (Figure 7A), which is equivalent to the early 1st trimester human fetal retinal
development, transcriptionally [40,41,232,242,269]. However, in 1st trimester human fetal retina, while
CRB2 labelling is found at the subapical region adjacent to adherens junctions in putative photoreceptor
inner segments and the apical villi of radial glial progenitor cells, CRB1 is almost below detection level
(Figure 7B). Subsequently, in mid 2nd trimester human fetal retina CRB1 and CRB2 labelling could be
clearly detected at the subapical region adjacent to adherens junctions between putative photoreceptor
inner segments and in the apical villi of radial glial progenitor cells/Müller glial cells. In addition
to CRB1 and CRB2 expression other CRB complex members PALS1, MUPP1, and PAR3 were found
to be expressed in 1st and 2nd trimester human fetal retina. In 1st trimester human fetal retina we
also found PATJ expression this was not analyzed in 2nd trimester retina. The onset of CRB1 and
CRB2 expression and other members of the CRB complex in the human fetal retina was found to be
recapitulated in early versus late differentiated human induced-pluripotent stem cell (iPSC)-derived
retinal organoids [129].
In the adult mammalian retina CRB1, CRB2, and CRB3 proteins localize at the subapical region in
the Müller glial cells of mice, non-human primates and humans (Figure 7C–E). However, while CRB3
is present at the subapical region of photoreceptors in all three species, the expression patterns of CRB1
and CRB2 at the subapical region of photoreceptors differs between the three species (Figure 7C–E).
CRB2 is present at the subapical region of mouse photoreceptors, whereas CRB1 is not (Figure 7C).
In non-human primates both CRB1 and CRB2 are present in photoreceptors (Figure 7D). In cadaveric
human retinas collected 2-days after death CRB1 is present at the subapical region whereas CRB2 is
present at vesicles in the photoreceptor inner segments but at some distance from the subapical region
(Figure 7E) [130,132,270,271]. Interestingly, all 3 CRB proteins in the adult human retina are detected in
the photoreceptor inner segments at a distance from the outer limiting membrane [272]. Additionally,
CRB3 is also detected in the inner retina of mice, non-human primates and humans [132,270,273]. All of
the ultrastructural immuno-electron microscopy studies using anti-CRB on adult human cadaveric
retina were carried out using two-days-old tissue samples, and might for that reason differ with
the results obtained when using freshly collected non-human-primate retinas. In other studies, a
negative correlation between protein abundance and post-mortem time has been found in the human
retina [274,275].
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Figure 7. Schematic picture of the localization of the CRB proteins in mammalian adult retinal Müller
glial and photoreceptor cells. (A–E) CRB1 (red) and CRB2 (blue) proteins localize at the subapical
region in mouse (A) and human (B) retinal progenitors cells and adult Müller glial cells of mice (C),
non-human primates (D) and humans (E). However, the expression of CRB1 in the early developing
human retina is low and sporadic. Additionally, the expression patterns of CRB1 and CRB2 at the
subapical region of adult photoreceptors differs between the three species. CRB2 is present at the
subapical region of mouse photoreceptors, whereas CRB1 is not (C). In non-human primates both CRB1
and CRB2 are present in photoreceptors (D). In cadaveric human retinas collected 2-days after death
CRB1 is present at the subapical region whereas CRB2 is present in the photoreceptor inner segments
but at some distance from the subapical region (E). PRC: Photoreceptor; MGC: Müller glial cells.
In the adult mouse RPE, 1st and 2nd trimester human fetal RPE, and human iPSC-derived RPE
CRB2 has been found to be expressed [129,276]. In the both human fetal and iPSC-derived RPE CRB2
immuno-EM labeling was found above adherens junctions and tight junctions in the apical membrane
and microvilli [129].
9. CRB1 and Leber Congenital Amaurosis
Leber congenital amaurosis (LCA) is an early-onset disease leading to blindness from near birth
with CRB1 mutations accounting for 7–17% of cases and affecting approximately 10,000 patients
worldwide [235,277–279]. Currently, there is no treatment available for CRB1-LCA patients, but
proof-of-concept gene supplementation studies have shown functional rescue in CRB1 retinitis
pigmentosa (RP) mouse models which sets a ground work for proof-of-concept in CRB1-LCA-like
mouse models [272]. CRB1 gene mutations cause LCA8 with patients having severely attenuated
or non-recordable ERG, abnormal pupillary reflex and nystagmus and their retinas have abnormal
layering with reports of the retina being thickened, thinned or unchanged [280–289]. Mutations in
CRB1 also lead to the development of RP with patients developing night blindness and a progressive
loss of visual field due to rod degeneration [92]. CRB1 mutations are associated with RP type 12
and are characterized by preservation of the para-arteriolar retinal pigment epithelium (PPRPE)
and, due to macular involvement, a progressive loss of visual field. Disease onset can be from
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early childhood, however, some patients do not exhibit symptoms until after the first decade of
life [290–292]. Additional CRB1 clinically relevant features include macular atrophy, keratoconus,
Coats-like exudative vasculopathy, RP without PPRPE, pigmented paravenous chorioretinal atrophy,
and nanophthalmos [288,293–297].
Human stem cell-derived retinal organoids which mimic retinal disease are an excellent tool
for understanding disease mechanisms as well as a platform for testing therapeutic strategies.
Other teams, including our own, are investigating pathobiology and disease mechanism of stem
cell-derived retinal organoids from CRB1 patients. We, have recently shown for the first time that three
hiPSC lines (LUMC0116iCRB; LUMC0117iCRB; LUMC0128iCRB) from CRB1 RP patients showed a
phenotype similar as previously found in 3 month-old Crb1KO RP mice when differentiated into retinal
organoids [129,130]. LUMC0116iCRB has c.3122T>C p.(Met1041Thr) homozygote missense mutations.
LUMC0117iCRB has 2983G>T p.(Glu995*) and c.1892A>G p.(Tyr631Cys) mutations. LUMC0128iCRB
has c.2843G>A p.(Cys948Tyr) and c.3122T>C p.(Met1041Thr) missense mutations. Mutations are
mapped to their protein location in Figure 6C. Compared to control retinal organoids (Figure 8A),
CRB1 patient derived retinal organoids at DD180 showed disruptions at the OLM demonstrated by
ectopic photoreceptor nuclei above the OLM and altered localization of CRB complex members at the
OLM (Figure 8B,D). Furthermore, the CRB1 variant proteins localized to the subapical region above the
adherens junctions, as in controls, but additionally showed a curved and broadened expression pattern
(Figure 8C,E). Mislocalization of the CRB1 variant protein was also found mislocalized in the apical
area of the NBL [129]. However, these studies are in their early stages with the underlying effects of
the variant CRB1 proteins on protein-protein interactions and downstream cell signaling pathways
still to be elucidated. Many rodent models of CRB retinal degeneration exist and have provided us
with a deep insight into the pathobiology and mechanisms underlying CRB disease [130,144,232,235].
CRB1-LCA-like models have further built on our previous data [132,298,299].
One of the main working hypothesis that we draw from our four CRB1-LCA-like models is that
CRB2 protein levels may be lower or that a less functional variant is of CRB2 is expressed in CRB1
LCA patients compared to less severe CRB1 retinal diseases [132,298,299]. Clinical reports of CRB1
LCA patients have shown that degeneration can affect all quadrants of the retina while other reports
show restriction to the inferior retina [285,288,300,301]. This is highly suggestive of the presence of a
modifying factor. Variants of CRB2 have been associated with retinal aberrations and more recently
a missense mutation of CRB2 has been found to cause retinitis pigmentosa [134,302]. Additionally,
CRB2 is present in the fetal human retina in the first-trimester, whereas CRB1 expression starts from
the second trimester [129]. In the mouse, both CRB1 and CRB2 are found in the early embryonic
retina [232,242,269]. Therefore, missense variants of CRB2 in humans are likely to have small but
important effects on retinal diseases. A number of transcript variants have been reported for CRB1,
and new novel isoforms of CRB1 are reported in the mouse and human retina and may also lead to
the phenotypic variability in CRB1 patients [144,303]. Currently there has been no link between CRB3
mutations and retinal disease.
The four CRB1-LCA-like models had both alleles of Crb2 disrupted in either retinal progenitor
cells (ΔRPC), immature photoreceptors (ΔimPRC), or Müller glial cells (ΔMG) on genetic backgrounds
with either reduced levels of (Crb1KO/WTCrb2ΔRPC) or complete knockout of Crb1 (Crb1KOCrb2ΔRPC,
Crb1KOCrb2ΔimPRC, Crb1KOCrb2ΔMG). All of these models had abnormally layered and transiently
thickened retina, disruptions of the outer limiting membrane and ectopic localization of mitotic
progenitors, cycling cells, and immature photoreceptors. The thickened retinas observed were in
part due to the ectopic birth or displacement of early progenitors which we found increased in the
Crb1KOCrb2ΔRPC and Crb1KOCrb2ΔimPRC mouse retinas, but not in the Crb1KOCrb2ΔMG. This led to adult
retinas in which we detected ectopic cells in the ganglion cell layer either sporadically (Crb1KOCrb2ΔRPC),
at the peripheral retina (Crb1KOCrb2ΔMG), or within most of the retina (Crb1KOCrb2ΔimPRC), or
throughout the retina (Crb1KOCrb2ΔRPC). We hypothesize that CRB1 LCA patients which exhibit a
thickened retina and abnormal layering do so due to similar mechanisms as found in our CRB1-LCA-like
21
Genes 2019, 10, 987
mouse models, displacement or the ectopic birth of progenitor cells, cycling cells, and immature
photoreceptor cells [132,285,298,299]. Additionally, the reported thinned or unchanged retinal thickness
of CRB1 LCA patients is likely due to measurements made when significant retinal degeneration
had already occurred. In our CRB1-LCA-like mouse models we detected transient changes in retinal
thickness [288,289].
Figure 8. Disruptions at the outer limiting membrane in retinal organoids from CRB1 retinitis pigmentosa
(RP) patients. Schematic depiction of healthy (A) and CRB1 patient (B,C) derived retinal organoids.
(A) In healthy organoids CRB1 is located at the subapical region adjacent to the adherens junctions.
(B,D) In retinal organoids from CRB1 retinitis pigmentosa patient (LUMC0116iCRB) disruptions of
the outer limiting membrane (OLM) and ectopic photoreceptors have been found. (C,E) Additionally,
budding of the apical membrane and mislocalization of the CRB1 variant in the NBL also occurs. Scale
bars (D,E), 20 μm. Panels (C,D) are modified from [178] under a Creative Commons license.
While in the Crb1KO/WTCrb2ΔRPC and Crb1KOCrb2ΔRPC mouse models no differences in
retinal degenerations were reported between superior/inferior or central/peripheral retina, the
Crb1KOCrb2ΔimPRC and Crb1KOCrb2ΔMG retina showed superior/inferior or central/peripheral
phenotypes, respectively [132,298,299]. Interestingly, a new Crb1Crb2 double knockout mouse
model which disrupted both alleles of Crb2 in rods (Δrods) on a genetic background lacking Crb1
(Crb1KOCrb2Δrods) does not have an LCA-like but RP-like phenotype. The Crb1KOCrb2Δrods retinas have a
phenotype that mainly affects the peripheral and central superior retina [304]. These differences may be
attributed to opposing gradients of mouse CRB1 and CRB2 at the subapical region between the superior
and inferior retina as well as the contribution of CRB1 and CRB2 to either photoreceptors (CRB2) or
Müller glial cells (CRB1 and CRB2) [130,270,271]. Another common feature of the CRB1-LCA-like
mouse models is the early formation of retinal rosettes [132,298,299]. A comparison of the Crb1Crb2
double knockout mouse models can be found in Table 1.
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Rosette formation has been extensively described in many retinal conditions including retinitis
pigmentosa, diabetic retinopathy, and retinoblastoma [305–307]. The formation of rosettes has been
attributed to the disruption of the OLM both chemically and genetically [130,231,233,266,308–312].
A defining hallmark of CRB mouse models is the formation of photoreceptor rosettes which may be
concurrent with the loss of polarity in a CRB dependent manner. The more severe CRB models have a
low level of total CRB, less stable AJs and thus an earlier phenotype onset and rosette formation. The
less severe CRB models have a higher level of total CRB, more stable AJs and thus a later phenotype
onset and rosette formation [144]. Rosette formation is preceded by aberrant localization of retinal cells
into the subretinal space at foci where loss of adhesion is found. In the developing retina, this is usually
seen as “volcanic-like” cell eruptions, while in the mature retina this is seen as a loss of complete rows
of photoreceptors [130–132,232,270,298,299]. The Crb1KOCrb2ΔMG retina has a peripheral to central
degenerative phenotype. At P1 in the Crb1KOCrb2ΔMG, retina rosettes can be detected peripherally
while only protrusions into the subretinal space are found in the central retina. By P14 the peripheral
rosettes are gone due to advancement of the phenotype, but rosettes can now be found in the central
retina [132]. Differences in the number of aberrant cells in early- versus late-disrupted OLM phenotypes
likely arise from both the extent of OLM disruption as well as the developmental stage of the retina.
Earlier cells are less mature/competent and are still undergoing division and migration changes. Rosette
formation is likely independent of any increased cell proliferation seen in early-onset RP-like and
LCA-like CRB models as rosettes are also present in later onset CRB, CRB-related, and non-CRB mouse
models that do not exhibit changes in proliferation [130–132,232,298,299,310,311,313].
Although the mechanism by which rosettes are formed in retinal disease is not fully alluded to, it
has been related to changes in the extracellular matrix, adhesion molecules, and the cytoskeleton, all
of which can be affected by an imbalance between apical and basal polarity domains [314–317]. Loss
of CRB in mutant mouse models may not be uniform due to opposing gradients of CRB1 and CRB2
proteins in the superior versus inferior retina as well as the non-uniform localization of CRB between
photoreceptors (CRB2) and Müller glial cells (CRB1 and CRB2), leading to imbalance of CRB levels
at the OLM in the mutant models [130,270,271]. Differences in adjacent apical levels of CRB are well
studied as this is part of the process for tube invagination, similar mechanisms in opposing CRB levels
between adjacent cells may lead to rosette formation, which are in fact invaginations of the apical
retinal surface [318–320].
10. Gene Augmentation for Hereditary Retinopathies
Gene augmentation, via recombinant adeno-associated virus (rAAV) delivery, is currently the “go
to” therapeutic strategy for targeting hereditary retinal diseases. Luxturna (voretigene neparvovec-rzyl)
has led the way for eye gene therapeutics by becoming the first FDA- and EMA-approved AAV gene
therapy for patients with biallelic RPE65 gene mutations [321,322]. As such a large number of
AAV mediated gene therapeutics are currently going under clinical trials focused on the treatment
of achromatopsia, autosomal recessive retinitis pigmentosa, choroideremia, Leber hereditary optic
neuropathy, retinitis pigmentosa, X-linked retinitis pigmentosa, X-linked Retinoschisis, and wet
age-related macular degeneration (summarized in Table 1, Alves and Wijnholds 2018 [323]). The clinical
success of rAAV mediated eye gene therapeutics is in part due to its low toxicity; the small amount
of rAAV required to infect the retinal pigment epithelium or retina; the surgical accessibility of
the eye; the large number of non-invasive techniques for monitoring disease progression, such as
ERG, scanning laser ophthalmoscopy (SLO) and spectral domain optical coherence tomography
(SD-OCT); and the immune-privileged status of the eye, having a good safety profile with low
immunogenicity. Additionally, rAAV vectors can transduce both dividing but also non-dividing cells
such as photoreceptors and display varied cell tropisms due to a plethora of capsid variants [323,324].
Wild type AAVs are small non-enveloped single stranded DNA viruses that belong to the
parvovirus family in the genus Dependovirus and as such require assistance for replication. Cell
surface receptors such as heparin sulfate and sialic acid mediate AAV endocytosis. AAV is then
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processed through the cytosol too the nucleus where it is uncoated and processed into nuclear episomal
structures. The AAV genome includes three open reading frames which express the Replication
(rep), Capsid (cap) and assembly activating protein (aap) genes. Two T-shaped 145 nucleotide-long
inverted terminal repeats (ITRs) flank the genome. The ITRs and the four proteins encoded by the
rep gene, Rep78, Rep68, Rep52, and Rep40, are needed for genome replication and packaging. Virion
proteins (VP1), VP2, and VP3 from cap gene transcripts form an icosahedral symmetry shell ~26 nm in
diameter defined by 60 subunits in a molar ratio of 1:1:10 (VP1:VP2:VP3). The assembly of the virions
is promoted by the scaffolding function of AAP. However, in rAAV the rep and cap genes and the
element required for site-specific integration into the genomic locus AAVS1 are deleted. This means for
replication a helper plasmid containing the rep and cap genes along with helper genes from adenovirus
(E4, E2a, and VA) must be supplied [324].
Development of a CRB-based gene therapy approach was particularly challenging due to the
cDNA size of 4.2 kb for human CRB1. With the addition of promoter, polyadenylation, and ITR
sequences this is at the very edge of the approximate 4.7 kb packaging space of rAAV. Additionally,
human CRB1 cDNA required codon optimization to achieve sufficient levels of expression. However,
alternative strategies employing the use of the 3.85 kb human CRB2 cDNA and the development of
minimal promoters for the expression of CRB proteins in photoreceptors and Müller glial cells has led
to proof-of-concept for a CRB-based gene therapeutic [272,325]. These proof-of-concept pre-clinical
studies found both morphological and functional rescue in two CRB1-RP-like mouse models when
using an AAV-CRB2-based gene therapy vector. We found that expression of CRB1 was deleterious
in CRB1 RP-like mouse models but not in wild-type mice. The CRB2-based gene therapy used a
combination of AAV9 and the ubiquitous CMV promoter to target both photoreceptors (cone and rods)
and Müller glial cells to achieve rescue. No rescue was achieved if either photoreceptors or Müller glial
cells were targeted independently. We hypothesize that physiological relevant levels of CRB proteins
are required at the subapical regions in neighboring photoreceptors and Müller glial cells [272]. There
are a large number of transcript variants for CRB1 [144]. The Kay lab has identified a number of novel
CRB1 isoforms in both mouse and human retina [303].
Cultured human iPSC-derived retinal organoids recapitulate well the human fetal retina, and
might therefore be good models to test gene therapy vectors [143]. Recently we used transgene
expression assays in human iPSC-derived retinal organoids and adult cadaveric human retinal explants
to assess the tropism of three AAV serotypes: AAV9, AAV5, and ShH10Y using the ubiquitous CMV
promoter. We found a preference of AAV5 and ShH10Y445F over AAV9 to infect Müller glial cells in
hiPSC-derived retinal organoids. We observed as well a higher efficacy of AAV5 than ShH10Y445F or
AAV9 serotypes for infection of photoreceptors and Müller glial cells in cultured human donor retinal
explants. Together, our data indicate that AAV5 serotype in combination with the CMV promoter
may be a viable strategy to express the CRB gene in human photoreceptors (rods and cones) and
Müller glial cells [129]. An additional clinically relevant finding we discovered was the higher efficacy
of AAV5-CMV-GFP, ShH10Y445F-CMV-GFP, and AAV9-CMV-GFP to express in Müller glial cells
than photoreceptors in human retinal explants lacking photoreceptor segments. This indicated (1)
that in the absence of photoreceptor segments there is an increased bioavailability of AAV vectors,
allowing targeting of less-abundant/preferred receptors for AAV uptake; (2) that there may be a
common mechanism of active AAV uptake to photoreceptors through there segments, e.g., putative
sites of receptor-dependent or -independent clathrin- and caveolae-mediated endocytosis; (3) that
intact photoreceptor segments allow for efficient AAV5 gene therapy vector transduction of human
photoreceptors, whereas loss of intact photoreceptor segments allows for efficient AAV5 gene therapy
vector transduction of Müller glial cells [129].
11. Concluding Remarks
Human stem cell-derived retinal organoids faithfully recapture in part many of the facets of
the human fetal retina, including retinal cell type diversity, morphological cues, synaptic wiring,
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and light sensitivity. Improved retinal organoid culturing methods using bioreactors or microfluidic
organ-on-a-chip technology, which also allows for tight control of the physiological microenvironment,
bring us a further step towards an in vivo like retina [167,215,326]. Furthermore, retinal organoid
models derived from patients may be used in conjunction with two-photon imaging and light sheet
microscopy as well as tissue clearing methods such as DISCO and PACT [47,169,327–329]. This will
allow unparalleled analysis of live and fixed cellular events including spatiotemporal process such as
proliferation, differentiation and migration. Additionally, new methods such as ferrofluid droplets as
mechanical actuators allow analysis of the mechanics of 3D developing tissues. This tool in combination
with optogenetics or calcium imaging would provide insight into how neuronal and mechanical
responses may influence each other in retinal development and disease [330,331]. Together, these are
all valuable tools to further evaluate the mechanisms by which the misregulation of the apical CRB and
PAR complexes affects retinogenesis leading to the severe retinal degeneration seen in LCA patients.
Additionally, CRB-based gene augmentation is a viable option for CRB1-related retinitis pigmentosa
and needs to be further evaluated for CRB1-related LCA.
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Abstract: Gene therapy using adeno-associated viral (AAV) vectors currently represents the most
promising approach for the treatment of many inherited retinal diseases (IRDs), given AAV’s ability to
efficiently deliver therapeutic genes to both photoreceptors and retinal pigment epithelium, and their
excellent safety and efficacy profiles in humans. However, one of the main obstacles to widespread
AAV application is their limited packaging capacity, which precludes their use from the treatment of
IRDs which are caused by mutations in genes whose coding sequence exceeds 5 kb. Therefore, in
recent years, considerable effort has been made to identify strategies to increase the transfer capacity of
AAV vectors. This review will discuss these new developed strategies, highlighting the advancements
as well as the limitations that the field has still to overcome to finally expand the applicability of AAV
vectors to IRDs due to mutations in large genes.
Keywords: AAV; retina; gene therapy; dual AAV
1. Introduction
The eye is an ideal target for gene therapy thanks to its small and enclosed structure, relative
immune privilege and easy accessibility [1,2]. This has boosted attempts at developing gene therapy
approaches for the treatment of a large number of inherited retinal diseases (IRDs) over the recent
decades [3,4]. Confirmation of the advancements in the retinal gene therapy field came in the last two
years with the approval of the first gene therapy product for an IRD, Luxturna [5]—an adeno-associated
viral (AAV) vector-based therapy for a form of Leber Congenital Amaurosis [6]—in the US, first, and
then in Europe. The recombinant AAV vector on which Luxturna is based is the most widely used
vector for retinal gene delivery. AAV are small (25 nm), nonenveloped, icosahedral viruses belonging
to the Parvoviridae family [7]. They package a linear single-stranded DNA genome of ~4.7 kb, flanked
by two 145 bp long palindromic inverted terminal repeats (ITRs) [7]. These ITRs form hairpin-loop
secondary structures at the strand termini and are the only viral sequences that are retained in cis
in the recombinant AAV vector genome [7]. Recombinant vectors based on AAV have fast become
popular in the gene therapy field because of their excellent safety profile and low immunogenicity
which allows for long-term expression of the therapeutic gene, at least in post-mitotic tissues, so
that most experimental therapy studies require only a single vector administration. Additionally,
dozens of different AAV variants have been identified thus far, each of them with unique transduction
characteristics. This allows the user to select the most appropriate AAV serotype to transduce the
retinal cell layer of interest. Indeed, following subretinal delivery, virtually all the AAV serotypes
tested efficiently transduced the retinal pigment epithelium (RPE), while the levels of transduction of
photoreceptors, which are the main therapeutic target cells in most IRDs, varied significantly among
different serotypes [4,8]. AAV5, AAV7, AAV8 and AAV9 serotypes have all been demonstrated to
efficiently transduce photoreceptors [4,8]. Additional serotypes with increased retinal transduction
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abilities have also been identified through either rational design or directed evolution [4,8]. This is
one of the most attractive features of AAV vectors for retinal gene therapy, since alternative, both
non-viral and viral, vectors tested thus far have shown more limited transduction abilities of adult
photoreceptors [2,9]. For all the above described reasons, AAV have been used in many successful
preclinical and clinical studies [3,4]. Clinical trial data collected over a decade have confirmed the
overwhelming safety of AAV vectors delivered intraocularly and shown many instances of efficacy in
treating previously incurable IRDs.
However, one of the main limitations to a broader application of AAV vectors for retinal gene
therapy is their packaging capacity, which is restricted to approximately 5 kb of DNA [10]. This vector
capacity is a critical issue, given the fact that approximately 6% of all human proteins have a coding
sequence (CDS) that exceeds 4 kb [11] and that, in addition to the CDS of the therapeutic gene and the
ITRs, a gene therapy vector needs to include, as a minimum, a promoter and a polyadenylation signal
(polyA). Thus, the treatment of disorders caused by mutations in genes over 4 kb in size, including
those causative of common IRDs, is currently not achievable using standard AAV vector-mediated
approaches. The development of strategies to overcome AAV packaging limitation has therefore
become a key area of research within the gene therapy field.
2. Strategies for Large Gene Delivery
Two types of strategies have been developed for large gene delivery via AAV: one is based on
the “forced” packaging of oversized genomes (i.e., larger than 5 kb) in a single AAV vector (oversized
AAV vectors); the other relies on the delivery of portions of large transgenes in two AAV vectors,
which recombine through various mechanisms in the target cell, leading to the reconstitution of the
full-length gene (dual AAV vectors) (Table 1).
Table 1. Adeno-associated viral (AAV) vector-based strategies for large gene delivery.
Strategy Advantages Limitations
Oversized AAV No need to identify optimal splittingpoints/region of overlap Genome highly heterogeneous in size
Trans-Splicing Dual AAV Genomes with discrete nature
Non-directional concatemerization (with only one
concatemer being productive)
Need to identify optimal splitting points
Efficiency dependent on splicing across the inverted
terminal repeat (ITR) junction
Potential production of shorter protein products
Overlapping Dual AAV
Genomes with discrete nature
No additional foreign or artificial DNA
elements required
Need to identify the optimal region of overlap for
efficient homologous recombination
Potential production of shorter protein products
Hybrid Dual AAV
Genomes with discrete nature




Need to identify optimal splitting points
Efficiency dependent on splicing across the ITR
junction
Potential production of shorter protein products
2.1. Oversized AAV Vectors
Several research groups have tried to encapsidate large genes in a single AAV vector [12–14].
These “oversized” AAV vectors have been found to successfully express full-length proteins in vitro
and in the retina of IRD models to levels which led to significant and stable improvement of the
phenotype [12,15]. However, the genome contained in oversized AAV vectors was found to be not a
pure population of intact large-sized genomes but rather a mixture of genomes highly heterogeneous
in size [14,16–19]. Thus, it was proposed that full-length protein expression from oversized AAV
vectors was achieved, following infection, through the re-assembly of truncated genomes in the target
cell nucleus [14,16–19]. The efficiency of the transduction of oversized AAV vectors in the retina
in comparison to alternative platforms for large gene delivery (i.e., dual AAV vectors, discussed
below) has been assessed in various studies and found to be variable. Whereas some studies found
considerably high levels of transgene expression from oversized AAV vectors [14,15], others showed
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efficient large protein reconstitution only upon dual AAV vector delivery [20,21]. Both the design and
purification process of oversized AAV vectors were hypothesized to be critical for the success of the
strategy, as the use of transgenes slightly above 5 kb can give rise to genomes with longer overlaps
compared to the use of transgenes largely exceeding AAV cargo capacity, and this can drive more
efficient re-assembly of oversized AAV vectors. Along this line, it was shown that the fractionation
of oversized AAV vector preparations can be explored to promote selection of the genomes with the
highest transduction properties in the final viral preparation [14]. However, despite the optimization
and ability of this strategy to reconstitute large genes expression in vivo, consistently shown in various
studies, the heterogenous nature of oversized AAV genomes poses major safety concerns, limiting
their further application in clinical settings.
2.2. Dual AAV Vectors
An alternative strategy for AAV-mediated large gene delivery is the generation of dual AAV
vectors. In this strategy, large transgenes are split into two separate AAV vectors that, upon co-infection
of the same cell, reconstitute the expression of a full-length gene via intermolecular recombination
between the two AAV vector genomes. This ideally doubles AAV cargo capacity, allowing delivery of
transgenes up to about 9 kb. Various dual AAV vector strategies have been developed (referred to as
trans-splicing [22], overlapping [23] and hybrid [24] dual AAV vector strategies), which differ in the
mechanism they use to reconstitute the transgene.
2.2.1. Trans-Splicing Dual AAV Vectors
The trans-splicing approach relies on the natural ability of AAV ITRs to concatemerize in order to
reconstitute full-length genomes [22,25]. In this approach, the two vectors carry two separate halves of
the transgene, without regions of sequence overlap; the 5’-half vector has a splice donor (SD) signal at
the 3’ end of the AAV genome, while the 3’-half vector carries a splice acceptor (SA) signal at the 5’ end
of the AAV genome (Figure 1).
Figure 1. Schematic representation of the trans-splicing dual AAV approach for large gene reconstitution.
The first vector includes the promoter, the 5’-half of the coding sequence (CDS) and the splicing donor
(SD) signal; the second vector includes the splicing acceptor (SA) signal, the 3’-half of the CDS and
the polyadenylation signal (PolyA). Concatemerization of the two vectors, involving the right-hand
inverted terminal repeat (ITR) of the first vector and the left-hand ITR of the second vector, reconstitutes
the full-length gene. After transcription, splicing leads to the removal of the ITR structure at the
junction point, with restoration of the full-length, mature RNA of the transgene.
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This allows splicing of the concatemerized ITR structure that forms in the middle of the therapeutic
CDS following tail-to-head concatemerization of the two AAV genomes to obtain a single large mRNA
molecule. This approach was first tested about 20 years ago, and historically represents the first
developed approach for AAV-mediated large gene delivery. Since then, many studies have shown the
efficacy of this strategy to reconstitute large genes. The major limitation of this platform, however,
is that concatemerization can occur between any of the ITR of the two vectors. This may lead to the
formation of both forms of circular monomers of each AAV, as well as two-vector linear concatemers
in a number of orientations of which only one (i.e., tail-to-head concatemer) is productive to restore
full-length gene expression [26]. Attempts at favoring the formation of concatemers in the correct
orientation have been made (as discussed in the “Limitations of dual AAV vectors” paragraph).
An additional limiting step of trans-splicing vectors is splicing across the ITR junction, the efficiency
of which is dependent on both selection of the optimal exon–exon junction for splitting the large
therapeutic gene [27] as well as the efficiency of splicing across the ITR structure [28]. To overcome the
first issue, synthetic SD and SA signals have been developed, which mediate high rates of splicing
independently of the gene that needs to be delivered [29]. Yet, since the sequence surrounding the
splicing signals has an impact on splicing efficiency, careful selection of the splitting point is required.
2.2.2. Overlapping Dual AAV Vectors
In the overlapping approach, the transgene is split into two halves sharing homologous overlapping
sequences, such that the reconstitution of the large gene expression cassette relies on homologous
recombination [23] (Figure 2).
Figure 2. Schematic representation of the overlapping dual AAV approach for large gene reconstitution.
The first vector includes the promoter and the 5’-half of the coding sequence (CDS) and the second
vector includes the 3’-half of the CDS and the polyadenylation signal (PolyA). A portion of the sequence
of the large transgene is repeated in both vectors (at the 3’ end of the CDS of the first vector and at
the 5’ end of the CDS of the second vector). Thus, the full-length transgene expression cassette is
reconstituted through homologous recombination of the overlapping regions in the two vectors. ITR:
inverted terminal repeat.
As it has been designed, the overlapping approach is the simplest in design and requires less
foreign or artificial DNA elements when compared to the other approaches. However, as the success
of this strategy is critically dependent upon the ability of the overlapping region to mediate efficient
homologous recombination, much work is needed to determine the optimal CDS overlapping region
to be used for each transgene. Furthermore, data obtained so far have also highlighted that the
success of this strategy is dependent on the retinal cell type being targeted, since the efficiency of the
repair mechanism on which overlapping dual AAV vectors rely for large gene reconstitution is tissue
dependent, as discussed below.
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2.2.3. Hybrid Dual AAV Vectors
To overcome the main limitations of the previously described platforms (i.e., the lack of
preference for directional tail-to-head concatemerization of the trans-splicing approach and the
need for optimization of the CDS overlap for each transgene in the overlapping approach), a
third transgene-independent dual AAV approach was developed: the hybrid dual AAV vectors.
This approach is a combination of the trans-splicing and overlapping approaches, as it is based on
the addition of a highly recombinogenic exogenous sequence to the trans-splicing vectors in order to
increase recombination efficiency [24]. This recombinogenic sequence is placed downstream of the SD
signal in the 5’-half vector and upstream of the SA signal in the 3’-half vector, so to be spliced out from
the mRNA after recombination and transcription (Figure 3).
Figure 3. Schematic representation of the hybrid dual AAV approach for large gene reconstitution.
The first vector includes the promoter, the 5’-half of the coding sequence (CDS), the splicing donor (SD)
signal and the highly recombinogenic exogenous sequence (HR); the second vector includes the highly
recombinogenic exogenous sequence, the splicing acceptor (SA) signal, the 3’-half of the CDS and the
polyadenylation signal (PolyA). Joining of the two AAV vector genomes to reconstitute the full-length
gene can occur through either: 1. concatemerization of the two vectors through the inverted terminal
repeats (ITR), as for trans-splicing dual AAV vectors; or 2. homologous recombination mediated by the
region of homology included in both vectors. In both cases, after transcription, splicing leads to the
removal of the junction point, with restoration of the full-length, mature RNA of the transgene.
The hybrid dual AAV approach is potentially more effective than the other dual AAV vector
approaches, since full-length gene reconstitution can occur through both homologous recombination
mediated by the highly recombinogenic exogenous sequence as well as concatemerization through the
ITRs [24]. The recombinogenic sequences used thus far to induce the recombination between hybrid
dual AAV vectors have been derived from regions of either the alkaline phosphatase gene (AP) [24,30]
or the F1 phage genome (AK) [21]. The inclusion of the exogenous sequence allows the promotion
of high levels of homologous recombination between the two vector genomes, independently of
the transgene to be delivered. However, similarly to the trans-splicing approach, the sequences
surrounding the splicing signals still have an impact on splicing efficiency. Thus, careful selection of
the splitting point is recommended to achieve maximal efficacy of large gene reconstitution.
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3. The Choice of the Best Platform for Large Gene Delivery to the Retina
The efficacy of both oversized and dual AAV vectors in the retina has been evaluated in a number
of studies using different reporter and therapeutic genes, such as ABCA4 and MYO7A mutated in
Stargardt disease (STGD1) [31] and Usher syndrome type 1B (USH1B) [32], respectively. However,
literature describing these platforms is often conflicting. Initial studies in the retina reported a better
performance of oversized AAV vectors compared to dual AAV strategies [14,15]. These results,
however, might be due to both design and purification processes, which favor the generation of
oversized vectors with high transduction properties [14], as well as to the less than optimal design
of the dual AAV platform that was used as a comparison. One study, as an example, relied on the
use of overlapping dual AAV vectors with a large region of overlap (1365 bases) that had not been
optimized and, therefore, might potentially have a low efficiency of recombination [15]. Reconstitution
from overlapping dual AAV vectors has also been found to occur at variable levels in different
studies [15,20,21,26,33]. The most critical aspect of an overlapping dual AAV vector strategy is the
event of recombination between the two halves of the transgene. This is influenced by both the
sequence of the transgene and the cell type that is targeted, since different cell types could possibly
deploy different DNA repair mechanisms. Some studies have found that long regions of overlap
may lead to higher levels of transgene reconstitution [26]. However, it has recently been shown
that optimization of the overlapping region is a prerequisite to achieve sustained levels of transgene
expression in photoreceptors, since the efficiency of reconstitution is not directly proportional to the
length of the regions of overlap [33]. It has been suggested that if the regions are too short, they might
not be able to efficiently mediate interactions with the opposing viral genome, whereas longer regions
of overlap may be less available for such interactions due to secondary structure formation. In line
with this hypothesis, a screening of overlapping regions ranging from 23 to 1173 bp identified an
overlap of 207–505 bp as the best performing for overlapping dual AAV-mediated reconstitution of
ABCA4 at therapeutic levels [33]. Thus, optimization of the overlapping region is essential to achieve
sustained levels of transgene expression in photoreceptors. The targeted tissue also plays an important
role in the success of the overlapping dual AAV approach since homologous recombination is typically
associated with dividing cells, while low levels of homologous recombination are found in post-mitotic
cells as neurons [34]. Along this line, studies have reported inefficient transduction of photoreceptors
mediated by overlapping dual AAV vectors [15,21,26], whilst more efficient reconstitution was found
in the RPE [21]. Other groups, however, have found efficient transduction of photoreceptors using
overlapping dual AAV vectors [20,33], highlighting that the identification of highly recombinogenic
regions of overlap in the transgene overcomes the limitations related to the inability of specific cell
types to mediate efficient homologous recombination [33].
More consensus on the efficacy of trans-splicing and hybrid dual AAV vectors can be found in
literature. A number of studies have indeed shown the ability of these strategies to reconstitute large
transgenes in the retina [20,21,26,35,36] at levels which were higher compared to the other dual AAV
strategies tested side by side [20,21,26], and which resulted in improvement of the retinal phenotype of
animal models of IRDs [21,37]. This is possibly due to a more limited requirement of the optimization of
these platforms compared to the others, since joining of the two halves of the transgene, with a discrete
nature, occurs through the ITRs and/or a region of overlap known to be highly recombinogenic. Notably,
the success obtained in the delivery of the large MYO7A gene to the retina [21] has led to the planning of a
Phase I/II clinical trial, which will test the safety and efficacy of the hybrid dual AAV platform developed
in the retina of USH1B patients (https://cordis.europa.eu/project/rcn/212674_it.html). Importantly, the
results of this trial will definitively shed light on the efficiency of dual AAV vectors-mediated large
gene delivery in the human retina.
Prompted by the success shown by dual AAV strategies, researchers have attempted at further
expanding AAV cargo capacity in the retina up to 14 kb by adding a third vector to the dual system,
generating triple AAV vectors [38]. This was found to be achievable, but at the expense of efficiency.
Indeed, the levels of transduction achieved in the retina of a mouse model of Alstrom syndrome with
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triple AAV vectors have led to only a modest and transient improvement of the phenotype [38]. On
the other hand, the levels of transduction mediated by triple AAV vectors in the large pig retina were
found to be significantly higher than in the mouse retina, as also observed with dual AAV vectors [38].
These results bode well for further optimization of this platform.
4. Limitations of Dual AAV Vectors
Currently, all the dual AAV vector approaches have shown similar issues: variable success and
expression of unwanted truncated products from single half-vectors. For all dual AAV platforms to be
successful, a cell must necessarily be co-infected by at least one AAV vector including the 5’- and one
including the 3’-half of the expression cassette. We and others have shown that co-transduction by two
AAV vectors is quite efficient in the small subretinal space [11,21,36], which thus represents a favorable
environment for developing dual AAV vector-based gene therapy approaches.
So far, however, all the studies performed have shown that none of the dual AAV approach
matches the levels of expression achieved with a single AAV vector [21,26,36]. Various strategies have
been explored to increase the efficiency of dual AAV vector-mediated large gene reconstitution.
One option is to increase vector dose and/or use AAV serotypes with higher tropism for the
target cells in order to maximize rates of co-infection by both half vectors. A recent study has,
however, suggested that an increase in vector dose does not proportionally correlate with increased
levels of protein expression in the retina [26]. This suggests that, once efficient co-transduction is
achieved, a further increase in vector genome amounts does not provide significant advantages [26].
Attempts at achieving higher levels of transduction by using alternative AAV serotypes have not
been found consistently to result in higher transduction levels. Some studies have shown that use
of capsid-engineered AAV variants with higher retinal transduction abilities, as tyrosine mutants
capsids [39], led to higher levels of transgene expression from overlapping dual AAV vectors compared
to naturally occurring AAV serotypes [20,33]. However, delivery of hybrid dual AAV vectors using
an in-silico designed, synthetic vector (Anc80L65), which has also been shown to transduce retinal
cells with a higher efficiency than AAV8 [40], led to almost identical levels of protein reconstitution
compared to dual AAV8 vectors [26].
Another approach explored to increase transduction levels from dual AAV vectors has been
maximizing the chances of both trans-splicing and hybrid AAV vectors to generate concatemers
in the productive orientation, by forcing concatemerization of the ITRs, through the use of vectors
carrying heterologous ITRs (i.e., ITR from different AAV serotypes at the opposite ends of the viral
genome) [41]. Indeed, by generating trans-splicing vectors with heterologous ITR from serotypes 2
and 5 it has been shown that it is possible to reduce both the ability of each vector to form circular
monomers and to increase directional tail-to-head concatemerization. This resulted in increased levels
of transgene reconstitution compared to the use of vectors with homologous ITRs [41,42]. However,
we have later shown that inclusion of heterologous ITRs in hybrid dual AAV vectors does not provide
a significant advantage in full-length transgene reconstitution over the use of vectors with homologous
ITRs [37]. This is consistent with the idea that hybrid dual AAV concatemerization is already partially
driven in the correct orientation by the presence of highly recombinogenic regions. An additional
strategy which has been used to direct AAV vectors concatemerization in the proper orientation is
the use of a single-strand DNA oligonucleotide displaying homology to both of the distinct AAV
genomes [43]. Alternatively, strategies that can improve dual AAV vector transduction efficiency by
positively modulating AAV transduction steps, as the delivery of kinase inhibitors along with AAV
vectors, have also been tested [44].
Another major drawback of dual AAV vectors, observed in some studies, is the production of
truncated protein products from each of the single AAV vectors [20,21,33,37]. We and others have
shown that, both in vitro and in the retina, truncated proteins from the 5′ half vector that contains the
promoter sequence and/or from the 3′ half vector, due to the low promoter activity of the ITR, are
produced. This issue can however be efficiently overcome by the use of the CL1 degron, a C-terminal
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destabilizing peptide that shares structural similarities with misfolded proteins and is thus recognized
by the ubiquitination system [45,46]. Inclusion of this short (16 amino acids in length) degron mediates
selective degradation of the truncated product from the 5′ half vector [37], without either affecting
full-length protein reconstitution or significantly reducing the packaging capacity of the platform.
More recently, McClements et al. have shown how the design of dual AAV vectors can also influence
production of truncated proteins by the generation of unintended cryptic translation start sites and/or
polyA signals [33]. Thus, the design of these platforms requires multiple considerations and adaptation,
which may include codon optimizations to remove cryptic genetic signals. Furthermore, given the
expression of such unwanted protein products, confirmation of the safety of dual AAV vectors is an
important open question. While our preliminary data have shown no evident alterations of retinal
morphology and functionality in mouse and pig eyes injected with dual AAV vectors [21,37], formal
toxicity studies are required to elucidate this aspect.
5. Alternative Strategies to Allow AAV-Mediated Large Gene Delivery
Additional strategies to deliver large transgenes via AAV vectors are being actively investigated.
Attempts at identifying AAV vectors with expanded cargo capacity, based on either protein libraries and
directed evolution [47] or site directed mutagenesis to add positively-charged residues at lumenally
exposed sites within the capsid [48], have been described. Alternatively, it has been shown that
oversized AAV2 vector genomes can be effectively packaged in the capsid of human Bocavirus 1
(HBoV1) [49,50], an autonomous parvovirus relative of AAV, with a 5.5 kb genome. Testing of these
vectors in the retina might lead to the identification of novel suitable vectors for large gene delivery.
The development of different short regulatory elements has also been attempted to reduce the
size of the expression cassette and allow delivery of transgenes that exceed the AAV packaging
capacity [51–55]. However, this often led to reduced levels of transgene expression. The combination
of short synthetic enhancers and promoters was found to be useful for providing increased levels of
expression of large transgenes [56]. Other studies have however shown that, despite optimization,
some transgenes were more difficult than others to reconstitute from oversized AAV vectors when
using short promoters [57].
The use of cDNA encoding for truncated versions of large proteins, which retain their functionality
(i.e., a minigene), has also been achieved with some success [58]. However, all these approaches still
cannot be easily applied to a large number of genes that exceed the AAV cargo capacity, since extensive
optimization and testing would be required for each one of them.
6. Conclusions and Outlook
The growing number of clinical trials that show good safety and efficacy of the subretinal delivery
of AAV vectors are contributing to the establishment of AAV as vectors of choice for retinal gene
transfer. Expanding AAV cargo capacity over 5 kb is however a prerequisite to allow this platform to be
used as a tool for the efficient delivery of a larger number of therapeutic genes. Recent proof-of-concept
studies that used dual and triple AAV vectors to deliver large genes to the retina have shown that it is
feasible to transfer genes with a CDS larger than 5 kb. Yet, these studies have highlighted that there
is no one-fits-all dual AAV vector system, since dual AAV approaches have shown different relative
efficiency in different studies. Clearly, the tissue being targeted, as well as the transgene that needs
to be delivered, drastically influences transduction efficiency. Thus, careful design of the platform
for each therapeutic application is required to achieve maximal efficacy. The planned clinical trial
for USH1B will help defining whether the levels of expression achieved with dual AAV vectors are
therapeutically relevant in humans. While the need of manufacturing two or more vectors to treat each
disorder might represent a challenge of dual/triple AAV platforms, yet the retina is a favorable tissue
for development of these approaches due to the fact that it requires delivery of only a small amount of
vector. This reduces the total amount of vectors that needs to be produced.
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Retinal transduction with multiple AAV vectors has been shown to reach lower levels compared
to a single AAV vector. These levels were not sufficient to result in therapeutic efficacy for some
diseases [38]. Consequently, alternative strategies should be explored.
Systems that rely on mechanisms different than those exploited by dual AAV vectors for large gene
reconstitution might be investigated, including trans-splicing of pre-mRNAs [59] or intein-mediated
protein trans-splicing [60]. Genome editing is also a rapidly expanding field of research, and could
represent an interesting option for correction of mutations in genes whose delivery through AAV
vectors is precluded by the large CDS size. A number of aspects for this approach however still need to
be further explored. First, in the retina, where homologous recombination occurs at low rates, genome
editing tools for the precise correction of a mutation will most probably need to exploit alternative
repair mechanisms such as non-homologous end joining used for homology-independent targeted
integration [61]. The efficiency of such approaches in the retina is still unknown. Secondly, the delivery
of genome editing tools in post-mitotic tissues, such as the retina, might not be as safe as delivery in
more proliferative tissues, considering the fact that their expression will persist long term after a single
subretinal injection.
In conclusion, important steps forward have been made towards the treatment of IRDs due
to mutations in large genes, which now seems an achievable goal. The optimization of these and
the newly emerging platforms will allow expansion of the number of IRDs that are treatable using
AAV-mediated gene therapy.
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Abstract: Advances in molecular research have culminated in the development of novel gene-based
therapies for inherited retinal diseases. We have recently witnessed several groundbreaking clinical
studies that ultimately led to approval of Luxturna, the first gene therapy for an inherited retinal
disease. In parallel, international research community has been engaged in conducting gene therapy
trials for another more common inherited retinal disease known as choroideremia and with phase III
clinical trials now underway, approval of this therapy is poised to follow suit. This chapter discusses
new insights into clinical phenotyping and molecular genetic testing in choroideremia with review
of molecular mechanisms implicated in its pathogenesis. We provide an update on current gene
therapy trials and discuss potential inclusion of female carries in future clinical studies. Alternative
molecular therapies are discussed including suitability of CRISPR gene editing, small molecule
nonsense suppression therapy and vision restoration strategies in late stage choroideremia.
Keywords: choroideremia; gene therapy; REP1; inherited retinal disease; treatment
1. Introduction
Choroideremia is a rare X-linked recessive inherited retinal disease caused by sequence variations
or deletions in the CHM gene which are usually functionally null mutations, leading to deficiency in
Rab escort protein 1 (REP1) [1–3]. The estimated prevalence is 1 in 50,000 males. Although REP1 is
expressed ubiquitously, in humans choroideremia appears only to affect the retinal pigment epithelium
(RPE) layer of the eye, leading to a characteristic clinical phenotype of progressive centripetal retinal
degeneration. In Ancient Greek, the name choroid derives from χóριoν (khórion, “skin”) and εἶδoς
(eîdos, “resembling”). The suffix ‘eremia’ (ἐρημία) was added to describe the barren appearance (from
the root word meaning wasteland or desert). Hence the literal translation of choroideremia is, in relation
to the eye, ‘the skin-resembling part is deserted’. Interestingly, the incorrect spelling ‘choroideraemia’
has been used previously, but this may be based on misinterpretation of the suffix being derived from
αἷμα (haima, blood), into which the ‘ae’ diphthong is still substituted in many non-US English usages.
Importantly however, despite reference to the choroid in the name, the disease is now known to be
driven primarily by the loss of the RPE, followed by the secondary degeneration of photoreceptors
and choroidal atrophy [4]. Recent evidence has shed light on the molecular mechanisms of REP1
contribution to retinal degeneration in choroideremia, describing its essential role in post-translational
modification of proteins and in intracellular trafficking of molecules [5]. The process affects primarily
the RPE and pigment clumping is the first sign, long before photoreceptor loss. However, since the
RPE has an essential role in retinal isomerization in the visual cycle which is more important for rod
compared to cone function and hence rod function is impaired quite early in the disease process.
As a result, the disease presents with early childhood nyctalopia, but the majority of patients retain
excellent visual acuity until the very end stages of disease, presumably because Müller cells can still
contribute to the cone visual cycle in the absence of RPE [6–8].
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In this chapter we review advances in molecular therapies that have resulted in the development
of adeno-associated vector (AAV) gene replacement therapy for choroideremia. The therapy is
currently being explored in multiple clinical trials worldwide, having recently reached phase III in
the development (Table 1). We discuss new insights into the clinical phenotyping and genotyping of
choroideremia male patients and female carriers, including progress from the natural history studies,
that will aid disease characterisation, monitoring of disease progression and interpretation of clinical
trial endpoints. The review discusses current knowledge and progress in molecular mechanisms of
choroideremia and the development of emerging potential therapies.
Table 1. Summary of interventional gene therapy clinical trials in choroideremia.
















































































































No reports to date
2. Choroideremia Phenotype
Choroideremia manifests with a pathognomonic fundus appearance characterised by progressive
degeneration of retina and choroid (Figure 1). The degeneration starts in a ring around the mid-periphery
of the retina and expands both centripetally towards the fovea and anteriorly to the pars plana [7,15,16].
The anatomical changes are accompanied by loss of functional scotopic vision and the reduction of the
mid-peripheral visual field that begins during the first and second decade of life. The visual acuity is
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generally well preserved until late in the disease process, usually until the fifth decade of life, when the
degeneration starts to encroach onto the fovea [6–8,15,16].
It remains somewhat unclear whether the RPE, the retina and the choroid are all primarily affected,
or whether one or more of these tissues is secondarily affected during the pathogenesis of choroideremia [4].
There is however mounting indirect evidence that the RPE is the primary site of the disease in
choroideremia, with the inner (photoreceptor) and outer (choroidal) layers degenerating through
secondary mechanisms [5]. The unique pattern of preserved retina and RPE, as seen on autofluorescence
imaging (Figure 1), with sharply demarcated edges is very different from many other retinal diseases
where preserved regions are more circular or oval. This appearance is, however, almost identical in
dominantly inherited RPE65 retinal diseases. Since RPE65 is only expressed in the RPE, we know that
this phenotype is a feature specific to the RPE (presumably, RPE cell death), giving indirect evidence
that choroideremia is a disease driven by RPE loss. The confounding variable in choroideremia is
that the REP1 protein is expressed throughout the body [17] and the name ‘choroideremia’ gives the
impression that this is primarily a choroidal degeneration. This is not the case, however, because any
disease or treatments such as cryotherapy that destroys the RPE layer alone, will eventually lead to
secondary atrophy of the underlying choroid, in a similar manner. In other words, choroideremia is the
phenotype of complete RPE cell loss. The other relevant factor is that male patients with choroideremia
can develop choroidal new vessels (Figure 2) and this clearly shows that the choroidal vasculature
has the capacity to regenerate in certain cases. Finally, we know from female carriers (Figure 3) that
the pattern of RPE loss is very similar to that in carriers of ocular albinism. There is no evidence of X
inactivation leading to patchy loss of the choroid independently in female carriers.
Figure 1. Retinal imaging in choroideremia. Widefield optomaps, Optos, Dumfernline, UK (A,B) and
Heidelberg Spectralis imaging, Heidelberg, Germany (C–F) showing choroideremia phenotype in
an affected male. Colour fundus photographs (C,D) show extensive retinal degeneration with choroidal
atrophy and visualisation of underlying pale sclera. Fundus autofluorescence (E,F) shows typical
patterns of sharply demarcated areas of remaining tissue (hyperfluorescent) against atrophic retina
(hypofluorescent background). Mesopic microperimetry, MAIA CenterVue SpA, Padova, Italy (G,H)
measures central retinal sensitivity that closely maps areas of residual retina as seen on autofluorescence.
Sensitivity maps are shown with corresponding histograms of threshold frequencies. Spectral domain
optical coherence tomography, Heidelberg, Germany (I,J) shows retinal structure in cross-section with
distribution of ellipsoid zone (yellow line) and preserved inner retinal layers.
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Figure 2. Retinal imaging in a choroideremia patient showing an area of scaring from an old choroidal
neovascular membrane in the left eye. Fundus autofluorescence (A,B), fluorescein angiography (C,D),
indocyanine green angiography (E,F) and spectral domain optical coherence tomography (G) with
arrows marking the old scar. Imaging was performed with Heidelberg Spectralis, Heidelberg, Germany.
It is also possible that REP1 expression may be important for rod photoreceptor function [18].
Processing of post-mortem tissue from patients can make histological analyses difficult, and studies
using advanced imaging techniques have provided somewhat equivocal results in terms of evidence
of independent rod degeneration in humans in areas of the retina where the underlying RPE cells are
unaffected by the disease [6,8,18–20]. Since patients with choroideremia maintain excellent visual acuity
until the very late stages of the disease [6–8], it is likely that the REP1 deficiency is not a significant
factor for the cone photoreceptors.
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Figure 3. Retinal imaging in two female choroideremia carriers. Phenotype of an asymptomatic
mild carrier with Snellen visual acuity of 6/5 in both eyes is shown from (A–F) and a carrier with
a ‘geographic-pattern’ phenotype and reduced visual acuity of 6/7.5 in the right eye and 6/12 in the left
eye is shown from (G–L). Fundus autofluorescence showing very early signs of fine ‘salt and pepper’
mottling (A,B) compared with coarse mottling and atrophic patches resembling geographic patterns
(G,H). Mesopic microperimetry, MAIA CenterVue SpA, Padova, Italy showing sensitivity maps with
corresponding histograms of threshold frequencies. Near-normal central retinal sensitivity is found in
mild, asymptomatic carriers (C,D) compared to reduced retinal sensitivity in affected carriers especially
in the left eye of the above case (I,J). OCT imaging is clinically insignificant in mild, asymptomatic
carriers (E,F) whereas some disruption of retinal pigment epithelium (RPE) and ellipsoid zone is
observed in the affected carrier, particularly in the left eye (K,L).
Elucidating the pattern of degeneration in choroideremia may help us understand the basis of
the disease and how it progresses [16]. It is not known why the degeneration in choroideremia starts
in the equatorial region before spreading anteriorly and posteriorly to reach the macula. The retinal
pigment epithelial cell density is roughly similar at 5000 cells per mm2 throughout the posterior
eyecup. Gyrate atrophy of the choroid however may develop in a similar distribution, although this is
in contrast to age-related macular degeneration, which is very much focused in the region around
the fovea. In a recent study it was shown that the rate of degeneration in choroideremia followed
an exponential decay function and was very similar across patients of different ages [21], but the key
factor that determined the severity of the disease was the age of onset of degeneration. It may therefore
be possible to predict the severity of the disease simply by measuring the residual area in a patient at
a given age, because the progression is likely to be constant in the absence of treatment.
The centripetal degeneration in choroideremia has two phases by fundus autofluorescence-mottled
RPE up to the edge and a more central zone of smooth RPE, both of which shrink progressively. In more
advanced stages of the disease there is a total loss of smooth zone. The anatomical basis for these two
zones is not immediately clear, but it may be that the slightly increased RPE cell density and much
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thicker choroid at the posterior pole provides some degree of protection against the metabolic stress
caused by REP1 deficiency. Recent evidence suggests that there is less preserved autoflourescence area
in nasal macula that may be more vulnerable to degeneration [16]. Further studies are necessary to
determine whether the RPE zones can predict the health status of the overlying photoreceptors and
how these might be affected following treatment.
3. Choroideremia Genotype
The choroideremia gene, CHM (OMIM #300390), encodes the REP1 protein, a 653 amino acid
polypeptide essential for intracellular trafficking and post-translational prenylation of proteins within
the human eye. Currently, there are 346 mutations registered on Leiden Open Variation Database,
LOVD3 (www.lovd.nl/CHM). Almost all of the identified sequence variations regardless of mechanism,
are predicted to be null [3,22–25]. The mechanisms include insertions and deletions (minor, a few
nucleotides, and major involving up to the entire gene length), splice site mutations, missense changes
and point mutations that result in stop codons (premature termination codons). Novel mutations
have recently been identified involving a deep-intronic region [26] and a promoter region [27] of the
CHM gene.
Compared with other genetic diseases including inherited retinal disease, choroideremia has
a surprisingly low number of disease-causing missense mutations. This would suggest that the REP1
protein, with 3 principal domains, has no catalytic domains with corresponding mutational hotspots
within the gene. This is in contrast to genes that encode enzymes (such as retinitis pigmentosa GTPase
regulator gene) that typically have such hotspot regions (e.g., ORF15 region). This supports the role of
REP1 as a chaperone protein, enhancing activity of another protein, which is important in cell structure
and stability.
Recent evidence shows that the majority of missense mutations are disproportionately found
to be single point C to T transitions at C-phosphate-G (CpG) dinucleotides, spread across 5 of only
24 CpG dinucleotides in the entire CHM gene [25]. This is consistent with the evolutionary loss of CpG
dinucleotides through destabilising methylation and subsequent deamination. Notably, the 5 locations
were the only sites at which C to T transitions resulted in a stop codon. Future de novo mutations are
likely to arise within these destabilised hotspot loci.
Molecular genetic testing offers means of confirming the clinical diagnosis in choroideremia and is
mandatory for the inclusion in gene therapy clinical trials. It also offers a means of identifying carriers
and establishing presymptomatic diagnoses in families that carry a pathogenic change. The rate of
mutation detection via next generation sequencing has been reported as high as 94% [25]. In cases of
unidentified mutations, it is important to request sequencing of the above mentioned deep-intronic
and promoter regions, that are not routinely sequenced, to check for pathogenic variations. In addition,
functional in-vitro assay that measure levels of REP1 in peripheral blood cells and its prenylation
activity [17], can support clinical diagnosis and confirm variants of uncertain pathogenicity. In this
regard, choroideremia is different to retinitis pigmentosa, because the unique choroideremia phenotype
can justify the additional resources needed to sequence the entire CHM genomic region.
3.1. Genotype–Phenotype Correlation in Choroideremia
Although the clinical phenotype can vary in terms of the age of onset of retinal degeneration and
rate of progression, no evidence has been found for genotype–phenotype correlation with regard to
onset of symptoms, decline in visual acuity and visual fields [23–25], or in the residual retinal area of
fundus autofluorescence [25]. The reasons for this are not fully understood, but the lack of correlation
may be due to the near universal absence of REP1 irrespective of the causative mutation that range from
single point missense changes to whole gene deletions. The phenotypic variation in choroideremia
may in part be explained by the degree to which the absence of REP1 can be compensated by other
prenylation proteins such as REP2, which shares 95% of its amino acid sequence with REP1 [26,27].
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In addition, genetic modifiers and environmental factors may play roles in the onset and progression
of degeneration in choroideremia.
3.2. Molecular Mechanisms of Choroideremia
The molecular mechanisms involved in the pathology of choroideremia have recently been
reviewed in great detail [5]. However, some basic concepts are worth re-stating and outlining to aid
understanding of the disease. The gene that is disrupted in choroideremia produces REP1 protein.
Unlike in many other inherited retinal diseases, this protein is not directly involved in the process
of phototransduction or in cellular signalling within the retina. Instead, REP1 is a key player in the
addition of prenyl groups (prenylation) to the Rab family of GTPases (Rabs). Such hydrophobic
prenyl groups are thought to be necessary to anchor Rabs to the membranes of intracellular organelles
and vesicles [28].
In the absence of REP1, there is an observable deficit in the prenylation of several different
types of Rabs, and their association with membranes appears to be impaired [29]. Because Rabs
themselves act as important regulators of intracellular membrane trafficking, many fundamental
cellular processes can potentially be impacted by this deficit. Information from a variety of sources
points to a deficit in melanosome trafficking, a delay in phagosome degradation and an accelerated
accumulation of intracellular deposits in RPE cells caused by loss of REP1 [4,18,30–33]. The cellular
deficits of photoreceptors themselves have been less studied, but it has been suggested that there is
mislocalisation of opsin and shortening of photoreceptor outer segments in mice that is independent of
RPE degeneration [4].
Fortunately, the absence of REP1 does not appear to be catastrophic for all human cells, which is
likely due to the fact that there is a built-in redundancy in this system, provided by the presence of
the CHML gene [34,35]. The CHML gene is thought to be an autosomal retrogene of CHM, created
by the reverse transcription of the mRNA of the original gene and reinsertion in a new genomic
location that occurred sometime during vertebrate evolution. The protein product of CHML, known as
REP2, appears to be able to largely compensate for the loss of REP1. Although a prenylation deficit of
certain Rabs can be detected in several cell types of the body [29,36,37], a single report of a systemic,
blood-related, clinical phenotype have not been substantiated [38,39] and loss of REP1 appears to
cause cellular dysfunction and death that is limited to specific ocular tissues and manifest as a specific
disease of the retina. Differential spatial expression does not provide an obvious answer, as both REP1
and REP2 are expressed ubiquitously.
In truth, the reason why absence of REP1 drives a specific degeneration of the RPE and
photoreceptor cells remains a mystery. Perhaps more than other cell types, RPE and photoreceptor
cells require acute and sensitive regulation of intracellular membrane trafficking to fulfil their cellular
functions. Combined with the fact that there is not any appreciable post-natal replacement of these
cells, it may simply be that these cell types are sensitive to the generalised, ongoing prenylation
deficit, become ‘worn-out’ early than usual, and undergo a type of accelerated aging and cell death.
Alternatively, it has been proposed that REP1 has a selective affinity to particular Rabs that are of
special significance to the cell types affected in the disease. For example, it has been suggested there is
a particular requirement for correctly prenylated Rab27a to mediate melanosome trafficking in RPE
cells [29,40] and Rab6, 8 and 11 might be important in targeting rhodopsin-bearing vesicles to the
photoreceptor outer segment [41,42]. Biochemical assays have suggested that REP1and REP2 have
largely overlapping substrate specificities but differences in the association with other catalytic units
within the prenylation process might contribute instead [43–45].
3.3. Gene Therapy for Choroideremia
Gene based therapies show great promise for the treatment of inherited retinal disease, including
choroideremia [46]. Recent advances have paved a successful progression of gene therapy clinical trials
on choroideremia (Table 1). The first phase I/II trial started in Oxford, UK in 2011, using a subretinal
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delivery of AAV2-REP1 in 14 male patients with choroideremia [9,10]. The two-year trial results were
recently reported [11] with median gains in visual acuity (measured by Early Treatment Diabetic
Retinopathy Study, ETDRS chart) of 4.5 letters in treated eyes versus 1.5 letter loss in untreated
eyes across the cohort at 24 months post treatment. Six treated eyes gained more than 5 ETDRS
letters. In two patients with the greatest gains in visual acuity, improvements were noted by
6 months post treatment, and sustained at up to 5 years of follow-up. Two patients in the cohort
had complications, one related to surgery (retinal overstretch and incomplete vector dosing) and
the other had postoperative inflammation. Both of these events resulted in protocol changes which
included developing an automated subretinal injection system and a more prolonged post-operative
immunosuppressive regimen.
These encouraging safety and efficacy signals prompted additional trials using the same vector
(sponsored by Nightstar Therapeutics, UK) at other international sites including Canada (NCT02077361),
USA (NCT02553135) and Germany (NCT02671539) all reporting similar results [12–14], following
which a phase III trial started in 2017 at multiple international sites. Independent to the Nightstar
led trials, another phase I/II trial (NCT02341807) using a similar AAV vector construct (without the
woodchuck hepatitis virus posttranscriptional regulatory element) begun in 2015 in Philadelphia, USA.
The results of this trial are expected in the coming years.
The above-mentioned early phase I/II gene therapy clinical trials recruited patients with advanced
disease with early efficacy signals suggesting that vision can be restored following treatment. Reassuring
safety data, following improvements in the surgical technique, prompted initiation of a phase II
trial (NCT02407678) sponsored by University of Oxford that included patients with early central
degeneration and normal visual acuity. The REGENERATE trial recently completed recruitment of
30 male patients with choroideremia with prediction that earlier intervention might slow down or halt
the degeneration prior to irreversible structural disorganisation.
The solstice study is an observational, long-term follow up study of 100 participants that will
evaluate the safety and efficacy of the AAV2-REP1 used in the above-mentioned interventional
choroideremia trials.
The outcomes of clinical trials are measured in terms of clearly defined clinical endpoints,
which predict the success and ultimately the approval of new treatments. These outcomes must be
selected carefully to capture the most sensitive and reliable measures of the disease progression during
the course of a clinical trial and will critically depend on the stage of retinal degeneration. In the
reported choroideremia trials, the primary endpoint was the change from baseline in best-corrected
visual acuity (BCVA) in the treated eye compared to the untreated eye with evidence of gains in
vision after gene therapy in treated eyes. This suggests that BCVA can be used as a viable primary
outcome in cases of advanced choroideremia, where disease process has already affected the visual
acuity. Indeed, the phase III STAR trial is using BCVA as a primary outcome measure. However,
in patients with early disease stage with near-normal vision, BCVA may not be the most sensitive
outcome measure, especially since the visual loss in choroideremia typically progresses very slowly.
Thus, for the REGENERATE trial, secondary endpoints including the measure of central visual field
by microperimetry and anatomical measures such as fundus autofluorescence and optical coherence
tomography may prove to be additional valuable outcomes. However, measurements of these
secondary outcomes may not always be straightforward, and need to be interpreted with caution. For
example, the remaining autofluorescence area may not be easily demarcated, even with the use of
automated algorithms, which may influence area measurements especially following sub-retinal gene
therapy which may differentially affect central (para-foveal) and peripheral areas of the treated island.
4. Should We Treat Female Carriers in the Future?
Heterozygous female choroideremia carriers often show generalized RPE mottling due to random
X-inactivation (Figure 3A–F) and are usually asymptomatic or show early deficits in dark adaptation.
In some carriers a coarser pattern of degeneration is seen, with patches of atrophy interspersed with
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normal tissue (Figure 3G–L). Usually, a mild reduction in retinal function is observed with this carrier
phenotype. Occasionally, however, female carriers manifest with more severe male-like pattern of
retinal degeneration with associated deficit in visual function [47]. This is most likely the result of
skewed X-inactivation, or the proportion of cells expressing the mutant X chromosome, which occurs
during early retinal development.
Choroideremia gene therapy trials are currently including affected male subjects only. For the
majority of female carriers who are mildly affected and asymptomatic or have minor deficits in night
vision or visual fields, treatment may not be necessary. Such functional deficits are usually slowly
progressing with the majority of cases being able to maintain driving standard vision. However,
the more severe female carrier phenotypes, with associated visual field loss and reduction in visual
acuity, are likely to benefit from gene therapy and could be included in future clinical trials. Careful
characterisation and geneotype-phenotypes correlations will help with the inclusion criteria and give
insight into the optimal timing for successful gene therapy.
5. Alternative Therapies
The potential therapy that has been discussed in this review is gene replacement/augmentation
therapy. This is the therapy that has advanced the furthest clinically but there are other potential
therapies worth considering.
Instead of adding a working copy of the CHM gene, it may instead be possible to alter the patient’s
own copy with gene editing. Techniques to achieve this, such as zinc finger nucleases or Tal-effector
nucleases (TALENs), have existed for some time, but the clinical relevance of these techniques has been
somewhat limited by the low editing efficiencies generally achieved. The development of CRISPR/Cas
(clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9) technology
has given gene editing a renaissance for two reasons. Firstly, gene-editing efficiency appears to be
generally better, with the potential to be more clinically meaningful. Secondly, in the CRISPR/Cas9
system, most of the investigational medicinal product can remain the same and only a specific RNA
guide sequence needs to be developed to target a site within the disease specific gene—this is more
attractive in terms of a clinical development pathway. Gene editing therapy is most useful when there
is a need to correct or silence a mutated gene, such as when a missense mutation leads to production of
dominant negative or toxic gain-of-function protein, which normally manifests as autosomal dominant
and semi-dominant disease [48]. Because the vast majority of mutations in choroideremia are effectively
null and therefore result in no detectable protein [24] there is no compelling need to develop a gene
editing approach, and simply adding a correct copy as an episomal transgene would be sufficient to
result in a therapeutic effect. Correcting the genomic copy of the gene might provide higher confidence
of a correct and sustained level of expression, given that the gene would be subject to regulation by
its normal transcriptional regulation and epigenetic environment. However, there is evidence that
expression from a transgene can be sustained for years when using the appropriate delivery vector
and expression cassette [49]. For choroideremia, there is no cell type in which ectopic expression
may be predicted to cause a problem, as the protein in normally ubiquitously expressed. In terms of
the level of expression, we know that the level of restored REP1 expression is inversely proportional
to the prenylation deficit, and so far there is no evidence of overexpression causing toxicity [50].
Although it may be theoretically possible to develop a gene editing approach for some mutations
that cause choroideremia, using CRISPR/Cas9, the effectiveness of such strategies has not yet been
well established in the retina. Therefore, as gene editing might offer only marginal benefits over gene
replacement, it is not currently an attractive strategy of treating choroideremia.
Another therapy that has been suggested and developed is the use of drug-stimulated translational
read-through (RT) of premature termination codons (PTC). Nonsense mutations arise when a point
mutation converts an amino-acid codon into a PTC that can cause premature translational termination
of the mRNA, and subsequently inhibit normal full-length protein expression. Occasionally, instead
of translational termination, read-through occurs. Here, a partial mispairing of codon–anticodon is
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successful, an amino acid is incorporated and protein synthesis continues. Small molecule translational
read-through inducing drugs (TRIDs) exist that form the basis of the proposed therapy [51]. Nonsense
mutations are the cause of choroideremia in over 30% of patients [52], so, although this will not be
appropriate for all patients, there is a significant proportion in which it might be used.
Translational read-through inducing drugs have been used in clinical trials for life-limiting
congenital diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis. Early trials
appeared to successfully suppress premature stop mutations in patients, but there were concerns over
toxicity and the need for repeated intramuscular or intravenous dosing. A newer read-through drug,
Ataluren (PTC124), showed a good safety profile when administered orally and the clinical benefit
shown in DMD has led to its approval in the EU for this disease [53]. Although no adverse effects have
been observed so far, even the approximately 48 weeks of administration given in the clinical studies
do not approach the decades of treatment that would be necessary for choroideremia. Preclinical work
in the lower-vertebrate, zebrafish model has been important in developing the proof-of-concept, as
this is currently the only existing model of choroideremia with a nonsense mutation [54,55]. However,
absence of the CHML (REP2) gene in zebrafish means that the CHM mutation is lethal—-translational
read-through inducing drugs increase the lifespan of the zebrafish model but this is outcome is not
directly clinically relevant. The ability of TRIDs to rescue the Rab prenylation defect in fibroblast of
a patient with a particular choroideremia nonsense mutation is encouraging, despite the fact that
levels of full-length REP1 protein remained below the level of detection [55]. Given the relatively slow
disease progression and the potential risks and cost to the patient from long-term administration of
TRIDs, it would be judicious to establish that the correction of the prenylation deficit by TRIDs is
present in fibroblast from patients with the equivalent nonsense mutations in which treatment will be
attempted in any clinical study [56].
It might be argued that systemic or ocular administration of TRIDs has the potential to treat
a larger area of retina when compared to gene therapy, as the former might spread by local diffusion
while the latter is limited by the extent of the subretinal bleb. However, to our knowledge, the local
concentration achieved in the posterior segment of the eye has never been measured when TRIDs
are taken orally or administered locally. The effect of TRIDs appears to often follow an inverted
u-shaped dose-response curve, so the pharmacokinetics of therapy may be critical important [57].
Until such questions are addressed, it would appear that translational read-through inducing drugs do
not represent a superior strategy compared to gene replacement therapy.
Recent work has identified that antisense oligonucleotides (AONs) may also provide another
potential therapy for choroideremia [58]. In some cases of choroideremia, deep-intronic mutations
can create a cryptic splice acceptor site that results in the insertion of a pseudoexon in the CHM
transcript. This disrupts gene function, and specific AONs can be designed to bind to the pre-mRNA
and redirect the splicing process, potentially returning it to a normal, working transcript [59,60].
For choroideremia, AONs therapy has shown some promising in vitro results but is further along the
clinical development pathway for several inherited disorders, including other forms of inherited retinal
dystrophy [59,60]. As AON therapy relies on particular types of mutations, it will not be relevant for
all cases of choroideremia and such a strategy is most attractive when conventional gene replacement
therapy is not possible because of the large size of the coding sequence of the genes involved, such as
in CEP290-associated Leber congenital amaurosis [59,60].
The therapies above aim to slow down or stop the degeneration of the retina and RPE and are
obviously the preferred choice. However, it is also worth considering strategies that might restore
vision in the late stages of the disease, when the majority of photoreceptors have already been lost.
Cell transplantation is an interesting strategy for the treatment of inherited retinal disease, but this might
present a significant challenge in late-stage choroideremia, where RPE and choroid have been lost along
with the degenerating photoreceptors. A more feasible approach may be to use some form of retinal
prosthesis. Although most systems rely on surviving inner retinal layers, with intact ganglion cell nerve
conduction, there is no dependence on survival of the RPE, photoreceptors or choroid. The Argus II
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retinal prosthesis, an epiretinal device approved for commercial use in advanced retinal degeneration
in the EU and USA, has been implanted in at least one patient with choroideremia [61]. This device has
a very good safety profile and various improvements in visual function have been reported, although
these vary widely between individuals [62]. Other devices exist or are in development (44-channel
suprachoriodal Bionic Eye Device (NCT03406416) Melbourne, Australia and Intelligent Retinal Implant
System, IRIS V1 (NCT01864486) and V2 (NCT02670980) Pixium Vision SA) that could theoretically
restore much greater levels of visual function than the Argus II, however, stopping cell loss, even at
a late-stage will likely still result in a better functional outcome. Another potential therapy to restore
vision in choroideremia is to render the remaining cells of the retina sensitive to light by ectopically
expressing light-sensitive ion channels or opsins. This strategy, known as optogenetics, has its own
considerations and challenges, which will not be discussed extensively here. Suffice to say, a number
of systems are in various stages of pre-clinical development and are beginning to be investigated in
clinical trials [63–65]. Again, the level of vision that can be restored by this method is likely to be
relatively crude, however, this is likely to be comparable to any retinal prosthesis and may offer specific
benefits such as less invasive surgery and potential restoration of a wider visual field.
6. Summary
Molecular mechanisms in choroideremia are well established. Ultimately, the absence or reduced
prenylation of REP1 activity disrupts intracellular trafficking pathways leading to accumulation of
toxic products and premature degeneration of the retina and vision less. Logically then, replacement
of REP1 to the retinal tissue, via gene-based therapy, could restore cellular function and slow down
the degeneration. Multiple clinical trials are underway testing this hypothesis. The trials are using
subretinal delivery of AAV2-REP1 to target surviving central islands of the retina with promising
safety and early efficacy results.
Despite ubiquitous expression of REP1, a robust systemic association with choroideremia has
not been identified, although the prenylation defect is visible in assays of the peripheral blood cells.
This assay can be used to support the diagnosis of choroideremia. It is not known why the retina
is the only part of the body that becomes clinically affected by the lack of REP1 activity. Moreover,
the complex interactions between different retinal cell types during the pathogenesis of choroideremia
mean that it is difficult to deconvolve the exact order in which RPE, photoreceptors and the choroid
degenerate. It appears likely that the RPE is directly affected by the loss of REP1, and is a key driver of
pathogenesis, but the importance of primary or secondary degeneration of photoreceptors is less clear.
Elucidating these mechanisms may help us to understand what triggers the onset of clinically significant
degeneration and how the rate of degeneration in each cell type might be affected following treatment.
Evidence to date has shown no apparent genotype–phenotype correlation within the spectrum
of reported CHM mutations, with regard to the onset of symptoms and the rate of functional visual
decline. Since variations in male phenotypes cannot be explained by mutations in CHM only, genetic
modifiers or environmental factors must play a role in the onset and progression of degeneration in
choroideremia. Ongoing natural history studies are adding insight into the progression of the disease
and the characteristics of the clinical phenotype that will help to establish the optimal therapeutic
window for choroideremia. Female carriers should be enrolled into natural history studies with aim to
offer gene therapy (under the realm of clinical trials) to those affected by skewed X inactivation.
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Abstract: Mutations affecting the Retinitis Pigmentosa GTPase Regulator (RPGR) gene are the commonest
cause of X-linked and recessive retinitis pigmentosa (RP), accounting for 10%–20% of all cases of RP.
The phenotype is one of the most severe amongst all causes of RP, characteristic for its early onset and
rapid progression to blindness in young people. At present there is no cure for RPGR-related retinal
disease. Recently, however, there have been important advances in RPGR research from bench to
bedside that increased our understanding of RPGR function and led to the development of potential
therapies, including the progress of adeno-associated viral (AAV)-mediated gene replacement
therapy into clinical trials. This manuscript discusses the advances in molecular research, which
have connected the RPGR protein with an important post-translational modification, known as
glutamylation, that is essential for its optimal function as a key regulator of photoreceptor ciliary
transport. In addition, we review key pre-clinical research that addressed challenges encountered
during development of therapeutic vectors caused by high infidelity of the RPGR genomic sequence.
Finally, we discuss the structure of three current phase I/II clinical trials based on three AAV vectors
and RPGR sequences and link the rationale behind the use of the different vectors back to the bench
research that led to their development.
Keywords: Retinitis Pigmentosa GTPase Regulator; gene therapy; adeno-associated viral; Retinitis
Pigmentosa (RP)
1. Introduction
Inherited retinal diseases, most of which are retinitis pigmentosa (RP), affect 1 in 4000 people
worldwide. The hallmark of this heterogeneous group of disorders is premature degeneration of rod
and cone photoreceptors that leads to early vision loss. RP can be inherited as an autosomal recessive,
dominant, X-linked, oligogenic, or mitochondrial trait. X-linked RP is one of the most severe forms of
retinal degeneration and it accounts for 10%–20% of all RP cases [1–3]. To date, only 3 genes have been
identified to be associated with X-linked pattern of inheritance. Mutations in the Retinitis pigmentosa
GTPase regulator (RPGR) gene accounts for over 70% of X-linked RP cases whereas less common forms
of the disease are caused by retinitis pigmentosa 2 (RP2) and 23 (RP23 or OFD1) genes [4,5].
RPGR-related X-linked RP is characterised by severe disease in males with early onset and rapidly
progressing sight loss that leads to legal blindness commonly by the fourth decade of life [2]. The classic
rod-cone phenotype with peripheral pigmentary retinopathy, waxy optic disc pallor and vascular
attenuation makes it often indistinguishable from other forms of RP. Less commonly, a cone-rod
phenotype manifests with early central cone degeneration and accompanying loss of visual acuity.
Female carriers of the RPGR disease are typically asymptomatic with a characteristic phenotype
that manifests as a radial streak pattern originating from the fovea [6,7]. Rarely, however, skewed
X-inactivation leads to more severe male-like phenotype with associated visual impairment [8].
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At present, there is no approved treatment for retinitis pigmentosa caused by mutations in RPGR.
Several treatment options have been under investigation and with the emergence of novel gene-based
therapies for inherited retinal disease, this seems the most logical strategy to develop for the RPGR
disease. Due to its severe phenotype, relatively high incidence and the fact that more commonly
mutated genes such as ABCA4 or USH2A are too large to be packaged into AAV vectors, the RPGR
disease has drawn significant interest amongst scientific and clinical research communities over the last
years. However, due to the inherent instability in the retina-specific RPGRORF15 isoform sequence [9–12]
the production of the therapeutic AAV-mediated RPGR vector has been very challenging. In attempts
to improve the sequence stability and fidelity several approaches have been explored including codon
optimisation [13–15], which has allowed generation of vectors for use in human trials. In this review we
discuss recent advances in the understanding of RPGR gene structure and its evolutionary conservation
that has led to an improved understanding of protein’s molecular function and mechanisms implicated
in the pathogenesis of RPRG-related retinal dystrophy. The pre-clinical development of gene therapy
vectors that has resulted in their progression into three phase I/II clinical trials is covered in detail,
including discussion on three different RPGR cDNA sequences used in the trials.
2. Structure and Function of Retinitis Pigmentosa GTPase Regulator (RPGR)
The human RPGR gene is located on the short arm of the X-chromosome (Xp21.1). The gene
exhibits a complex expression pattern with 10 alternatively spliced isoforms, five of which are protein
coding [16]. The first transcript to be identified in association with X-linked retinitis pigmentosa, was the
constitutive RPGREx1-19 isoform. In humans, the RPGREx1-19 isoform contains 19 exons and expresses
a full-length messenger RNA transcript of 2448 bp, which generates an 815 amino acid sequence that
forms ~90 kDa protein in a variety of tissues [17]. Since this initial characterisation, multiple alternative
transcripts have been identified, including the retina-specific RPGRORF15 variant [10,16,18]. This variant
contains exons 1–14 of constitutive RPGR with the exon ORF15 derived from alternatively spliced exon
15 and intron 15 (Figure 1A). The RPGRORF15 isoform is 3459 bp, encoding a 1152 amino acid sequence
which forms a ~200 kDa protein. As with the widely expressed variant, amino acids 54–367 (exons
3–10) form a regulator of chromosome condensation 1 (RCC1)-like domain. The alternative ORF15
exon consists of a highly repetitive purine-rich sequence coding for multiple acidic glutamate-glycine
repeats. This is followed by a C-terminal tail region rich in basic amino acid residues, called the
basic domain.
The reason for this complex expression pattern of the RPGR protein remains largely unknown,
but may be related to the functional role of its splice isoforms in various cell types. The RPGR protein
is widely expressed in vertebrate tissue including eye, brain, lung, testis and kidney. In the eye, the
two major isoforms, RPGREx1-19 and RPGRORF15 are predominantly localised to the photoreceptor
connecting cilia [19] and less consistently, to the nuclei and photoreceptor outer segments of some
species [20]. The connecting cilium is a critical junction between the inner and outer photoreceptor
segments, controlling the bidirectional transport of opsin and other proteins involved in the
phototransduction cascade and the overall health and viability of the photoreceptors. Attempts
are ongoing to elucidate further the expression patterns of RPGR through evolutionary characterisation
of RPGR domains across species and via molecular interactions of RPGR with other proteins in order
to shed light on the exact role of the RPGR protein.
The RCC1-like domain, present in both major splice forms, adopts a seven-bladed β-propeller
structure and it is strongly conserved across evolution, in vertebrates and invertebrates [9]. This domain
has been implicated in a regulatory role of small GTPases. It is thought to enable RPGR to act as a Ran
guanine nucleotide exchange factor and RPGR has been shown to upregulate the guanine nucleotide
exchange factor RAB8A, associating with the GDP-bound form of RAB8A to stimulate GDP/GTP
nucleotide exchange [21]. The RCC1-like region also interacts with: RPGR interaction protein 1
(RPGRIP1), which links it to the connecting cilium of photoreceptor cells [19]; the lipid trafficking
protein phosphodiesterase 6D (PDE6D) [22]; two chromosome-associated proteins important for the
72
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structural maintenance of chromosomes, SMC1 and SMC3 [23] and two ciliary disease-associated
proteins nephrocystin-5 (NPHP5) [24] and centrosomal protein 290 (CEP290) [25].
 
Figure 1. Retinitis Pigmentosa GTPase Regulator (RPGR) gene structure and splicing variants. (A) Human
RPGR gene exon-intron structure showing the combination of exons 1 to 19 to create the constitutive
protein isoform, and alternative splicing of exon 15/intron 15 that creates the RPGRORF15 variant.
(B) Mouse RPGR gene exon-intron structure showing the combination of exons 1 to 18 to create the
constitutive protein isoform and alternative splicing of intron 14 creates the RPGROFR15 variant.
The retina-specific ORF15 domain is also highly evolutionarily conserved across varied species,
indicating a functional importance (Table 1). However, in contrast to the RCC1-like domain, the ORF15
domain is unique to vertebrates, suggesting a role that is unique to the ciliary-derived photoreceptors
of “simple” vertebrate eyes, compared to the rhabdomeric photoreceptors of “compound” invertebrate
eyes. Hence, the ciliary-based transport of cargoes such as rhodopsin, which is at least 10 times more
abundant in vertebrates than invertebrates, fits with this hypothesis. ORF15 homology and a region of
high AG content of >80% is identifiable in a range of species although the length varies—the mouse
73
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ORF15 is shorter than the human ORF15, Figure 1A). This purine-rich region of ORF15 (97.5% purines
within 1kb in humans) encodes the glutamine-glycine rich domain that ends in a basic C-terminal
domain, which is also highly conserved, suggesting that it constitutes another functional region.
This basic domain, which is unique to RPGRORF15, interacts with at least two proteins, a chaperone
protein nucleophosmin and a scaffold protein whirlin [26]. Neither protein is unique to vertebrate
photoreceptors, but nucleophosmin is present in metaphase centrosomes during cell division, while
whirlin helps to maintain ciliary structures within the eye and ear.
Table 1. Evolutionary conservation of DNA and amino acid sequences of RPGRORF15 variants
across selected species. All data were extracted from NCBI database files with comparisons performed
in Geneious Prime 2017.10.2. For Homo sapiens, details were extracted from gene files NG_009553.1
and 6103 combined with mRNA file NM_001034853.2. * The conserved basic domain of the human
RPGRORF15 coding sequence was used for predictions of ORF15 locations in all other species sequences
by homology alignment. For Mus musculus data, gene files NC_000086.7 and 19893 were aligned with
the basic domain of human RPGRORF15 and the partial sequence file AF286473.1 to identify the predicted
ORF15 variant. For Canis lupus familiaris data, gene files 403726 and AF148801.1 were aligned with the
basic domain of human RPGRORF15 and the partial sequence file AF385629.1. For Pan troglodytes data,
files 4465569 and XM_024352988 were used. For Gorilla gorilla gorilla, files 101149059, the basic domain
of human RPGRORF15 and the partial sequence AY855163.1 were combined. For Macaca mulatta, files
714316, the basic domain of human RPGRORF15 and the partial sequence file AY855162.1 were combined.
Finally, Xenopus tropicalis sequence predictions were achieved from files 733454 and XM_018091818.1.
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The function of the repetitive glutamine-glycine-rich domain itself has been difficult to establish
due to its variable length and relatively poor conservation at the individual amino acid level, although
the overall charge and repeat structure length remain conserved in vertebrates. However, recent
evidence shows that this intrinsically disordered region is heavily glutamylated [27], a post-translational
protein modification that adds glutamates to target proteins to affect their stabilisation and folding.
This process is known to be essential for the function of tubulins in intracellular trafficking [28].
Furthermore, this glutamylation has been shown to be achieved by tubulin tyrosine ligase like-5
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(TTLL5) enzyme, which interacts directly with the basic domain of the OFR15 to bring it into the
proximity of glutamylation sites along the glutamine-glycine-rich repetitive region [29]. The role of the
ORF15 region is of course critically important to photoreceptor function, because otherwise ORF15
mutations would not be pathogenic since the RPGREX1-19 variant is still expressed in these cells. Hence
in-frame deletions in the ORF15 region lead to progressive loss of function as the deletion length
increases [13].
3. Molecular Mechanisms and Pathogenesis of RPGR-Related X-Linked Retinitis
Pigmentosa (RP)
Molecular mechanisms and pathogenesis of RPGR-related X-linked RP have been under
investigation for several decades. The drive to better understand the disease process comes from the
high incidence with mutations in the gene encoding RPGR accounting at least 70% of X-linked RP
and up to 20% of all RP cases [2–4]. Moreover, the disease is associated with one of the most severe
phenotypes among inherited retinal diseases with central visual loss occurring early in adult life [2].
This coupled with the developments in genetic therapies has given impetus to a large number of
studies aimed to uncover the pathogenic mechanisms.
Despite ubiquitous expression of the constitutive RPGR variant in ciliated cells throughout the
body, the RPGREx1-19 has yet to show a firm association with any human disease. The RPGR-related
phenotype seems to be confined to the retina and several studies have established an essential role
for RPGRORF15 in photoreceptor function and survival [10,11]. Genetic studies have shown that
mutations in the RPGRORF15 result in abnormal protein transport across the connecting cilium, which
can lead to photoreceptor cell death [12,30,31]. However, there are reports in the literature that describe
RPGR-related X-linked retinitis pigmentosa syndrome comprising of retinitis pigmentosa, recurrent
respiratory tract infections and hearing loss [32,33]. These findings point to the abnormalities in
respiratory and auditory cilia in addition to the photoreceptors. In addition, as photoreceptors develop
from ciliated progenitors, it has been postulated that the axoneme may play a role in their early
development. Sperm axonemes were thus studies in patients with X-linked retinitis pigmentosa and a
significant increase in abnormal sperm tails was observed [34]. Similar findings have been reported in
another syndromic ciliopathy, the Usher syndrome [35].
Mutations in RPGR account for ~70% of cases of X-linked RP and have been identified across
exons 1–15, yet up to 60% of mutations occur in the ORF15 region [10,30]. The repetitive nature of
the glutamate-glycine region in ORF15 is prone to adopt unusual double helix DNA conformations
or triplexes that are thought to promote polymerase arrest and block replication and transcription.
These imperfections are likely to contribute to genome instability and account for the high frequency of
mutations in this region, known as the mutation ‘hot spot’ of the RPGR. Surprisingly, no disease-causing
mutations have been reported in exons 16–19 [36].
The most common mutations are small deletions that lead to frameshifts followed by nonsense
mutations [30]. Within ORF15, the most common mutations are microdeletions 1–2, or 4–5 bp [10],
that cause frameshifts leading to truncated forms of the protein and in particular, loss of the C-terminus.
Small in-frame deletions or insertions (and missense changes) that can alter the length of ORF15 region
by a few base-pairs (e.g., up to 36, equivalent to 9 amino acids in this population based study [37],
are seemingly well tolerated [38]. Thus, despite being a coding region, this domain has a surprisingly
high rate of tolerable indels within primate lineages, suggesting a rapidly evolving region [9]. However,
recent evidence shows that larger deletions in the ORF15 region significantly affect the degree of
RPGR glutamylation, which may subsequently influence its function and ability to associate with
the cilium and other interacting factors [29]. Thus, frame shift mutations that lead to loss of the
C-terminal basic domain are invariably disease causing [12]. In addition, mutations that lead to the
loss of TTLL5 enzyme, the basic domain-binding partner that mediates RPGR glutamylation, abort
glutamylation process and cause RPGR-like phenotype in humans [39]. This further supports the
critical role of glutamylation in normal RPGRORF15 function. It remains intriguing that despite its
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ubiquitous expression, the RPGREx1-19 is unable to compensate for the loss of function of RPGRORF15
in the retina to rescue the phenotype. It is possible that the alternative splicing in the retina could
favour the RPGRORF15 variant, so the majority of transcripts will be the RPGRORF15 isoform, with
few constitutive variants available to compensate. One study failed to identify the constitutive
transcript in the retina [18], which supports the finding that the constitutive isoform is expressed early
in development in a mouse before its levels decline and the RPGRORF15 becomes the predominant
isoform [26]. Notably, the constitutive variant lacks the glutamate-glycine repetitive region and given
the importance of this domain for the normal function of RPGRORF15 in the photoreceptors, perhaps
it is not so surprising that the constitutive variant cannot offer the same functional benefit as the
RPGRORF15 variant.
4. Clinical and Genetic Diagnosis of RPGR-Related X-Linked RP
The diagnosis of RPGR-related retinal dystrophy is made on the basis of presenting symptoms
and retinal signs seen on clinical examination and various imaging modalities. In addition, study
of family history showing X-linked inheritance (no male to male transmission) and genetic testing
identifying the pathogenic mutation are important in confirming the diagnosis. In cases of uncertain
diagnosis and unequivocal genetic test results we have adopted several important steps, which are
discussed below, in order to minimise the risk of establishing an incorrect diagnosis, and administering
the patient with an incorrect gene if recruited into a gene therapy clinical trial.
RPGR-related retinal dystrophy is associated with a very heterogeneous phenotype that ranges
from pan-retinal rod-cone to predominant cone dystrophy (Figure 2). The phenotype is generally more
severe with faster progression compared to other forms of RP and median age of legal blindness of
approximately 45 years old, which is much younger than in other RP genotypes [40]. Most patients lose
their peripheral vision first, followed by the loss of central vision. Recent evidence suggests that the
rod-cone phenotype is found in 70% of patients, the cone-rod in 23% and the cone phenotype in 7% of
patients with X-linked RPGR related retinal dystrophy [2]. The study shows that the onset of symptoms
was in early childhood in rod-cone dystrophy (median age 5 years) and in third decade in cone-rod and
cone dystrophy, although the age range was very wide (between 0 and 60 years). However, cone-rod
and cone dystrophies were associated with a more severe phenotype and the probability of being
blind at the age of 40, with visual acuity of less than 0.05 LogMAR (3/60 or 20/400) observed in 55% of
patients with cone-rod and cone dystrophy compared to only 20% in rod-cone dystrophy.
The RPGR phenotype (Figure 2) has been associated with anatomical changes including central
retinal thinning of the outer nuclear layer as seen on retinal cross-sections taken by optical coherence
tomography [40,41]. The junction between the inner and outer photoreceptor segments, better known as
the ellipsoid zone, can be used as an important predictor of central retinal function and for monitoring of
disease progression. [42]. Thus, the disruption of the ellipsoid zone can be detected with corresponding
early reduction in visual acuity and retinal sensitivity as measured by microperimetry. In addition,
autofluorescence can be used to assess the health of the retinal pigment epithelium with early signs of
hyper-autofluorescence indicating accumulation of lipofuscin and related metabolites as a by-product of
photoreceptor outer segment degradation. Later in the disease process, areas of hypo-autofluorescence
become evident indicating outer retinal atrophy with loss of retinal pigment epithelium cells. The RPGR
phenotype is often associated with para-foveal hyper-autofluorescent rings, which decline exponentially
with disease progression [43]. Constriction areas are correlated highly with baseline area and age,
where younger subjects had greatest rate of progression. No correlation with genotype was observed
in this study. In the cone-rod phenotype, however, the area of hypo-autofluorescence associated with
a surrounding hyper-autofluorescent ring tends to increase in size with disease progression and is
inversely related to electroretinogram amplitude [44]. Ongoing natural history studies are promising
to shed more light on the natural progression of the RPGR disease phenotypes and provide better
understanding and interpretation of clinical trial endpoints used in current interventional gene therapy
trials (Table 2).
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Figure 2. Clinical phenotypes associated with RPGR retinal degeneration—rod-cone phenotype (early
stage (A–C) and a more advanced stage (D–F)) and cone-rod phenotype (G–I). The phenotypes are
captured by Heidelberg fundus autofluorescence, (left column), MAIA microperimetry measuring
central retinal sensitivity (central column; sensitivity is represented by a heat map: green/yellow—
normal/mildly reduced; red/purple—reduced; black—not measurable) and Heidelberg optical coherence
tomography showing retinal structures in cross-section (right column). In rod-cone phenotype
there is extensive peripheral retinal atrophy with relative preservation of central retina as seen on
autofluorescence associated with para-foveal hyper-autofluorescent ring (A). This is confirmed by
near normal central retinal sensitivity (B) and preservation of ellipsoid zone (C). In more advanced
stages of the disease there is reduction in size of the para-foveal hyper-autofluorescent ring (D) with
corresponding reduction in retinal sensitivity (E) and length of ellipsoid zone (F). In contrast, in cone-rod
phenotype there is early loss of para-foveal photoreceptors with associated hypo-fluorescent ring and
marked reduction of retinal sensitivity with corresponding loss of the ellipsoid zone.
Female carriers of RPGR mutations also show high phenotypic variability [7] (Figure 3). The carrier
phenotype includes asymptomatic females with near-normal clinical appearance, macular pattern
reflex with different degrees of pigmentary retinopathy and severely affected females with clinical
phenotype that results from skewed X chromosome inactivation and is indistinguishable from the male
pattern. Female carriers with male pattern dystrophy should be considered for RPGR gene therapy as
discussed below.
The molecular diagnosis using next-generation sequencing (NGS) is usually a robust approach in
determining pathogenic variants in RP. However, the ORF15 region of RPGR is not normally sequenced
with NGS methods and is currently only performed upon specific request. Moreover, sequencing of
the ORF15 region in RPGR is notoriously difficult and error-prone. Overlapping reading frames and
polymorphic deletions/insertions add further complexity to the detection of true mutations. Additional
precautions must, therefore, be taken with interpreting the sequencing data so that small deletions
are not confused with artefacts that would lead to spurious results. In cases of uncertainty, testing
should be repeated. In addition, the full RP panel should be performed to exclude other pathogenic
variants including the sequencing of RP2 and OFD1 X-linked genes. This comprehensive molecular
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genetic analysis together with the RPGR phenotype and a clear family history of X-linked inheritance,
including evidence of a carrier phenotype, forms the basis of inclusion criteria into gene therapy clinical
trials. In addition, a recent study describes an in vitro assay for determining the pathogenicity of
RPGR missense variations [45]. The strategy is based on the RPGR protein interaction network, which
is disrupted by missense variations in RCC1-like domain in RPGR, and could help to differentiate
between causative missense mutations and non-disease-causing polymorphisms.
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Figure 3. Clinical phenotype of RPGR female carriers. Fundus autofluorescence (Heidelberg)
showing a typical macular radial pattern or ‘tapetal’ reflex in a female carrier of an RPGR mutation
(A,B). Random X-chromosome inactivation generates clones of normal or affected photoreceptors giving
rise to this mosaic pattern. Blue reflectance (C,D) and multicoloured (E,F) modes using Heidelberg
scanning laser ophthalmoscope can be very helpful in showing the macular reflex.
5. Treatment Options for RPGR-Related X-Linked RP
Several non-gene based treatment approaches have been investigated for the preservation of
vision in X-linked RP including a nutritional supplement, docosahexaenoic acid [46] and a ciliary
neurotrophic factor [47] both of which were unable to prevent photoreceptor degeneration and visual
loss. For patients with advanced disease, electronic retinal devices have demonstrated proof-of-concept
in their ability to restore crude vision [48,49]. However, the unpredictability of benefit for individual
patients and the high price of these devices make it economically difficult to maintain their availability
for the treatment of patients with RP. Another potential strategy, optogenetics, is under investigation
and has shown promising results for vision restoration in advanced retinal degeneration [50,51].
Emerging gene-based therapy using the AAV vector is currently the most promising therapeutic
strategy for RPGR X-linked RP. The size of the coding sequence of RPGRORF15 (3.5 kb) is within the AAV
carrying capacity and the relatively high prevalence and disease severity have justified development of
this therapy. However, the repetitive sequence of ORF15 not only makes it a hotspot for mutations but
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also creates challenges for therapeutic vector production. Attempts to generate AAV vectors for RPGR
gene-supplementation strategies have been thwarted by the poor sequence stability of the ORF15 region
and transgene production has struggled to control spontaneous mutations and maintain the complete
sequence [13,52–55]. AAV gene therapy in two RPGR X-linked RP canine models that carry different
ORF15 mutations [55] provided proof of concept for treating RPGR mutations within the ORF15 region.
AAV2/5-mediated sub retinal gene delivery of a full-length human RPGR-ORF15 cDNA [10], driven
by either the human interphotoreceptor retinoid-binding protein (hIRBP) promoter or the human
G-protein-coupled receptor kinase 1 (hGRK1) promoter, prevented photoreceptor degeneration and
preserved retinal function in both canine models. However, the AAV2/5.RPGR vector was found
to have multiple mutations within the purine-rich exon 15 region that led to toxic effects in mice at
higher doses [52] thus posing safety questions for human applications. In an attempt to improve the
sequence stability, a step-wise cloning approach was used to generate the correct full-length RPGRORF15
coding sequence (the purine-rich region was generated first and then ligated to the rest of the DNA
sequence) [53], which was packaged into the AAV8.GRK1.RPGRORF15 vector and evaluated in the
Rpgr-KO mouse. However, despite improved stability, some vector preparations were still ridden with
micro-deletions that led to expression of alternatively spliced truncated forms of the RPGR protein that
was mislocalised to photoreceptor inner segments and only a partial rescue of the phenotype in treated
mice. The truncated forms of the protein were further investigated for their ability to rescue the RPGR
phenotype in the Rpgr-KO mouse [13]. The short (314 out of 348 ORF15 codons deleted) and the long
(126 out of 348 codons deleted) forms of the RPGRORF15 were tested. The long form demonstrated
significant improvement in the disease phenotype, whilst the short form failed to localise correctly
in the photoreceptors and showed no functional rescue of the phenotype. Importantly, as discussed
above, large deletions in the ORF15 region can affect the glutamylation of the protein and lead to
impaired function. Indeed, a follow-up study by the same group tested these truncated vectors [29]
for their glutamylation capacity. Unsurprisingly, the long form demonstrated significantly impaired
glutamylation (only 30% of the full length protein), whereas the short form showed no detectable
glutamylation of the RPGR protein.
To circumvent these issues, the research team of Fischer and colleagues (2017) generated a
full-length, human, codon-optimised version of RGPRORF15 to stabilise the sequence, remove cryptic
splice sites and increase expression levels from the therapeutic transgene [14]. This enabled reliable
cloning and vector production. The resulting AAV8.coRPGRORF15 vector was shown to offer therapeutic
rescue in two mouse models of X-linked RP (Rpgr-/y and Rd9). This vector is now being used in a
Phase I/II/III gene therapy clinical trial in humans (NCT03116113). In addition, the codon optimised
form of the RPGR vector used in the canine studies [15] and the truncated form of the RPGR with
near-total OFR15 deletion [13] are also being tested in ongoing clinical trials (NCT03316560 and
NCT03252847 respectively) as will be discussed further in the next section. A very recent study used a
bioinformatics approach as an alternative method to develop a molecularly stable RPGR gene therapy
vector [56]. The strategy identified regions of genomic instability within ORF15 and made synonymous
substitutions to reduce the repetitive sequence and thus increase the molecular stability of RPGR. The
codon optimized construct was validated in vitro in pull-down experiments and in a murine model,
demonstrating production of functional RPGR protein.
6. Gene Therapy Clinical Trials for RPGR-Related X-Linked RP
The results of the pre-clinical studies described above support the use of AAV-based gene therapy
for RPGR-related X-linked RP in humans, in the early to mid-stage of the disease. Ideally, patients
with moderately reduced visual acuity and constricted visual fields, but a preserved central ellipsoid
zone, should be recruited into gene therapy trials for best expected therapeutic benefits. Interestingly,
development of RPGR therapy from bench to bedside has resulted in setting-up of three multi-centre
dose-escalation gene-therapy clinical trials (see Table 2 for details). Each trial is using a different
combination of AAV vector variant and RPGR coding sequence (Figure 4). Specifically, the Nightstar
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Therapeutics (now Biogen Inc) sponsored trial (NCT03116113) is using the wild-type AAV8 vector
with a human rhodopsin kinase promoter and a human codon optimised full-length RPGRORF15 cDNA
sequence (AAV2/8.hRK.coRPGRORF15). The second trial sponsored by Meira GTx (NCT03252847) is
using a wild-type AAV2/5 capsid with a truncated, non-codon optimised RPGR sequence under control
of the human rhodopsin kinase promoter (AAV2/5.hRK.RPGRORF15). The third trial conducted by
Applied Genetic Technologies Corporation (NCT03316560) is using mutated AAV2 capsids (capsids with
single tyrosine to phenylalanine (YF) mutations) packaged with full-length, codon optimised human
RPGRORF15 sequence also driven by the rhodopsin kinase promoter (AAV2tYF.GRK1.coRPGRORF15).
Figure 4. AAV vector constructs used in current gene therapy trials: (A) the Nightstar Therapeutics
(now Biogen Inc) trial, NCT03116113; (B) the Applied Genetic Technologies Corporation trial,
NCT03316560; (C) the MeiraGTx trial, NCT03252847.
The pre-clinical studies that led to the development of vectors used in human trials were described
in detail in the previous section. However, the rationale for using the three different vectors deserves
further discussion. The coding sequence used in the Meira GTx trial is an abbreviated form of human
RPGRORF15 sequence. The rationale provided for using the truncated form, which arose through a
spontaneous mutation resulting in deletion of one third of the ORF15 region, was because the deletion
led it to become more stable, thereby reducing the rate of further recombination errors and potential
mutations. Interestingly, the authors also showed that further shortening of this critical ORF15 region
significantly affects the protein function, leading to mislocalisation of the protein in photoreceptors
and no functional or morphological rescue in a mouse model, confirming the importance of the ORF15
region for photoreceptor function. Importantly, a further study demonstrated that the post-translational
glutamylation is reduced by over 70% in this abbreviated form of the RPGRORF15, significantly affecting
trafficking of molecules critical for photoreceptor function [29]. However, since RPGR is not expressed
highly in photoreceptors, it is possible that over-expression of RPGR with gene therapy can compensate
for the reduced trafficking ability. The truncated construct was shown to rescue the photoreceptor
function in a murine model of X-linked RP [13]. However, the mouse RPGRORF15 is naturally shorter
than the human RPGRORF15 with an abbreviated ORF15 region (see Figure 2 and Table 1) much like the
engineered abbreviated human construct used in the human trial. Thus, it may not be so surprising
that the abbreviated human construct led to the rescue in a murine model, as the two sequences are
very similar and the murine model has a milder phenotype compared to humans. The efficacy of
this shortened version of RPGRORF15 has not been evaluated in canine models of X-linked RP and the
results from human trials are awaited in anticipation.
The constructs used in the AGTC and the Nightstar Therapeutics (now Biogen Inc.) trials are
very similar and encode the full-length human wild-type RPGRORF15 protein. Both constructs applied
codon optimisation that was shown by Fischer et al. to confer greater sequence stability with higher
expression levels than wild-type RPGR sequence, whilst not affecting the glutamylation pattern in the
RPGR protein. The codon-optimised RPGR rescued the disease phenotype in two mouse models of
X-linked RP [14] and was recently also validated in the RPGR canine model [15] showing transduction
of both rods and cones and preserving the outer nuclear layer structure in the treated retina. The results
of the phase I/II trials are expected in the near future.
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7. Summary
X-linked RPGR-related RP is a heterogenous group of disorders with no clear genotype–phenotype
correlation. Both rod-cone and cone-rod retinal dystrophies are seen with relatively early onset and rapid
progression to blindness that is related to mutations that cause loss of function of this key photoreceptor
protein. The complex expression pattern of the RPGR gene through cryptic splice sites that create
multiple isoforms poses challenges in elucidating its function. However, mounting evidence suggests
that retina-specific RPGRORF15 is unique to vertebrates and plays a crucial role in regulating protein
trafficking between inner and outer segments as well as in microtubular organisation. Importantly,
RPGRORF15 contains a characteristic repetitive purine-rich region that is highly glutamylated and only
the glutamylated RPGRORF15 is fully functional. Thus, any mutations that reduce the glutamylation
process adversely affect RPGR protein function. In addition, the ORF15 region created challenges for
the researches interested in developing RPGR gene-based therapies as the repetitive region made it
unstable and prone to mutations. The current approach in developing a codon-optimised version of
the RGPRORF15 to stabilise the sequence, remove cryptic splice sites and increase expression levels
from the therapeutic transgene is now being used in humans, following proof-of-concept studies in
murine and canine models of X-linked RP. This approach has allowed the rapid progression towards
the first in-human gene therapy trial (NCT03116113) for X-linked RP, which began in March 2017.
In parallel, two additional independent research consortia have been developing gene therapies for
the RPGR disease. With recent approval of gene replacement therapy Luxturna, for the treatment of
RPE65-related retinal disease, the precedence for approval of future gene-based therapies has been set
and results of the RPGR early phase clinical trials are awaited with great expectation.
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Abstract: Enhanced S-cone syndrome (ESCS) is caused by recessive mutations in the photoreceptor
cell transcription factor NR2E3. Loss of NR2E3 is characterized by repression of rod photoreceptor
cell gene expression, over-expansion of the S-cone photoreceptor cell population, and varying degrees
of M- and L-cone photoreceptor cell development. In this study, we developed a CRISPR-based
homology-directed repair strategy and corrected two different disease-causing NR2E3 mutations
in patient-derived induced pluripotent stem cells (iPSCs) generated from two affected individuals.
In addition, one patient’s iPSCs were differentiated into retinal cells and NR2E3 transcription was
evaluated in CRISPR corrected and uncorrected clones. The patient’s c.119-2A>C mutation caused
the inclusion of a portion of intron 1, the creation of a frame shift, and generation of a premature
stop codon. In summary, we used a single set of CRISPR reagents to correct different mutations in
iPSCs generated from two individuals with ESCS. In doing so we demonstrate the advantage of using
retinal cells derived from affected patients over artificial in vitro model systems when attempting to
demonstrate pathophysiologic mechanisms of specific mutations.
Keywords: induced pluripotent stem cell (iPSC); clustered regularly interspaced short palindromic
repeats (CRISPR); homology-directed repair (HDR); Enhanced S-Cone Syndrome (ESCS); NR2E3
1. Introduction
Enhanced S-cone syndrome (ESCS) is an autosomal recessive retinopathy that results from
mutations in the photoreceptor cell transcription factor, NR2E3 (Nuclear Receptor Subfamily 2, Group
E, Member 3). NR2E3, which is specifically expressed in the outer nuclear layer of the human retina [1],
is a direct transcriptional target of NRL, a key regulator of photoreceptor cell genesis. Work in animal
models has shown that NR2E3 acts to repress cone photoreceptor cell gene expression and promote rod
photoreceptor cell fate commitment. Specifically, loss of NR2E3 function hinders rod photoreceptor cell
development and drives over-expansion of the S-opsin-positive cone photoreceptor cell population
(i.e., blue cones) [2–6], which is normally the least prevalent of the photoreceptor cell subtypes.
Patients with ESCS present with increased sensitivity to blue light (due to overabundance
of short wavelength sensitive S-cones), early onset impairment of night vision (due primarily to
lack of functional rod development) and varying degrees of sensitivity to green and red light (due
to varying abundance of medium wavelength sensitive M-cones and long wavelength sensitive
L-cones). Although the disease is progressive in nature, clinically evident retinal degeneration is often
highly-variable, ranging from a relatively mild and nearly static disorder in some individuals to a very
severe and progressive disease in others [1,7–10].
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To date, more than 33 different disease-causing mutations in NR2E3 have been described [1,11,12].
In addition to ESCS, mutations in NR2E3 can also cause more severe forms of retinal disease, including
Goldmann-Farve syndrome (GFS) or autosomal dominant retinitis pigmentosa (adRP). Of these
mutations, the majority are in either DNA- (e.g., c.219G>C; p.(Arg73Ser)) or ligand-binding (e.g.,
c.932G>A; p.(Arg311Gln)) domains of the NR2E3 protein [11,13]. That said, one of the most common
NR2E3 mutations reported in the United States is c.119-2A>C [13], which falls within the canonical
splice acceptor site of intron 1. To demonstrate the functional effect of this mutation, Bernal and
colleagues transiently transfected COS7 cells with an expression plasmid containing a copy of the
NR2E3 gene harboring the c.119-2A>C variant [14]. Sequence analysis revealed that in addition to the
normal transcript, an aberrant transcript that lacked exon 2 and contained a premature stop codon in
exon 3 was also present [14].
Understanding how different disease-causing NR2E3 genotypes alter retinal development and
give rise to the observed spectrum of clinical outcomes is of particular interest and relevance to
investigators attempting to develop treatments based on photoreceptor cell replacement. Specifically,
by understanding exactly how genes such as NR2E3 function, we may be able to strategically guide
developing photoreceptor cells down a more cone-selective path (i.e., alter NR2E3 function to increase
cone genesis without causing widespread photoreceptor cell degeneration). To evaluate the effects of
different NR2E3 variants on photoreceptor cell fate, we have used CRISPR-based genome editing of
human patient-derived induced pluripotent stem cells (iPSC). Human iPSCs have several advantages
over animal models for this type of work. Unlike animal models, iPSCs can be generated from patients
with known disease-causing variants on genetic backgrounds that are demonstrably permissive of
the disease. By correcting the patients’ mutations one at a time, one can readily evaluate the role of
a specific variant on gene expression and phenotypic outcome. Correlating these in vitro findings
with the patients’ clinical history may provide a better understanding of how variants in each of the
different NR2E3 domains influence photoreceptor cell fate decisions.
To correct retinal disease-causing variants in patient-derived iPSCs, we and others have used
CRISPR-based genome editing [15–22]. Unlike the more cumbersome ZFN- and TALEN-based
approaches, which require the development of elaborate genomic targeting complexes, the CRISPR
method relies on the use of small single guide RNAs (sgRNAs) that can be easily synthesized to
direct human codon-optimized Cas9 nuclease to specific genomic targets. Cas9 induces double-strand
DNA breaks that can subsequently be repaired via fairly error-prone non-homologous end joining
(NHEJ), or via the more precise homology-directed repair (HDR) mechanism [15]. The advantage
of the HDR-based strategy, even for mutations within the deep intronic space where NHEJ could be
used, is that a single HDR repair template and set of sgRNAs is often sufficient to correct a variety of
different mutations that are contained within a limited genomic space (e.g., an HDR template spanning
exons 1 through 3 would cover both the above-mentioned c.119-2A>C splice site mutation and the
p.(Arg73Ser) variant contained within the NR2E3-DNA binding element). By using the same set of
reagents to correct a variety of mutations in different cell lines, one can control for differences related
to reagent variability while increasing throughput.
In this study, we developed a CRISPR-Cas9-based HDR strategy to correct two different NR2E3
mutations in iPSCs generated from two patients with clinically-diagnosed and molecularly-confirmed
ESCS: Patient 1 harbors homozygous c.119-2A>C mutations, and Patient 2 harbors compound
heterozygous p.(Arg73Ser) and p.(Arg311Gln) mutations. The close proximity of c.119-2A>C and
p.(Arg73Ser) allowed the same sgRNA and HDR reagents to be used to correct iPSC lines generated
from both individuals. Genomic correction of both mutations was confirmed by PCR and Sanger
sequencing. To demonstrate the utility of this system for elucidating disease mechanism, iPSCs
obtained from Patient 1, both before and after CRISPR correction, were differentiated down a
photoreceptor cell lineage. Analysis of the NR2E3 transcript revealed that, prior to CRISPR correction,
patient-derived retinal cells completely lack wild-type messages and instead express a mutant
transcript that contains a portion of intron 1, which causes a frameshift and the creation of a premature
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stop codon. Following monoallelic CRISPR correction, the expression of the wild-type NR2E3 transcript
was restored.
2. Materials and Methods
2.1. Patient-Derived iPSCs
This study was approved by the Institutional Review Board of the University of Iowa
(project approval #200202022) and adhered to the tenets set forth in the Declaration of Helsinki.
The dermal fibroblast-derived iPSCs used in this study were generated from two patients with
molecularly confirmed ESCS. These previously described cell lines were generated using current
good manufacturing practices in a clean room environment and validated using scorecard and
karyotypic analysis [23]. Consistent with the patients’ clinical diagnoses and unlike control individuals,
differentiation of these lines gave rise to S-opsin-positive blue cone photoreceptor cell-dominated
retinal organoids, which lack rod photoreceptor cells [24].
2.2. Cloning of CRISPR-Cas9 and HDR Donor Constructs
The sgRNAs used in this study were designed to target the region of NR2E3 that contains the
c.119-2A>C (Patient 1) and c.219G>C; p.(Arg73Ser) (Patient 2) mutations using the Benchling platform
(www.benchling.com) or the Optimized CRISPR Design Tool (crispr.mit.edu). Guides were cloned
into our previously described bicistronic construct expressing a human codon-optimized Streptococcus
pyogenes Cas9 (spCas9) nuclease [17,18]. A homology-directed repair (HDR) construct was synthesized
by GenScript. As described previously, the HDR plasmid contains 450–750 bp of homologous sequence
flanking a floxed puromycin resistance gene followed by the Herpes Simplex Virus type 1 thymidine
kinase (vTK) gene [16].
2.3. Screening of NR2E3-specific sgRNAs
sgRNA and CRISPR-Cas9 constructs were transfected into HEK293T cells (ATCC) using
Lipofectamine 2000 (Thermo Fisher Scientific) and cleavage was assessed via a T7 endonuclease
1 (T7E1) assay using NR2E3-specific primers (Table S1) as described previously [17,18]. Control iPSCs
were transfected with 2 μg of plasmid using the Neon transfection system as described previously [16].
2.4. Delivery of sgRNA-Cas9 and the HDR Contruct to NR2E3-Patient-Specific iPSCs
The CRISPR-Cas9 machinery was delivered to iPSCs and analyzed as described previously [16–18].
Briefly, the sg4-spCas9 and HDR plasmids were transfected at a 1:2 molar ratio into patient iPSCs
with Lipofectamine Stem (Thermo Fisher Scientific; Patient 1) or Neon electroporation (Thermo Fisher
Scientific; Patient 2). Puromycin (0.5 μg/mL) selection was performed as previously described [16],
and surviving colonies were PCR screened for HDR incorporation and sequenced to confirm correction.
The puroR-vTK cassette was removed by Lipofectamine Stem transfection of Cre recombinase, and
cells were treated with 40–400 nM Ganciclovir to select for those with vTK removal. The top off-target
sites (Table S2) were determined using the Benchling platform (https://benchling.com/) and analyzed
using the T7E1 assays as described above.
2.5. Retinal Differentiation
Undifferentiated iPSCs cultured on Laminin-521 coated culture dishes in Essential 8 medium
(Thermo Fisher Scientific) were transitioned to Matrigel (Corning) coated culture dishes in mTESR1
medium (StemCell Technologies). Transitioned cells were passaged every 4–5 days using 1mg/ml
dispase (Thermo Fisher Scientific). Differentiation was initiated through embryoid body (EB) formation
as previously described [25]. Briefly, EBs were generated on ultra-low adhesion plates and transitioned
from mTESR1 to neural induction medium (NIM - DMEM/F12 (1:1), 1% N2 supplement, 1%
non-essential amino acids, 1% Glutamax (Thermo Fisher Scientific), 2 μg/ml heparin (Sigma) and
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0.2% Primocin (Invivogen)) over a three day time period. EBs were maintained free-floating in NIM
until day 7, at which time they were induced to adhere to tissue culture-treated plates overnight in
NIM supplemented with 25% fetal bovine serum (FBS). Media was replaced with NIM minus FBS on
day 8 and the adherent EBs were fed with NIM every other day until day 16. On day 16, the entire
EB outgrowth was mechanically lifted using a cell scraper and transferred to retinal differentiation
medium (RDM - DMEM/F12 (3:1), 2% B27 supplement, 1% non-essential amino acids, 1% Glutamax
and 0.2% Primocin). Three-dimensional aggregates maintained in RDM give rise to both retinal
organoids and non-retinal neurospheres that can be isolated based on their morphological appearances.
Retinal organoids were isolated and dissociated at 5–6 weeks using Accutase (StemCell Technologies)
and cells were subsequently plated onto laminin (Sigma) coated tissue culture plates. Cells were
maintained in RDM and collected at a series of time points for RNA analysis.
2.6. Reverse Transcription PCR
Total RNA was extracted from cells using either the NucleoSpin RNA extraction kit
(Machery-Nagel) or TRIzol (Thermo Fisher Scientific) following the manufacturer’s protocol. cDNA
was generated with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) using
200 ng of RNA template. NR2E3 transcript was amplified using BIOLASE DNA polymerase (Bioline)
and NR2E3 specific primers (Table S1). PCR products were separated on an agarose gel and bands
were excised, purified using the QIAquick Gel Extraction Kit (Qiagen) and subcloned using the PCR2.1
TOPO TA cloning kit (Invitrogen). Colonies were subsequently picked and Sanger sequenced using
M13(-20)F or M13R primers.
3. Results
3.1. Testing CRISPR-Cas9 Guide Cleavage in HEK293T Cells and iPSCs
The goal of this study was to develop a CRISPR-Cas9 homology-directed repair strategy suitable
for the correction of disease-causing mutations in iPSCs generated from two independent patients
with molecularly confirmed NR2E3-associated enhanced S-cone syndrome (Figure 1A,B). As enhanced
S-cone syndrome has a recessive mode of inheritance (such that correction of only one allele would
be expected to mitigate the disease phenotype) and the p.(Arg73Ser) mutation on the paternal allele
of Patient 2 is within 100 bps of the c.119-2A>C mutations in Patient 1, we hypothesized that a
single CRISPR-Cas9 HDR cassette would be sufficient for the correction of iPSCs generated from
both individuals. We began by designing and testing 5 different sgRNAs that utilized the spCas9
PAM sites. To determine the efficiency of cleavage, we evaluated nonhomologous end joining (NHEJ)
using T7E1 assays in HEK293T cells transfected with each sgRNA and spCas9. While no cleavage was
detected in controls (i.e., untransfected cells), all 5 guides induced cleavage and indel formation with
similar efficiencies in the transfected cells (Figure 1C). The ability of all 5 guides to direct specific DNA
cleavage was subsequently evaluated in iPSCs generated from a normal non-diseased individual. As
with HEK293T cells, all 5 guides induced DNA cleavage and indel formation; however, more robust
cleavage was detected in cells that received sg2 and sg4 (Figure 1D). As the PAM sequence used by
sg4 could be readily modified with a synonymous mutation in the HDR cassette that would prevent
re-cleavage events without altering the predicted amino acid sequence, this guide was chosen for all
subsequent patient-specific genome repair experiments.
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Figure 1. Analysis of CRISPR-Cas9 sgRNA mediated cleavage efficiency. A,B: Schematics depicting
genomic disease-causing mutations in Patient 1—homozygous c.119-2A>C mutations (A) and Patient
2—compound heterozygous p.(Arg73Ser) and p.(Arg311Gln) mutations (B). C,D: Representative gel
images of T7E1 assays in HEK293T (C) and control induced pluripotent stem cells (iPSCs) (D) for 5
different sgRNAs. No transfection control: (-).
3.2. CRISPR Correction of the NR2E3 c.119-2A>C mutation in Patient-Specific iPSCs using
Homology-Directed Repair (HDR)
To correct the c.119-2A>C and p.(Arg73Ser) variants in iPSCs generated from the patients described
in Figure 1, we designed an HDR donor cassette with ~500 bps of homologous sequence upstream and
downstream of the sg4 cleavage site (Figure 2A). As indicated above, to prevent re-cleavage events, we
included a synonymous variant in the sg4 PAM site (CGG>CGA). To select for cells that incorporated the
HDR sequence, a puromycin resistance cassette under the control of the mPGK promoter was added to
intron 1 as previously described [16,18]. In addition, the stop codon in the puromycin resistance sequence
was replaced with a porcine 2A peptide (P2A) coding sequence, followed by the Herpes Simplex Virus
type 1 thymidine kinase (vTK) gene (thymidine kinase phosphorylates ganciclovir, a nucleoside analog,
which disrupts DNA synthesis and induces cell death) and a downstream polyadenylation sequence
(PA) [16]. The entire cassette, mPGK-PuroR-vTK-PA, was flanked by loxP sites that enabled removal
of the cassette via Cre recombinase [16]. Following Cre recombinase transfection, treatment of cells
with ganciclovir allowed for the selection of cells that had lost the cassette [16]. Patient 1 iPSCs were
transfected with sg4NR2E3-spCas9 and the HDR construct via lipofection. Puromycin selection was
subsequently performed as described in the methods section. Following selection, cells were clonally
91
Genes 2019, 10, 278
expanded and screened for incorporation of the HDR sequence via PCR using a forward primer in the
PA sequence (Figure 2A,F1) and a reverse primer outside the HDR cassette (Figure 2A,R1). Eighteen
of the 25 screened clones amplified the expected PCR product, indicating incorporation of the HDR
cassette (Figure S1). We chose 2 clones, clone 16 and clone 17, to confirm genomic correction. PCR was
performed using primers that spanned the mutation (Figure 2A,F2,R2) and the PCR product was TA
cloned. Sequencing demonstrated that all products from clone 17 still had the disease-causing c.119-2A>C
mutation. However, 5 of the 12 clones from the clone 16 PCR product showed a normal sequence,
indicating a monoallelic correction of the c.119-2A>C variant (Figure S2). Clone 16 was subsequently
transfected with Cre recombinase to remove the floxed PuroR-vTK cassette. After a second transfection
with Cre recombinase, some cells containing the PuroR-vTK cassette still remained (Figure 2C). To select
for cells that lacked the PuroR-vTK cassette, cultures were treated with ganciclovir, which resulted in
the removal of the PuroR-vTK containing cells (Figure 2C). PCR products using primers outside the
PuroR-vTK cassette (Figure 2D,F2) and homology arm (Figure 2D,R2) demonstrated equal amounts of
genomic DNA. To evaluate off-target cutting events, the top 10 off-target sites and 2 additional exonic
loci selected from the top 24 off-target sites, each predicted via Benchling, were analyzed. T7E1 assays
were performed with genomic DNA from unmodified control and CRISPR-corrected cells. We observed
no evidence of off-target events at any of the genomic loci evaluated; that is, we observed no cleavage
products that were specific to the corrected cells (Figure S3).
Figure 2. CRISPR-based homology-directed repair of the c.119-2A>C mutation in patient-derived iPSCs.
(A): Schematic diagram depicting the genotype pre-CRISPR correction and the homology-directed
repair (HDR) cassette designed to repair the c.119-2A>C mutation: Homologous sequence upstream
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and downstream of the loxP flanked puromycin resistance (PuroR), viral thymidine kinase (vTK), and
SV40 polyadenylation (PA). (B): Schematic depicting the genotype following CRISPR-based repair:
Monoallelic correction results in a cell line that contains one corrected allele and one mutant allele. (C):
Representative gel image of the genomic PCR confirming incorporation of HDR cassette in clone 16
and cassette removal following transfection of Cre recombinase and selection with ganciclovir (Cre-2,
+Gan). (D): Representative gel image of genomic PCR from the same samples presented in panel C to
demonstrate similar amounts of DNA. PCR products were also used for sequencing to confirm the
correction of clone 16.
3.3. CRISPR Correction of the NR2E3 p.(Arg73Ser) Mutation in Patient-Specific iPSCs using HDR
As indicated above, the p.(Arg73Ser) mutation in Patient 2 is located 100 bps away from the
c.119-2A>C mutations in Patient 1. We therefore wanted to determine if the same HDR cassette and
genome editing strategy used to correct Patient 1’s iPSCs could be used to correct iPSCs generated from
this individual (Figure 3A). The same plasmids were delivered; however, instead of Lipofectamine
Stem, electroporation was used to determine if a different delivery method could also be used to
achieve robust correction. We observed a similar efficiency with electroporation; specifically, 20 of 24
clones screened had a PCR product that indicated incorporation of the HDR cassette (Figure S4,F1,R1
primers). Patient 2 is a compound heterozygote, and only the p.(Arg73Ser) mutation was targeted
using this HDR cassette. As a result, extra screening was needed to identify clones that had the HDR
sequence specifically incorporated into the p.(Arg73Ser)-containing paternal allele as opposed to the
maternal allele, which is wild-type at this location (Figure 3A). To identify patient-derived iPSCs that
had the paternal p.(Arg73Ser) allele corrected, PCR products obtained from 6 clonally expanded iPSC
lines were sequenced using the F2/R2 primer pair. Following this analysis, clone 6 was found to be
corrected. None of the 18 sequencing reactions performed on DNA obtained from clone 6 contained
the p.(Arg73Ser) variant (Figure S5). Not surprisingly, the p.(Arg311Gln) mutation in exon 6, which
lies outside of the region of homology covered by the HDR cassette, was still present (Figure S5). A
single transfection with Cre recombinase and subsequent selection with ganciclovir resulted in the
removal of cells containing the PuroR-vTK cassette (Figure 3C, Cre+Gan). PCR products using both
sequencing primer sets F2/R2 and F3/R3 revealed equal amounts of genomic DNA (Figure 3D,E).
Using the same strategy described for Patient 1 above, Patient 2 iPSCs were evaluated for off-target
cleavage events. As shown in Figure S6, indel formation was identified in OT7. However, as OT7 is
located within the middle of an intronic region of a non-retinal gene, it would not be predicted to affect
retinal cell development, health, and/or function. Collectively, the above-described findings indicate
that a single HDR cassette can be used to successfully correct iPSCs obtained from two independent
patients with separate disease-causing mutations in the gene NR2E3.
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Figure 3. CRISPR-based homology-directed repair of the p.(Arg73Ser) mutation in patient-derived
iPSCs. (A): Schematic diagram depicting the genotype pre-CRISPR correction and the HDR cassette
used to repair the p.(Arg73Ser) mutation: Homologous sequence upstream and downstream of the loxP
flanked puromycin resistance (PuroR), viral thymidine kinase (vTK), and SV40 polyadenylation (PA).
(B): Schematic depicting the genotype following CRISPR-based repair: One corrected allele and one
mutant allele harboring the p.(Arg311Gln) mutation. (C): Representative gel image of the genomic PCR
confirming incorporation of the HDR cassette in clone 6 and cassette removal following transfection
of Cre recombinase and selection with ganciclovir (Cre, +Gan). D,E: Representative gel images of
the genomic PCR using the same samples in panel C to demonstrate similar amounts of DNA. PCR
products were also used for sequencing to confirm the correction of clone 6 in one allele (D) and the
presence of the p.(Arg311Gln) mutation in the other allele (E).
3.4. CRISPR-based Restoration of the NR2E3 Transcript in Patient-derived Retinal Cells
NR2E3 is a nuclear transcription factor that is required for rod photoreceptor cell genesis; thus,
to confirm that CRISPR-based genomic correction restores expression of NR2E3 transcript, iPSCs
(Figure 4A–C) were differentiated toward a retinal cell fate. The iPSCs generated from Patient 1,
who is homozygous for the c.119-2A>C splice site mutation, were predicted to have the most overt
molecular phenotype. Thus, Patient 1’s cells were chosen for the transcriptional analysis. As shown in
Figure 4, at 5–6 weeks post-differentiation, three-dimensional optic vesicles generated from control
(D), affected patient (E), and CRISPR-corrected (F) iPSCs appear to develop normally. To evaluate
the normal kinetics of NR2E3 expression, control iPSC-derived retinal cells were harvested at 6–20
weeks following initiation of differentiation. NR2E3 expression is first detected after approximately 10
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weeks of differentiation and is strongly expressed between weeks 13–20 (Figure 4G). After 9 weeks
of differentiation, the wild-type NR2E3 transcript was detectable in CRISPR-corrected as opposed to
non-corrected iPSC-derived retinal progenitor cells (Figure 4G). By week 14, the robust expression
of wild-type NR2E3 transcript could be detected in CRISPR-corrected retinal cells (Figure 4G).
Interestingly, at this timepoint, a second larger transcript could also be detected in both corrected and
uncorrected cells (Figure 4G). Following gel purification and sequencing, we found that the upper
band actually contained two novel transcripts that differ by only 32 bps (which explains why they
appear as a single product on a 2% agarose gel). The larger transcript included 143 bps of intron 1
followed by exon 2, and the smaller contained 111 bps of intron 1 followed by exon 2. In both cases,
the inclusion of this intronic sequence resulted in a frame shift and the creation of a premature stop
codon just 47 bps downstream of the canonical exon 1 boundary (Figure S7). In summary, monoallelic
genomic correction of the c.119-2A>C variant in patient-derived iPSCs restores the cells ability to make
wild-type NR2E3 transcript during retinal cell differentiation.
Figure 4. Correction of c.119-2A>C restores expression of normal NR2E3 transcript in patient-derived
retinal cells. A–C: Bright-field images of control (A), Patient 1 (B) and CRISPR-corrected Patient
1 (C) iPSCs. D–F: Bright-field images of control (D), Patient 1 (E) and CRISPR-corrected Patient 1
(F) optic vesicles at 5 weeks following initiation of differentiation. G: NR2E3 transcript analysis by
semi-quantitative PCR in control and Patient 1 iPSC derived retinal cells before (-) and after (+) CRISPR
correction at various time points following the initiation of differentiation; 18S rRNA was amplified as
a loading control.
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4. Discussion
The discovery of iPSCs, the creation of protocols for successful tissue-specific differentiation,
and the development of CRISPR-based genome editing have collectively enabled scientists to study
pathophysiology in human tissues like the retina that are usually inaccessible in living individuals.
For example, our ability to generate photoreceptor cells from patients with molecularly-undiagnosed
retinitis pigmentosa allowed us to demonstrate how a newly identified mutation in the gene male germ
cell associated kinase (MAK) causes photoreceptor cell-specific disease [26]. Similarly, by generating
retinal pigmented epithelial cells from a patient with suspected RPE65 associated Leber congenital
amaurosis (LCA), we were able to demonstrate that a novel intronic variant in a child of Haitian
ancestry, which could have easily been a non-disease causing ethnic polymorphism, altered splicing
and normal transcript production [27]. In the burgeoning field of retinal gene therapy, where molecular
confirmation of a patient’s disease-causing genotype is required for enrollment in a clinical gene
augmentation trial, the ability to use these approaches to demonstrate that a patient truly has the
disease being targeted will be invaluable.
In addition to being useful for confirming a patient’s disease-causing genotype, disease-specific
phenotypes identified in patient-derived cells (which can be confirmed via CRISPR-based genomic
correction) are proving to be helpful for the evaluation and development of novel therapeutics. For
instance, we recently demonstrated how AAV-based replacement of CLN3 and mitigation of the
molecular phenotype in patient-derived photoreceptor cells was preferable for the demonstration of
treatment efficacy to the use of an animal model that does not accurately recapitulate the disease [28].
In the current study, we demonstrate how patient-derived iPSCs and CRISPR-based genome editing
can be used to evaluate the molecular phenotype associated with the rare disease, enhanced S-cone
syndrome. As indicated in the introduction, enhanced S-cone syndrome is caused by mutations in the
gene NR2E3, which disrupt rod photoreceptor cell development and result in overproduction of blue
cones. By identifying how genetic alterations in NR2E3 expression alter both disease progression and
the percentage of cone and rod photoreceptor cells, we may be able to further refine our current retinal
differentiation protocols.
From a photoreceptor cell replacement perspective, to restore high-acuity vision, transplantation
of high-density cone photoreceptor cells will be required. There are a few promising strategies for
isolating cones from retinal organoids, which depending on cell line and differentiation protocol used
can have different percentages of rods vs. cones that result from using current retinal differentiation
protocols (reviewed in References [29,30]); however, all of them require a large scale culture in order
to obtain a sufficient number of cones following selection for retinal transplantation. A method for
directing retinal differentiation along a cone selective path would be a valuable improvement. Typically,
we and others have taken cues from developmental biology and designed experiments to vary the type,
dosage, and timing of exogenous factor delivery as we attempt to accelerate or shift differentiation
in one direction or another [31–35]. Although not a traditional approach, taking cues from naturally
occurring genetic disease, where single base pair changes can drastically alter the phenotypic outcome,
may also be useful. As we demonstrate in this manuscript, a single CRISPR-based HDR strategy can
be used to correct a variety of different mutations spanning several exons of NR2E3. By comparing
these changes to both in vitro phenotype and patient history, it may be possible to identify variants
that selectively promote cone cell genesis with little or no associated retinal degeneration.
Although unexpected, one of the more interesting findings that we report in this study pertains to
the molecular mechanism of the c.119-2A>C variant and is in opposition to a previous publication on
this subject [14]. It is important to note that the previous study was performed prior to the widespread
use of iPSCs and the development of CRISPR-based genome editing, and as a result, the authors elected
to test the function of this variant by transiently transfecting COS7 cells (transformed green monkey
kidney cells) with an expression plasmid that contained the NR2E3 gene harboring the c.119-2A>C
mutation. Transcriptional analysis in their system indicated that this mutation resulted in skipping of
exon 2, which caused a frameshift and creation of a premature stop codon in exon 3 [14]. In our study,
96
Genes 2019, 10, 278
by focusing on endogenously expressed NR2E3 in human patient-derived photoreceptor cells, we
found that the c.119-2A>C mutation in fact generates an abnormal transcript that includes a segment
of intron 1 followed by exon 2, which also causes a frameshift and the creation of a premature stop
codon. Interestingly, analysis of the wild-type and mutant alleles using the ESEFinder 3.0 program
(rulai.cshl.edu) revealed a difference in predicted splicing factor binding sites. An SRSF1 site was found
to be present in the wild-type but absent in the mutant, and an SRSF6 site that is absent in wild-type
was found to be present in the mutant. We suspect that the change in splice factor binding activated a
cryptic splice acceptor site in intron 1 in the iPSC-derived retinal cells rather than a skipping of exon 2
as observed in the previous COS7 study. The reason that the cryptic splice site was not used in the
COS7 system could simply be due to species and cell type-specific differences in the splicing machinery.
That is, it is possible that the splicing machinery used by monkey kidney cells is somewhat different
from that used by human photoreceptor cells. Regardless, this finding illustrates the importance of
using the appropriate cell type, obtained from the species of interest, when making inferences about
the function of different genetic variants. This will be especially true when attempting to determine
the pathogenicity of newly identified genetic variants in the age of clinical molecular medicine.
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Abstract: The recurrent missense variant in Nuclear Receptor Subfamily 2 Group E Member 3
(NR2E3), c.166G>A, p.(Gly56Arg) or G56R, underlies 1%–2% of cases with autosomal dominant
retinitis pigmentosa (adRP), a frequent, genetically heterogeneous inherited retinal disease (IRD).
The mutant NR2E3 protein has a presumed dominant negative effect (DNE) by competition for dimer
formation with Cone-Rod Homeobox (CRX) but with abolishment of DNA binding, acting as a
repressor in trans. Both the frequency and DNE of G56R make it an interesting target for allele-specific
knock-down of the mutant allele using antisense oligonucleotides (AONs), an emerging therapeutic
strategy for IRD. Here, we designed gapmer AONs with or without a locked nucleic acid modification
at the site of the mutation, which were analyzed for potential off-target effects. Next, we overexpressed
wild type (WT) or mutant NR2E3 in RPE-1 cells, followed by AON treatment. Transcript and protein
levels of WT and mutant NR2E3 were detected by reverse transcription quantitative polymerase chain
reaction (RT-qPCR) and Western blot respectively. All AONs showed a general knock-down of mutant
and WT NR2E3 on RNA and protein level, showing the accessibility of the region for AON-induced
knockdown. Further modifications are needed however to increase allele-specificity. In conclusion,
we propose the first proof-of-concept for AON-mediated silencing of a single nucleotide variation
with a dominant negative effect as a therapeutic approach for NR2E3-associated adRP.
Keywords: retinitis pigmentosa; autosomal dominant; NR2E3; G56R; putative dominant negative
effect; gapmer antisense oligonucleotides; allele-specific knockdown
1. Introduction
Retinitis pigmentosa (RP, MIM 268000) encompasses a group of progressive inherited retinal
diseases (IRDs) characterized by the loss of peripheral vision with the development of tunnel vison
and subsequent loss of central vision [1]. Thirty to forty percent of all RP cases show autosomal
dominant inheritance and currently 30 genes underlying autosomal dominant RP (adRP) have been
identified [2,3]. One of them is the Nuclear Receptor Subfamily 2 Group E Member 3 (NR2E3, MIM
604485) gene, encoding a photoreceptor-specific nuclear receptor [4]. NR2E3 is part of a multi-protein
complex with Neural Retina Leucine Zipper (NRL, MIM 162080) and Cone-Rod Homeobox (CRX,
MIM 602225). This complex has a dual role in the development and function of rod photoreceptors by
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co-occupying the promoter and/or enhancer regions of photoreceptor-specific genes in the rod cells.
In this way, NR2E3 suppresses cone gene expression and activates the expression of rod genes [5–7].
Mutations in NR2E3 have been linked with autosomal recessive IRDs such as Enhanced S-cone
syndrome (ESCS, MIM 268100) and Goldmann-Favre syndrome (GFS, MIM 268100). Furthermore, one
specific founder variant in the DNA-binding domain of NR2E3, c.166G>A, p.(Gly56Arg) known as
G56R has been found to cause 1%–2% of all adRP cases, being enriched in European populations and
North American families of European descent [8–11]. This pathogenic variant is unique because of its
presumed dominant negative effect (DNE) characterized by competition for dimer formation with CRX
but loss of the necessary DNA-binding, which is caused by disruption of the α-helical DNA-binding
motif [12,13] (Figure 1).
This DNE and the recurrence of the G56R mutation make it an interesting target for modulation with
antisense oligonucleotides (AONs). AONs can bind their target RNA and recruit the RNAse-H1 enzyme,
which degrades the RNA part of the formed RNA:DNA duplex and subsequently downregulates
the target of interest [14]. Allele-specific knock-down using AONs or RNA interference has already
been tested for various targets that exert a gain of function or dominant negative effect, such as TMC1
(MIM 606706) for autosomal dominant hearing loss (MIM 606705) [15], COL6A2 (MIM 120240), and
COL6A3 (MIM 120250) for Ullrich myopathy (MIM 254090) [16–18], DNM2 (MIM 602378) for autosomal
dominant centronuclear myopathy (MIM 160150 [19], RHO (MIM 180380) for adRP [20], GCAP1 (MIM
600364) for adRP, and cone-rod dystrophy (MIM 602093 [21] and HTT (MIM 613004) for Huntington
disease (MIM 143100) [22,23].
Recently, significant advances in AON-mediated therapy have been made in the field of IRD.
For example, a recent clinical trial assessed intravitreal injections of an AON to restore correct splicing in
ten patients with Leber Congenital Amaurosis (MIM 611755) due to a frequent deep-intronic mutation
c.2991+1655A>G in CEP290 (MIM 610142) [24]. This has a potential impact on other subtypes of IRD
and other AON-mediated approaches are currently being investigated [25–30].
Here, we aimed to design and test the capacity of AONs to knock down the adRP-associated
G56R mutation in an allele-specific manner, being one of the first studies employing allele-specific
AONs to target a single nucleotide variation in IRD.
Figure 1. Cont.
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Figure 1. Schematic overview of the dominant negative effect of G56R Nuclear Receptor Subfamily 2
Group E Member 3 (NR2E3) (A) and allele-specific silencing of G56R using antisense oligonucleotides
(AONs) (B). (A) Both wild type (WT) and mutant alleles are transcribed and translated. The wild type
protein is able to form homo-dimers and bind the DNA, in complex with Neural Retina Leucine Zipper
(NRL). The mutant protein is competing for binding with Cone-Rod Homeobox (CRX) and this complex
is no longer able to bind the DNA, which leads to a failure of both potentiation of rod specific genes and
activation of cone specific genes. (B) Using AONs, the mutant allele can be selectively downregulated,
whereby the WT protein is binding the DNA in complex with both NRL and CRX. This complex is
able to properly activate the rod specific genes and repress the cone specific genes, which would halt
degeneration of the photoreceptors. Adapted from [18].
2. Materials and Methods
2.1. AON Design
A region of 150 bp around the c.166G>A mutation (Ensembl release 85) at the mRNA level was
analyzed using Mfold software (version 3.6). Partially open or closed regions were identified using the
ss-count tool. This led to the design of nine gapmer AONs overlapping with c.166G>A, differentiating
in length of the DNA gap region, length of the RNA flanks, and the position of the mutation in the gap.
Furthermore, we included the same nine gapmer AONs containing a locked nucleic acid (LNA) at the
site of the mutation. Final AON sequences were analyzed using the OligoAnalyzer Tool (Integrated
DNA Technologies, Coralville, IA, USA) to ensure that the GC content ranged between 40% and 60%
and that the self-complementarity of the AON is above −9 kcal/mol. All nine AON pairs were analyzed
for off-targets using Bowtie and Bowtie2 (Ensembl release 85), allowing a maximum of two mismatches.
All AONs were chemically modified by adding a phosphorothioate (PS) backbone to the complete
AON sequence and 2-O-Methyl sugar modifications to the RNA flanks. AONs were generated by
Eurogentec (Seraing, Belgium) and were dissolved in sterile TE-buffer to a final concentration of
100 μM.
2.2. Generation of Mutant c.166G>A Expression Construct
A wild type (WT) NR2E3 (NM_014249) complementary DNA (cDNA) expression construct
(OriGene, Rockville, MD, USA, TC308926) was used as a basis for mutagenesis. The c.166G>A
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mutation was inserted using the Q5 site-directed mutagenesis kit (New England Biolabs, Ipswich,
MA, USA), and mutation-specific primers were designed with the NEBaseChanger software (version
1.2.8, New England Biolabs, Ipswich, MA, USA) (Supplementary Table S1). Mutagenized plasmids
were transformed in One Shot TOP10 competent cells (Invitrogen, Life Technologies, Carlsbad, CA,
USA) and DNA was subsequently isolated with the NucleoBond Xtra Midi/Maxi kit (Macherey-Nagel,
Düren, Germany). The entire NR2E3 insert was sequenced and selected plasmids were grown to obtain
larger quantities. Sequencing primers can be found in Supplementary Table S1.
2.3. Cell Culture and AON Transfection Experiments
hTERT RPE-1 cells (ATCC, Manassas, VA, USA, CRL-4000™) were cultured in DMEM:F12 medium
(ATCC, Manassas, VA, USA) supplemented with 10% fetal calf serum, 1% penicillin-streptomycin,
1% MEM non-essential amino acids, and 0.01 mg/mL hygromycin B. RPE-1 cells were seeded in six
well plates at 1.5 × 105 cells/well. After 24 h, cells were co-transfected in duplicate with 2 μg of WT or
mutant NR2E3 plasmid or an empty control vector and 0.25 μM of AON, using DharmaFECT kb DNA
transfection reagent (Dharmacon, Lafayette, CO, USA) according to manufacturer’s instructions. Cells
were grown for 48 h until confluence.
2.4. RNA Isolation and Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)
Total RNA was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany) with on-column
DNase digestion (Qiagen, Hilden, Germany) according to manufacturer’s instructions. A second
DNase treatment was done using the Heat&Run genomic DNA (gDNA) removal kit (ArcticZymes,
Tromsø, Norway). cDNA was synthesized with the iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA, USA) using 1 μg of messenger RNA (mRNA).
Reference genes that are stably expressed in RPE-1 cells were first determined using a GeNorm
analysis, integrating the M and V analysis. The average pairwise variation M of a particular gene with
all other control genes was determined as the standard deviation of the logarithmically transformed
expression ratios. In addition, the systemic variation V was calculated as the pairwise variation
for repeated RT-qPCR experiments on the same gene (qbase+, Biogazelle, Ghent, Belgium) [31].
The following reference genes were tested for stability: HMBS, SDHA, HPRT1, PPIA, GUSB, and TBP.
Primer sequences are listed in Supplementary Table S1.
Next, the expression level of NR2E3 was determined using intron-spanning primers (Primer3Plus,
version 2.0). Data analysis was done using the qbase+ software (Biogazelle, Ghent, Belgium) with
following reference genes for normalization: HMBS, SDHA, and TBP. Primer sequences are listed in
Supplementary Table S1. Transfection and RT-qPCR were performed twice.
2.5. Western Blot Analysis
Cell lysates were collected in Leammli lysis buffer supplemented with complete protease inhibitor
cocktail (Sigma-Aldrich, St. Louis, MO, USA) and phosphatase inhibitors (Sigma-Aldrich, St. Louis,
MO, USA). Protein concentrations were measured using the Pierce BCA protein assay kit (Thermo
Scientific, Waltham, MA, USA). A total of 25 μg of protein sample was reduced by incubation at 98 ◦C
with 1M DTT. SDS-PAGE was performed using NuPAGE™ 4%–12% Bis-Tris protein gels (Invitrogen,
Life Technologies, Carlsbad, CA, USA). Subsequently, proteins were transferred to a nitrocellulose
membrane using the iBlot®2 System (Life Technologies, Carlsbad, CA, USA). Membranes were
incubated in 2% membrane blocking agent (GE Healthcare Life Sciences, Chicage, IL, USA) in 1x
tris-buffered saline with Tween-20 (TBST) for 2 h at room temperature and immunolabeled with a
primary antibody (anti-NR2E3, #AB2299, Millipore, Burlington, MA, USA) diluted 1:1000 in blocking
buffer for 16 h at 4 ◦C. Membranes were probed with a secondary antibody (anti-rabbit IgG, HRP-linked
antibody #7074, Cell Signaling Technologies, Danvers, MA, USA) diluted 1:2500 in blocking buffer for
2 h at room temperature. Membranes were developed using the SuperSignal® West Dura Extended
Duration Substrate kit (Thermo Scientific, Life Technologies, Waltham, MA, USA) and scanned with
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the ChemiDoc-It® 500 Imaging System (UVP, Upland, CA, USA). Subsequently, membranes were
stripped using the Restore PLUS Western Blot Stripping Buffer (Life Technologies, Carlsbad, CA,
USA) and probed with a β-tubulin primary antibody (ab6046, Abcam, Cambridge, UK) as an internal
loading control. The antibody was diluted 1:2000 in blocking buffer and incubated for 1 h at room
temperature. Membranes were subsequently probed with a secondary antibody (anti-rabbit IgG,
HRP-linked antibody, Cell Signaling Technologies, Danvers, MA, USA) diluted 1:2500 in blocking
buffer for 1 h at room temperature. The development was done as described above. Relative densities
of NR2E3 were measured on three independent Western blots using Image J (version 1.8.0_112) and
normalized against β-tubulin. Statistical analysis was done using an unpaired t-test.
3. Results
3.1. AON Design
We designed nine gapmer AONs targeting the c.166G>A mutation but shifted the oligonucleotides
each time a few bps, as it is known that only a few bps difference can lead to a complete abolishment of
inhibitory activity of AONs due to secondary or tertiary structures that restrict binding possibilities of
the AON [32]. Furthermore, LNA modifications increase the difference in melting temperature between
duplexes formed with a perfectly matched target versus a mismatched target and are thus possibly
increasing the allelic-discrimination potency of AONs [33,34]. Hence, we included nine gapmer AONs
containing a LNA modification at the site of the mutation. An overview of gapmer AONs around the
site of the mutation, differentiating in length of the gap region, length of RNA flanks, and position of
the mutation can be found in Table 1. Three pairs of gapmer AONs were finally selected that contain
no complete match between the AON sequence and the full human gDNA sequence, and are further
referred to as AON1–6 (Table 1). All three pairs have a 5-10-5 composition containing a DNA-gap
region with 10 PS modified nucleotides, which is needed to allow cleavage of the RNAse-H1 enzyme.
The gap region is flanked on both sides by 5 2′-O-Methyl PS RNA nucleotides.
3.2. NR2E3 mRNA Expression Analysis
All AONs were transfected in RPE-1 cells together with either the WT or mutant NR2E3 cDNA
expression construct to test whether the AONs induce selective silencing of the mutant NR2E3 mRNA
and protein. For normalization of RT-qPCR expression data, we first determined reference genes
that are stably expressed in RPE-1 cells using a GeNorm M and V analysis [31] testing following
genes: HMBS, SDHA, HPRT1, PPIA, GUSB, and TBP (Supplementary Figure S1). HMBS, TBP, and
SDHA are the most stably expressed in RPE-1 cells (V < 0.15, lowest M values) and will be used in
further experiments.
Next, relative quantities of WT and mutant NR2E3 were determined using RT-qPCR of the
harvested mRNA. All AONs show a non-selective knock-down of both WT and mutant NR2E3
(Figure 2). However, when calculating the residual expression percentage after treatment relative to
the non-treated sample, samples treated with AON2, 4, and 6 show lower remaining expression in the
mutant versus the WT sample (Table 2). Interestingly, these AONs contain the LNA modification at
the site of the mutation, possibly increasing the discrimination capacity of the AON [33].
105






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Genes 2019, 10, 363
Table 2. Relative expression values of messenger RNA (mRNA) from wild type (WT) or mutant (MT)
NR2E3 overexpressed in RPE-1 cells and subsequently treated with AON1–6. Residual expression after
AON treatment was calculated relative to the non-treated (NT) sample (=100%). SEM = standard error
of relative expression values.
AON Expression WT NR2E3 (%) SEM (%) Expression MT NR2E3 (%) SEM (%)
NT 100.00 3.84 100.00 4.01
AON1 33.22 4.06 37.37 2.86
AON2 59.55 6.12 46.15 9.65
AON3 27.98 5.98 38.04 3.51
AON4 33.76 2.94 30.15 4.89
AON5 30.10 4.95 38.16 3.87
AON6 31.81 4.94 29.89 4.26
 
Figure 2. Quantitative polymerase chain reaction (qPCR)-based expression analysis of messenger RNA
(mRNA) from wild type (WT) or mutant (MT) NR2E3 overexpressed in RPE-1 cells and subsequently
treated with AON1–6. All AONs lead to a partial knockdown of WT or MT NR2E3 mRNA expression.
Error bars represent the standard error of the relative quantities. Mock transfected cells were transfected
with an empty vector and show no NR2E3 expression.
3.3. NR2E3 Protein Expression Analysis
In parallel to mRNA expression analysis, Western blot analysis was performed to investigate
whether the effects seen on mRNA level could be recapitulated on the protein level. A direct comparison
of all conditions on the same gel was not possible, as the number of samples was too high. Therefore,
a comparison of treated versus non-treated, and mutant versus WT samples was made per AON
on the same gel. Three independent Western blots showed a clear partial knock-down of WT and
mutant NR2E3 protein for all AONs (Figure 3A). Relative densities were calculated using β-tubulin for
normalization. Unpaired t-tests between the non-treated sample and the treated samples revealed
p-values between <0.0001 and 0.0328 (except for WT NR2E3 treated with AON4, p-value: 0.058)
(Figure 3B). Transformation of these relative densities into percentages showed no clear difference
in allele-specificity between AONs with or without LNA at the site of the mutation, as was seen for
the mRNA expression. Instead, all AONs, except for AON2, seem to preferentially downregulate the
mutant NR2E3, with AON5 being the most specific one (Table 3).
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Figure 3. Western blot analysis. Wild type (WT) or mutant (MT) NR2E3 was overexpressed in RPE-1
cells and subsequently treated with AON1–6. (A). Upper images represent NR2E3 protein visualization,
lower images represent β-tubulin visualization. (B). Densitometric analysis for three independent
Western blots. Left panel represents WT samples, right panel represents MT samples. All AONs lead to
a partial knock-down of WT and MT NR2E3 protein (p-values between <0.0001 and 0.0328). Error bars
represent standard deviation between relative densities.
Table 3. Relative protein expression values from wild type (WT) or mutant (MT) NR2E3 overexpressed
in RPE-1 cells and subsequently treated with AON1–6. Average residual protein expression after
treatment with AON1–6 was calculated from three independent blots relative to the non-treated (NT)
sample (=100%).









We aimed to investigate if the adRP-associated NR2E3 mutation G56R with a dominant negative
effect would be amenable to allele-specific knock-down using AONs. As other NR2E3 mutations
that have been found in autosomal recessive IRDs, such as enhanced S-cone syndrome (ESCS, MIM
268100), have a loss-of-function effect, we hypothesized that the c.166G>A allele could function as
a therapeutic target for selective suppression [35] (Figure 1). Effective allele-selective approaches
employing AONs have already been described for dominant mutations in COL6A2 [18], RHO [20], and
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HTT [22]. However, gapmer AONs targeting a single nucleotide variation have not yet been described
for IRD.
As NR2E3 expression is mainly limited to the photoreceptors, we co-transfected WT or mutant
expression constructs in RPE-1 cells, together with each of the six AONs targeting the c.166G>A allele.
A general decrease in NR2E3 expression could be seen for all AONs both on the mRNA and protein
level, but not limited to the mutant NR2E3. However, on the mRNA level, a subtle mutant-specific
preference could be seen for AON2, 4, and 6. Interestingly, these contain the LNA modification at the
site of the mutation. On the protein level, a preferential mutant-specific knock-down could be observed
for all AONs except for AON2 in three independent experiments. Apart from the fact that Western
blot is a semi-quantitative technique, the observed mRNA-protein differences may be attributed by
other factors, e.g., different gapmer AON activities in the nucleus versus cytoplasm [18].
The six evaluated AONs downregulate NR2E3 expression to 28%–60% at the mRNA level
and to 9%–70% at the protein level. Importantly, in the context of the dominant negative NR2E3
mutation, a complete AON-induced knock-down of the mutant allele is not required. Morphological
or cellular improvements resulting from moderate reductions in mutant protein while preserving the
WT protein [20] or from shifting the WT-mutant protein ratio [16,17] have been described respectively.
Gualandi et al. showed that AON-targeting of a common single nucleotide polymorphism (SNP)
caused a global suppression of COL6A2 mRNA, albeit preferentially involving the mutated allele
(10% difference in mutant versus WT allele ratio). Overall, this led to a significant improvement of the
severe cellular phenotype in patient fibroblasts [16].
In order to increase the allele-specificity of the AONs targeting NR2E3 mutation G56R, both
the cellular system and AON sequences could be modified. As we had no access to patient-derived
induced pluripotent stem cells (iPSCs) differentiated to photoreceptor precursor cells (PPCs) at the
start of the study, we used an overexpression cellular system either for mutant or WT NR2E3. This is
not representing the true biological situation however, in which both mutant and WT NR2E3 are
expressed, exerting a dominant negative effect. In NR2E3 expressing patient-derived cells, competition
for AON binding might lead to a stronger allele-specificity of the AON. In this respect, iPSCs have
recently been reprogrammed from patient fibroblasts with the c.166G>A mutation [36]. These cells
will further be differentiated to PPCs [37], which will represent a relevant cellular model for further
AON development.
Apart from using a different cellular system, several modifications to the AONs could be made to
obtain a more selective knock-down of the mutant allele. A first potential modification could be shifting
the AONs a few bps. Already three positions of AONs targeting the mutation have been investigated
here, but several studies showed that even a change of one bp can have a substantial influence on
allelic discrimination [38,39]. Next, reducing the length of the AONs could have positive effects on
the discrimination capacity. The AONs used in this study have a 5-10-5 conformation. However,
it has been shown that a long AON sequence can reduce the allele-specificity [18]. Shortening the
AONs to 16 nucleotides could increase specificity on the one hand [39,40], but lead to an increase
of possible off-target effects on the other hand (see Table 1). Finally, it has been suggested that the
discrimination of single nucleotides between RNA alleles can be improved by introducing certain
arrangements of mismatches between the RNA/AON duplexes, as the presence of non-canonical bps
decreases the thermodynamic stability of the duplexes. In case of a G>A transition, it has been shown
that the presence of G-dT in the WT RNA duplex instead of A-dT does not disturb the duplex structure.
However, introducing tandem purine mismatches at the 5′ end of the DNA gap strongly diminishes
thermodynamic stability. This, combined with the third mismatch at the site of the mutation, has been
shown to reduce the cleavage efficiency of the WT RNA [41].
In conclusion, we have designed and investigated gapmer AONs to elicit allele-specific silencing
of a recurrent dominant negative mutation in the NR2E3 gene implicated in 1%–2% of cases with
adRP. We showed that the region of interest is accessible to AON-induced RNAse-H1 cleavage and
that AON-targeting of G56R caused a global suppression of NR2E3 mRNA and protein, with limited
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mutation-specificity. Further studies will evaluate different modifications to AONs, and will validate
gapmer AONs in a relevant patient-derived cellular model. Finally, our findings provide the first
proof-of-concept for AON-mediated silencing of a single nucleotide variation with a dominant negative
effect as a therapeutic approach for dominant IRD.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/5/363/s1,
Figure S1: GeNorm analysis to determine the number and most stable reference genes. Table S1: PCR primers.
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Abstract: The health and function of our visual system relies on accurate gene expression. While
many genetic mutations are associated with visual impairment and blindness, we are just beginning
to understand the complex interplay between gene regulation and retinal pathologies. MicroRNAs
(miRNAs), a class of non-coding RNAs, are important regulators of gene expression that exert their
function through post-transcriptional silencing of complementary mRNA targets. According to recent
transcriptomic analyses, certain miRNA species are expressed in all retinal cell types, while others are
cell type-specific. As miRNAs play important roles in homeostasis, cellular function, and survival of
differentiated retinal cell types, their dysregulation is associated with retinal degenerative diseases.
Thus, advancing our understanding of the genetic networks modulated by miRNAs is central to
harnessing their potential as therapeutic agents to overcome visual impairment. In this review, we
summarize the role of distinct miRNAs in specific retinal cell types, the current knowledge on their
implication in inherited retinal disorders, and their potential as therapeutic agents.
Keywords: microRNA; retina; photoreceptors; rods; cones; bipolar cells; Müller glia; retinal inherited
disorders; retinitis pigmentosa; retinal degeneration
1. miRNA Biogenesis and Function
MicroRNAs (miRNAs) are a class of highly conserved ~22 nucleotide (nt)-long non-coding RNAs
that have a repressive impact on gene expression in a sequence-specific manner (Figure 1). These
miRNAs are derived from partially complementary primary RNA transcripts (pri-miRNA) produced
mainly by RNA polymerase II, but also by RNA polymerase III. Pri-miRNAs self-anneal to form hairpin
or stem–loop structures, which are subsequently cleaved 11 base pairs (bp) from the base of the hairpin
stem by the miRNA-processing complex, a protein ensemble that contains the Drosha ribonuclease
and the DiGeorge Critical Region 8 (Dgcr8) protein [1]. The resulting 70 nt-long sequence is known as
precursor miRNA (pre-miRNA) and is characterized by a 5’ phosphate and a 2-nt overhang at the 3’
end [2]. Alternatively, miRNAs also result from splicing events independently of Drosha and Dgcr8 [3].
Pre-miRNAs are subsequently exported out of the nucleus for the next processing step in which the
Dicer endoribonuclease creates a cut ~22 nt away from the cleaving site of the miRNA-processing
complex. Thereby, an additional 5’ phosphate and a new 2-nt 3’ overhang are generated at the opposite
end of the double-stranded RNA [4]. The final miRNA structure is thus a duplex formed by partially
complementary 22 nt-long RNA sequences with 5’ phosphates and 2-nt 3’ overhangs at both ends. In
the last processing step, these duplexes are incorporated into the Argonaute protein, which is a member
of the RNA-induced silencing complex (RISC), where one of the strands is removed. The strand that
remains bound to Argonaute coordinates the search of, and pairing to, partially complementary target
mRNA transcripts [1,5]. Upon binding their mRNA targets, miRNAs either induce their degradation,
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promote their deadenylation, or reduce their translational efficacy [6]. As individual miRNAs can
have thousands of mRNA targets, they represent potent regulators of gene expression at the systems
level [7,8]. To date, there are 1917 annotated human miRNA sequences (miRbase v22, access date
2019-05-13) [9].
Figure 1. MicroRNA (miRNA) pathway. miRNA biogenesis starts in the nucleus where partially
self-complementary RNA polymerase II or III transcripts from a miRNA gene or from an intronic region
assemble into a hairpin-like structure known as primary (pri)-miRNA. Pri-miRNAs are cleaved by the
DiGeorge Critical Region 8 (Dgcr8)/Drosha complex and transported to the cytoplasm via Exportin 5. In
the cytoplasm, pre-miRNAs are cleaved by the Dicer/HIV-1 TAR RNA binding protein (TRBP) nuclease
complex, thereby giving rise to a miRNA duplex. This duplex is then loaded onto the Argonaute (AGO)
protein, a component of the RNA-induced silencing complex (RISC), where one of the two strands
is discarded while the other serves to search complementary transcripts. Targets bound by miRNAs
exhibit reduced translational efficiency, mainly as a consequence of mRNA cleavage or deadenylation.
The miRNA pathway can be modulated by introducing miRNA mimics (green) or miRNA inhibitors
(red). shRNA is small hairpin RNA.
Dysregulated miRNA expression during development can lead to severe defects and is connected
to many pathological conditions such as cancer, neurodegenerative diseases, heart failure, diabetes,
and inherited genetic disorders [10]. In mature organs and tissues, miRNAs support the robustness of
gene networks and buffer against the fluctuations in gene expression often resulting from stochastic
modulation and environmental stress [11]. As their metabolic activity is considerably high and they
are often exposed to high levels of external stress, photoreceptors are highly vulnerable to cell death in
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retinal degenerative diseases. In this context, miRNAs play an important role in photoreceptor survival
and function [12]. Moreover, as not all retinal disease phenotypes have been linked to specific genes,
altered miRNA expression may underlie the emergence and progression of certain retinal disorders.
Thus, exploring the function and gene regulatory networks of these and other non-coding RNAs is of
the utmost importance. A dominant mutation in miR-204, for instance, is the genetic cause of retinal
degeneration associated with ocular coloboma, a genetic developmental disorder characterized by
keyhole-shaped defects in various eye structures [13]. It is thus tempting to speculate that miR-204 is
not the sole case of a miRNA giving rise to an ocular disease, and that altered expression of non-coding
RNAs might lead to other retinal disorders. Here, we discuss some of the known functions of miRNAs
in the adult retina.
2. Controlling Cellular miRNA Expression
The deliberate modulation of gene expression through the use of non-coding RNAs, commonly
referred to as RNA interference [14], has been extensively utilized in basic and biomedical research.
Small hairpin RNAs (shRNAs), for instance, are artificial RNA molecules with a hairpin region processed
by the same machinery as miRNAs and effectively acting as miRNA mimics [15,16]. Normally, shRNAs
are designed to match the sequence of specific RNA molecules, which they target and downregulate
upon delivery. The production of such shRNA molecules is driven by regular promoter elements
within a plasmid or a viral vector. Standard gene delivery techniques can be applied to express the
shRNA of interest in target cells. This system can also be used to overexpress specific miRNAs [17].
Alternatively, the consequences of miRNA overexpression can be studied by inserting them within
artificial intron systems. In general, shRNA vectors are particularly interesting for silencing dominant
disease-causing transcripts and their use in retinal cell types was established already over a decade
ago [18].
Vice versa, for downregulating or silencing miRNAs, commonly used techniques include
“antagomirs” [19] and so-called miRNA “sponges” [20]. Whereas antagomirs are chemically engineered
oligonucleotides, miRNA sponges are RNAs with artificial tandem binding site arrays for specific
miRNAs. Hence, these sponge sequences compete with physiological targets for miRNA binding,
which ultimately leads to reduced silencing of primary mRNA targets. Sponge cassettes can be
delivered to retinal cell types by adeno-associated viruses (AAV) [21], which are powerful clinically
approved vectors for ocular gene transfer [22,23]. Thus, the therapeutic use of non-coding RNAs
is presently growing at an accelerated pace due to increased knowledge of miRNA functions and
the wide adoption of technologies that facilitate control of their expression levels in distinct retinal
cell types.
3. Photoreceptor–miRNAs as Cell Maintenance and Survival Regulators
Rod photoreceptors are sensory neurons essential to night vision. To investigate the impact of
miRNA deficiency in these cells, rod photoreceptor-specific Dicer conditional knock-out (cKO) mice
have been generated. As mentioned above, Dicer is the endoribonuclease responsible for the second
cleavage step in the canonical miRNA biosynthesis pathway. These mice were generated by crossing
a Dicer1fl/fl line with mice expressing Cre recombinase exclusively in mature rods. Loss of Dicer1 at
postnatal day 28 (P28), a time-point at which rods are mature and postmitotic, was reported to lead to
outer segment disorganization in eight-week-old mice, followed by robust retinal degeneration and
loss of visual function by 14 weeks. Notably, cKO mice did not exhibit significant defects in either
phototransduction or the visual cycle before the onset of retinal degeneration, suggesting that the main
role of miRNAs in rods is to support photoreceptor survival [24].
Additional studies have aimed at revealing the functions of miRNAs in cone photoreceptors,
which are essential for high-acuity and daylight vision. Cone photoreceptor-specific miRNA-deficient
mice have been generated by crossing Dgcr8fl/fl animals with mice expressing Cre recombinase solely
in differentiated cones. In these mice, the Dgcr8 protein was only gradually depleted over time as a
115
Genes 2019, 10, 377
consequence of its prolonged half-life. Thus, loss of miRNA processing was first detected at P30 and
was complete only by P60. The lack of miRNAs in these animals resulted in the progressive loss of
cone outer segments, and therefore in low sensitivity to high light levels. However, cones without
outer segments did not degenerate in spite of their severely altered gene expression profiles. The latter
suggests a crucial role for miRNAs in regulating genetic pathways essential to cone outer segment
maintenance and function, but not to cone survival [17]. On the other hand, a recent study reported
that the conditional knockout of Dicer in cones results not only in outer segment loss but also in a
more severe phenotype with enhanced cone cell death [25]. For proper phenotype interpretation,
the targeted miRNA biogenesis proteins, Dgcr8 versus Dicer, are of importance as Dgcr8 knockouts
may have residual miRNA expression from splicing products. Although these reports also differed in
the cone-specific Cre driver lines used and in the onset of miRNA loss, together they provide strong
evidence for the importance of miRNAs on photoreceptor homeostasis, function, and survival.
4. The Impact of the miR-183/96/182 Cluster on Photoreceptors
The miRNAs of the miR-183/96/182 cluster play important functional roles in multiple sensory
tissues, as evidenced by their expression not only in the retina [26,27], but also in the inner ear [28],
the olfactory and gustatory epithelium [27], and in dorsal root ganglia mechanosensory neurons [29].
miR-183, -96, and -182 are expressed as a single polycistronic transcript and exhibit significant sequence
similarity in their seed regions. Thereby, they possess shared targets and can partially substitute
each other’s function. This overlap in function explains why targeted deletion of only one of these
three miRNAs, i.e., miR-182, results in no visible alterations in retinal development [30]. More
importantly, although these three miRNAs possess distinct targets, the majority of such targets are
involved in identical pathways [31]. In the retina, the miR-183/96/182 cluster is enriched in rod and cone
photoreceptors with transcript levels reduced in dark and increased in light conditions (Figure 2). Such
dynamic changes in expression levels are the consequences of rapid miRNA decay and of increased
transcription, respectively. The latter suggests that miRNA metabolism, in general, is higher in neurons
than in other cell types, possibly due to neuronal activity [21].
The function of the miR-183/96/182 cluster was examined in a transgenic mouse line expressing a
miRNA sponge for all three cluster miRNAs exclusively in mature rods [32]. Retinae from these mice
displayed no detectable morphological or functional changes, likely because the sponge activity was
insufficient to capture all mature miRNA molecules of such a highly expressed cluster. Nonetheless,
after 30 min exposure to high light intensities (10,000 lux), transgenic mice but not wild type animals
showed severe retinal degeneration, indicating that reduced levels of cluster miRNAs have an impact
on rod function and survival. More severe retinal defects and retinal degeneration were observed in a
miR-183/96/182 cluster knockout mouse model [33], although the miRNAs of the cluster were also
missing during photoreceptor development, when cluster expression is tightly controlled [34]. Hence,
in this case it is impossible to distinguish the functions of the miR-183/96/182 cluster in development
from those in adulthood. Nevertheless, together these knockdown and knockout studies suggest
that this cluster plays a neuroprotective role in the retina. Remarkably, re-introducing miR-182 and
-183 in Dgcr8 cKO cones, i.e., cones depleted of all other miRNAs, has been reported to prevent the
loss of cone outer segments [17]. Considering that miR-182 and -183 constitutes around 70% of all
cone miRNA content, it is likely that these play major roles in cone functionality, including in the
modulation of outer segment maintenance. Furthermore, overexpression of the miR-183/96/182 cluster
in embryonic stem cell-derived retinal organoids induces the formation of light-responsive short outer
segments [17], while in human RPE cells in vitro it triggers their reprogramming to neurons [35].
In this sense, a number of the cluster’s targets have been validated, including pro-apoptotic genes, like
Casp2 [32], genes important for survival such as Rac1 coding for the small GTP-binding protein [36],
and neurotransmitter transporters like the voltage-dependent glutamate transporter Slc1a1 [21] as well
as the sodium- and chloride-dependent glycine transporter Slc6a9 [36]. The latter, together with the
neurogenic effects of overexpressing the miRNAs within this cluster in different cell types, suggests
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that the miR-183/96/182 cluster is central to photoreceptor homeostasis and serves as a pro-survival
factor in stress conditions.
Figure 2. MiRNAs acting as modulators of retinal cell behavior. In the vertebrate eye, the retinal
pigment epithelium (RPE) separates the retina from the subretinal space. Within the outermost layer
of the retina, rod and cone photoreceptors sense light with their outer segments (OS). Photoreceptor
bodies reside within the outer nuclear layer (ONL), and their axons protrude into the outer plexiform
layer (OPL), where they synapse with excitatory bipolar cells and inhibitory horizontal cells. The
bodies of these cells, as well as of amacrine cells, which create inhibitory synapses with the axons of
bipolar cells, reside in turn within the inner nuclear layer (INL). The electrochemical signal produced
by photoreceptors during phototransduction is transmitted through bipolar cells to ganglion cells
via synaptic connections in the inner plexiform layer (IPL). In a final step, ganglion cells send this
information to higher brain areas through their axons, which bundle up to form the optic nerve. An
additional cell type within the retina is Müller glia. These cells play key roles in the support of neuronal
functions and in mediating the reaction to a number of physiological signals, including immune
responses. Müller glia feet form the outer limiting membrane (OLM), which separates photoreceptor
OS from their somata. Within the retina, miRNAs play central roles in health and disease. Recognized
miRNA species associated to the functionality of specific retinal cell types are shown with validated
targets between parentheses. GCL, ganglion cell layer; ILM, inner limiting membrane.
5. miR-124 Protects Photoreceptors from Apoptosis
MiR-124 is enriched in neurons of the central nervous system [37,38] including the retina [39], and
is one of the most well studied miRNA species. In the retina, miR-124 is expressed in all neuronal cell
layers, but most prominently in photoreceptor outer (OS) and inner segments (IS). As both humans
and mice possess three miR-124 loci, the generation of a complete miR-124 knockout model has been
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challenging. Recently, a full miR-124 KO (i.e., all six genomic copies) was achieved in a human induced
pluripotent stem cell model of neurogenesis [8]. Neurons generated from KO cells displayed altered
morphological and functional features and decreased long-term viability, pointing to the importance of
miR-124 in neuronal survival. Of note, among the three miR-124 paralogs (a-1, a-2, and a-3), miR-124a-1
has been previously identified by in situ hybridization as the predominant form expressed in the
developing mouse retina, with miR-124a-2 being detected at very low levels and miR-124a-3 expression
being almost negligible [40]. In agreement with this, knocking out the miR-124a-1 host gene, i.e., the
retinal non-coding RNA 3 (Rncr3), abolishes miR-124 expression almost entirely in the mouse cone
photoreceptor layer. Additional consequences of miR-124a-1 KO included cone mislocalization and
apoptosis, decreased expression of cone-specific genes, and reduced light-responsiveness [40].
A validated target of miR-124a in the retina is Lhx2. Indeed, the miR-124a-mediated
downregulation of Lhx2 mRNA levels is necessary for cone survival [40]. As depletion of Dgcr8 in
adult cones does not cause cone degeneration, it is very likely that miR-124 is effective in these cells
early during development but that after differentiation they remain unaffected by miR-124 deletion.
In agreement, neurogenesis is hindered neither in the complete miR-124 KO in vitro model nor in
miR-124a-1 KO mice, although increased apoptosis was observed over time in both cases. Moreover, as
cones but no other retinal neurons degenerate in miR-124a-1 KO mice, it is possible for the compensatory
effects of the other two miR-124 paralogs to be insufficient in these photoreceptors but more potent in
other retinal cell types.
In the retina, miR-124 is expressed not only in photoreceptors but also in neurons within the inner
nuclear layer and the ganglion cell layer. An altered distribution of miR-124 expression from primarily
the outer nuclear layer to the inner nuclear layer has been reported to occur in age-related macular
degeneration (AMD) patients and mouse models of retinal degeneration [41], with such changes
being followed by miR-124 depletion at later degeneration stages. Moreover, environmental stress
factors, such as high light intensities, are speculated to induce the translocation of this miRNA from
photoreceptors to Müller glia (MG) cells, where it targets the CC-chemokine ligand 2 (Ccl2). Ccl2 is a
pro-inflammatory chemokine that attracts microglia/macrophages and that is produced and released by
MG cells in response to retinal damage [42]. Further, this chemokine is upregulated in both neovascular
and atrophic forms of AMD [43] and in retinitis pigmentosa [44]. By downregulating Ccl2, miR-124
translocation would thus dampen the inflammatory cascade and promote photoreceptor survival.
After prolonged stress, on the other hand, miR-124 depletion results in highly pro-inflammatory
environments and thereby in subsequent photoreceptor degeneration. Supporting these observations,
Ccl2 downregulation has been shown to reduce photoreceptor cell death in animal models of retinal
degeneration [44–46]. Notably, intravitreal administration of miR-124 mimics decreases retinal
inflammation and photoreceptor cell death, while preserving retinal function [41]. The latter might be
a consequence, at least partially, of increased Ccl2 targeting.
6. miRNA Functions in Inner Retinal Neurons
For the maintenance and survival of retinal cell types other than photoreceptors, miRNAs are also
remarkably important. For example, miR-125b has been described as a regulator of neuritogenesis
during remodeling in rod bipolar cells after retinal degeneration [47]. Similarly, in retinal ganglion
cells (RGCs), miRNA expression profiles and functions have been investigated. RGCs are responsible
for sending the visual information collected by photoreceptors to higher brain areas via the optic
nerve, and their damage is a hallmark of glaucoma. In retinae of a glaucoma mouse model, nine
miRNAs (out of 17 tested) were identified as differentially expressed relative to controls. Among
those nine miRNAs, the pro-apoptotic miR-16, -497, -29b, and let-7a were downregulated, while the
anti-apoptotic miR-27a was upregulated. Whereas let-7a exerts its apoptotic function by inducing
neurodegeneration via Toll-like receptor signaling, miR-16, -29b, and -497 negatively regulate the
apoptosis regulator Bcl-2. These alterations in miRNA expression profiles suggest a shift towards a
protective anti-apoptotic phenotype [48]. In a different mouse model of glaucoma, downregulation
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of miR-149 led to an increased RGC number and minimized ultrastructural RGC alterations [49]. In
this study, betacellulin (Btc) was also identified as a miR-149 target. BTC is a mitogen influencing the
activation of the PI3K/AKT signaling pathway, which mediates RGC protection via its pro-survival and
anti-apoptotic effects. Further, in the N-methyl-D-aspartate (NMDA)-induced glaucoma mouse model,
significant reductions in RGC viability were accompanied by miR-93-5p downregulation [50]. Reduced
miR-93-5p levels in these mice, in turn, resulted in the elevated presence of its target phosphatase and
tensin homolog (PTEN), which promotes autophagy of RGCs via the AKT/mTOR pathway. Confirming
the central role of miR-93-5p in this context, the reduced viability of RGCs isolated from retinae of
NMDA-induced glaucoma animals was counteracted either by overexpressing this miRNA species or
by transfection with a miR-93-5p mimic.
In mouse models of optic nerve injury, increased expression of specific miRNAs has also been
detected. miR-21 expression, for instance, correlated with reactive MG gliosis. Whereas activated MGs
are neuroprotective after injury in the acute response phase, they later acquire a pro-inflammatory and
pro-apoptotic phenotype. Modulating MG gliosis in both the acute and chronic post-injury phases in
these mice resulted in enhanced RGC survival and functionality and led to improvements in retinal
structural integrity [51]. Often, however, the protective roles of distinct miRNAs in RGCs have been
assessed in vitro. In rat RGC-5 cells, for instance, overexpression of miR-187 was reported to suppress
apoptosis and promote proliferation by targeting Smad7 [52]. Similarly, upregulation of miR-211 was
shown to downregulate Frs2 and to decrease the extent of cell death in RGC-5 cells subjected to a
high-pressure challenge [53]. These results hint at a protective effect of miR-187 and miR-211 on RGCs.
On the other hand, lentivirus-mediated down-regulation of miR-100 has been described to reduce
hydrogen peroxide-induced RGC apoptosis and to enhance neurite growth by activating the AKT/ERK
and TRKB pathways through phosphorylation [54]. In a similar experimental approach, hydrogen
peroxide-induced apoptosis of RGC was described to decrease upon miR-134 downregulation. In this
case, a luciferase reporter assay confirmed that miR-134 directly interacts with the cyclic AMP-response
element-binding protein (Creb), a transcription factor with central roles in neuronal protection that
modulates the expression of the anti-apoptotic proteins BDNF and Bcl-2. Thus, inhibiting miR-134
effectively reduces apoptosis levels by allowing the enhanced translation of CREB and, consequently,
the upregulation of its downstream targets BDNF and Bcl-2 [55].
7. The role of miRNAs in Müller Glia Development and Function
MiRNAs play an important role in retinal development as described in several studies using
Dicer conditional knockouts [56–58] (summarized in [59]). One study in particular reported that the
blockade of miRNA genesis in an αPax6-Cre mouse model prevented the development of late retinal
progenitors and their progenies, including MG [60]. Specifically, three miRNAs have been identified
as key regulators of the early to late developmental transition in retinal progenitors, namely let-7,
miR-125, and miR-9 [61,62]. Thus, miRNAs may be involved in MG differentiation. As mentioned
above, the miRNA expression of whole retinae has been previously profiled [63,64]. Since the vast
majority of retinal cells are rod photoreceptors and MG account for only around 2% of them [65], the
profiling and identification of MG-specific miRNAs requires FACS-purification or primary cultures.
Two independent studies have so far aimed at identifying these miRNAs. The authors of the first
study isolated MG from P8 retinae and cultured the cells before miRNA profiling. The culture period,
however, was not clarified. In this study, miR-143, miR-145, miR-214, miR-199a, miR-199b*, and
miR-29a were identified as highly expressed [66]. In the second study, miR-204, miR-125b, and miR-9
were identified as MG-specific miRNAs (mGliomiRs) in reporter-labelled (RlbpCreERT-dtTomato)
FACS-purified P11/P12 murine MG [67]. These three miRNAs had high expression levels in MG, with
increasing levels from P11 to adulthood. Moreover, besides these MG-specific miRNAs, a distinct set
of miRNAs had similar expression levels in both neurons and glia (termed shared miRNAs). This set
includes most members of the let-7 family and miR-29a. Thus, it is conceivable that miR-125, miR-9,
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and let-7 are not only key regulators in the early to late progenitor transition [61], but that they are also
important for MG maturation and function.
A remaining question was whether miRNAs are required for proper MG function. This
was addressed in a Dicer cKO study using a MG-specific Rlbp-CreERT:tdTomato:Dicerfl/fl reporter
mouse [68]. Dicer deletion was induced in these mice by tamoxifen administration at P12, when MG
are differentiated, as well as in one-month old animals. Over a period of 6–12 months, glia aggregated
abnormally, leading in turn to massive structural disturbances. Although MG usually do not express
the Bcan gene, which encodes a chondroitin sulfate proteoglycan, RNA-Seq showed this to be the most
highly upregulated gene in these cells. Notably, this phenotype was primarily the consequence of miR-9
loss. miR-9 targets the 3’UTR of Bcan, and its administration in vitro or ex vivo prevented abnormal
glia development and/or partially restored overall retinal structure. Although in these mice miRNAs
were only deleted in MG and not in neurons, a massive loss of photoreceptors was also observed. More
importantly, retinal remodeling also subsequently ensued. Remodeling generally occurs as a result of
photoreceptor degeneration [69]. Interestingly, MG from human retinitis pigmentosa tissue displayed
similar cell aggregation and were positive for Brevican (the protein encoded by Bcan). This suggests
that not only loss of or disturbances in neuronal miRNAs, but also dysregulation of the glial miRNA
biogenesis machinery could be causative of retinal diseases [68]. This hypothesis is further supported
by MG ablation studies showing that the dysfunction of this cell population plays an important role in
retinal diseases [70–73].
8. miRNAs in Müller Glia De-Differentiation and Their Potential Regeneration Capacity
Although there are miRNAs specific to retinal progenitors, neurons, and MG, and despite many
of these miRNAs playing important roles in cell fate decisions, their capacity to alter the fate of mature,
fully-differentiated cells remains controversial. In contrast to mammalian retinae, the fish retina can
regenerate completely after injury. Remarkably, MG are the cells that mediate the regeneration process.
MG de-differentiate to progenitors, proliferate, migrate, and differentiate de novo into all retinal
cell types, including RGCs and photoreceptors. Key regulators in this regenerative process are the
Acheate-scute family bHLH transcription factor 1 (Ascl1) and the RNA-binding protein Lin-28, which
are both regulated by the miRNA let-7 [74,75]. Additional factors discovered to be involved in this
process include Wnt [76] and Shh [77], which are regulated by the miRNA let-7 in fish and mouse.
Notwithstanding, the mechanisms of MG reprogramming in mice, especially at adult ages, are more
intricate and involve epigenetic alterations [78].
The brain-enriched miR-124 is known to regulate neurogenesis [39,41,67,79]. Accordingly,
overexpression of miR-124 in MG-derived mouse progenitors in vitro results in twice as many
βIII-Tubulin-positive cells as in wild-type control cells [66]. This indicates that this neuronal miRNA
can be used to direct retinal progenitor like-cells towards a neuronal fate, as it has previously been
observed on neural stem cells [80,81]. Moreover, when miR-124 alone or in combination with
miR-9/9* was overexpressed in P12 mouse MG in vitro, MG de-differentiated into Ascl1-expressing
progenitor-like cells that later on expressed mature neuronal markers including Map2, Calbindin,
and Calretinin. The underlying mechanism for this process is known to require the RE1-silencing
transcription factor (Rest) pathway [67], an evolutionarily conserved transcriptional regulator that
inhibits neuronal gene expression in non-neuronal cells such as glia or fibroblasts [82–84], and whose
inhibition by miR-124 enhances the expression of neuronal genes [85–87]. In addition, miR-124 has
recently been described to promote axon growth in RGCs differentiated from young rat retinal stem
cell-derived MG by silencing the REST complex [88]. Besides miR-124, miR-28 has also been reported
to potentially play a role in photoreceptor differentiation. MG-derived progenitors treated with
anti-miR-28 exhibited Crx and Rhodopsin expression while miR-28 overexpression did not [89]. In this
case, however, the underlying mechanisms remain elusive.
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9. Global miRNA Alterations in Retinal Diseases
Retinitis pigmentosa (RP) is a complex inherited retinal disease that emerges from a heterogeneous
pool of mutations [90]. Yet, irrespective of the underlying mutation, clinical manifestations are often
similar and include progressive photoreceptor loss and visual impairment. To determine if miRNA
dysregulation is involved in the pathophysiology of RP, miRNA expression levels have been interrogated
in multiple mouse models of retinal degeneration. One study examined the miRNA expression profile of
two rhodopsin (Rho) mutants (recessive rho–/– knockout and dominant P347S-Rhodopsin, also known as
R347) and two RDS/Peripherin mutants (recessive rds–/– null mutant and dominant Δ307-rds) [91]. The
authors reported all four mouse models to exhibit miR-96, -182, and -183 downregulation, and miR-1,
-133, and -142 upregulation. The dysregulated miRNA signature of isolated rods as well as of whole
retinae of R347 and Δ307-rds mice were similar. These findings suggest that altered miRNA profiles
are indeed associated with RP, irrespective of the causative mutation or of its dominant or recessive
nature. However, the miR-183/96/182 cluster is highly expressed in photoreceptors and therefore its
downregulation might be a consequence of the massive rod photoreceptor degeneration rather than
causative of RP. In a follow-up study, C-terminal Binding Protein 2 (Ctbp2) was validated as a miR-1
target, with Slc6a9 and Rac1 being recognized by miR-9, -182, and -183 [36]. CTBP2, a major component
of specialized synapses, was shown to be co-expressed with the miR-1/133 cluster in photoreceptors, and
its levels were reported to decrease in photoreceptor synaptic regions of R347 retinae. The latter suggests
that miR-1/133 may play a role in regulating synaptic remodeling at photoreceptor synapses by targeting
Ctbp2. In contrast, Slc6a9, which encodes one of the two main transporters involved in removing glycine
from the synaptic cleft, was co-expressed with miR-1/133 exclusively in cone photoreceptors.
The retinal degeneration 10 (rd10) mouse is a commonly used model of autosomal recessive
retinitis pigmentosa and has been utilized to study miRNA expression patterns in early retinal
degeneration [92]. In these mice, a spontaneous mutation in the rod phosphodiesterase (Pde) gene leads
to photoreceptor death from post-natal day 16 on as a result of calcium dysregulation [93]. By using
microarrays to profile the expression of over 1900 miRNAs in rd10 retinae, 152 differentially expressed
miRNAs have been identified after (P17, P19, and P22), but also shortly before (P15) the initiation of
photoreceptor apoptosis [92]. The miRNAs identified as differentially expressed prior to the onset of
apoptosis include miR-6240, miR-6937-5p, miR-3473b, and miR-7035-5p, which are likely involved in
the disease etiology. On the other hand, miR-155-5p, miR-142-5p, and miR-146a-5p were differentially
expressed after the onset of apoptosis. Thus, it remains unclear whether these miRNAs counteract or
enhance disease progression. By comparing differentially expressed miRNAs with inversely correlated
mRNAs and performing gene ontology and biological pathway analyses, a large number of miRNA
targets were revealed to encode factors involved in apoptosis, the inflammatory response, calcium
signaling, visual perception, and phototransduction.
The differential expression of miRNAs in the context of retinal degenerative diseases has
also been studied in canine models. Notably, the early onset retinal degeneration models Xlpra2
(RPGRORF15-microdeletion), Rcd1 (PDE6B-mutation), and Erd (STK38L-mutation), as well as the
slowly progressing Prcd (PRCD-mutation) model, have been reported to exhibit similar miRNA
expression profiles as healthy control dogs both prior to and at the peak of photoreceptor cell death [94].
Divergences were reported to arise only during the chronic cell death stage, with anti-apoptotic
miRNAs such as miR-9, -19a, -20, -21, -29b, -146a, -155, and -221 being upregulated and pro-apoptotic
miR-122 and miR-129 being downregulated. Although the miRNA species differentially expressed in
canine and murine models of retinal degeneration are not identical, available reports hint at miRNAs
playing a role in counteracting the degenerative processes characteristic of diseased retinae by delaying
photoreceptor cell death.
A number of additional studies have interrogated the retinal miRNA expression profile in response
to injury. Inducing photoreceptor death by ablating MG, for instance, leads to the differential expression
of 16 miRNAs, with miR-142, miR-146, and the miR-1/133 cluster in particular exhibiting increased
expression levels [95]. In this study, increased miR-133 expression was mainly detected within the
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outer nuclear layer, where it targets the anti-apoptotic gene cyclin D2. In fact, the cyclin D2 family
has been reported to play a neuroprotective role in retinal degeneration [96]. Unexpectedly, a positive
correlation between miR-133 and cyclin D2 was also reported, suggesting that miR-133 up-regulates the
expression levels of its own target. Further, in models of light-induced photoreceptor death, 37 miRNAs
have been described to increase in expression upon light damage, including seven that regulate the
inflammatory response (miR-125, -155, -207, -347, -449, -351, -542). Among the latter, miR-155 is of
particular interest as it is linked to the progression of the inflammatory response through the targeting
of complement factor H (Cfh) [97], a major inhibitor of the alternative complement pathway [98].
Moreover, upregulation of miR-155 has been detected in both mouse and canine models of inherited
retinal diseases [92,94], suggesting that the roles of certain miRNAs are conserved across species and,
more notably, shared in different injury response contexts.
The miRNA profile of human retinae has been recently investigated via high-throughput
sequencing [99]. The assessment of miRNA expression levels in 16 retinae from healthy donors
led to the detection of 480 miRNA species with more than 3000 variants. Of note, the five most highly
expressed miRNAs accounted for 70% and the top 20 miRNAs for almost 90% of the entire retinal
miRNA profile. Moreover, the miRNAs miR-182 and miR-183 were the most prevalent miRNA species
in retinal neurons and miR-204 was the most abundant miRNA in retinal pigment epithelium (RPE) cells.
Some of these highly expressed human miRNAs coincide with those previously identified in murine
retinae by microarray analyses and RNA in situ hybridization experiments [27,64,100,101], pointing
to their potentially conserved retinal functions across mammalian species [102]. It is known from
animal models that miRNA expression patterns change over the course of retinal development [64,101]
and that such dynamic miRNA expression profiles are crucial to retinal cell differentiation (reviewed
in [59]). Altogether, it is very likely that the impact miRNAs have in animal models is transferable to
human retinal cell types in health and disease. This further implies that particular miRNAs may be
used as disease biomarkers and, additionally, that the precise modulation of their expression levels
might represent a valuable therapeutic strategy for the treatment of diverse retinal inherited disorders.
10. Conclusions
We are in the process of understanding the complex functions of miRNAs in retinal health and
disease. Further studies are required to obtain coherent pictures of gene expression regulators in order
to harness their potential use not only as biomarkers but also to treat and counteract retinal diseases.
As individual miRNA species have the potential to orchestrate entire genetic programs, the possibility
to use them as master regulators to stabilize or reset the cellular state of neurons and glial cells in the
retina is highly promising.
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Abstract: Mutations in CEP290 encoding a centrosomal protein important to cilia formation cause a
spectrum of diseases, from isolated retinal dystrophies to multivisceral and sometimes embryo–lethal
ciliopathies. In recent years, endogenous and/or selective non-canonical exon skipping of mutant
exons have been documented in attenuated retinal disease cases. This observation led us to consider
targeted exon skipping to bypass protein truncation resulting from a recurrent mutation in exon 36
(c.4723A> T, p.Lys1575*) causing isolated retinal ciliopathy. Here, we report two unrelated individuals
(P1 and P2), carrying the mutation in homozygosity but affected with early-onset severe retinal
dystrophy and congenital blindness, respectively. Studying skin-derived fibroblasts, we observed
basal skipping and nonsense associated–altered splicing of exon 36, producing low (P1) and very
low (P2) levels of CEP290 products. Consistent with a more severe disease, fibroblasts from P2
exhibited reduced ciliation compared to P1 cells displaying normally abundant cilia; both lines
presented however significantly elongated cilia, suggesting altered axonemal trafficking. Antisense
oligonucleotides (AONs)-mediated skipping of exon 36 increased the abundance of the premature
termination codon (PTC)-free mRNA and protein, reduced axonemal length and improved cilia
formation in P2 but not in P1 expressing higher levels of skipped mRNA, questioning AON-mediated
exon skipping to treat patients carrying the recurrent c.4723A > T mutation.
Keywords: Leber congenital amaurosis and allied retinal ciliopathies; CEP290; Flanders founder
c.4723A > T nonsense mutation; Cilia elongation; spontaneous nonsense correction; AON-mediated
exon skipping
1. Introduction
Leber congenital amaurosis (LCA, MIM204000) is a group of neonatal-onset and severe retinal
dystrophies and a leading cause of incurable blindness in childhood (Frequency 1:30,000; 20% of children
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attending schools for the blind in western Europe) [1]. It typically occurs as a non-syndromic disease
that displays large genetic, allelic and physio–pathological heterogeneity, challenging therapeutic
developments [2]. Mutations in CEP290 (MIM610142) encoding a widely expressed centrosomal
protein involved in cilia formation and maintenance [3], are the leading cause of the disease, referred to
as LCA type 10 (LCA10; MIM611755) [4,5]. Despite early-onset visual loss, LCA10 individuals display
prolonged (>30 years) sparing of central photoreceptors with intact visual brain pathway, creating the
conditions to develop therapies built on correcting genetic lesions [6]. A large number of LCA10-causing
mutations are reported, including the highly prevalent c.2991 + 1655A >G (p.Cys998*) and c.4723A > T
(p.1575Lys*) variants involved in 10% and 2.5% of all LCA cases, respectively [5,7]. The c.2991 + 1655A
> G change activates a deep intronic cryptic splice site and introduces a frameshifting pseudo-exon in
the mRNA [8–11]. Antisense oligonucleotides (AONs) have proven effective to redirect the splicing
machinery towards the consensus splice sites and bypass protein truncation in primary fibroblasts,
IPSC-derived 3D retinal organoids and humanized mice carrying the mutation [8,10,12]. Subsequently,
a phase I/II clinical trial (NCT03140969) has been launched which demonstrated safety and clinical
relevance (vision improvement) of intravitreal injections of splice-modulating oligonucleotide [13].
The c.4723A > T variant, like the vast majority of CEP290 mutations, is predicted to truncate the
protein and is amenable to gene augmentation therapy. However, this approach is challenging due
to both the CEP290 cDNA size (7.4 Kb) which over-exceed cargo capacities of AAV vectors (<5 Kb)
preferred in the field of retinal diseases [14–16] and risk of overexpression toxicity [17,18]. Interestingly,
consistent with an important role in cilia metabolism, CEP290 mutations have been associated with
additional human phenotypes, including oculo-renal Senior Loken syndrome (SLSN6, MIM610189),
oculo-cerebro-renal Joubert syndrome (JBTS5, MIM610188) and embryo-lethal Meckel syndrome type
4 (MKS; MIM611134) [19]. Observation of endogenous basal exon-skipping producing low-levels
of alternatively spliced coding CEP290 mRNAs has inspired a model of pathogenesis according
to which disease severity is a function of the amount of CEP290 a cell can produce from mutant
alleles [20]. Consistently, low levels of premature termination codon (PTC)-free CEP290 mRNA
produced by endogenous basal alternative splicing and/or nonsense associated altered splicing have
been identified in fibroblasts from individuals with biallelic CEP290 truncating mutations but mild
retinal phenotypes [21–23]. Lessening the disease through somatic frame-restoration mechanisms is
reminiscent of genetic reversion in dystrophin-positive muscular fibers from individuals with Duchene
muscular dystrophy which inspired AON-mediated exon skipping to bypass dystrophin truncation and
switch the disease to attenuated Becker muscular dystrophy. Following this example, we considered
AON-mediated skipping of CEP290 exon 36 to bypass protein truncation resulting from the c.4723A
> T nonsense mutation. Here, studying fibroblasts from two unrelated individuals homozygous
for the mutation and controls, we show combination of endogenous and selective exon skipping
producing a minimally shortened CEP290 mRNA and a protein that localized at the centrosome.
Cilia analysis revealed no major anomaly but a significant axonemal elongation. Using AON specific
to the donor consensus splice-site of exon 36 in patient and control fibroblasts, we were able to increase
the abundance of the alternatively spliced mRNA and shortened protein and to reduce axonemal
length. However, fibroblasts with highest levels of alternatively spliced products displayed reduced
ability to ciliate, questioning the relevance of AON-mediated exon skipping to treat patients carrying
the recurrent c.4723A > T mutation.
2. Materials and Methods
2.1. Genetic Analysis
P1 and P2, two unrelated simplex cases born to apparently non-consanguineous parents originating
from the transnational Flanders region were addressed to the Molecular Diagnosis Unit of our Genetic
Department for molecular diagnosis of early-onset and severe retinal dystrophy. Patient DNAs were
subjected to panel-based molecular testing of 199 genes involved in retinal dystrophies (Figure S1) and
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variant datasets were filtered using the Polydiag software of the Polyweb series developed in-house.
Biallelism for apparently homozygous CEP290 c.4723A > T variant was assessed by Sanger sequencing
of parental DNA using primers specific to CEP290 exon 36 (Supplementary Materials, Table S1). Written
informed consents were obtained from all participating individuals and the study was approved by
the Comité de Protection des Personnes “Ile-De-France II” (3 March 2015/DC 2014–2272).
2.2. In Silico Analysis of the Nonsense c.4723A > T (p.Lys1575*) Mutation on Splicing
The consequence of the c.4723A > T substitution on splicing was assessed using several prediction
softwares, as previously described [21].
2.3. Cell Culture
Fibroblast cell lines were derived from skin biopsies of affected subjects (P1 and P2) and three
healthy individuals (C1–C3). A table recapitulating their genetic and clinical features is presented in
Table S2. Primary fibroblasts (<15 passages) were cultured as previously described [21].
2.4. AON and Transfection
AON specific to the donor splice site of CEP290 exon 36 was identified using software prediction
tools (m-fold and ESEfinder3.0 programs available online at http://mfold.rna.albany.edu/ and http://rulai.
cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi respectively) and following general recommendations [24].
The sequence of H36D (+98 −11) AON was as following: 5′-UAGAAUCUUACCCAAG
CCGUUU-3′.
This AON was synthetized by Eurofins Genomics (St. Quentin Fallavier, France) and contains
2′-O-methyl RNA and full-length phosphorothioate backbone. Cells at 80% confluence were transfected
with different concentrations of H36D AON, ranging from 20–300 nmol/L, in Opti-MEM supplemented
with 10% fetal bovine serum using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instruction. Cells were harvested for mRNA or protein analysis between 4 and 72 h.
2.5. RNA Analysis
RNA isolation from fibroblasts and wild-type human fetal retina (22 weeks) and cDNA synthesis
were performed according to previously described methods [21].
Reverse transcription-PCR (RT-PCR) was performed using 2 μL of cDNA as described
previously [21]. CEP290 splicing isoforms were amplified using primer pairs specific to exons 35 and
37 (Figure S2 and Table S3) and PCR products were resolved in a 3% agarose gel.
For real-time quantitative PCR (RT-qPCR), cDNA (5 μL of a 1:25 dilution) were amplified using
primers specific to the full-length and skipped isoforms, respectively (Figure S2 and Table S4), according
to the protocol described in Barny et al. 2018. The human β-glucuronidase (GUSB, NM_000181.3) and
P0 large ribosomal protein (RPLP0, NM_001002.3) mRNAs were used to normalize the data. The data
were analyzed as described previously [8].
2.6. Protein Analysis
For Western blot analysis, total proteins from treated and untreated cells were extracted and
quantified as described previously [21], and the relative abundance of CEP290 protein was estimated
by densitometry using β-Actin as reference in each cell line.
For immunocytochemistry analysis, cells were grown for 24 h on coverslips in 12-well plates to
reach 90–100% confluence and either transfected using the H36D (+98 −11) AON or left untreated.
After 24 h, treated and untreated cells were serum-starved for 48 to 72 h before cold methanol fixation
and immune-labeling of ARL13B, CEP290, CP110, IFT88, pericentrin, RAB8A, γ-Tubulin and/or
acetylated α-Tubulin. Immunofluorescence images were acquired and processed to analyze cilia
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abundance, axonemal length, subcellular localization and/or staining intensities. All experimental
procedures and analytical methods were described in Barny et al., 2018.
2.7. Statistics
All statistical analyses were run using the Prism6 software, and the significance was determined
using one-way ANOVA with post hoc Tukey’s test. The data obtained from C1–C3 were systematically
pooled for immune-labelling analysis. Error bars reflect the standard errors for the mean (SEMs).
3. Results
3.1. Panel-Based Molecular Diagnosis Testing Identifies Homozygosity for the CEP290 c.4723A > T Founder
Mutation in Two Individuals with Congenital Retinal Dystrophy of Variable Severity
We studied two apparently unrelated non-consanguineous sporadic cases of Belgian and/or French
Flanders origin addressed for congenital retinal dystrophy with no extraocular involvement. The first
individual (P1) presented at birth with nystagmus, photoaversion, hyperopia (+6 diopters LRE),
absent cone-derived electroretinogram but present, yet highly hypovolted, rod-derived responses.
He experienced spontaneous improvement of his visual capacities in the first decade of life. At the
age of 20 years, he displayed a tubular visual field with a visual acuity (VA) of 20/67 (RE) and
20/50 (LE) and thin retinal vessels, optic nerve atrophy and peripheral pigmentary deposits at the
fundus. While the initial symptoms suggested early-onset severe cone-rod dystrophy, this outcome is
consistent with a rod-dominant LCA-like disease referred to as early-onset severe rod-cone dystrophy.
The second individual (P2) presented with a typical LCA10-associated disease, i.e., a stationary
congenital blindness with nystagmus, inability to follow lights or objects and flat cone- and rod-derived
electroretinographic responses. Panel-based molecular diagnosis for inherited retinal dystrophies
(199 genes) and Sanger-based familial segregation analysis identified homozygosity for the Flanders
founder CEP290 c.4723A > T (p.Lys1575*) mutation in the two cases.
3.2. In Silico Analysis Suggests That the CEP290 c.4723A > T Mutation Induced Nonsense-Associated
Altered Splicing
We analyzed the effect of the c.4723A > T mutation on splicing by using prediction software
solutions scrutinizing splice signals and exonic splicing silencer (ESS)/exonic splicing enhancer (ESE)
binding sites. The mutation had no effect on the canonical splice sites of exon 36 (not shown), but it
increased the exon 36 ESS/ESE ratio, thus elevating the susceptibility of skipping compared to the
wild-type sequence (Table 1). The substitution of the c.4723 adenine into a guanine but not a cytosine
is predicted to have the same effect.
Table 1. Impact of the c.4723A > T mutation on exonic splicing silencer (ESS) and exonic splicing
enhancer (ESE) motifs within the CEP290 exon 36.
Nucleotide
EX-SKIP Predictions HOT-SKIP Predictions Skipping Predictions of
Mutant Allele Compared
to WT Allele
ESS ESE ESS/ESE ESS ESE ESS/ESE
c.4723
(exon 36)
A 12 88 0.14 2 17 0.12 -
T 19 75 0.25 9 4 2.25 Higher chance
G 13 87 0.15 3 16 0.19 Higher chance
C 11 82 0.13 1 11 0.09 Lower chance
Nucleotide change effect at position c.4723 on ESS and ESE motifs according to EX-SKIP and HOT-SKIP prediction
programs. The wild-type (WT) and mutant alleles identified in this study are marked in italic and bold, respectively.
ESS = Exonic splicing silencer; ESE = Exonic splicing enhancer.
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3.3. mRNA Analysis Supports c.4723A > T-Mediated Nonsense-Associated Altered Splicing and Basal
Endogenous Alternative Splicing of Exon 36
Agarose gel analysis and Sanger sequencing of RT-PCR products generated from P1 and P2
skin fibroblast mRNAs carrying the c.4723A > T variant in homozygosity using primers specific to
CEP290 exons 35 and 37 (Figure S2 and Table S3) detected the full-length mutant cDNA (CEP290) and
a PTC-free alternatively spliced product lacking exon 36 (CEP290Δ36). Control fibroblasts expressed
the full-length wild-type cDNA but the CEP290Δ36 product was undetectable, contrasting with human
retina where both isoforms were identified. These observations indicate that CEP290 exon 36 undergoes
endogenous basal skipping in the retina and that, consistent with in silico analysis, the c.4723A >
T variant induces nonsense-associated altered splicing (Figure 1A). Interestingly, RT-qPCR analysis
using primers specific to the CEP290Δ36 isoform (Figure S2 and Table S4) detected the product in
control fibroblasts (Figure 1C). Consistent with expression below the threshold of agarose gel detection,
the abundance of the CEP290Δ36 mRNA in controls was approximately one-tenth that measured in
patient cells (Figure 1C). This observation supports some contribution of endogenous basal exon
skipping in CEP290-frame-restoration documented in P1 and P2 mutant fibroblasts. RT-qPCR analysis
using primers specific to the full-length mutant/wild-type cDNA (Figure S2 and Table S4) showed
reduced abundance of the mutant product in P1 and P2 cell lines compared to the wild-type counterpart
in controls supporting nonsense-mediated RNA decay (NMD) of the mRNA carrying the nonsense
c.4723A > T variant (Figure 1B).
 
Figure 1. Naturally occurring exclusion of CEP290 exon 36 encompassing premature stop codon.
(A) Analysis of CEP290 transcript extracted from wild-type human fetal retina (Retina), control (C1–C3)
and patient (P1 and P2) cell lines. Image of agarose gel and Sanger sequencing electropherograms
showing amplicons produced using primer pairs surrounding mutant exon 36 and corresponding
sequences. The boxes close to electropherograms summarize the exonic organization and phasing
of each reverse transcription (RT)-PCR fragment. White asterisks point to heteroduplex products.
Red arrows show the position of the premature termination codon (PTC) within exon 36 CEP290
isoform. (B) Relative expression levels of WT (grey bar) and mutant (black bars) full-length and skipped
(CEP290Δ36; hatched bars) CEP290 mRNAs in control (C represents pooled values of C1–C3) and patient
(P1 and P2) fibroblasts as determined by RT-qPCR. Bars correspond to the mean ± SEM derived from
ten independent experiments. **** p ≤ 0.0001, n.s = not significant.
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3.4. Protein Analysis Detects Low Levels of a CEP290 Protein That Localizes at the Centrosome in Patient
Fibroblasts Homozygous for the c.4723A > T Nonsense Mutation
Western blot analysis of protein extracts from serum-starved P1 and P2 fibroblasts detected
minimal amounts of a CEP290 product around 290 KDa (Figures 2 and 3C) that localized at the
centrosome upon immunocytochemistry analysis (Figure 3A,B). These results indicate that the PTC-free
alternatively spliced product lacking exon 36 was translated into a stable protein that can be recruited
at the centrosome as does the wild-type protein.
Figure 2. Effect of the natural exclusion of PTC-encoding exon 36 on CEP290 protein production.
(A) Immune detection of the CEP290 and β-Actin in control cell lines (C1–C3) and mutant fibroblasts
(P1 and P2). (B) Quantification of CEP290 abundance relative to β-Actin in control (C represents the
pooled values of C1–C3) and patient fibroblasts. Bars correspond to the mean value ± SEM from four
independent experiments. ** p ≤ 0.01, n.s = not significant.
3.5. Cilia Analysis of Serum-Starved Patient Fibroblasts Shows Apparently Normal RAB8A Localization at the
Centrosome but Elongated Axonemes
CEP290 exon 36 encodes 36 amino-acids contributing to the CEP290 domain that binds RAB8A,
the recruitment of which at the centrosome leads to the release of the cilia formation-suppressor CP110,
hence initiating ciliogenesis during transition of the cells from proliferation to quiescence [25–27].
Interestingly, RAB8A immune-labeling in quiescent fibroblasts showed comparable localization at
the basal body in patient and control fibroblasts, suggesting that the absence of information encoded
by exon 36 does not alter the recruitment of RAB8A at the centrosome (Figure 4A,B). Furthermore,
we observed comparable CP110 abundance at the centrosome of control and P1 fibroblasts indicating
correct release upon RAB8A recruitment (Figure 4C,D). In contrast, the amount of CP110 at the
centrosome of P2 cells was significantly higher than in control and P1 cells (p ≤ 0.0001; Figure 4C,D).
Whether CP110 accumulation in P2 could be correlated to reduced abundance of CEP290Δ36aa protein
compared to P1 is possible but remains hypothetic as the difference in CEP290Δ36aa amounts was not
statistically significant between patient cell lines. Consistent with normal and impaired CP110 release,
cilia abundance was in the normal range and reduced in P1 and P2 fibroblasts, respectively (p ≤ 0.001;
Figure 5A,B).
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Figure 3. CEP290 expression assessment in quiescent cells. (A) Representative images of CEP290
(green) localization in quiescent control and mutant fibroblasts. Acetylated α-tubulin (Ac-tub; red) is
used to stain the ciliary axoneme. As in control cell lines (C1–C3), CEP290 is correctly localized at
the base of the cilia in patient (P1 and P2) fibroblasts. Scale bar, 5 μm. (B) Centrosomal localization
of CEP290 (green) in control and mutant fibroblasts. The γ-tubulin (γ-tub; red) labeling is used as a
centrosomal marker. Image scale bar, 5 μm and inset scale bar, 2 μm. (C) Quantification of the CEP290
immunofluorescence intensity at the basal body in each cell line (C represents the pooled values of
C1–C3). Each dot depicts the labeling intensity of the protein in individual cells from six microscope
fields (recorded automatically). The solid line indicates the mean. **** p ≤ 0.0001, n.s = not significant.
A.U. = arbitrary unit.
 
Figure 4. Localization and abundance of CEP290 centriolar satellite partners. (A) Representative
images of RAB8A (red) localization in the cilia from control (C1–C3) and mutant (P1 and P2) fibroblasts
induced to quiescence. ARL13B (green) labeling is used to mark the ciliary membrane. Scale bar, 5 μm.
(B) Quantification of RAB8A-positive cilia in each cell line (C represents the pooled values of C1–C3).
Bars correspond to the mean ± SEM (n ≥ 50 cilia for each group). n.s = not significant. A.U. = arbitrary
unit. (C) Representative images of CP110 (green) centrosomal staining in quiescent control and mutant
fibroblasts. Centrosomes are stained by γ-tubulin (γ-tub.; red). Image scale bar, 5 μm and inset scale
bar, 2 μm. (D) Quantification of CP110 immunofluorescence intensity at centrosomes in quiescent
fibroblasts (C represents the pooled values of C1–C3). Each dot depicts the labeling intensity of the
protein in individual cells from six microscope fields (recorded automatically). The solid line indicates
the mean. **** p ≤ 0.0001, n.s = not significant. A.U. = arbitrary unit.
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Figure 5. Ciliogenesis and axonemal trafficking. (A) Representative images of cilia in the quiescent
control (C1–C3) and mutant (P1 and P2) fibroblasts. The cilium axoneme is labeled with acetylated
α-tubulin (Ac-tub; red) and the basal body using pericentrin as a marker (PCN; green). Scale bar,
5 μm. (B) Percentage of ciliated cells and (C) length of cilia axonemes in control and patient fibroblasts.
A minimum of 90 ciliated cells were considered for each cell lines. (D) Representative images of IFT88
(green) localization along the cilium in quiescent control (C1–C3) and mutant (P1 and P2) fibroblasts.
Acetylated α-tubulin (Ac-tub; red) staining was used as a marker of the ciliary axoneme. Scale bar,
5 μm. (E) Quantification of IFT88-positive cilia. Bars represent the mean ± SEM (n ≥ 80 cilia for each
group). C regroups the values of C1–C3. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, n.s = not significant.
On another note, measuring cilia length, we observed statistically significant axonemal elongation
in both patient cell lines compared to controls (mean axonemal sizes of 4.4 μm in P1 and 4.9 μm in
P2 versus 3.9 μm in controls, p ≤ 0.0001; Figure 5A,C). Cilia in P2 expressing lower amounts of the
CEP290Δ36aa isoform at the centrosome displayed significantly longer axoneme than P1 counterparts
(p ≤ 0.01; Figure 5A,C), further supporting a possible correlation between the severity of cilia phenotype
and the amount of minimally shortened CEP290 cells are able to produce from mutant alleles.
As observed in controls cells, IFT88 immune-labelling in patient fibroblasts revealed this
intraflagellar trafficking (IFT) complex B protein all along the axoneme (Figure 5D,E), assuming
that the abnormal cilia elongation in patient cells is not related to a defect of the anterograde trafficking
driven by IFT88.
3.6. Targeting the Consensus Donor Splice Site Enables Dose- and Time-Dependent Skipping of CEP290
Exon 36
The RNA conformation around CEP290 exon 36 and splicing regulatory elements were predicted
in silico using m-fold and ESEfinder3.0 programs to design splice switching AON. We designed
2′-O-methyl-phosphorothioate (2′-OMePs) AON targeting the donor site (H36D (+98-11)) (Figure 6).
The AON was delivered in patient and control fibroblasts at a final concentration of 150nM for 24h
prior to mRNA analysis. Treatment with H36D (+98 − 11) AON elevated significantly the abundance
of products lacking exon 36 and reduced by half the amount of full-length mutant and wild-type
products in patient and control fibroblasts, respectively (Figure 7). Due to NMD, the abundance
of the full-length mutant was significantly reduced in patient compared to control cells (Figure 7B).
Consistent with a switch from a mRNA prone to NMD to a PTC-free isoform, the abundance of the
alternatively spliced product lacking exon 36 in patient fibroblasts was comparable to that of controls
upon treatment with the H36D (+98 − 11) AON. Treatment with the transfection reagent alone did not
alter CEP290 expression whatever the cell line (Figure 7).
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Figure 6. Antisense oligonucleotides (AONs)-mediated splicing alteration of CEP290 pre-mRNA to
bypass protein truncation. An exonic mutation in CEP290 pre-mRNA (c.4723A > T, in red) introduces a
PTC within exon 36 to CEP290 mRNA. Administration of AON (in black), targeting the splice donor
site (H36D), is predicted to alter splicing by blocking the recognition of exon 36. Exclusion of exon 36
(CEP290Δ36) should allow bypassing protein truncation while maintaining the reading frame, and lead
to the production of near full-length CEP290 protein.
 
Figure 7. Effect of AON-mediated exon 36 skipping on CEP290 mRNAs. (A) RT-PCR analysis of
CEP290 transcripts expressed in control (C3) and patient (P1 and P2) fibroblasts untreated or treated for
24h with lipofectamine alone or associated to H36D AON. Images of agarose gel showing amplicons
produced using primer pairs surrounding mutant exon 36. (B) Relative expression levels of full-length
(black bars) and exon 36-skipped (grey bars) CEP290 mRNAs in control (C1–C3) and patient (P1 and P2)
fibroblasts as determined by RT-qPCR. Bars show the mean ± SEM from three independent experiments.
C represents the pooled values of C1–C3. **** p ≤ 0.0001, n.s., not significant.
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To assess dose-dependent skipping efficiency, patient and control fibroblasts were treated with
increasing doses of H36D (+98 − 11) AON for 24 h, revealing that the amount of alternatively splice
products lacking exon 36 reached a maximum in almost all cell lines at an AON concentration of 75
nmol/l (Figure 8A). At this concentration, we observed accumulation of alternatively splice products
and CEP290 proteins with treatment time (Figure 8B–D).
Figure 8. Optimization of transfection conditions. (A) RT-qPCR analysis of reverse transcribed CEP290
mRNA extracted from control (C1–C3) and patient (P1 and P2) fibroblasts untreated or after transfection
of increasing doses (20 nM to 300 nM) of H36D oligonucleotide. The graph shows the mean amounts
(±SEM) of full-length (CEP290; black bars) and exon 36-skipped transcripts (CEP290Δ36; grey bars) from
three independent experiments. C regroups the values obtained for C1–C3. *** p ≤ 0.001, **** p ≤ 0.0001,
n.s., not significant. (B) RT-qPCR analysis of reverse transcribed CEP290 mRNA extracted from control
(C1–C3) and patient (P1 and P2) fibroblasts untreated or treated during increasing times of treatment
(4 h to 72 h) with 75nM of H36D oligonucleotide. The graph shows the amounts of full-length (CEP290;
black bars) and exon 36-skipped transcripts (CEP290Δ36; grey bars). C corresponds to C1–C3 pooled
values. (C) CEP290 protein analysis in control (C3) and mutant (P1 and P2) cell lines untreated or treated
with 75nM of H36D during 24 h or 48 h. (D) Relative quantification of CEP290 protein abundance
depending on treatment time. β-Actin was used for normalization.
3.7. AON-Mediated Skipping Allows to Bypass Protein-Truncation but May Not Restore Full
CEP290 Functions
The abundance of full length CEP290 mRNA in control cells treated with 75nM of H36D (+98 − 11)
AON for 48 h was around 60% that of untreated control cells, as determined by RT-qPCR (Figure 8B),
indicating that approximately 40% of full length CEP290 pre-mRNA underwent AON-mediated
skipping of exon 36. The amount of CEP290 protein (full-length + Δ36aa) was comparable in treated
and untreated cells (Figure 9A,B, left), suggesting that the CEP290Δ36aa isoform is stable. Yet, treated
cells displayed a moderate diminution of CEP290 staining at the centrosome (p ≤ 0.05, Figure 9C) with
statistically significant, yet minimal, alteration of CP110 centrosomal staining (p ≤ 0.05, Figure 9D).
The abundance of ciliated cells tended to be slightly diminished (95.5% versus 92.5%, Figure 9F) as
was the mean axonemal length (3.9 μm versus 3.6 μm, p ≤ 0.01, Figure 9E). Together, these results
suggest that the CEP290Δ36aa isoform interferes with the wild-type counterpart and can compromise
ciliation, possibly through disorganization of centriolar satellites. The same treatment in P1 cells,
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allowed a highly significant increase in CEP290Δ36aa protein abundance, as determined by western
blot and immunocytochemistry analyses (Figure 9A–C). Interestingly, the intensity of CEP290 staining
at the centrosome reached that of treated control cells (Figure 9C). However, expressing increased
levels of CEP290Δ36aa isoform in cells deprived of wild-type CEP290 altered the dynamics of centriolar
satellites, as documented by increased dispersion of CP110-specific centrosomal staining (p ≤ 0.001,
Figure 9D). Consistently, the proportion of ciliated cells tended to diminish (89% versus 79.8%) upon
AON treatment (Figure 9F), as did axonemal length (4.4 μm versus 3.5 μm, p ≤ 0.0001, Figure 9E). In P2,
AON treatment also led to a significant increase in the centrosomal abundance of the CEP290Δ36aa
isoform (p ≤ 0.0001, Figure 9C). However, the amount of this product was significantly reduced
compared to the counterpart in treated P1 cells (p ≤ 0.001). We observed a reduced impact of the
treatment on centriolar satellites (Figure 9D) compared to P1, cilia abundance tended to minimally
increase (Figure 9F) and cilia length significantly decreased (p ≤ 0.0001, Figure 9E).
Figure 9. AON-treatment effect at protein level and impact on ciliation. (A) CEP290 protein analysis in
control and mutant cell lines untreated or treated during 48 h with 75 nM of H36D. (B) Quantification
of CEP290 protein abundance relative to β-Actin. Bars correspond to the mean value ± SEM from
three independent experiments = not significant. A.U. = arbitrary unit. (C) Quantification of CEP290
immunofluorescence intensity at the basal body in each cell line. Each dot depicts the labeling intensity
of the protein in individual cells recorded automatically from six microscope fields. The solid line
indicates the mean. (D) Quantification of CP110 immunofluorescence intensity at centrosomes in
quiescent fibroblasts. All automatic intensity measures were recorded from six fields. (E) Percentage
of ciliated cells and (F) length of cilia axonemes in control and mutant fibroblasts. A minimum of 90
ciliated cells were considered for each cell lines. C corresponds to C1–C3 pooled values. * p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, n.s = not significant, A.U. = arbitrary unit.
4. Discussion
Targeted exon skipping is gaining a growing interest in rare hereditary diseases involving cell
types as diverse as myocytes, keratinocytes or motor neurons. Recently, renal cells were added to this
list with the report on AON-mediated rescue of Joubert phenotypes in patient-derived primary tubular
cells and in a murine model with CEP290 mutations [28]. Photoreceptors of these individuals and more
generally of individuals carrying PTCs in skippable CEP290 exons certainly deserve consideration.
Here, we used skin-derived fibroblasts from two unrelated individuals carrying a CEP290 nonsense
founder mutation to implement AON-mediated frame-restoration to non-syndromic retinal diseases.
CEP290 is expressed in the transition zone at the base of cilia of multiple cells systems. There, it bridges
the cilia membrane and the axoneme by binding the cellular membrane to microtubules through
sequences in the amino-terminal and myosin-tail homology domains, respectively [29]. The integrity of
this bridge, known as the ciliary gate CEP290 [3], is essential to allow proper ciliation as demonstrated by
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reduced cilia formation and/or aberrant axonemal ultrastructure in cells from patients carrying CEP290
mutations [8,19] and in cellular and in-vivo models of Cep290 knockdown [10,30–32]. Studying the
ciliation ability of fibroblasts from the two individuals carrying the c.4723A > T mutation, we observed
normal to discreetly reduced abundance of ciliated cells upon serum starvation, suggesting the
production of a CEP290 protein from mutant alleles. Accordingly, we observed expression of an
alternatively spliced CEP290 mRNA lacking exon 36 encompassing the PTC and low levels of CEP290
protein. The PTC-free mRNA product was detected both in patient and control cells, though with
minimal amounts in controls. This observation indicates (i) that CEP290 exon 36, like exons 6, 10, 18,
32, 41, 46, and 51 [20,21,33], undergoes endogenous non-canonical basal exon skipping in wild-type
skin fibroblasts and (ii) that the A to T transversion at position c.4723 enhances skipping. In silico
analysis which predicted that the variation lies within an ESE indicates that skipping augmentation is
promoted through nonsense-associated altered splicing. Indeed, ESE sequences are usually purine- or
A/C-rich [34,35]. Introducing a T into an artificial polypurine sequence mimicking a DMD ESE has
been reported to reduce enhancer activity, in particular when it introduced a nonsense codon [36].
Accordingly, the introduction of a T at position c.4723 is predicted to reduce significantly the strength
of ESE and increase the chance of exon skipping, whereas the introduction of a G and a C has a minimal
and no effect, respectively (Table 1).
During the transition of cells from proliferation to quiescence, ciliation is initiated by
CEP290-mediated recruitment of RAB8A at the centrosome, leading to the release of the cilia formation
suppressor CP110 [25–27]. Preserved ability of P1 and P2 fibroblasts to ciliate upon serum starvation
indicated that the CEP290Δ36 mRNA was translated into a protein isoform able to recruit RAB8A despite
the loss of 36 CEP290 residues involved in binding. Accordingly, immune-staining demonstrated
the presence of CEP290 and RAB8A at the centrosome. The abundance of CEP290 in P1 and P2
cells were 40% and 30% of the wild-type levels in controls, respectively. Despite reduced CEP290
abundance, the intensity of CP110-specific staining at the centrosome of P1 cells was comparable to
controls, indicating a normal release that was further supported by a normal abundance of ciliated
cells. In contrast, P2 cells which tended to express slightly less CEP290Δ36 mRNA and CEP290Δ36aa
protein exhibited moderate, yet statistically significant, reduction in CP110 release and, accordingly,
in cilia abundance. As to why P2 cells tend to express diminished amounts of CEP290Δ36 isoform,
the reduced abundance of full length mutant mRNA in P2 compared to P1 suggests a depletion of full
length mutant pre-mRNA from which the skipped isoform arises. Whether this observation would
result from increased NMD in P2, similar amounts of CEP290Δ36 isoform should be measured in the
two cell lines. Further studies using NMD inhibitors could help in addressing this interesting question.
Whatever the mechanism, these results further support the predictive model of CEP290-associated
pathogenesis and it would be tempting to correlate the severity of the retinal disease of P2 compared to
P1 (congenital blindness vs. measurable VA of 20/67 (RE) and 20/50 (LE) at 20 years, respectively) to a
reduced abundance of CEP290Δ36aa product in photoreceptor cells. Evidence of abundant endogenous
basal skipping of exon 36 in human retina makes this hypothesis plausible. However, this cannot
be demonstrated, in particular since the level of endogenous and selective (if any) skipping of exon
36 in the photoreceptors of affected individuals cannot be anticipated from the CEP290 genotype as
determined by sequencing of exon and intron boundaries only. Variants in other CEP290 regions and/or
in genes encoding proteins important to endogenous and/or selective exon skipping, the mechanisms
of which are not or poorly known, could contribute to the individual CEP290 pre-mRNA splicing
variability. Along the same lines, it is worth mentioning that three individuals carrying the c.4723A
> T mutation were reported to present with LCA and intellectual disability, autistic behavior or
cerebro-renal anomalies consistent with Joubert syndrome [5,7,37]. Whether the extraocular expression
in these individuals is due to reduced skipping of exon 36 in the brain and/or the kidney or to
additional mutations is opened to debate. Further, consistent with a correlation between the abundance
of centrosomal CEP290 and the cilia phenotype of fibroblasts, AON-mediated augmentation of the
amount of CEP290Δ36aa at the centrosome of P2 fibroblasts improved the ciliary phenotype. However,
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a more important increase in P1 cells aggravated the cilia phenotype, supporting the view that
the CEP290Δ36 mRNA encodes an imperfectly functional protein, the expression of which might be
preferable compared to knock-out, provided it is not too high. This indicates that exon 36 encodes
an important functional region of CEP290. The centrosomal depletion of CEP290 in control cells
expressing significant levels of CEP290Δ36 mRNA (40% of total CEP290) upon AON treatment, suggests
that the CEP290Δ36aa has reduced ability to associate to the centrosome, predicting a diminution of
RAB8A recruitment, possibly aggravated by the loss of 36 amino-acid participating to the binding of
RAB8A. The centrosomal retention of the CP110 cilia formation-suppressor along with the cilia defect,
yet minor, we observed that controls on the AON treatment are consistent with this view.
Intriguingly, while the majority of fibroblasts from individuals homozygous for the c.4723A > T
mutation were able to produce a primary cilium upon serum starvation, we observed a highly significant
elongation of cilia. Axonemal elongation with normal or abnormal ultrastructure has been originally
reported in kidney tissues, cultured kidney-derived cells and skin-derived fibroblasts from individuals
or animal models with cystic kidney diseases involving BBS4 (MIM600374), NEK8 (MIM609799, NPHP9),
KIF7 (MIM611254, JBTS12), TMEM67 (MIM609884, MKS3), KIAA0556 (MIM616650, JBTS26) [38–44],
and in fibroblasts from individuals affected with rod-cone dystrophy and hearing loss due to CEP78
mutation [45]. Recently, CEP290-associated cilia elongation has been described in primary renal
epithelial cells from three individuals affected with Joubert syndrome. Two of them were compound
heterozygous siblings carrying the c.2817G > T (splice alteration and p.K939N) and c.2848insC
(p.Q950Pfs*6) mutations in exon 25 and 26, respectively [46]. The skipping of either exon would
preserve the reading frame, leading to the production of a minimally shortened protein that would lack
part of the NPHP5 and/or CCD2D2A binding domains. Consistent with positive ciliation, hURECs
derived from one of the two siblings expressed minimal amounts of a CEP290 product as determined
by western blot analysis. But, the third individual was a sporadic case homozygous for the c.5668G
> T (p.G1890*) mutation in exon 41. This in-frame exon has been reported to undergo endogenous
basal exon skipping in fibroblasts [20], producing a minimal loss of the microtubule binding domain.
Yet, consistent with tissue variability of CEP290 pre-mRNA splicing [10,21,33,47], RT-PCR analysis
of hURECs from the patient harboring elongated cilia showed no skipping of exon 41, Western blot
analysis and immunocytochemistry detected no CEP290. Furthermore, siRNA-mediated knockdown
of CEP290 led to elongated cilia [46].
To our knowledge, this is the first study showing elongated cilia in fibroblasts for individuals
affected with non-syndromic retinal diseases rather than an impairment of cilia formation [8,10,12,21,32].
This observation in two unrelated individuals homozygous for the same mutation strongly supports
genotype–phenotype correlation.
It has been proposed that the length of the axoneme which elongates from the basal body is
regulated by the balance between the rates of anterograde and retrograde IFT [48]. Whether axonemal
elongation in fibroblasts from patients carrying the c.4723A > T mutation is due to alteration of IFT
certainly merits consideration. In particular, addressing this question might help in understanding
the relation between the abundance of the CEP290Δ36aa protein isoform and ciliation and whether
AON-mediated axonemal shortening of patient cell cilia may be regarded as a positive read-out of
treatment efficiency.
In summary, here we report expression of a PTC-free CEP290 mRNA resulting from endogenous
and selective exclusion of exon 36 encompassing the founder CEP290 c.4723A > T nonsense mutation
in two apparently unrelated individuals. We show that a CEP290 isoform is produced that localizes
to centrosomes and that cilia are produced upon serum starvation, yet improperly, as demonstrated
by significant axonemal elongation. We demonstrate that increasing the quantity of the CEP290
mRNA lacking exon 36 through the use of AON increased the abundance of the CEP290 product at
the centrosome and allowed axonemal shortening. However, while a moderate quantity of CEP290
product ameliorated cilia formation, a high abundance compromised cilia formation. Whether this
would occur in photoreceptor cell is an important question, especially knowing that mRNA metabolism
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is higher in the retina than in any other cell type [49], that CEP290 transcripts are far more expressed
in neural retina compared to other tissues and organs [19] and that CEP290 pre-mRNA splicing in
iPSC-derived 3D optic cups has been shown to differ significantly from that observed in fibroblasts [10].
AON-mediated skipping of exon 36 in iPSC-derived retinal organoids from individuals carrying the
c.4723A > T mutation would certainly merit consideration to address this burning question.
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Abstract: Deep-sequencing of the ABCA4 locus has revealed that ~10% of autosomal recessive
Stargardt disease (STGD1) cases are caused by deep-intronic mutations. One of the most recurrent
deep-intronic variants in the Belgian and Dutch STGD1 population is the c.4539+2001G>A mutation.
This variant introduces a 345-nt pseudoexon to the ABCA4 mRNA transcript in a retina-specific
manner. Antisense oligonucleotides (AONs) are short sequences of RNA that can modulate splicing.
In this work, we designed 26 different AONs to perform a thorough screening to identify the most
effective AONs to correct splicing defects associated with c.4539+2001G>A. All AONs were tested
in patient-derived induced pluripotent stem cells (iPSCs) that were differentiated to photoreceptor
precursor cells (PPCs). AON efficacy was assessed through RNA analysis and was based on correction
efficacy, and AONs were grouped and their properties assessed. We (a) identified nine AONs with
significant correction efficacies (>50%), (b) confirmed that a single nucleotide mismatch was sufficient
to significantly decrease AON efficacy, and (c) found potential correlations between efficacy and some
of the parameters analyzed. Overall, our results show that AON-based splicing modulation holds
great potential for treating Stargardt disease caused by splicing defects in ABCA4.
Keywords: antisense oligonucleotides; Stargardt disease; inherited retinal diseases; splicing modulation;
RNA therapy; ABCA4; iPSC-derived photoreceptor precursor cells
1. Introduction
Stargardt disease (STGD1; MIM:248200) is an autosomal recessive condition affecting the retina,
and was first described in 1909 by the German ophthalmologist Karl Stargardt [1]. The clinical
hallmark of STGD1 is progressive bilateral impairment of central vision. Impairment in visual acuity
and progressive bilateral atrophy of photoreceptors and the retinal pigment epithelium (RPE) are
accompanied by the accumulation of toxic fluorescent deposits of lipofuscin in the macula [2,3].
The underlying genetic causes of the disease are mutations in the ABCA4 gene that encodes the
ATP-binding cassette transporter type 4 subfamily A (ABCA4). The ABCA4 protein belongs to the
superfamily of membrane-bound ATP-binding cassette transporters [4]. It translocates the visual cycle
metabolites, all-trans-retinal and N-retinylidene-phosphatidyl ethanolamine (N-retinylidene-PE), from
the lumen to the cytoplasmic side of photoreceptor disc membranes [5]. The decrease in ABCA4 activity
causes an accumulation of toxic retinal derivatives, which eventually results in RPE and photoreceptor
cell death [6,7]. Over 900 disease-associated variants in ABCA4 have been described [8,9], causing a
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wide range of phenotypes ranging from STGD1 to cone–rod dystrophy, depending on the severity of
the mutation [10,11].
STGD1 cases can be explained by biallelic mutations in either the coding sequence or in the
intronic regions of ABCA4 [12]. Around 10% of cases carry intronic variants that result in the
insertion of pseudoexons (PEs) into the final ABCA4 mRNA transcript [4,9,13–20]. Such mutations
are an ideal target for antisense oligonucleotide (AON) therapy. AONs are short synthetic RNA
molecules that can interfere with the processing of pre-mRNA [21] and thereby modulate splicing.
Modified AONs employed to correct splicing defects have been extensively studied in the field of
inherited retinal diseases (IRDs) for genes such as CEP290 [22–27], USH2A [28], CHM [29], OPN1 [30],
or ABCA4 [18,20,31]. The first splicing modulation strategy described for a retinal disease was targeting
a recurring deep-intronic variant (c.2991+1655A>G) in the CEP290 gene, underlying recessive Leber
congenital amaurosis (LCA; MIM:611755). This mutation results in the generation of a cryptic splice
donor site leading to a 128-nt pseudoexon with a premature stop codon between exons 26 and 27.
AONs used to block the pseudoexon showed successful restoration of the original mRNA both in vivo
and in vitro [22,24–27] and have recently shown promising results in the first clinical trial with AONs
for IRDs [32].
Another mutation that causes a pre-mRNA splicing defect and is amenable to AON therapy is the
c.4539+2001G>A variant in ABCA4 [13–15], which is recurrently found in the Belgian and Dutch STGD1
population. Recently, our group described the molecular mechanism by which c.4539+2001G>A
and the adjacent c.4539+2028C>T mutations in ABCA4 lead to insertion of a retina-specific 345-nt
pseudoexon that is predicted to result in premature termination of protein synthesis (p.Arg1514Leufs*36).
The c.4539+2001G>A variant enhances a predicted exonic splice enhancer and creates a new SRp55
motif. This was the first reported insertion of a pseudoexon into a retinal gene due to the creation of new
exonic splicing enhancer (ESE) motifs rather than the generation of new cryptic splice sites, although
other examples have been described previously [33,34]. By using AON technology, we were able to
restore correct splicing with two of the four AONs (AON1–4) that were used (AON1 and AON4) [18].
In this study, we performed an in-depth screening of a large set of AONs targeting the entire
pseudoexon region to identify the most effective AON(s) against the splicing defect caused by the
c.4539+2001G>A mutation. In total, 26 AONs were screened in retinal precursor cells differentiated
from patient-derived induced pluripotent stem cell (iPSC), and their efficacy in correcting splicing
defects was assessed. Subsequently, properties of the most effective AONs were compared in order to
identify potential parameters for a better design of AONs in the future.
2. Materials and Methods
2.1. Study Design
The objectives of this study were to (1) perform an in-depth screening of AONs targeting the
pseudoexon introduced by the recurrent c.4539+2001G>A deep-intronic variant in ABCA4, (2) identify
the best AON(s) to correct the pre-mRNA splicing defect caused by this mutation using patient-derived
photoreceptor precursor cells (PPCs), and (3) identify potential correlations between AON characteristics
and their efficacy that can provide new insights into a better AON design. Twenty-two new AONs
targeting the pseudoexon were designed and tested together with four previously described AONs [18].
Fibroblast cells obtained from a skin biopsy of a Stargardt individual carrying the deep-intronic variant
were cultured, reprogrammed into iPSCs, and subsequently differentiated to PPCs. All 26 AONs
and two sense oligonucleotides (SONs) were designed along the pseudoexon. Upon AON delivery,
subsequent RNA analysis by RT-PCR was performed to assess the efficacy of the splicing redirection
for each AON. After semiquantification of the rescue, AONs were classified into different groups, and
the properties of the AONs were compared to identify parameters that could improve the AON design.
Two separate differentiation experiments were performed. RNA analysis was performed in triplicate
to reduce technical variability.
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2.2. AON Design
Previously, four AONs were designed targeting the top SC35 motifs and the mutation itself [18].
For the detailed screening that was the subject of this study, the entire pseudoexon plus the flanking
regions were analyzed for their RNA structure to identify the open and closed regions. Subsequently,
AONs were designed according to previously described guidelines independently of the potential
motifs that they were targeting [35,36]. All AON sequences and properties are provided in Table 1.
After AON design, targeted regions were analyzed to predict potential exonic splicing enhancer
(ESE) motifs using either an ESE finder (http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?
process=home), which allows for the detection of SRSF1, SRSF2, SRSF5, and SRSF6, or using RBPmap
(http://rbpmap.technion.ac.il/index.html), which allows for the identification of 94 potential binding
sites for RNA binding proteins. All AONs were 2’OMe-PS (2’O-methyl phosphorothioate) and were
purchased from Eurogentec (Liege, Belgium). Sequences and general parameters of the 26 AONs and
2 SONs are depicted in Table 1.
2.3. Subjects
A skin biopsy was collected from a Dutch individual with STGD1 carrying the ABCA4 variants
c.4539+2001G>A (p.Arg1514Leufs∗36) and c.4892T>C (p.Leu1631Pro) to establish a fibroblast cell line,
as described previously [18]. Our research was conducted according to the tenets of the Declaration of
Helsinki and after gathering written informed consent from the STGD1 individual. The procedures for
obtaining human skin biopsies to establish primary fibroblast cell lines were approved by the local
ethical committee (2015-1543).
2.4. iPSC Differentiation into Photoreceptor Precursor Cells (PPCs)
Fibroblast cells were reprogrammed into iPSCs, as previously described [18]. PPCs were obtained
after following a 2D differentiation protocol [37]. Briefly, iPSCs were dissociated with ReLeSR (Stemcell
Technologies) and plated in 12-well plates coated with matrigel (Corning, Tewksbury, MA, USA) to form
a monolayer. Essential-Flex E8 medium was changed to differentiation medium (CI) when reaching
confluence. The CI medium consisted of DMEM/F12 supplemented with nonessential amino acids
(NEAA, Sigma Aldrich, Saint Louis, CA, USA), B27 supplements (Thermo Fisher Scientific, Waltham,
MA, USA), N2 supplements (Thermo Fisher Scientific), 100 ng/μL of insulin growth factor-1 (IGF-1,
Sigma Aldrich), 10 ng/μL of recombinant fibroblast growth factor basic (bFGF, Sigma Aldrich), 10 μg/μL
of Heparin (Sigma Aldrich), 200 μg/mL of recombinant human COCO (R&D Systems, Minneapolis,
MN, USA), and 100 μg/mL of Primocin (Invivogen, Toulouse, France). Half of the medium was replaced
every day for 30 days. On day 28, PPCs were treated with 1 μM of AON. AONs were first mixed with
the medium without any transfection reagent and were subsequently added to the cells. Twenty-four
hours later, cycloheximide (CHX) was added to the medium (final concentration 100 μg/mL), and on
day 30 (48 h post-AON delivery and 24 h post-CHX treatment), cells were collected.
2.5. RNA Analysis
RNA was isolated from patient-derived PPCs using the Nucleospin RNA kit (Machery Nagel,
Düren, Germany) following the manufacturer’s instructions. One microgram of total RNA was used for
cDNA synthesis using SuperScript VILO Master Mix (Thermo Fisher Scientific) and was subsequently
diluted with H2O to a final concentration of 20 ng/μL. Reverse transcription-PCR (RT-PCR) was
performed with 10 μM of each primer, 2 μM of dNTPs, 2.5 mM of MgCl2, 1 U of Taq polymerase
(Roche, Basel, Switzerland), and 80 ng of cDNA in a total reaction of 25 μL using the following PCR
conditions: 2 min at 94 ◦C, followed by 35 cycles of 30 s at 94 ◦C, 30 s at 58 ◦C, and 70 s at 72 ◦C, with a
final extension of 2 min at 72 ◦C. Actin was amplified to serve as a loading control. All PCR products
were resolved on 2% agarose gels and were confirmed by Sanger. Fiji software was used to perform a
semiquantitative analysis of the bands in which the values were normalized against the housekeeping
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gene ACTB [38]. For that, the band representing the 345-nt pseudoexon, plus half of the value of the
heteroduplexes, and the partial pseudoexon skipping band were counted as aberrant. The other half
of the heteroduplexes together with the correct band were considered to be correct transcripts. We
observed a nonspecific band that was not considered for the analysis. The list of primers is provided in
the Supplementary Materials, Table S1.
2.6. qPCR
The cDNA samples were obtained as described above from iPSCs at day 0, and the nontreated PPCs
at day 30 (both replicates) were used for quantitative real-time PCR (qPCR) to assess the differentiation
process: qPCR was performed using GoTaq qPCR master mix (Promega, Madison, WI, USA). Three
technical replicates were done for each of the two biological replicates. The list of primers is provided
in the Supplementary Materials, Table S1.
2.7. AON Classification and Common Properties
Once the rescue was assessed, AONs were classified into 5 groups: Highly effective (>75%
correction), effective (between 75% and 50%), moderately effective (between 50% and 25%), poorly
effective (between 25% and 0%), and noneffective (no correction detected). For the study of the
properties of each group, the groups poorly effective and noneffective were combined into one single
group, as well as the highly effective and effective groups, generating three new groups: Effective,
moderately effective, and poorly effective. Using this information, several potential correlations
between AON properties, target motifs, and their efficacy were assessed, with the aim of establishing
possible improvements in the AON design. Statistical analyses were performed using GraphPad
Prism. Given the low numbers for some of the groups, normality could not be assessed, and therefore
nonparametric tests were used.
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3. Results
Previously, we showed that the variants c.4539+2001G>A and c.4539+2028C>T cause the insertion
of a 345-nt pseudoexon in a retina-specific manner. Four AONs (AON1 to AON4) targeting this
region were designed according to previously described guidelines [35,36,39] and were assessed in
PPCs. Our results showed that two AONs (AON1 and AON4) were able to restore correct ABCA4
splicing by skipping the pseudoexon in a mutation-dependent manner. AON1 was specific for the
c.4539+2001G>A variant and was not able to correct the splicing defect caused by the c.4539+2028C>T
mutation, suggesting that one nucleotide mismatch can already impair rescue efficacy. Here, we
screened the entire pseudoexon region in order to identify potential new targets that can promote
splicing redirection with a higher efficacy by designing 22 new AONs.
3.1. Screening and Selection of AONs
The entire pseudoexon (345 nt) together with its flanking regions were subjected to AON design.
A total of 22 new AONs were designed throughout the entire region (Figure 1A). The AON design
parameters, such as melting temperature (Tm), GC content, and free energy were assessed in order
to have optimal sequences when possible (e.g., Tm > 48 ◦C, GC content between 40% and 60%).
Subsequently, to further assess what AONs were targeting, we predicted the RNA structure of the
region using mfold software [40]. We also checked the ESE motifs that were present in the region
using an ESE finder (http://rulai.cshl.edu/) or the potential RNA binding protein sites using RBPmap
(http://rbpmap.technion.ac.il/). Overall, all AONs were covering the pseudoexon or its splice sites and
were targeting all types of regions (predicted to be more closed or open) and motifs.
Patient-derived iPSCs heterozygously carrying the c.4539+2001G>A mutation in conjunction
with another ABCA4 mutation on the other allele were differentiated into PPCs. Differentiation of the
cells was assessed by qPCR. The results showed a differentiation toward retinal lineage with a clear
increase in ABCA4 expression (Supplementary Materials, Figure S1). As we already described, the
345-nt pseudoexon was only visible upon inhibition of nonsense-mediated decay (NMD) (Figure 1B).
Therefore, PPCs were first treated with the corresponding AON and after 24 h were subjected to
cycloheximide (CHX) treatment to inhibit NMD. RNA analysis was performed by RT-PCR (Figure 1B).
We then semiquantified the amount of aberrant transcript (Figure 1C). Remarkably, three AONs were
able to almost completely rescue the splicing defect (AON4, AON17, and AON18). Interestingly,
we also observed that four AONs (AON7, AON13, AON14, and AON16) caused the appearance of
additional bands. Some of them represented partial pseudoexon skipping, while others turned out to
be potential artifacts due to mis-splicing, although we could not exactly determine the splicing sites.
Sequencing results determined that the partial-exon skipping observed in AON14 and AON16-treated
samples was a partial skipping of exon 30 (previously described in Reference [18]) together with
partial skipping of the first 142 nt of the pseudoexon (splice acceptor site in c.4539+2035). In the
case of AON13, we identified partial pseudoexon exclusion, but we could not determine the splice
acceptor site. In the case of AON7, we could not determine both splice sites (acceptor and donor), and
it was probably an aberrant mRNA caused by the AON treatment. Using the average of the cells not
treated with AONs but subjected to CHX treatment and the ones treated with the sense oligonucleotide
(SON), we established the basal levels (~29%) of the ABCA4 aberrant transcript (Figure 1C). These
values were used to establish the percentage of correction for each AON (Figure 2A). Five groups were
determined: Highly effective (correction >75%, n = 3), effective (75%–50%, n = 6), moderately effective
(50%–25%, n = 8), poorly effective (25%–0%, n = 9), and noneffective (0% or even increasing the amount
of pseudoexon). These groups are depicted in Figure 2A according to different colors in the graph.
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Figure 1. AON-based pseudoexon skipping efficacy. (A) Schematic representation of the 345-nt
pseudoexon insertion caused by the c.4539+2001G>A mutation and the location of the 26 AONs and
the 2 sense oligonucleotides (SONs). Blue oligonucleotides refer to previously studied molecules [18].
Red asterisks represent mismatches with the pseudoexon sequence created only by the c.4539+2001G>A
mutation (namely an A at position c.4539+2001 and a C at position c.4539+2028). (B) Representative
image of an RT-PCR performed on patient-derived photoreceptor precursor cells (PPCs) upon AON
treatment. ACTB was used to normalize samples. An heteroduplex band was observed in all samples,
containing the correct and the pseudoexon-included transcripts. AON-derived partial skipping was
observed in samples AON14 and AON16. Double bands highlighted with an * (lanes AON7 and
AON13) indicate artifacts derived from the AON treatment, and splice sites could not be identified upon
Sanger sequencing. In most of the lanes, we identified a PCR artifact (nonspecific band). (C) Percentage
of aberrant transcript after semiquantification. NT: Nontreated; CHX: Cycloheximide. Error bars
indicate average ± SD.
3.2. Analysis of the Properties of the AONs
Once the efficacy of all AONs was estimated, we subdivided them into three larger groups:
Effective (n = 9 comprising all AONs with an efficacy > 50%), moderately effective (n = 8 with efficacies
between 25% and 50%), and poorly effective (n = 7, the rest). AONs containing a mismatch (AON12
and AON15) were not used in these analyses, as the decrease in the efficacy was due to the mismatch.
This was shown by the fact that both AON1 and AON14 (perfectly matching the c.4539+2001G>A
allele, but containing a mismatch for the PE induced by the c.4539+2028C>T mutation) correct the
splice defect associated with c.4539+2001G>A.
We first analyzed the basic parameters: Melting temperature (Tm), GC content, and length
(Figure 2B). We found a statistically significant correlation (two-tailed Spearman test) for the Tm and
GC content parameters (p = 0.0012 and p = 0.0041, respectively). In both cases, the higher the value
was, the more efficient the AON was (Supplementary Materials, Figure S2). The Tm average of the
three groups ranged from 54.21 ◦C (effective) to 50.19 ◦C (poorly effective). The differences in Tm
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between groups was statistically different (p = 0.0292, nonparametric one-way ANOVA), while the GC
content was nearly significant (p = 0.0611). When comparing all different groups separately, statistically
significant differences were observed between the groups of effective AONs and poorly effective AONs
for Tm (p = 0.0256, Mann–Whitney test) and GC content (p = 0.0127). No differences were observed for
the length of the AONs.
Other important parameters when designing AONs are the free energy of the AON molecule
itself, the dimer, and the binding energy to the target. The free energy of the AON molecule and its
dimer did not show any correlation nor difference between groups. Interestingly, the binding energy
showed a significant correlation (p = 0.0391) with efficacy. We analyzed the groups separately, and
although no statistically significant differences were found, the effective group showed a trend toward
significance when compared to the moderately effective (p = 0.0673, Mann–Whitney test) and the
poorly effective (p = 0.0712, Mann–Whitney test) groups. Consistently, the highest binding energies
corresponded to the three most effective AONs (AON4, AON17, and AON18). Interestingly, when
these three values were separated, the tendency of the effective group disappeared. In contrast, these
three AONs only showed a statistically significant higher binding energy compared to the other three
groups (Figure 2C).
Next, we checked the common serine and arginine-rich splicing factors (SRSFs): SF2 (SRSF1),
SC35 (SRSF2), SRp40 (SRSF4), and SRp55 (SRSF5)) using an ESE finder (Supplementary Materials,
Figure S3). All motifs that were partially or completely covered by an AON were counted and assigned
to the particular AON. We did not find any correlation between the percentage of correction and the
presence of these motifs. However, we noticed that the strength of some of the motifs was different
between groups. For that, we categorized all the motifs found by assigning them a number according
to the strength of the predicted score (lowest = 1, second lowest = 2, etc.). After that, the average for
each AON was calculated. Interestingly, a statistically significant correlation (p = 0.0066, two-tailed
Spearman test) was observed for the categorized SRp40 motifs. In this case, the strongest motifs were
correlating with the poorly or moderately effective AONs, and the lowest with the effective ones
(Figure 2D). However, when pooling all groups together, differences were not statistically significant.
No other differences were detected for any of the other three SRSF motifs, except for SC35, where
significant differences were observed when comparing effective versus moderately effective AONs
(p = 0.0316, Mann–Whitney test; Supplementary Materials, Figure S3).
Finally, we used RBPmap to predict potential RNA protein-binding motifs. Again, each motif
detected in the region was assigned to each AON when partial or complete overlap occurred. First,
manual filtering of the motifs was done by checking which motifs were common to all AONs in
each group. Unfortunately, none of the motifs were shared between all effective AONs. AON18
was the one behaving differently than the rest, almost not sharing any motif with the others. When
AON18 was left out of the filtering, SRSF3 appeared as a common motif not only in the effective group,
but also in the poorly and moderately effective groups. When assessed in more detail (Figure 2D),
a statistically significant negative correlation was observed (p = 0.0188, two-tailed Spearman test).
The analysis per group revealed a significant difference between the effective and poorly effective
groups (p = 0.0431) and close to significance between the moderately and poorly effective groups
(p = 0.0622). Categorized SRSF3 did not show significant differences. The second most recurrent motif
in the poorly effective group was MBNL1. Given the fact that all but one poorly acting AON contained
this predicted motif, we performed statistical analyses to determine whether the presence of MBNL1
motifs correlated with the lower performance of some AONs. Indeed, a significant correlation was
observed (p = 0.0025), implying an association between the presence of these motifs and a low AON
performance (Figure 2D). When differences between groups were assessed, only the effective group
showed a statistically significant lower number of MBNL1 when compared to the poorly effective
group (p = 0.0309). The total amount of motifs detected by RBPmap showed a nearly significant
negative correlation with efficiency (p = 0.0522). However, when groups were analyzed separately, this
trend completely disappeared (Supplementary Materials, Figure S4).
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Figure 2. Assessment of AON efficacy and correlations. (A) Percentage of correction for each AON.
AONs are located according to their position in the c.4539+2001G>A-specific pseudoexon. Colors
indicate the efficacy classification that was established. (B–C) Representation of the statistical analyses
for general parameters taken into account for AON design. (D) Analysis of the influence of certain
motifs in AON efficacy. Error bars in all graphs indicate average ± SD.
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4. Discussion
The fact that the eye is an isolated, immunoprivileged, and easily accessible organ makes it a
very attractive model for molecular therapies. In addition, IRDs are progressive diseases that offer a
window of opportunity for treatment. However, the high genetic heterogeneity in IRDs hampers the
development of new therapies. AONs have been shown to be an auspicious approach to treat splicing
defects causing IRDs. They have been shown to be safe and easy to deliver to the retina without
the necessity of any vector. Furthermore, recent results from a phase 1/2 clinical trial to correct the
splicing defect introduced by a deep-intronic mutation in CEP290 showed the great potential that these
molecules hold. In this study, we screened 26 AONs targeting a pseudoexon product of a recurrent
deep-intronic mutation (c.4539+2001G>A) in the ABCA4 gene with the intention of identifying the
most promising AON molecules to eventually treat STGD1.
We designed and tested 26 different AONs located across the 345-nt pseudoexon. In total, three
highly effective AONs were identified: AON4, AON17, and AON18. All of them showed similar
efficacies (76.42%–76.97%). Another six AONs (AON1, AON9, AON10, AON14, AON23, and AON24)
corrected the pre-mRNA splicing defect with an efficacy of more than 50%. Previously, we showed that
AON1 was only effective when the change c.4539+2001G>A was present, as the pseudoexon containing
the change c.4539+2028C>T was not removed. This highlighted the fact that for 2’OMe/PS chemically
modified AONs, one mismatch could dramatically affect the splicing redirection efficacy. Here, we
demonstrated again that one mismatch was enough to prevent AON-based splicing modulation.
For that, we generated the same AON1 but with a wild-type nucleotide (AON12). Furthermore,
we also designed an AON specific for the c.4539+2028C>T variant (AON15) and a corresponding
AON with a wild-type change (AON14). As expected, the mutation-specific AON (AON15) did not
redirect splicing in this cell line, while the one perfectly matching the target did (AON14). Interestingly,
AON14, although its correction efficacy was around 50%, is not considered a very promising AON for
future studies since it was one of the four AONs (together with AON7, AON13, and AON16) that
showed novel aberrant bands in RT-PCR. In this particular case, both AON14 and AON16 caused an
unexpected (AONs binding on top of the novel splice acceptor site at position c.4539+2035) partial
pseudoexon exclusion together with an already described partial exon 30 skipping [18]. However,
this was clearly induced by these two AONs, which bind in the same region. However, for AON7
and AON13, we were not able to determine how the aberrant band was generated due to the lack of
predicted splicing sites, and therefore we considered them artifacts. We previously observed a similar
effect for another variant, and we concluded that this was either a PCR artifact or, due to the fact
that AONs can interfere with RNA structure and the splicing machinery, some aberrant mis-spliced
transcripts that may have appeared [20].
After classifying the AONs into three groups, we tried to identify common properties that could
eventually lead to a better AON design. When analyzing the groups, we found correlations with the
Tm and the GC content. Previously published guidelines [35,36,39] have indicated that Tm should be
above 48 ◦C and the GC content between 40% and 60%. Based on our analyses, it seems that if the
temperature is higher than 51 ◦C and the GC content close to 60%, the chances of designing an AON
with a good efficacy are higher. According to previous guidelines, the binding energy should stay
between 21 and 28. However, our best AON molecules had binding energies to the target of more
than 30. Moreover, based on correlations that we were able to identify, AONs targeting predicted
SRSF3 or MBNL1, as well as strong predicted SRp40 motifs, might show poorer efficacies. Although
some of these parameters have been shown before to be relevant to AON design, it is important to
mention that the efficacy of an AON molecule also can depend on the type of cell, tissue, or organ.
In that sense, the parameters established above might be valid only for AONs delivered to retinal
cells, and further confirmation in cells of other origins needs to be addressed. Unfortunately, this
comparison was not possible in our case due to the fact that although ABCA4 is lowly expressed in
fibroblast cells, the splicing defects observed for some mutations, including c.4539+2001G>A, are not
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recapitulated in those cells. Most probably this is because the splicing retinal machinery may have
different efficacies or recognition sites [41,42].
In our previous studies, AON1 showed an efficacy of ~75% [18]. However, in this study, only
~51% correction was detected, although the PPCs were derived from the same patient iPSC line. One
explanation could be that in our previous study, we only detected around 25% of pseudoexon insertion,
while in this study we were able to detect more pseudoexon-including transcripts (~30%). This could
therefore have modified the correction ratio. In addition, the inhibition of NMD by CHX is not always
complete, and therefore variability in the detection of the pseudoexon transcript (subjected to NMD)
might have been variable between experiments and samples. Another possible explanation could be
differences between the AON batches. All of these factors, either alone or in combination, could have
influenced the differences observed between the two studies.
Finally, as discussed above, AON4, AON17, and AON18 showed the highest efficacies. However,
AON18 did not show that much similarity to the other two AONs other than a high binding energy.
AON18 did not share obvious targeted predicted motifs with either of the two highly effective AONs
(Supplementary Materials, Figure S5). We also checked the secondary structure of the RNA and all
three AON target partially closed regions. Therefore, the slightly higher efficacy might have been
related to the binding to the target itself and the disruption of the secondary structure rather than the
motifs that were blocked by the molecule. In addition, when comparing the sequences to see which one
could be a potential candidate for further development, we observed that all three AONs contained
stretches of Gs and Cs (which are recommended to be avoided). AON4 and AON17 contained a G
stretch of four and three Gs, respectively, while AON18 contained two stretches of three and four Cs.
Nevertheless, given their efficacy, all three molecules might be potential good candidates for further
therapeutic studies.
5. Conclusions
In conclusion, we designed 26 AONs targeting a 345-nt pseudoexon caused by the recurrent
c.4539+2001G>A deep-intronic mutation in ABCA4. In total, nine AONs showed promising efficacies
(correction above 50%). We identified three AONs promoting a correction superior to 75%. For AON
design, we suggest increasing the minimum Tm to 50 or 51 ◦C, the GC content close to 60%, and
the binding energy to around 30 to target retinal pseudoexons, although this needs to be tested and
confirmed using other targets. Overall, we demonstrated that AON-based splicing modulation holds
great potential for treating Stargardt disease caused by splicing defects in ABCA4.
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Abstract: The light sensing outer segments of photoreceptors (PRs) are renewed every ten days due to
their high photoactivity, especially of the cones during daytime vision. This demands a tremendous
amount of energy, as well as a high turnover of their main biosynthetic compounds, membranes, and
proteins. Therefore, a refined proteostasis network (PN), regulating the protein balance, is crucial for
PR viability. In many inherited retinal diseases (IRDs) this balance is disrupted leading to protein
accumulation in the inner segment and eventually the death of PRs. Various studies have been
focusing on therapeutically targeting the different branches of the PR PN to restore the protein balance
and ultimately to treat inherited blindness. This review first describes the different branches of the
PN in detail. Subsequently, insights are provided on how therapeutic compounds directed against the
different PN branches might slow down or even arrest the appalling, progressive blinding conditions.
These insights are supported by findings of PN modulators in other research disciplines.
Keywords: protein trafficking; protein folding; protein degradation; chaperones; chaperonins; heat
shock response; unfolded protein response; autophagy; therapy
1. Introduction
The rod and cone photoreceptor (PR) cells are the most abundant cell types in the human retina,
with ~6.4 million cones and up to 125 million rods per adult retina [1]. PRs are highly specialized,
polarized neurons of neuroepithelial origin, consisting of morphologically and functionally distinct
cellular compartments, including a synaptic terminal, an inner segment (IS), an outer segment (OS),
and a connecting cilium bridging the IS and OS. The classical division into rods and cones is based
on their different OS morphology and differential expression of subtypes of opsin. The rod outer
segments are long, thin, rod-shaped organelles containing rhodopsin in large stacks of membranous
discs, allowing to process variations in dim-light conditions, but they lose this ability in bright light
conditions. The OSs of cones represent a shorter conical organelle containing either S-opsin, M-opsin,
or L-opsin, which are less sensitive compared to rhodopsin, but are perfectly suited to process bright
light of different wavelengths, allowing color vision [2].
Despite the difference in photosensitivity, the process of converting light stimuli into biochemical
signals, the phototransduction cascade, is almost indistinguishable between rods and cones [3,4].
In rods, upon capture of a photon, the chromophore 11-cis retinal, which is conjugated to a rhodopsin
molecule, undergoes a conformational change that isomerizes it to all-trans retinal leading to the
activation of rod opsin. The activated opsin molecule is now able to bind and subsequently activate the
G-protein, transducin. Transducin consists of three subunits: Gα, Gβ, and Gγ. In its inactive state, Gα
is bound to a GDP. When transducin gets activated by rhodopsin, this GDP is replaced by a GTP and
subsequently Gα dissociates from the Gβγ subunit. The GTP bound Gα is now able to displace one
of the two inhibitory γ-subunits of cGMP-specific 3′,5′-cyclic phosphodiesterase (PDE6) causing the
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exposure of one of the two catalytic sites of the PDE6αβ heterodimer (PDE6α’ for cones). The exposed
catalytic sites are now able to hydrolyze multiple cGMP molecules to 5′-GMP. In the dark state, cGMP
binds to its specific cation channel allowing a steady movement of cations into the OS, which is
compensated by the efflux of cations from the OS by Na+/Ca2+, K+ exchangers (NCKXs) [5]. Due to the
hydrolysis of cGMP, its levels decrease causing the closure of cation channels in the OS. The resulting
hyperpolarization of the OS membrane spreads throughout the cell, eventually reaching the synaptic
terminal. Here, the hyperpolarization causes closure of calcium channels and subsequently a decrease
in calcium-dependent synaptic glutamate release [3,4], which activates the glutamate receptors of the
bipolar cells postsynaptically, transducing the brain-bound electrical signal [6].
The phototransduction cascade, carried out in only a few milliseconds, is based on capture
of one single photon in dim light. However, in bright daylight conditions, immense amounts of
photons are caught by the human PRs, mainly cones, every second, which causes toxic photo-oxidative
damage to the OS components. These components, which include most proteins involved in the
phototransduction cascade, are therefore continuously renewed (~10% every day for human PRs), by
incorporating newly synthesized PR discs at the OS base, and shedding the oldest membrane discs at
the cell’s tip [7,8]. The shed OS tips are subsequently phagocytosed by the retinal pigment epithelium
(RPE) cells, which is the highest active phagocytic process in our body [9,10]. Because of this highly
active protein turnover, a mutation in a gene encoding a protein involved in this machinery most often
leads to PR cell death, a classical hallmark of many inherited retinal diseases (IRDs).
IRDs are a genetically heterogeneous group of rare eye disorders with a progressive manifestation
causing vision loss or even complete blindness [11]. Mutations in many genes that are required for
PR function were found to be causative for IRDs. These include genes encoding proteins involved in
protein trafficking, splicing, energy metabolism, and photoreceptor structure [12]. The compartments
of PRs most prominently implicated in IRDs are the OS and the connecting cilium. The connecting
cilium correlates with the transition zone of a primary cilium and functions as a gatekeeper to regulate
the molecular composition of the OS. Thus, the OS, connecting cilium, and the immediately adjacent
basal body, form the photoreceptor sensory cilium, one of the most highly specialized primary cilia,
fully optimized for photoreception and transduction [13,14]. Hence, IRDs with defects in these
compartments are referred to as retinal ciliopathies [11].
Defects in the conserved ciliary processes mostly manifest as syndromic ciliopathy conditions,
affecting multiple organs. The most prominent ciliopathies in which the retina is affected
are Bardet–Biedl syndrome (BBS), Joubert syndrome (JS), Meckel–Gruber syndrome (MKS), and
Senior–Løken syndrome (SLS) [4,11]. Because PRs are highly specialized, polarized neurons, retinal
ciliopathies often also occur in a nonsyndromic fashion, affecting ciliary proteins specific to rods
and/or cones. Based on the PR cell type affected, different IRDs can be categorized, including retinitis
pigmentosa (RP), Leber congenital amaurosis (LCA), cone-rod dystrophy (CRD), and achromatopsia
(ACHM) [4,11].
RP is the most common form of inherited blindness worldwide, with a prevalence of about 1:4000
people. The cells that are affected initially in RP are the rods leading to night blindness and loss of
peripheral vision. Secondary, cones are most often also affected as the disease progresses [15].
LCA is the most severe form of inherited retinal degeneration, causing patients to suffer from
severe visual impairment to complete blindness before the first year of life. With LCA, both rods and
cones are affected at early stages often leading to complete blindness [16].
Another early onset form of hereditary retinal dystrophy is CRD, which manifest in the opposite
order compared to RP, since in CRD cones are initially affected, followed by the loss of rods [17].
A disease in which specifically the cones deteriorate is ACHM, most often leading to complete
color blindness [18].
Apart from some specific exceptions, most of the above described blinding conditions are still
considered incurable. However, significant and promising progress has been made with therapeutic
studies targeting specific genes and/or mutations, most prominently by employing gene augmentation
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and antisense-oligo nucleotide (AON)-based techniques [19,20]. Yet, a major disadvantage of these
treatments is that they are complex and invasive for the patient. On top of that, for nearly every
mutation, a personalized approach needs to be developed. Therefore, there is a high interest in
pharmacological agents with a broad range of disease targets. To discover such agents, a growing
number of studies have focused on a common phenomenon seen in many IRDs before the actual
death of rods and cones: the accumulation and/or misfolding of proteins in the inner segment of the
photoreceptors [21].
This phenomenon can be explained by the malfunction of several processes, all involved in protein
homeostasis or proteostasis. A first process is the disruption of protein transport from the IS to the OS
(Figure 1A). As the OS lacks the biosynthesis machinery for proteins and lipids, all of the components
required for OS morphogenesis, maintenance, and sensory functions must be transported from the
endoplasmic reticulum (ER), located in the IS, to the OS [2], across the connective connecting cilium stalk.
Therefore, defects in this transport most often lead to the accumulation of proteins in the IS. Another
process involved in the accumulation of proteins in the IS is the dysregulation of pathways involved in
protein degradation, including ER-associated degradation (ERAD) and autophagy (Figure 1C). Finally,
also incorrect folding of specific proteins due to loss-of-function mutations can results in protein
accumulation in the IS (Figure 1B). An accumulation of misfolded proteins in the ER membrane or
in the cytoplasm of the PRs can induce the heat shock response (HSR) and/or the unfolded protein
response (UPR). Continuous activation of these responses will ultimately lead to death of PRs [21].
In this review the above mentioned branches of the proteostasis network will be described in detail.
Subsequently, we will explain how potential therapeutic agents directed against these branches might
slow down or even arrest the dramatic blinding conditions, supported by findings of PN modulators
in other research disciplines.
2. The Different Branches of the Proteostasis Network
2.1. Pathways Involved in Protein Trafficking
2.1.1. Chaperones Involved in Lipid-Dependent Trafficking
Many PR-specific proteins depend on post-translational lipid modifications, including prenylation
and myristoylation, for correct localization to the OS and their anchoring at one of the OS membranes [22].
Protein prenylation involves the transfer of either a farnesyl or a geranylgeranyl moiety to the C-terminal
cysteine(s) of the target protein by farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase-I),
respectively [23]. Several chaperones are involved in this prenylation process, including AIPL1, PDE6D,
and UNC119.
Aryl hydrocarbon receptor (AhR)-interacting protein-like 1 (AIPL1) was first discovered in
association with Leber congenital amaurosis (LCA) [24]. Mutations in the AIPL1 gene encoding
for AIPL1 results in LCA4, one of the most severe forms of LCA leading to blindness in early
childhood [25]. Since then, studies were set up to unravel the function of the AIPL1 protein. Studies
in AIPL1 knockdown and knockout mouse models revealed that AIPL1 functions as a chaperone for
PDE6 [26,27]. In these mouse models protein levels and activity of PDE6 were severely reduced, whereas
other photoreceptor proteins were unaffected. Other studies suggest that AIPL1 is also necessary
for the maintenance of PRs by enhancing the essential farnesylation reaction [28,29]. Several retinal
proteins, including PDE, transducin, and rhodopsin kinase (GRK1) are known to be farnesylated [30].
These findings are in line with the observed rapid degeneration of rods and cones in the animal models,
as well as in LCA4 patients.
Another chaperone, mainly involved in the trafficking of prenylated proteins, is PDE6D [8,31].
In mice, knockout of PDE6D results in mislocalization of prenylated PR proteins, including PDE6, GRK1,
and Gγ [32]. In human, mutations in PDE6D are associated with Joubert syndrome (JS) [33,34]. This
syndromic condition can be explained by mislocalization of other critical cargos of PDE6D important
for the development and stability of the primary cilium. These cargos include inositol polyphosphate
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5-phosphatase E (INPP5E) and retinitis pigmentosa GTPase regulator (RPGR) [33,35]. The trafficking
of these cargos comprises of several steps [36,37]. First, PDE6D solubilizes the prenylated protein from
the ER by sequestering the hydrophobic farnesyl or geranylgeranyl tail. Subsequently, PDE6D targets
the cargo to the destination membrane by association with a peripherally membrane bound docking
protein. Finally, binding of the displacement factor ARL3 to PDE6D causes a reduction in size of the
hydrophobic cavity resulting in the release of the cargo [38]. PDE6D can now travel back to repeat
its cycle.
UNC119 shares significant sequence and structural homology with the prenyl-binding protein
PDE6D [37]. Similar to PDE6D, UNC119 is also a subject of ARL3-dependent cargo release, and therefore
the transport mechanism of PDE6D and UNC119 are highly identical. However, a remarkable difference
between PDE6D and UNC119 is the ARL3-dependent release of their cargo. In contrast to PDE6D, the
hydrophobic pocket of UNC119 is expanded upon binding of ARL3, thereby weakening the interaction
with the cargo instead of squeezing the lipid out of the hydrophobic pocket [39]. This might be partly
explained by the binding of different lipid moieties of both chaperones. Whereas PDE6D sequesters
prenylated proteins, UNC119 is known to bind myristoylated cargo [31,40]. UNC119 has been shown to
be important in the trafficking of transducin, which is myristoylated on its α-subunit [41]. In UNC119
knockout mice, the trafficking of transducin to the OS during dark adaptation was significantly
impaired, contributing to the observed slow retinal degeneration [42]. The observed mislocalization
of transducin in these mice is not complete, supporting the fact that transducin is trafficked by other
proteins, including PDE6D. Interestingly, a study performed in Pde6d;Unc119 double-knockout mice
showed partially improved rhodopsin kinase (GRK1) expression and trafficking in cones compared to
Pde6d single-knockout mice [43]. Based on these findings, the authors suggest that the transport by
PDE6D and UNC119 in cones might be interdependent. The improvement found in only cones is in
line with the relatively mild phenotype seen in patients with a truncating mutation in UNC119, which
is associated with late onset CRD [44].
2.2. Pathways Involved in Protein Folding
2.2.1. Chaperonins, Phosducins and Ric8A
In addition to the classic and ubiquitous molecular chaperones from the heat shock protein
superfamily (discussed below), various studies have focused on chaperones and co-chaperones
involved in folding and assembly of PR-specific proteins.
One of the PR-specific proteins that needs targeted guidance for its correct folding and assembly
is transducin. The folding and assembly of the full transducin protein complex is performed in two
distinct steps. In the first step, the so-called chaperonins or CCTs (chaperonins containing TCP-1) are
involved. CCTs are protein-folding ATPase complexes consisting of two stacked rings, which form
a central cavity [45]. The β-subunit of transducin (Gβ) is able to enter this cavity. Once transducin
enters, ATP binding occurs, resulting in the closure of the cavity by hydrolysis of the just bound ATP
molecule [46]. In addition to ATP, the folding of Gβ requires a co-chaperone, phosducin-like protein 1
(PhLP1). Binding of PhLP1 induces conformational changes of CCT that lock the β-propeller structure
of Gβ. Subsequently, Gβ rotates inside the cavity followed by its release in complex with PhLP1.
PhLP1 is required for the formation of the Gβγ dimer [47].
The second step involves the trafficking of the Gβγ dimer to the OS by phosducin, another
member of the phosducin family of proteins. Phosducin forms a complex with Gβγ by sequestering
the hydrophobic farnesyl residue of Gγ [48]. The farnesyl residue serves as a membrane anchor, which
targets Gβγ to the OS [49]. Another speculated function of phosducin is the protection of Gβγ against
ubiquitination and degradation by the proteasome [50].
CCTs are also involved in the folding and assembly of the BBSome [51], a protein complex that
regulates the ciliary import, export, and intraciliary trafficking of molecules [52]. Mutations in genes
coding for BBSome proteins most often result in the development of Bardet–Biedl syndrome, one of the
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syndromic ciliopathy conditions in which the retina is affected [53], as indicated in the introduction.
For some of the BBSome proteins it was shown that these proteins contain a β-propeller fold, similar
to Gβ [54]. Whether or not the folding and assembly of the BBSome proteins is comparable to the
situation of Gβ remains to be elucidated.
It remains largely unknown if the α-subunit of transducin also needs assistance in correct folding
and trafficking to the OS before it forms a heterotrimeric complex with Gβγ. However, evidence
is emerging that resistance to inhibitors of cholinesterase 8 (RIC8) proteins function as ubiquitous
chaperones for Gα [55]. The two known isoforms—RIC8A and RIC8B—each regulate specific classes
of Gα [56]. Although the specific PR class of Gα and its relation to RIC8 has not been investigated,
it has been shown that a closely related form interacts with RIC8A [57]. The proposed mode of
action of RIC8A is to positively regulate Gα by acting as a guanine nucleotide exchange factor (GEF).
RIC8A preferentially binds GDP-bound Gα and causes GDP release. Subsequently, RIC8A assists in
organizing a de novo nucleotide-binding pocket for binding of GTP. The RIC8A-Gα complex breaks
apart when a GTP molecule binds. Subsequent hydrolysis of GTP results in the binding of Gα to the
Gβγ yielding the fully assembled heterotrimeric complex [58]. Taken together, CCT together with
PhLP1 regulate the folding of the transducin β-subunit. Subsequently, Gβ forms a dimer with Gγ by
guidance of PhLP1. Finally, the Gβγ dimer is trafficked to the OS by phosducin, where it can bind to
Gα. RIC8A has been proposed as the chaperone of Gα and its assembly to the Gβγ dimer.
2.2.2. Heat Shock Response (HSR)
The HSR is known to be present in every living organism, and functions as an essential survival
mechanism against extracellular challenges, such as increased temperatures, and intracellular stressors
such as oxidative stress, that lead to protein misfolding [21,59]. The HSR is featured by an extremely
rapid activation of gene expression, leading to a remarkable increase in molecular chaperones, including
heat shock proteins (HSPs) [60]. In vertebrates, the HSR is regulated by a family of transcription
factors, which includes six members (HSF1-4, HSFX, and HSFY) [59]. HSF1 is believed to be the master
regulator of molecular chaperone synthesis upon protein misfolding [61]. Under normal physiological
conditions, monomeric HSF1 is repressed and localized in the cytosol by interacting with molecular
chaperones, including HSP90, HSP70, and the chaperonin CCT. When a threshold of misfolded proteins
is reached, the chaperones dissociate from HSF1 leading to trimerization and nuclear accumulation of
HSF1 followed by transcriptional activation of HSPs. The major HSPs involved in the HSR include
HSP90, HSP70, and HSP60 [61].
HSP90 and HSP70 are able to associate with the hydrophobic regions of the protein, and thereby
preventing binding to other hydrophobic moieties [61]. Subsequently, they assist in the folding of these
hydrophobic regions in such a way that the hydrophobic groups are not exposed. Furthermore, they
aid in overcoming the energy thresholds of the intermediate folding states of the protein [62]. Similar
to HSP90 and HSP70, the chaperonin HSP60 is also able to bind hydrophobic residues of proteins.
In contrast, the barrel-shaped HSP60 is more passively involved in the folding of proteins by creating a
favorable microenvironment for the hydrophobic regions in its central cavity [63].
2.2.3. Unfolded Protein Response (UPR)
A more specific cellular stress response related to the ER is the UPR. The UPR is activated in
response to an accumulation of unfolded and/or misfolded proteins in the lumen of the ER [64].
The activation of the UPR aims to reduce ER stress and restore proteostasis in three distinct ways:
an initial response to reduce protein synthesis, a second wave of increased production of molecular
chaperones involved in protein folding to increase folding capacity, and finally the degradation of
misfolded proteins when the folding capacity is insufficient to restore functional protein balance.
It is generally accepted that a member of the HSP70 family, BiP/GRP78, is the key regulator in the
activation of the UPR [65]. BiP has been shown to associate with all three transmembrane sensors of the
UPR, including inositol requiring enzyme-1 (IRE1) α and β, protein kinase RNA (PKR)-like ER kinase
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(PERK), and activating transcription factor 6 (ATF6) α and β. Under normal physiological conditions,
BiP associates with the ER luminal domain of IRE1 and PERK via its ATPase domain, maintaining
them in an inactive monomeric state.
The interaction of BiP with ATF6 masks a binding site to coat protein-II (COP-II) vesicles, thereby
preventing ATF6 translocation to the Golgi. Upon ER stress, BiP dissociates from the sensors and
binds to misfolded proteins. Subsequently, IRE1 and PERK are able to oligomerize followed by their
trans-autophosphorylation and ATF6 traffics to the Golgi for further processing and activation.
Dissociation of BiP from IRE1 results in the activation of its RNase domain. This activation is
sustained by binding of HSP47 to the luminal domain of IRE1, thereby hindering the binding of
BiP [66]. Subsequently, a single mRNA encoding for X-box binding protein 1 (XBP1) is targeted for
non-conventional splicing [67].
These spliced XBP1s trigger the expression of molecular chaperones and components of ERAD in
order to relieve the load on the ER and eventually restore protein balance [68]. One of the upregulated
chaperones is the ER resident co-chaperone ERdj4, which eases and stabilizes the binding of BiP [69].
Furthermore, it has been shown that protein disulfide isomerase A6 (PDIA6) plays an important role in
the conversion of IRE1 to its monomeric state [70]. Based on these findings, it is speculated that ERdj4
and PDIA6 are important regulators of the IRE1 negative feedback loop. Activation of PERK leads to
phosphorylation of the α-subunit of eukaryotic translation initiation factor 2 (eIF2α), thereby hindering
the conversion of eIF2-GDP to eIF2-GTP by the GEF eIF2B [71]. The inactivation of eIF2α leads to
overall decrease in mRNA translation and thus protein synthesis. Although, global mRNA translation
is reduced, some specific mRNAs are favored to be translated, including activation transcription
factor 4 (ATF4) [72]. ATF4 is able to activate the transcription of various genes involved in protein
folding, autophagy, and apoptosis, including CCAAT/enhancer-binding protein (C/EBP) homologous
protein (CHOP), ER oxidoreductin 1 (ERO1), and growth arrest and DNA damage-inducible protein
(GADD34). GADD34 plays a role in the negative feedback loop for PERK by acting as a cofactor
in the dephosphorylation of eIF2α [73]. CHOP and ERO1 mainly play a role in prolonged PERK
activation [74], which will be discussed below.
Under ER stress, ATF6 binds to COP-II vesicles and traffics to the Golgi [75]. Here, it is cleaved by
proteases S1P and S2P resulting in a cytosolic fragment [76]. This fragment travels into the nucleus to
regulate transcription of specific UPR genes, including CHOP and XBP1. Interestingly, XBP1s and ATF6
are able to heterodimerize, and subsequently induce the expression of genes involved in ERAD [77].
2.3. Pathways Involved in Protein Degradation
2.3.1. ER-associated Degradation (ERAD)
Folding and maturation of proteins is a complicated process that is highly susceptible to errors.
Up to 30% of all newly synthesized proteins are affected by such errors and are therefore degraded
by the proteasome before they reach their defective mature state [78]. An important player in
proteasomal-dependent protein degradation is ERAD. The process of ERAD can be divided into three
consecutive steps: recognition of misfolded proteins in the ER, retrotranslocation of these proteins into
the cytosol, and ubiquitin-dependent degradation by the ubiquitin–proteasome system (UPS) [79].
The recognition of misfolded proteins depends on the detection of substructures within
proteins, including exposed hydrophobic regions, unpaired cysteine residues, and immature
glycans [80]. The latter involves the lectin-type chaperones calnexin and calreticulin, which can
bind to glycans possessing the Glc3Man9GlcNAc2 structure produced by deglucosylation [81].
Incompletely or misfolded proteins undergo multiple rounds of reglucosylation by uridine diphosphate
(UDP)-glucose:glycoprotein glucosyltransferase (UGGT) and subsequent folding by reassociation with
calnexin or calreticulin, eventually resulting in the mature protein conformation [82].
On the other hand, terminally misfolded proteins must be extracted from this calnexin/calreticulin
cycle. This extraction is regulated by the removal of terminal mannose residues from core
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glycans by mannosidases, including ER mannosidase I (ERMANI), ER degradation-enhancing
α-mannosidase-like protein 1 (EDEM1), EDEM3, or Golgi-resident mannosidase α class 1C member 1
(MAN1C1) [83–85]. In this way, ERAD can discriminate between terminally misfolded proteins and
their fully functional counterparts.
Since the ubiquitin-dependent degradation by the UPS is performed in the cytosol, terminally
misfolded proteins subjected to ERAD have to be transported through the ER membrane via a
transmembrane channel, called the retrotranslocon [86]. The exact composition of this channel is yet
unknown. However, it has been shown that the membrane protein Derlin-1 and various E3 ubiquitin
ligases are part of the retrotranslocon complex [87]. Once a small part of the substrate for ERAD is
exposed to the surface of the ER, the substrate becomes a subject for poly-ubiquitination. Subsequently,
the p97/valosin-containing protein (VCP), which is a member of the type II AAA+ protein family of
ATPases, together with its cofactors, possessing ubiquitin-binding domains (UBDs), cooperatively
produce a driving force for the retrotranslocation [88].
Retrotranslocated substrates for ERAD often possess exposed hydrophobic domains. Therefore, it
is important that these substrates should be rapidly transported to the UPS for degradation to prevent
aggregation. A chaperone complex consisting of BCL-2-associated athanogene 6 (BAG6), ubiquitin-like
protein 4A (UBL4A), transmembrane domain recognition complex 35 (TRC35), and co-chaperone small
glutamine-rich TPR-containing protein α (SGTA) has been shown to play an important role in the
trafficking of ERAD substrates to the UPS by binding to the hydrophobic domains [89].
2.3.2. Autophagy
Another very important process involved in protein degradation is autophagy. Multiple forms
of autophagy are known, including macroautophagy, chaperone-mediated autophagy (CMA), and
microautophagy [90].
Macroautophagy is the most common form of autophagy and therefore often referred to
simply as autophagy. Autophagy consists of multiple consecutive phases, including initiation,
nucleation, elongation, closure, and fusion to the lysosome. The initiation phase is tightly regulated by
AMP-activated protein kinase (AMPK) and mammalian target of rapamycin complex I (mTORC1) [91].
In addition, factors expressed resulting from ER stress are also able to trigger the initiation phase.
It all starts with the formation of the Unc-51-like kinase 1 (ULK1) complex followed by the
phosphorylation of the class III phosphoinositide 3-kinase (PI3KC3) complex I leading to the nucleation
of the phagophore [91,92]. Subsequently, autophagosome elongation and closure requires two
ubiquitin-like conjugation systems, including an ATG7 dependent system and an ATG5-ATG12
dependent system. Together they are responsible for the lipidation, by phosphatidyethanolamine (PE),
from cleavage of microtubule-associated protein 1 light chain 3 (LC3). Membrane sources in form of
lipids needed for the elongation of the autophagosomal membrane are provided by ATG9-dependent
vesicle trafficking. After closure of the autophagosomal membrane, the autophagosome has to fuse
with the lysosome to form an autolysosome in order to degrade its enclosed cargo [93].
A selective form of autophagy is CMA, which to date is only identified in mammals [94]. This
form of autophagy is specific for proteins containing a KFERQ motif in their amino acid sequence [95].
Heat shock cognate of the HSP70 family, HSC70, is able to recognize this motif and subsequently targets
these proteins to the lysosome [96]. Here, it binds to the lysosomal receptor LAMP-2A and facilitates,
together with its co-chaperones, in the unfolding process of the substrate in order to translocate it into
the lysosome [97].
Microautophagy is a process in which cytoplasmic cargo is directly engulfed into the lysosome [98].
This process is triggered by the same stimuli compared to common autophagy, but in contrast it mainly
facilitates the degradation of smaller substrates, including misfolded proteins. Similar to CMA, Hsc70
is involved in the protein cargo selection for degradation [99].
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Figure 1. Schematic representation of the different branches of the proteostasis network, divided
into trafficking, folding and degradation. (A) Trafficking: Protein prenylation involves the transfer
of either a farnesyl or a geranylgeranyl moiety to the C-terminal cysteine(s) of the target protein
by farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase-I), respectively. Chaperones
involved in regulation of this prenylation process and trafficking of prenylated proteins, include AIPL1,
PDE6D, and UNC119 (depicted in green). (B) Folding: Two responses that are activated upon protein
misfolding are the unfolded protein response (UPR) and the heat shock response (HSR). Both responses
result in enhanced expression of chaperones (depicted in green) in order to restore the correct folding
of proteins. (C) Degradation: ER-associated degradation (ERAD) results in the degradation of proteins
by the ubiquitin–proteasome system (UPS). Another pathway of protein degradation is autophagy.
Background colors in figure (green, blue, and red) correspond with background colors of Table 1.
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3. Therapeutic Approaches to Restore Protein Balance
The light sensing OS of PRs requires renewal every ten days due to its high photoactivity, especially
of the cones during daytime vision. This demands a high turnover of biosynthetic compounds, including
membranes and proteins). Therefore, a well-balanced proteostasis network is of particular importance
for the PRs. For many IRDs it has been shown that this balance in the PRs is disrupted, leading to
protein accumulation in the IS and eventually the death of photoreceptors. For this reason, several
studies have focused on therapeutically targeting the three main branches of the PR proteostasis
network to restore the protein balance. The different therapeutic approaches and their effects on PRs
are discussed below and summarized in Table 1.
3.1. Therapeutic Strategies Involved in Protein Trafficking
3.1.1. Targeting Protein Lipid Modifications
Agents targeting prenylation have been extensively studied in cancer research. The first agents
tested were FTase inhibitors used to target the farnesylation of K-Ras, which was shown to induce
several forms of cancer, including colorectal cancer and lung cancer [142]. Although some clinical
improvements were seen for different forms of cancer, these improvements could not be related to
inhibition of K-Ras. Subsequent experiments revealed that K-Ras was geranylgeranylated when
farnesylation was blocked by FTase inhibitors [143]. Therefore, inhibitors of GGTase-I emerged as
potential target for cancer therapy. However, a phase I clinical trial investigating a dual FTase and
GGTase-I inhibitor showed dose-limiting side effects in patients with locally advanced pancreatic
cancer, indicating that inhibition of prenylation has a broad detrimental effect on human health [102].
FTase inhibitors are also of particular interest in the Hutchinson–Gilford progeria syndrome (HGPS)
research field. HGPS is a rare premature-aging disease caused by a dominant de novo point
mutation in the LMNA gene, resulting in the expression of a mutant form of lamin A, also known
as progerin [144]. Progerin remains persistently farnesylated, which makes it a suitable candidate
for FTase inhibitors [100]. Although, promising improvements in bone structure, vascular stiffness,
and hearing have been obtained using FTase inhibitors in HGPS patients, nothing is reported about
possible dose-limiting side effects [101].
Despite the promising results of using FTase and GGTase-I inhibitors for targeting several forms
of cancer and HGPS, the side effects are of major concern; especially in the highly compartmentalized
PRs, where many proteins depend on prenylation for subcellular trafficking and anchoring. General
inhibition of prenylation would probably lead to underprenylation of many PR proteins leading to
mislocalization and accumulation of these proteins in the IS. Therefore, inhibition of prenylation in
PRs will rather accelerate protein accumulation than decreasing it.
3.2. Therapeutic Strategies Involved in Protein Folding
3.2.1. Targeting Chaperonins and Their Co-chaperones
The type II chaperonin CCT is proposed to be involved in the folding of approximately 10% of
newly translated cytosolic proteins [145]. Besides ATP, CCT also needs the co-chaperone PhLP1 for
the correct folding of these proteins [47]. It has been shown that inhibition of CCT by the transgenic
expression of a dominant-negative mutant of PhLP1 results in the malformation of the OS in mouse
photoreceptors [103]. Proteomic analysis revealed that the expression of several important PR proteins
was affected, including PDE6, rhodopsin, transducin, peripherin 2, ROM1, musashi-1, and UNC-119.
It could be possible that CCT is responsible for the folding of these proteins. Yet, only transducin has
been shown to be a direct substrate of CCT. Therefore, a more plausible explanation would be that
PhLP1 regulates the expression of these proteins in a CCT-independent manner.
Besides transducin, the BBSome is also a substrate for CCT for its correct folding and assembly.
It has been shown that some of the BBSome proteins, including BBS6, BBS10, and BBS12, can form a
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CCT-like complex together with CCT subunits. Interestingly, 50% of clinically diagnosed BBS cases are
caused by a mutation in one of these three genes. Furthermore, mutations in these genes result in a
more severe phenotype compared to other BBS proteins [105].
These findings highlight the importance of chaperone defects as pathogenic factors and therefore
as potential therapeutic targets. Surprisingly, chaperonins and their co-chaperones, such as PhLP1,
have not been investigated in relation to therapy. Especially PhLP1 would be an interesting therapeutic
target, because of its proposed CCT-dependent and CCT-independent regulation of important PR
proteins [104].
In cancer research, RIC8, functioning as GEF and chaperone for Gα, has been proposed as a
potential therapeutic target, since it has been shown that constitutive activation of Gα by somatic
mutations leads to development of various cancers [106]. Therefore, inhibition of RIC8 by small
molecules might reduce tumorigenesis. A constitutive active mutant of rod Gα has also been associated
to a form of congenital stationary night blindness [107]. RIC8 inhibition might therefore also alleviate
or delay this phenotype. However, as described earlier, the function of RIC8 in the PR has not been
investigated and inhibition of RIC8 would only be applicable to this specific mutation.
3.2.2. Targeting the Heat Shock Response (HSR)
HSP90, a component involved in the HSR, is commonly overexpressed in multiple forms of
cancer [146]. It has been proposed that cancer cells increase their HSP90 expression and thereby
change their proteostasis network in order to adapt to dysregulated and misfolded protein synthesis
as a consequence of rapid cell division [147]. For this reason, many studies have focused on
investigating HSP90 inhibitors. The first HSP90 inhibitor identified was geldanamycin, but this never
reached the clinical testing phase because of its poor applicability and toxicity [108]. Nevertheless,
geldanamycin paved the way for production of geldanamycin analogs, including 17-AAG/tanespimycin
and 17-DMAG/alvespimycin [109]. Although clinical testing was halted for these agents, it did provide
proof-of-principle that HSP90 is a relevant target for cancer therapy. Now, a new generation of
HSP90 inhibitors, including luminespib, onalespib, and ganetespib, show greater potency in clinical
testing [109].
HSP90 inhibitors have also been tested in models for retinal degeneration. Systemic administration
of 17-AAG accompanied by inner-blood retina barrier modulation in a mouse model of RP (RP10)
protects against photoreceptor degeneration induced by aggregating RP10-associated mutant IMPDH1
protein [110]. Furthermore, HSP90 inhibition by 17-AAG in a transgenic rat model of RP (R135L)
reduced the intracellular accumulation of the mutant protein and restored the localization of this
protein comparable to wild type controls [111]. Administration of another HSP90 inhibitor, HSP990,
in a different transgenic rat model of RP (P23H) resulted in enhanced visual function and delayed
photoreceptor degeneration. However, prolonged treatment with HSP990 leads to a reduction in
GRK1 and PDE6 protein levels followed by visual impairment [111]. The visual impairment caused
by prolonged HSP90 inhibition is in line with findings from a study in which four HSP90 inhibitors
were tested, including 17-AAG, 17-DMAG, luminespib, and ganetespib, in a rat retinal damage model.
Here, it was shown that prolonged inhibition with 17-DMAG and ganetespib results in PR cell death,
whereas there was no PR injury detected upon treatment with the other two agents [112].
These contradictory findings might be explained by the different modes of action of the HSP90
inhibitors, since the effect of 17-AAG was dependent on HSF1 in the P23H rat model, whereas its effect
was HSF1-independent in the R135L model. This is further supported by the notion that HSP90 is
known to facilitate the folding and assembly of more than 300 proteins [146]. Alternatively, agents that
induce the HSR in other ways might be more suitable as potential treatments for IRDs. A direct way to
target the HSR is by overexpressing the HSF-1 gene. A study in the p23H RHO RD rat model showed
a significant increase of scotopic electroretinogram (ERG) amplitudes compared to untreated controls
upon ectopic overexpression of HSF-1 by subretinal injection of AAV-HSF-1 [113].
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The hydroxylamine derivative arimoclomol might be a more indirect alternative agent to induce
the HSR. Treatment of transgenic rats, carrying a P23H rhodopsin mutation, with arimoclomol resulted
in improved PR OS structure and reduced rhodopsin accumulation in the IS, accompanied by prolonged
PR survival and improved visual responses [114]. It was shown that these improvements were mediated
by both the HSR and the UPR, thereby indicating that these responses are intertwined. Another great
advantage of arimoclomol is that it only acts on stressed cells. In this way, potential side effects, as a
consequence of inducing an HSR response in healthy cells present in the retina, are avoided.
3.2.3. Targeting the Unfolded Protein Response (UPR)
As described earlier, the UPR senses ER stress by using three transmembrane sensors, including
IRE1, PERK, and ATF6. In IRDs, mutations causing defective proteins can result in prolonged ER stress.
It has been shown that upon prolonged ER stress, downstream effectors of the PERK pathway, ATF4 and
CHOP heterodimerize. This results in increased protein synthesis, protein misfolding, and oxidative
stress, eventually leading to cell death [148]. Another branch of the UPR that gets hyperactivated upon
prolonged ER stress is IRE1. Hyperactive IRE1 cleaves microRNAs that normally inhibit proapoptotic
targets, thereby inducing apoptosis [149]. Because apoptosis as a consequence of ER stress is often
seen in PRs of IRD patients, therapeutically targeting UPR regulators or pathways involved in one of
the three branches of the UPR might promote PR survival and thereby visual function.
As discussed earlier, it is commonly accepted that BiP/GRP78 is the key regulator in the activation
of the UPR. Therefore, BiP might be a potential therapeutic target for relieving ER stress. Indeed,
studies have shown that subretinal delivery of AAV5-BiP to a transgenic rat model of RP (P23H) results
in reduction of PR cell death and improved ERG amplitudes [115]. Furthermore, a study in primary
human retinal pigmented epithelium cells (hRPE) showed that AAV2-BiP promotes the survival of
these cells under ER stress [116]. Both studies suggest that these improvements are due to a suppression
of apoptosis by downregulation of CHOP protein levels. For this reason, reducing CHOP levels might
be a promising strategy to alleviate ER stress. This notion is supported by a large body of evidence in
the field of Alzheimer’s Disease, cardiac hypertrophy, and diabetes, wherein they link CHOP to these
disease conditions [150].
Recently, several studies investigated the effect of CHOP reduction in the context of photoreceptor
degeneration. A first study was performed in a transgenic mouse model of RP (T17M) [117].
Subsequently, these mice were crossed with CHOP knockout mice in order to get T17M RHO
CHOPP−/− mice. Complete knockdown of CHOP in these mice resulted in photoreceptor cell death,
indicated by significant thinning of the outer nuclear layer, accompanied by a strong impairment in
visual function. In a similar experimental setup comparing P23H RHO CHOPP−/− mice with P23H
RHO mice, they found no effect on PR survival in young animals. In older mice, however, the central
retina of the CHOPP−/− mice was partly protected against degeneration [118]. Another study in
transgenic mice expressing human P23H rhodopsin also showed that knockout of CHOP had no effect
on the rescue of retinal degeneration [119]. These studies indicated that complete ablation of CHOP
has no positive effect in early developmental stages. As already described earlier, CHOP is mainly
involved in prolonged PERK activation. Therefore, reducing CHOP levels to physiological levels
during prolonged ER stress might be a better solution. This notion is supported by above described
findings in older mice.
Interestingly, knocking down the proapoptotic partner of CHOP, ATF4 in a T17M rhodopsin
mutant mouse model resulted in decreased retinal degeneration and improved PR survival [120].
Further support that the PERK branch of the UPR might be a promising therapeutic target comes
from studies investigating ER stress related diseases, including Alzheimer’s Disease (AD), amyotrophic
lateral disease (ALS), Parkinson’s Disease, and prion diseases [151,152].
In an Alzheimer’s disease mouse model it was shown that deletion of PERK resulted in decreased
phosphorylation of eIF2α and prevented deficits in protein synthesis leading to an improvement of
the AD phenotype in these mice [153]. Comparable results were obtained in prion-diseased mice by
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overexpressing GADD34, which plays a role in the negative feedback loop for PERK by acting as a
cofactor in the dephosphorylation of eIF2α [154]. Treatment of the prion-diseased mice with salubrinal,
an inhibitor of eIF2α dephosphorylation, had the opposite effect compared to GADD34 overexpression,
thereby supporting the positive effects of eIF2α dephosphorylation. The positive effect of the inhibition
of the PERK pathway is further supported by a study investigating the effect of the specific PERK
inhibitor, GSK2606414A, in prion-diseased mice [155]. Treatment with this inhibitor showed reduced
neuronal cell death leading to increased survival of these mice.
Surprisingly, opposing results were found for GSK2606414A and salubrinal treatment when
administered in P23H RHO transgenic rats. GSK2606414A treatment resulted in accelerated
photoreceptor cell death and further impaired visual function, whereas salubrinal treatment was found
to improve photoreceptor survival [121]. It could be possible that in some disease conditions or models
the PERK pathway is protective, whereas in other conditions it is rather a secondary effect of the
disease process. Therefore, targeting other branches of the UPR might overcome this issue.
Targeting the IRE1 branch of the UPR has been shown to be beneficial in multiple rodent
models, including a P23H RHO rat model [122]. In this model, intravitreal injection of KIRA6, which
allosterically inhibits the RNase domain of IRE1, showed increased photoreceptor survival.
Recently, an emerging role of reactive electrophilic species (RES) as key regulators for the UPR,
more specifically the IRE1 pathway, have been described [123]. Furthermore, RES have been reported
to be involved in ER-stress related diseases, including neurodegenerative diseases, amyotrophic lateral
sclerosis (ALS), and cancer [124–126]. The RES nitric oxide (NO) has been shown to modulate PDI and
IRE1 through S-nitrosylation and thereby inhibiting the IRE1 branch of the UPR [127,128]. Therefore,
modulation by RES might be a new potential therapeutic strategy for ER stress-associated diseases,
including IRDs.
Maybe the most interesting sensor of the UPR, in context of IRDs, is ATF6, because mutations in
ATF6 have been shown to cause autosomal recessive achromatopsia and early onset photoreceptor
degeneration, also affecting the macula [156,157].
Until recently, no compounds were available that specifically target the ATF6 branch of the UPR.
However, by cell-based screens a new class of pyrazole amides, named Ceapins, were identified as
selective inhibitors of ATF6α [129,130]. Ceapins selectively prevent transport of AFT6α to the Golgi
apparatus during ER stress. Interestingly, Ceapins have no toxic impact on unstressed cells, whereas
they increase ER stress sensitivity upon ER stress induction.
3.3. Therapeutic Strategies Involved in Protein Degradation
3.3.1. Targeting the ER-associated Degradation (ERAD)
One of the essential players in ERAD is p97/VCP, belonging to the type II AAA+ protein family of
ATPases. Because of its essential role in ERAD, VCP is proposed as a novel therapeutic target for the
treatment of various diseases, including cystic fibrosis, cancer, and neurodegenerative disorders [131].
Besides its function in retrotranslocation and protein degradation, VCP is also involved in many other
cellular processes, including mitosis, nuclear reformation, DNA/RNA repair, aggresome formation
and inflammatory signaling [158]. Therefore, for therapeutic applicability, selective intervention of
VCP is required to minimize the side effects. Small compounds, named Kyoto University Substances
(KUSs), might fulfill these criteria. KUSs have been shown to specifically inhibit VCP’s ATPase activity,
without affecting the cellular functions of VCP [131]. Administering KUSs, more specifically KUS121
or KUS187, by intraperitoneal injection in a rd10 mouse model resulted in preserved outer nuclear
layer (ONL) thickness and improved visual function measured by ERG.
Because of the unfolding properties of VCP also other AAA+proteins have been proposed as potent
therapeutic agents, especially in solving protein misfolding and aggregation in neurodegenerative
diseases. Although not functionally related to ERAD, the repurposing of two AAA+ proteins, including
Hsp104 and proteasome-activating nucleotidase (PAN) were shown to protect from protein misfolding
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in several neurodegenerative animal models [159]. Furthermore, transgenic expression of PAN in
rods of mice lacking the γ-subunit of transducin (Gγ−/−) resulted in increased photoreceptor survival
accompanied by preserved visual function [132].
Another possible therapeutic target of ERAD could be the enhancement of proteosomal
degradation. Important players in this process are the deubiquitination enzymes (DUBs), also
known as ubiquitin-specific proteases (USPs). USPs are known to cleave ubiquitin moieties from
proteins and thereby preventing these proteins from proteosomal degradation [133]. Therefore,
inhibiting USPs might work as a therapeutic approach to stimulate the degradation of misfolded
proteins by the proteasome. In cancer research inhibition of specific USPs, including USP7 and USP10,
has already been shown to have beneficial effects, by acting on the tumor suppressor p53 [134].
Depending on the type of mutation, p53 can either gain oncogenic properties or lose its tumor
suppressor ability [160]. Therefore, based on the mutant form of p53, either increasing or lowering the
levels of p53 could be beneficial. Inhibiting USP7, a negative regulator of p53, leads to increased p53
levels, whereas inhibiting USP10, a positive regulator of p53, leads to reduction of p53 levels [134].
With this in mind, the causative mutation for the disease has to be known, as well as the specificity of
the USP inhibitor before administering it to the patient. From discrepancies in findings of different
studies it cannot be concluded whether p53 is involved in the pathogenesis of PR cell death [161,162].
However, a recent study found a biallelic mutation in USP45 associated with LCA. This indicates that
USPs can play important roles in the pathogenesis of PR degeneration [163].
Another important issue to address is that DUBs associated with VCP have been suggested to
promote protein turnover by assisting in retrotranslocation instead of their traditional function in
preventing proteasomal degradation. Therefore, inducing these specific VCP associated DUBs might
have therapeutic potential [135].
3.3.2. Targeting Autophagy
One of the best known inducers of autophagy is rapamycin, which directly binds to mTORC1,
thereby inhibiting the mTOR pathway [164]. Because of its limited absorption, studies have been
focusing on investigating rapamycin analogs or rapalogs, including everolimus, temsirolimus, and
ridaforolimus. These mTORC1 inhibitors were highlighted as promising therapeutic agents in various
protein misfolding associated diseases, including neurodegenerative diseases and multiple forms of
cancer [165,166]. Also, a study in an RP rat model has shown the therapeutic potential of rapamycin in
treating blindness [136]. In this study, rod cell degeneration was slowed down, without affecting cones,
in a P23H rat model upon systemic administration of rapamycin. In contrast, other studies showed
that activation of the mTOR pathway promotes cone survival [167–169]. Taken together, these results
indicate that activation of autophagy is particularly protective for rods, but can have opposing effects
on cones.
Studies investigating other mTOR inhibitors, including ATP-competitive mTOR inhibitors, are
emerging [170]. Furthermore, indirect modulators of the mTOR pathway, including metformin and
nilotinib have also been shown to play a protective role in diabetes, cancer, and neurodegenerative
diseases via indirect activation of AMPK [171–173]. Contradictory results are found in mouse models
of retinal degeneration when treated with metformin. In diabetic mice, metformin treatment protected
against retinal cell death, whereas in a P23H RHO mouse model it accelerated the photoreceptor
degeneration, indicating different modes of action by metformin [137,138].
In addition to autophagy upregulators acting on the mTOR pathway, also mTOR-independent
autophagy upregulators have been widely studied, mainly in Huntington’s disease [174]. One such
agent is valproic acid (VPA), which upregulates autophagy by inhibiting inositol synthesis. In line
with findings in neurodegeneration models, VPA treatment in models for photoreceptor degeneration
can be detrimental or protective [139,175]. In a mouse model for Bardet–Biedl syndrome (BBS12−/−),
as well as in a Xenopus laevis model for RP (P23H) treatment with VPA resulted in photoreceptor
protection [139,140]. In contrast, a T17M X. laevis model of RP and the P23H-1 rat model showed
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exacerbated photoreceptor degeneration upon VPA treatment [15,139]. Even in mouse models with a
different mutation in the same gene (PDE6) this discrepancy in outcome was observed: VPA treatment
reduced photoreceptor loss in the rd1 model, whereas VPA treatment slightly accelerated photoreceptor
loss in the rd10 model [141]. Taken together, these studies indicate that the outcome of VPA treatment
depends on the genotype and even on the type of mutation. The conflicting results might be partly
explained by the different modes of action by VPA, since VPA is also acting as a histone deacetylase
(HDAC) inhibitor, thereby altering expression of different genes [176].
4. Discussion and Outlook
The OS of the PR can be considered as a highly specialized cilium responsible for the conversion of
light stimuli into electrical signals, also known as the phototransduction cascade. This cascade requires
a tremendous amount of energy as well as a continuous OS protein turnover to maintain cellular
homeostasis. Therefore, a perfectly balanced proteostasis network is of particular importance for the
PRs. In many IRDs this balance is disrupted leading to protein accumulation in the IS and ultimately
to PR cell death. Several attempts were made to restore this balance by therapeutically targeting
different branches of the proteostasis network, including protein trafficking, folding, and degradation.
For therapeutic intervention, it has to be taken into account that these different branches consist of
tightly intertwined processes, which depend on each other and influence each other’s function and
activation. For example, administration of the AMPK activator metformin to P23H RHO mice resulted
in enhanced trafficking of rhodopsin to the rod OSs. However, it still led to reduced PR function and
survival. Apparently, metformin did not succeed in full restoration of the correct folding of rhodopsin,
leading to increased destabilization of the OSs [137]. Taken together, enhancing protein trafficking
without improving protein folding will accelerate the disease progression rather than diminishing it.
Recently, also an intimate cross-talk between the UPR, more specifically IRE1, and ERAD has been
described [177]. On one hand, splicing of XBP1s by activated IRE1 promotes the expression of ERAD
components, while on the other hand ERAD serves as a feedback loop for IRE1 by targeting it for
degradation. This cross-talk is probably further extended to other branches of the UPR, since it has
been shown that the turnover of ATF6 is also regulated by ERAD [178].
Another issue that has to be taken into account for therapeutic intervention is that in some
disease conditions certain branches of the proteostasis network are protective, whereas in other disease
conditions it is a consequence of the disease process. Therefore, it is often not clear which branch of the
proteostasis network would be the most effective target to treat a certain disease type. Even different
mutations in the same gene causing similar disease conditions can have an effect on the treatment
outcome, indicated by contradictory findings in VPA treatment in the rd1 and rd10 mouse models [141].
This discrepancy might be partly explained by the severity of the gene mutations leading to different
rates of disease progression, since rd1 mice show rapid degeneration of PRs, whereas the rd10 mouse
model represents a more slowly progressive form of RP. With this in mind, therapeutic compounds
that have an positive effect on slow progressing forms of RP might not be suitable for fast progressing
forms of RP and early onset forms of blindness, such as LCA.
The animal model used for therapeutic testing, especially animals carrying a transgene, can
also influence therapeutic outcome. One such animal model carrying a transgene is the P23H RHO
rat model. Numerous different lines with various transgene expression exist [179–181]. It has been
shown that the amount of expression of the transgene can have an effect on the disease phenotype.
Even overexpression of wild type human rod opsin has been shown to induce PR degeneration [182].
In contrast, it has been shown that overexpression of wild type RHO partially rescues visual responses
in a P23H RHO rat model [113]. Nevertheless, studies using the P23H RHO rat model presented in
this review should be interpreted with caution, especially when translating therapeutic outcome to the
patient situation.
Instead of directly targeting the different branches of the proteostasis network, mimicking the
actions of these branches might also be a valuable therapeutic approach. The main action of the PERK
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pathway of the UPR is reducing the protein synthesis and thereby reducing the ER-stress load. This
action can also be regulated by targeting the epigenome, including histone acetylation. Enzymes that
play an important role in this acetylation process are the histone deacetylases (HDACs). Inhibiting
these HDACs was shown to be protective for PR cell death. Administration of the HDAC6 inhibitor
tubastatin A in an inherited blindness zebrafish model resulted in the rescue of retinal morphology
and visual function [183]. However, further investigation of the underlying molecular mechanisms is
necessary, since poor efficacy and safety have been reported for other HDAC inhibitors, including
VPA [176,184].
Another way to influence protein synthesis is by the regulation of splicing. The importance
of splicing in the retina is indicated by mutations found in the ubiquitously expressed pre-mRNA
processing factors (PRPFs), which only cause retinal-specific degeneration [185]. In situ gene editing of
a pathogenic, dominant mutation in PRPF31 resulted in the rescue of protein expression as well as
the phenotype [186]. The proof-of-principle for targeting splicing as potential therapeutic strategy is
further supported by the application of antisense oligonucleotides for the treatment of inherited retinal
diseases, including CEP290 associated LCA [20,187].
In addition to influencing protein synthesis, degeneration of PRs, which is the ultimate consequence
of sustained ER-stress and a key hallmark of IRDs, can also been seen as a therapeutic target. A broad
range of therapeutic agents is available that can be protective for PR cell death, including cell
death inhibitors, caspase modulators, and neurotrophic factors. Individual treatment of P23H-1 rats
with the known cell death inhibitors calpeptin, N-acetylcysteine, and necrostatin-1s all resulted in
improved photoreceptor function [188]. Furthermore, the chemical chaperone tauroursodeoxycholic
acid (TUDCA), which inhibits apoptosis by preventing BAX from being transported to the mitochondria
to initiate caspase release, has been shown to preserve cones in a LCA mouse model upon systemic
injection [189]. On top of that, direct inhibition of caspases by subretinal AAV delivered X-linked
inhibitor of apoptosis (XIAP) in two RP rat models protected PR structure and function [190]. Finally,
neurotrophic factors, including CNTF, BDNF, GDNF, LEDGF, PEDF, and RdCVF were also found to
have positive effects on PR survival [191]. However, the therapeutic potential of neurotrophic factors as
a general treatment may not outweigh the plausible risk of side effects. These side effects can be reduced
by carefully selecting the proper administration route, which accounts for every therapeutic agent
described in this review. In general, there are three possible delivery methods to reach the eye: systemic,
topical, and local. Each of these methods have their advantages and disadvantages [192]. Systemic
delivery is often accompanied by systemic side effects and drugs need to pass the blood–retinal barrier
first to perform their function, but it is less invasive compared to intraocular injections. Topical delivery
in form of eye drops or ointments is not invasive, but the chance that the therapeutic compound
reaches its destination is often an issue. Intraocular injection is the most invasive delivery method,
but most often also the most effective one. Furthermore, with this method the involvement of the
immune system is largely circumvented, as the eye is a largely immune-privileged organ, thereby
further reducing the risk of potential side effects. Intraocular delivery can be performed by injecting
the therapeutic compound by itself, but the cell penetrance and thus delivery efficiency is much higher
when the compound is packed into nanoparticles, for example [192].
Immense progress has been made in optimizing the delivery methods in combination with the drug
formulation, especially for gene augmentation and antisense-oligo nucleotide (AON)-based treatments.
Now, an increasing number of studies are aimed at developing broader applicable treatments, and
therefore are focused on therapies targetting the proteostatis network. Many of these studies show
hopeful results in delaying blinding conditions [111,114,121,122,131]. However, much effort has still to
be made to first efficiently halt the progression of IRD, let alone fully restore vision.
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Abstract: Photoreceptor physiology and pathophysiology is intricately linked to guanosine-3’,5’-cyclic
monophosphate (cGMP)-signaling. Here, we discuss the importance of cGMP-signaling for the
pathogenesis of hereditary retinal degeneration. Excessive accumulation of cGMP in photoreceptors
is a common denominator in cell death caused by a variety of different gene mutations.
The cGMP-dependent cell death pathway may be targeted for the treatment of inherited photoreceptor
degeneration, using specifically designed and formulated inhibitory cGMP analogues. Moreover,
cGMP-signaling and its down-stream targets may be exploited for the development of novel
biomarkers that could facilitate monitoring of disease progression and reveal the response to
treatment in future clinical trials. We then briefly present the importance of appropriate formulations
for delivery to the retina, both for drug and biomarker applications. Finally, the review touches on
important aspects of future clinical translation, highlighting the need for interdisciplinary cooperation
of researchers from a diverse range of fields.
Keywords: retina; cyclic GMP; apoptosis; necrosis; drug delivery systems; translational medicine
1. The Retina and Inherited Photoreceptor Degeneration
The retina transforms photons of light in electro-chemical signals, processes these signals,
and transmits light-dependent information to different areas of the central nervous system [1].
The human retina is affected by a large number of hereditary, typically monogenic diseases, causing
severe vision impairment or blindness [2,3]. Genetic diseases causing the degeneration and loss of the
light-sensitive photoreceptors in the retina are grouped under the term inherited retinal degeneration
(IRD) [4,5]. Photoreceptor loss in IRD-type diseases in most cases remains untreatable, making it a major
unresolved medical problem [2,6]. This review focuses on the guanosine-3’,5’-cyclic monophosphate
(cGMP)-signaling pathway and its role in IRD and how the components of this pathway may be
exploited both for the development of new therapies as well as for new biomarkers for the evaluation
of treatment efficacy.
In IRD-type diseases, the causative genetic defect typically causes a primary degeneration of rod
photoreceptors (rods), with subsequent, secondary loss of cone photoreceptors (cones), eventually
leading to complete blindness [4]. The result is an almost complete loss of the outer nuclear layer
(ONL) and outer plexiform layer of the retina, while the inner retina remains intact initially (Figure 1).
However, eventually in the inner retina the dendrites of bipolar and horizontal cells retract and an
extensive gliotic scar may form [7]. The secondary degeneration of cones can be a surprisingly slow
process, with some cones surviving for many years beyond the main degeneration phase [8].
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Figure 1. Schematic drawings of a healthy retina and a inherited retinal degeneration (IRD) retina.
(A) Illustration of the various layers of an intact, healthy retina, from the retinal pigment epithelium
(RPE) to the ganglion cell layer. Rod photoreceptors in the outer retina are shown in black, while cones
are indicated by red, green, and blue. (B) Degenerated IRD retina. The outer nuclear layer is almost
completely lost and the outer plexiform layer has essentially disappeared. Curiously, when the retina
has lost all functionality, a small number of cone photoreceptors may still be present, possibly for many
years beyond the loss of rod photoreceptors. BC = bipolar cell; GC = ganglion cell; MC =Müller glial
cell. Note that the retinal structure has been simplified for clarity and that not all retinal cell types
are shown.
The IRD group of diseases is characterized by a vast genetic heterogeneity, with disease-causing
mutations known in over 270 genes (https://sph.uth.edu/retnet; information retrieved April 2019). This
diversity severely hinders both the understanding of degenerative mechanisms and the development
of treatments. To complicate matters further, each of these IRD-linked genes may carry many
different types of either recessive or dominant mutations, ranging from complete loss-of-function to
gain-of-function [3]. At present, a rough estimate will put the total number of disease mutations to
amount to at least several tens of thousands. This enormous heterogeneity calls for the development of
treatment approaches targeting common mechanisms, that can effectively treat this condition regardless
of the underlying genetic causes.
2. cGMP-Signaling in Phototransduction and Degeneration
The physiology of photoreceptors and the phototransduction cascade critically depends on
the signaling of the second messenger molecule cGMP [9]. Mutations affecting genes related
to the phototransduction cascade often cause a dysregulation of cGMP, triggering a series of
down-stream processes, which eventually kill photoreceptors [10,11]. This highlights cGMP-signaling
as one principle common to many disease-causing mutations and, hence, as a plausible target for
therapeutic interventions.
In the phototransduction cascade, in the dark, high levels of cGMP in photoreceptor outer segments
(OS) allow for the sensitization of photoreceptor cells down to the level of single-photon sensitivity [12].
cGMP binds to and opens the prototypic phototransduction target, the cyclic nucleotide-gated channel
(CNGC), located in the outer membrane of the photoreceptor OS [13]. The CNGC opening allows for
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an influx of Na+ and Ca2+ into the OS, yet, at the same time K+ and Ca2+ ions are constantly extruded
via the Na+/Ca2+/K+ exchanger (NCKX). This continuous influx and outflow of ions in the absence
of light is referred to as the dark current [14]. The conformational change in the rhodopsin protein
brought about by the absorption of a photon of light, leads to the sequential activation of the G-protein
transducin and the phosphodiesterase-6 (PDE6). PDE6, which is located to the membranous disks
within photoreceptor OS, hydrolyses cGMP, leading to the closure of CNGC and a hyperpolarization of
the OS due to continued activity of NCKX. This in turn promotes the generation of an electro-chemical
signal that is transmitted to second order neurons [15].
The toxicity of high levels of cGMP for photoreceptors was already established by Deborah Farber
and Frank Lolley in the 1970s [10,16]. The discovery of disease-causing mutations in the PDE6 α
and β genes [17,18] provided an explanation for excessive photoreceptor cGMP levels. Many more
disease mutations are nowadays known to be associated with high cGMP-dependent photoreceptor
cell death, including mutations in the genes encoding for CNGC [19], rhodopsin [11], AIPL1 [20],
and photoreceptor guanylyl cyclase [21]. However, cGMP elevation was also found in cells with
mutations in genes that seem to have no obvious connection to cGMP metabolism. An example for
this situation are mutations in the PRPH2 gene [22], which encodes for an OS structural protein [23].
Overall, high cGMP and cGMP-dependent cell death are likely involved in a significant proportion
of IRD patients [24], making it an attractive target for therapeutic interventions, and additionally
highlighting it, or its downstream processes, for biomarker development.
3. Targeting cGMP-Signaling
cGMP acts as a second messenger and plays a critical role in the regulation of different processes
in many organisms. Cyclic nucleotide research began in the 1960s but the biological role of cGMP was
identified only in the 1980s thanks to two important discoveries: the cGMP synthesis stimulation by
the atrial natriuretic peptide (ANP) in the heart, and the cGMP synthesis stimulation by nitric oxide
(NO) in smooth muscle cells causing vasorelaxation [25]. In the retina, cGMP was identified in the
1970s when the presence of high activities of guanylate cyclase, as well as a protein kinase stimulated
by cGMP, were described in the OS of bovine rods [26]. Today, we know that cGMP, when localized to
the photoreceptor OS, is an essential component of the phototransduction cascade [9]. However, cGMP
also has targets outside the phototransduction cascade, notably protein kinase G (PKG; also referred to
as cGMP-dependent protein kinase, cGK), which appears to be highly relevant for photoreceptor cell
death [22].
3.1. Regulation of Photoreceptor cGMP Synthesis
The synthesis of cGMP is catalyzed by membrane guanylyl cyclases (GCs), which convert
guanosine 5´-triphosphate (GTP) into cGMP. Photoreceptor GCs work differently compared to other
membrane GCs: They do not respond to extracellular ligands, but instead are regulated by Ca2+-binding,
and GC activating proteins (GCAPs) [27]. GCAPs are proteins containing EF-hand motifs and once
these motifs are occupied by Ca2+ they inhibit cGMP production. In the darkness, when intracellular
Ca2+ is relatively high, photoreceptor guanylyl cyclases (RetGC1 and RetGC2) are inhibited by GCAPs
and do not synthesize cGMP. Illumination induces rhodopsin conformational changes, which enable
the activation of transducin, a GTP-binding protein. Activated transducin disinhibits PDE6, thereby
allowing the hydrolysis of cGMP and the closure of CNGC leading to the interruption of Ca2+ influx.
Since Ca2+ is constantly extruded via NCKX, CNGC closure quickly lowers intracellular Ca2+ levels.
In this situation, Mg2+ replaces the Ca2+ bound to GCAPs, activates RetGCs, and promotes the
synthesis of cGMP [27–29] (Figure 2).
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Figure 2. Phototransduction and the photoreceptor cGMP-Ca2+ feedback loop. Schematic
representation of the interplay between cGMP and Ca2+ in the photoreceptor outer segment (OS). (A) In
darkness, cGMP binds to the cyclic nucleotide-gated channel (CNGC). The opening of CNGC allows for
an influx of Na+ and Ca2+ into the photoreceptor OS. At the same time K+ and Ca2+ ions are constantly
extruded via Na+/Ca2+/K+ exchanger (NCKX) creating a continuous influx and outflow of ions called
the dark current. Ca2+ binds GC activating proteins (GCAPs), which inhibit the synthesis of cGMP by
limiting guanylyl cyclase (GC) activity. (B) In light, photon (hν) absorption induces conformational
changes in the rhodopsin protein. Rhodopsin stimulates the GTP-binding protein transducin to detach
from heteromeric G-protein complex, by replacing bound GDP with GTP. The activated transducin α
subunit binds to the PDE6 complex, abolishing the inhibitory effect exerted by its γ subunits. Activated
phosphodiesterase-6 (PDE6) hydrolyses cGMP to GMP, which in turn limits the CNGC opening and
leads to a reduction of Ca2+ influx. The closure of the CNGC and a hyperpolarization of the OS, due to
continued activity of NCKX, promote the generation of an electro-chemical signal that is transmitted
to second order neurons. When OS Ca2+ concentration is reduced, Mg2+ replaces the Ca2+ bound to
GCAP, reactivating GCAP and stimulating GC to synthesize cGMP, opening the CNGC again.
In this way, both cGMP and Ca2+ concentrations in the photoreceptor are closely linked by a
feedback loop that would normally limit the levels of both second messengers to their physiological
ranges [30]. The reasons why this feedback loop fails in IRD mutations are not currently known.
A major focus of IRD research in the past was on the role of CNGC and the Ca2+ influx that it mediates,
and a number of studies suggested that excessive activation of CNGC and too high intracellular Ca2+
levels would drive photoreceptor degeneration [31–33]. However, other, more recent studies failed
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to show a clear causal connection between Ca2+ and photoreceptor loss in IRD [15,34–36]. Therefore,
in the following section, we focus on the role of PKG in photoreceptor degeneration and how this may
be exploited for IRD therapy developments.
3.2. The Role of PKG in Normal Physiology
Elevation of cGMP intracellular concentration induces a binding-dependent activation of PKG,
a serine/threonine-specific protein kinase that phosphorylates a number of biological targets [37].
Mammals express two different genes for PKG: the PRKG1 gene encodes for the Iα and Iβ isoforms
of PKG I and is located on human chromosome 10, whereas the PRKG2 gene encodes PKG II and is
located on human chromosome 4. PKG is a homodimer of two identical subunits and each PKG subunit
consists of an N-terminal regulatory domain, an autoinhibitory sequence, two tandem cGMP binding
sites, and a C-terminal catalytic domain [38]. When cGMP binds to PKG it promotes a conformational
change, which liberates the catalytic site. In mammals, PKG I mediates many of the effects of NO/cGMP
on vasodilation, vascular smooth muscle cell relaxation, proliferation, and apoptosis. PKG II regulates
homeostasis of Na+, Cl−, endochondral ossification of bones, and various functions of the nervous
system [39]. Not much is known about the role of PKG in retinal photoreceptor cells and its significance
for the regulation of phototransduction. Immunohistochemical staining for PKG I and PKG II isoforms
revealed a predominant expression of PKG I in photoreceptors ONL [40], while PKG II seems to be
expressed in the inner nuclear layer (INL) and the ganglion cell layer (GCL) [41].
Important insight into the physiological functions of PKG isoforms also came from genetic
knock-out animals. A full knockout of PKG I (α and β) leads to defects in smooth muscles, intestinal
dysfunctions, growth defects, and dwarfism [42]. Interestingly, this effect could be rescued by the
reconstitution (knock-in) of the murine PKG (cGK) Iα or Iβ isozymes in smooth muscles [43] allowing
normal development. In sensory cells of the inner ear, a knock-out of the murine Prkg1 gene did not
affect hearing function in detectable ways, yet, Prkg1 knock-out animals were protected against acoustic
trauma and resistant against noise induced hearing loss [44]. When Prkg2 was knocked-out in mice,
the animals appeared generally healthy but showed a defect in the entrainment of circadian rhythm,
even though retinal morphology and function appeared normal [45]. It remains unclear whether PKG
II deficiency leads to changes in the photosensitive retinal ganglion cells. Overall, the results obtained
on animals deficient for PKG enzymes [37] suggest that targeted inhibition of PKG would unlikely
produce major adverse effects.
The idea that PKG activity plays a role in cell death has been widely established. For instance,
activation of PKG has been used for the induction of apoptosis in colon cancer cells and in human
breast cancer cells [46,47], and is linked to pro-apoptotic effects in ovarian cancer [48]. Excessive
activation of PKG has been shown to cause cell death in certain neuronal cell types [49,50]. Several
studies pointed to the importance of the cGMP/PKG-dependent cell death mechanism in photoreceptor
degeneration and demonstrated the existence of a non-apoptotic cell death mechanisms involving
cGMP-dependent over activation of PKG [11,22,51]. This evidence makes PKG a potential target for
neuroprotective strategies.
3.3. Effects of PKG Inhibition
The different physiological functions of PKG in different tissues suggest that its inhibition can lead
to various effects. For example, PKG inhibitors DT-2 and DT-3 have been demonstrated to decrease
NO-mediated vasodilation in isolated cerebral arteries [52]. Inhibitors of PKG could; therefore, be used
to antagonize vasoplegia, a hypotonic condition characteristic of anaphylactic shock [53]. Selective
inhibition of PKG Iα mediated by the balanol-derivative N46 reduced thermal hyperalgesia and
osteoarthritic pain in rats [54].
PKG inhibition in cancer treatment appears to have an ambiguous role. In some forms of cancer,
the effects seem to be very positive. For example, in colorectal carcinoma (CRC) cell lines inhibition
of NO/PKG/extracellular-signal-regulated kinases (ERK)-signaling mediated by the PKG-inhibitor
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KT5823 reduced migration and invasion in both scratch wound and modified Boyden chamber
assays [55]. PKG seems to exert a pro-apoptotic role in breast cancer cell lines [46]. Some of the
PKG inhibitors used in the experiments mentioned above may suffer from lack of specificity and
potency. For instance, KT5823 is an ATP-binding site inhibitor and works efficiently as a PKG inhibitor
in vitro [56]. However, it is also a weak inhibitor of PKC and PKA, both of which may constitute
potential competitive binding sites. [56,57]. Another PKG inhibitor, DT-2, a substrate-binding site
inhibitor, has been demonstrated to be inefficient in inhibiting PKG activity in several types of cells.
Furthermore, in whole-cell homogenates the PKG specificity over PKA for DT-2 appears to be lost [58].
To understand PKG cellular functions as well as the cGMP/PKG-dependent cell death mechanisms,
inhibitors or activators with very high selectivity are needed. A possible and valid alternative is the
use of cGMP analogues.
3.4. Design of cGMP Analogues to Inhibit PKG
Analogues of cGMP are a class of second messenger compounds able to inhibit or activate both
PKG isoforms (Iα, Iβ, and II) [59] and have been used in a multitude of research areas. Over the last
~40 years, the first generation of cGMP analogues have become standard tools for investigations of
biochemical and physiological signal transduction pathways [60]. More recently, newly developed PKG
activators have been shown to reduce proliferation in colon cancer cell lines [61], as well as in melanoma
cells [62]. The use of PKG inhibitors contributed to identify a common non-apoptotic cGMP-dependent
degeneration mechanism in different animal models for IRD [22]. In particular, cGMP analogues used
as PKG inhibitors carry the common motif of an Rp-configured phosphorothioate. Therein, sulfur
replaces one of the exocyclic oxygens of the 3’,5’-cyclic phosphate (equatorial (eq) position in Figure 3),
while the prefix “Rp” defines the configuration of this moiety according to Cahn–Ingold–Prelog
rules for chiral atoms. These compounds, further referred to as Rp-cGMPS analogues, are able to
bind to the cGMP-binding domains of PKGs, but do not evoke the conformational changes of the
enzyme required for activation of the catalytically active C-subunit [63]. This leads to a competitive
and reversible inhibition of the various PKG isoforms. Furthermore, Rp-cGMPS analogues were
shown to be resistant against hydrolysis by mammalian 3’,5’-cyclic phosphodiesterases (PDEs) [64],
the enzyme superfamily that metabolizes cGMP to 5’-GMP in vivo. Due to the sulfur in the cyclic
phosphate and other substituents, such as bromine, mainly introduced to the guanine nucleobase,
corresponding Rp-cGMPS analogues show improved lipophilicity leading to enhanced membrane
permeability compared to cGMP [53,60]. Schematic structural motifs of Rp-cGMPS analogues with
improved inhibitory potencies for PKGs are illustrated in Figure 3. Taken together, three factors
are responsible for the efficacy of sophisticated Rp-cGMPS analogues in biological systems: 1) The
improved stability against degradation, 2) the lipophilicity and membrane permeability, and 3) the
inhibitory potential for PKG.
As mentioned above, cGMP-signaling is central to phototransduction, but cGMP levels elevated
by excessive production or, conversely, by insufficient hydrolysis may trigger photoreceptor
degeneration. Between 2012 and 2016, the DRUGSFORD consortium generated over 80 novel
cGMP analogues that target and inhibit PKG, and showed that systemic intraperitoneal injections of
a selected liposome-formulated Rp-cGMPS analogue can protect photoreceptors from degeneration
in different animal models for IRD. This pharmacological treatment significantly preserved rod
and—indirectly—cone photoreceptors, ensuring the maintenance of retinal function [65]. This proof
of concept study also highlighted the versatility of cGMP(S) analogues, which can be designed and
formulated both to study the cellular functions of PKG and as new lead compounds for therapeutic
applications in IRD.
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Figure 3. Schematic structure of Rp-cGMPS analogues. Arrows illustrate typical structural positions in
Rp-cGMPS used for the introduction of substituents to generate Rp-cGMPS analogues with improved
inhibitory potency for cGMP-dependent protein kinase I or II. (A) Position 1, N2: Addition of
β-phenyl-1,N2-etheno-modifications (PET) with varying additional substituents (R1) to Rp-cGMPS [65,66].
(B) Position 8: Addition of halogens (e.g., bromine (Br)) or sulfur-connected aromatic ring systems with
varying additional substituents (R2) [65,67].
4. Pre-Clinical and Clinical Biomarkers for Inherited Retinal Degeneration
Neurodegenerative diseases are often characterized by a slow progression of neuronal cell loss,
sometimes over the course of several decades. This implies that disease symptoms may appear only
when the damage is advanced and thus the diagnosis is made at a late stage of the disease. The current
lack of effective treatment options for most neurodegenerative diseases, including those of the retina,
stems in part from a lack of biomarkers to detect neuronal cell death and to study its progression
and dynamics. In neurodegenerative diseases biomarkers are needed, not only to aid diagnosis and
monitor disease progression, but also, as new medicines are introduced, to detect the patient’s response
to treatment [68].
4.1. Review of Recent Retinal Biomarker Developments
Over the past decade there has been some progress in the identification and development of
biomarkers for retinal cell death, based on the increasing knowledge of the underlying mechanisms
behind retinal degeneration. Notably, several attempts have been made to develop molecular probes
that target specific degenerative processes [41,69,70].
Perhaps the most straight-forward approach for biomarker development in terms of clinical
applicability and patient friendliness would be biomarkers that could be analyzed in blood samples.
While to date there are no established biochemical blood markers for retinal degeneration, a study
published by Martinez-Fernandez de la Camara et al. [71] showed that in a group of patients affected
by retinitis pigmentosa (RP), the serum cGMP levels are increased by approximately 65%, compared to
a control group. These results were confirmed in an independent study on a family with autosomal
recessive RP due to homozygous mutations in the PDE6A gene [72]. The latter study also found cGMP
plasma concentration to have a good sensitivity, which means it can detect diseased subjects well,
but with a lower specificity, thus carrying the risk that healthy subjects could appear as having the
disease. Nevertheless, this example nicely illustrates the potential for the development of blood borne
biomarkers. On the other hand, given the high genetic heterogeneity of IRD-type diseases, it is unlikely
that a single blood-borne biomarker can be used for all patients. Most likely different mutations,
in different genes, will require separate biomarker developments. In the end, this could lead to assays
that consider maybe a few dozen different metabolic markers for IRD identification.
Photoreceptors are susceptible to oxidative stress because of their high metabolic rate as well as
their exposition to environmental factors, such as ultraviolet radiation or high oxygen tension. Hence,
it has been suggested that oxidative stress contributes to the pathogenesis of retinal degeneration [73].
In line with this concept, Martinez-Fernandez de la Camara and colleagues [71] determined the levels
of different markers of the antioxidant-oxidant status in aqueous humor and blood from RP patients,
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and compared them with those in healthy controls to confirm an alteration of this status. The authors
found reduced superoxide dismutase (SOD3) activity in aqueous humor as well as reduced SOD3
activity and increased TBARS (thiobarbituric acid reactive substances) formation in peripheral blood.
Even though these studies are promising it remains to be seen whether the specificity and sensitivity of
these parameters is sufficient for clinical biomarker applications.
Another strategy to assess retinal cell death is to detect and quantify substances released by
dying cells in ocular fluids. For instance, neurofilaments (Nf) are essential constituents of the axonal
cytoskeleton [74] and, during neuronal cell death and axonal degeneration in the retina, contents
of the cytoplasm such as Nf are released into the extracellular fluid [75]. From there, Nf diffuse
into the vitreous body and anterior chamber fluid, which are the two compartments adjacent to the
retina. Accordingly, in patients who underwent vitrectomy for retinal detachment, epiretinal gliosis,
or macular hole surgery, the neurofilament heavy-chain protein could be quantified from the human
vitreous body using an ELISA technique [75]. This could make Nf release a potential biomarker for
retinal degeneration, provided that vitreous samples can be obtained.
A non-invasive detection of retinal cell death was suggested in a study published by Cordeiro
and colleagues [76]. They established a proof-of-principle in reporting the use of fluorescent cell
death markers to temporally resolve and quantify the early and late phases of apoptosis and necrosis
of single nerve cells in glaucoma and Alzheimer’s disease animal models. More specifically, they
used Alexa Fluor 488-labelled Annexin V to identify apoptotic cells, as well as propidium iodide
to identify necrotic and late apoptotic cells. Fluorescence was visualized using confocal scanning
laser ophthalmoscopy. This initial animal study eventually led to a phase 1 clinical trial [69], which
established a proof-of-concept demonstrating that retinal cell death can be identified in the human
retina with increased levels of activity in glaucomatous neurodegenerative disease.
4.2. Using the cGMP Pathway for Biomarker Development
Cell death in IRD, and in other neurodegenerative diseases, is often thought to be governed by
apoptosis, a form of cell death that would display a number of characteristic markers, such as cytochrome
c leakage and activation of caspase-type proteases [77]. However, for photoreceptor degeneration in the
retina, a growing body of evidence suggests the involvement of non-apoptotic, alternative cell death
mechanisms [11,78]. In many cases photoreceptor cell death appears to be driven by cGMP-dependent
activation of CNGC [19] and may be even more prominently by PKG [22], also in the absence of functional
CNGC expression [79]. A number of cell death-related processes have been discovered down-stream of
cGMP-signaling, including excessive activation of histone-deacetylase [80], calpain-type proteases [81],
DNA-methyl-transferase [82] and poly-ADP-ribose-polymerase (PARP) [83,84]. Molecular probes
targeting these enzymes could be developed and used as biomarkers to detect cell death and study
its progression and dynamics in IRD. For instance, an assay previously adapted to resolve PARP
activity in photoreceptors ex vivo [41], and which relied on the incorporation of biotin labelled NAD+
residues as subunits in elongated poly-ADP-ribose chains (Figure 4), could potentially be used to this
effect. While the original assay required a two-step detection, using, first, biotinylated NAD+ and then
fluorescently-labelled avidin, in the future it may be possible to develop a single step assay. This might
then be used for direct in vivo detection, possibly via fluorescent scanning laser ophthalmoscopy [69].
Similar in vivo biomarkers for the cellular detection of retinal cell death might be developed in the
future, using molecular probes targeting cGMP-dependent processes, such as calpain- or caspase-type
proteases, histone deacetylases, or DNA-methyl-transferases.
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Figure 4. Incorporation of NAD+ as a biomarker for retinal cell death. At post-natal day 11 (P11), when
compared to wild-type (WT) retina (A), photoreceptors in the rd1 mouse model (B) display marked
incorporation of biotinylated NAD+. This is highly correlated with the TUNEL assay for cell death,
which at the same age detects only few cells in the WT situation (C), while large numbers are detected
in the rd1 outer nuclear layer (ONL; D). INL = inner nuclear layer, GCL = ganglion cell layer.
5. Delivery of Compounds to the Retinal Photoreceptors
Compounds targeting photoreceptor cGMP-signaling may have strong therapeutic potential and
can, at least in part, address the genetic heterogeneity of IRD-type diseases. Nevertheless, to develop
them into successful IRD treatments still requires the delivery of these compounds to the photoreceptor
cell, which in most cases will entail formulating the active compound in a suitable drug delivery
system (DDS).
5.1. Drug Delivery Systems (DDSs) for the Retina
The retina is protected from detrimental external agents (e.g., toxins, pathogens) by the
blood–retinal barrier (BRB), as well as other ocular barriers that prevent therapeutic agents from reaching
the photoreceptor cells in the retina [85]. To overcome this obstacle, a variety of different technical
approaches have been pursued, using different routes of administration, such as suprachoroidal
injection [86], subretinal injection [87], injection into the capsule of Tenon [88], and intravitreal
injection [89]. Each of these administration routes may require the use of an adapted DDS such as
glutathione conjugated liposomes [65]. Moreover, each of these routes have specific advantages and
disadvantages, but which ever administration route is chosen the drug formulation/delivery system
used will be critical to successful treatment development.
The use of different application (injection) routes in current clinical practice may be illustrated by
two examples: In gene therapy, the most frequently used technique (mostly in clinical trial but also
–since 2018–for FDA/EMA approved RPE65 gene therapy) is subretinal injection of gene constructs
delivered in adeno-associated-virus [90,91]. The procedure entails a detachment of the retina from the
RPE with the risk for significant and irreversible retinal damage [87]. However, since gene therapy
interventions are considered to be needed only once in a lifetime, the overall risk–benefit ratio for
subretinal injection is deemed acceptable [90]. For anti-vascular endothelial growth factor (VEGF)
medication, commonly used for the treatment of age-related-macular degeneration (AMD) and other
retinal diseases, the most frequently used route of administration is intravitreal injection [92]. This
form of application is easier to perform than subretinal injection and the risk for damage to the retina
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is far lower. On the other hand, anti-VEGF drugs require regular re-administration leading to a risk for
cumulative damage to the eye, notably intraocular infections [89].
While the last ten years have seen an important development and the appearance of many
innovative materials, designs, and technologies for retinal drug delivery, efficient and sustained drug
delivery to the photoreceptors remains a major challenge. Importantly, each compound or therapeutic
agent may require highly-adapted DDS, which additionally must comply with regulatory requirements
from the medicinal drug and product authorities [93]. Therefore, future research into new treatments
for IRD should take the retinal delivery problem into consideration as early as possible, and synchronize
the compound and delivery system development.
5.2. Retinal Drug Delivery: Local vs. Systemic Administration
Currently, the standard route of administration for retinal drugs, such as anti-VEGF medications,
is multiple dosing through intravitreal injection [89,94], while in the case of single-dose, gene
therapeutic agents subretinal injection is the preferred technique [95]. Among the advantages of these
local administration routes are the limited exposure of the whole body, not the least since the eye
is an encapsulated organ. When a treatment does eventually leak out into the systemic circulation,
even very high intraocular doses will be diluted about 10.000-fold (volume of the human eye ≈ 6.5 ml;
volume of the human body (70 kg) ≈ 66 l; note that this dilution factor will be smaller in children).
Therefore, the risk of systemic side-effects of intraocularly applied drugs appears rather small, even
though such effects have been reported in some cases after anti-VEGF medication [92].
Among the disadvantages of intraocular application are the patients´ discomfort, the need
for qualified doctors to perform the injections, and the low (but cumulative) risk for intraocular
inflammation [96]. Unfortunately, topical drug application is usually not possible because of the
various barriers surrounding the eye and retina, and the alternating lipophilic and hydrophilic nature
of these barriers, preventing most drugs from reaching the retina via this route [93].
Systemic drug application might be a more patient-friendly, alternative administration route,
yet, for the reasons laid out above, systemic application will require dramatically higher dosing to
reach comparable intraocular drug concentration. In addition, cyclic nucleotide analogues are rapidly
excreted via the renal system, strongly reducing bioavailability [65,97]. Both problems could potentially
be circumvented if a drug intended for the retina was combined with a targeted delivery formulation,
such as glutathione (GSH) conjugated liposomes [98]. Such liposomes were recently shown to allow
for sufficient drug delivery of PKG inhibitors to the photoreceptors of the retina to obtain a significant
morphological and functional rescue in animal models for IRD [65]. Nevertheless, given the potential
for systemic adverse effects and the strongly increased consumption of the (often expensive) drug
substance, it remains to be seen whether the systemic administration route will be viable in future
clinical settings.
6. Conclusions and Outlook
The cGMP-signaling system offers new opportunities for the development of innovative treatments
for IRD, as well as for the development of biomarkers that can assess treatment efficacy. Novel small
molecule analogues of cGMP allow PKG (and/ or CNGC) to be targeted, with high specificity, and have
shown to achieve marked photoreceptor protection in different animal models [22,65]. While this was
true for inhibitory cGMP analogues in forms of IRD connected to high photoreceptor cGMP levels,
it remains to be seen whether activator analogues would have protective capacity in situations where
photoreceptor cGMP is too low (e.g., in RetGC loss-of-function mutations [99]).
Nevertheless, translation of new drugs or biomarkers based on cGMP-signaling, and their
corresponding DDS, will require substantial development efforts, notably in the areas of ocular
pharmacokinetics, GMP manufacturing, safety and tolerability testing, clinical trial design, and suitable
clinical endpoints, etc. All these developments require expert knowledge and a broad interdisciplinary
oversight, which, unfortunately is rarely found in both basic and clinical researchers. This highlights the
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need for specific educational programs to train scientists in translational research. Another critical aspect
for successful translation into clinical practice is the progression into a viable commercial product that
can recoup the development costs and sustain further development and improvements. Additionally,
here a specific training and a sensitization of scientists for the requirements of commercialization
(e.g., protection of intellectual property, appropriate documentation, regulatory requirements, business
models in the rare disease space, etc.) will be important.
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Abstract: Many rare diseases course with affectation of neurosensory organs. Among them,
the neuroepithelial retina is very vulnerable due to constant light/oxidative stress, but it is also the
most accessible and amenable to gene manipulation. Currently, gene addition therapies targeting
retinal tissue (either photoreceptors or the retinal pigment epithelium), as a therapy for inherited
retinal dystrophies, use adeno-associated virus (AAV)-based approaches. However, efficiency and
safety of therapeutic strategies are relevant issues that are not always resolved in virus-based gene
delivery and alternative methodologies should be explored. Based on our experience, we are
currently assessing the novel physical properties at the nanoscale of inorganic gold nanoparticles for
delivering genes to the retinal pigment epithelium (RPE) as a safe and efficient alternative approach.
In this work, we present our preliminary results using DNA-wrapped gold nanoparticles (DNA-gold
NPs) for successful in vitro gene delivery on human retinal pigment epithelium cell cultures, as a
proof-of-principle to assess its feasibility for retina in vivo gene delivery. Our results show faster
expression of a reporter gene in cells transfected with DNA-gold NPs compared to DNA-liposome
complexes. Furthermore, we show that the DNA-gold NPs follow different uptake, internalization
and intracellular vesicle trafficking routes compared to pristine NPs.
Keywords: gene therapy; gold nanoparticles; DNA-wrapped gold nanoparticles; ARPE-19 cells;
retinal pigment epithelium; clathrin-coated vesicles; endosomal trafficking
1. Introduction
The dysfunction and death of photoreceptors are the main cause of vision loss in inherited retinal
diseases (IRDs), a group of mendelian rare disorders with high genetic and clinical heterogeneity.
After more than 30 years of intense clinical and genetic studies to identify IRD genes, around
300 causative genes have been identified that cause the dysfunction of photoreceptors or alter the
function of the adjacent retinal pigment epithelium (RPE), thus leading to the progressive attrition of
photoreceptors [1,2].
From the clinical side and most relevant to patients, the main challenge is to devise effective
treatments to halt the progression of the disease or regain visual capacity. Depending on the gene
and type of mutation, different molecular approaches for therapy can be devised; but, at least for
autosomal recessive retinal diseases, the most straightforward strategy is the restoration of a fully
functional version of the protein via DNA-based gene therapy, even though gene delivery to fully
differentiated and mature cells is not an easy task [3,4]. On the other hand, the eye is an excellent
target for gene therapy since it is accessible, amenable to non-invasive examination, possesses a
well-defined anatomy and is relatively immune privileged [3–5]. Ocular gene therapy for retinal
Genes 2019, 10, 289; doi:10.3390/genes10040289 www.mdpi.com/journal/genes203
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disorders is starting to be developed and the first commercial gene therapy to treat a severe infantile
genetic blindness (Leber congenital amaurosis caused by bi-allelic mutations in the RPE65 gene) was
approved last year. These and other ongoing therapies in different clinical trial phases are based on
adeno-associated virus (AAV) vectors [6]. However, viral gene delivery also raises several concerns,
such as small size capacity (maximum packaging size for 5 kb), high production costs, probability
of immunogenicity and inflammatory responses and their invasive route of administration to the
retina (subretinal microinjection), which have fostered basic research on non-viral vectors such as
nanoparticles (NPs) for gene delivery.
NPs are highly customizable, and can be designed and optimized for cellular uptake, bypassing
the degradative machinery of the cells and improving gene expression in the nucleus [7]. Although a
priori NPs might yield lower transgene expression levels compared to viral vectors, they overcome
most safety concerns of viral vectors, are cost-effective and easily customizable and, most relevant,
have a large DNA capacity, critical for gene delivery of large ocular disease genes [4,8]. All these
desirable characteristics make the study of NPs for gene delivery to ocular tissues (cornea, retina
and retinal pigment epithelium (RPE)) a research priority in order to explore viable alternatives to
viral vectors. Nanoparticles made from different materials that display distinct properties, such as
inorganic NPs, liposomes, solid lipids and polymeric NPs, have potential use in retinal cells [3,4,9,10].
Some successful attempts using compact DNA polycationic nanoparticles for gene delivery into the
retina of pre-clinical animal models have also been reported [11,12].
However, more basic research is still needed to provide a full toolbox of NPs for different uses
in the retina, including gene therapy. For instance, liposomal-based NPs, particularly those with
positive charges, show cytotoxicity at the large quantities required for efficient gene delivery [13].
The use of polyethilenimine (PEI)-coated NPs increases cellular uptake but PEI is also cytotoxic [3,9].
Gold NPs are mostly non-toxic, but cellular uptake strongly depends on their size and diameter. Several
reports indicate that gold NPs ranging between 20 and 50 nm are non-toxic [10]. Indeed, NPs display
different physicochemical properties depending on the size, shape, surface charge and hydrophilicity,
and these parameters directly impact cellular uptake by different types of vesicular and non-vesicular
entry pathways, thereby determining the endocytic route and the final destination of NPs. In gene
delivery, the internalization of NPs through the endosomes and eventual fusion of late endosomes with
lysosomes should be avoided since it involves the destruction of nucleic acids by lysosomal hydrolases
before the genetic material reaches the nucleus [7,14]. Moreover, it has been shown that the lysosomal
accumulation of inorganic NPs, elicited by the acidic conditions of the lysosomal cellular compartment,
enhance surface instability and ion release. Intracellular ion release is responsible for the cascading
events associated with nanoparticle-induced intracellular toxicity [15] and therefore, accumulation of
NPs in lysosomes should be avoided.
In this work, we explored the feasibility of gene delivery in cultured differentiated RPE cells using
DNA-wrapped gold NPs (DNA-gold NPs). In particular, we focused on cellular uptake and intracellular
endosomal trafficking routes of pristine gold NPs and DNA-gold NPs, showing that a higher proportion
of DNA-gold NPs (compared to pristine gold NPs) are internalized through clathrin-independent
routes that do not end up in late endosomes, thereby avoiding lysosomal degradation. These uptake
routes most probably allow faster gene delivery into the nucleus as measured by an early expression of
the green fluorescent protein (GFP) reporter gene.
2. Materials and Methods
2.1. ARPE-19 Cell Culture and Differentiation Conditions
Human ARPE-19 cells, acquired from ATCC (CRL_2302), were cultured in 1:1 Dulbecco’s Modified
Eagle’s Medium (DMEM) (ATCC, Manassas, VA, USA) and Ham’s F-12 Nutrient Mix (Life Technologies,
Carlsbad, CA, USA) supplemented with 10% foetal bovine serum (FBS) (Life Technologies, Carlsbad, CA,
USA) and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA, USA) in a 5% CO2 humidified
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chamber at 37 ◦C. For immunocytochemistry, human ARPE-19 cells (1.5 × 105cells/well) were seeded in
growth medium without antibiotics onto poly-L-lysine-coated coverslips in 24-well plates. To induce
differentiation, ARPE-19 cells were deprived of FBS for 48 h and maintained in a 1:1 media of DMEM
and Ham’s F-12 Nutrient Mix. Subsequently, 48 h post-differentiation, cells were transfected with either
nanoparticles or liposomes. For dynasore treatment, the media was changed at 48 h of differentiation,
cells were washed once in PBS 1×, and dynasore was added at 80 μM (final concentration) for 30 min.
Cell medium was then changed and cells were immediately nanotransfected.
2.2. Lipofection
After 48 h of differentiation, cells were co-transfected with the pEGFP reporter vector (500 ng/well),
using Lipotransfectine (Niborlab, Guillena, Spain) (DNA: Lipotransfectine ratio of 1:3) in differentiation
medium without antibiotics. This medium was replaced 5 h post-transfection with differentiation
medium with antibiotics. After 16 h or 48 h of transfection, cells were fixed with 4% PFA for 20 min at
RT and used for immunocytochemistry.
2.3. Gold NP Production and Nanotransfection
Gold nanoparticles (40 nm) at OD 1, stabilized in sodium citrate, were purchased from
Sigma-Aldrich (St. Louis, MO, USA) (S-741981). One hundred microliters of gold nanoparticles
at OD1 were spun down and resuspended in 10 μL of Milli-Q water and mixed with 1 μL
(0.250 μg/μL) of pEGFP plasmid DNA per well. Plasmid DNA-gold hybrid structures were produced
by allowing conditions in which double-stranded DNA (dsDNA) loops wrap over the surface of the
nanoparticle. The dsDNA-nanoparticle complexes made by this method have an excellent dispersion
in different solutions from water to cell culture medium [16]. DNA-wrapped gold nanoparticles
were introduced in each well with seeded cells. Photothermal plasmon resonance of the DNA-gold
nanoparticles was activated by white light irradiation [17]. Cells were allowed to grow for either 2 h
(for immunocytochemistry), or 16 h/48 h (for EGFP expression). For transfection efficiency studies,
cells were allowed to grow for 4 h before medium was changed. The details of the wrapping reaction
and cell-transfection are currently subject to a patent and published under standard free patent
procedures [18].
2.4. Immunocytochemistry
After 2 h, 16 h or 48 h post-transfection with either pristine gold NPs, DNA-wrapped gold
NPs or liposomes, cells were fixed with 4% PFA for 20 min at RT, washed in PBS (3 × 5 min),
permeabilized in 0.2% Triton X-100 (St. Louis, MO, USA) in PBS (20 min at RT), and blocked for 1 h in
4% sheep serum in PBS. Primary antibodies were incubated overnight at 4 ◦C in a 1:200 dilution in
blocking solution (rabbit anti-GFP, rabbit anti-EEA1, mouse anti-RAB7, all from Abcam, Cambridge,
UK). After incubation, coverslips with cells were rinsed in PBS 1× (3 × 5 min), incubated with the
corresponding secondary antibodies conjugated to either Alexa Fluor 488, 568 or 647 (Life Technologies,
Grand Island, NY, USA) (1:400) at RT (1 h) in blocking solution, nuclei were stained with DAPI
(Roche Diagnostics, Indianapolis, IN, USA) (1:1000), washed again in PBS 1× (3 × 5 min), mounted
in Mowiol 4–88 (Merck, Darmstadt, Germany) and analysed by confocal microscopy and optical
transmission microscopy (Zeiss LSM 880, Thornwood, NY, USA). To quantify GFP-positive cells,
coverslips were visualized in a ZOE™ Fluorescent Cell Imager (Bio-Rad, Hercules, CA, USA).
2.5. Imaging and Statistical Analyses
Image analyses were performed using ImageJ (FIJI) software 1.52i. Stack images from five
consecutive planes (0.46 μm of separation each) centred on the subcellular location with maximum
vesicle intensity were retrieved, segmented in the different channels (clathrin, EEA1, RAB7 or NP),
measured and analysed. In the case that the total concentration of the protein of interest had to be
determined, the fluorescence threshold value was manually selected and converted into a binary mask.
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Then, the binary mask of each protein was converted to area values. In the case that the area of the
nanoparticles had to be determined, the threshold value was restricted to the dark spots produced
by the plasmon resonance of the nanoparticles. The binary mask of NPs was superimposed over
the image of interest—for example, the mask of the NP field was superimposed over the image of
the clathrin-positive vesicles’ signal. Then, the intersection area between the two selected channels
generated a new image, of which the total intensity was determined. To calculate the percentage of
NPs in each type of intracellular vesicles, the area of intersection image (e.g., NPs on clathrin-positive
cells) was measured and compared to the total area covered by NPs. For statistical analysis, three
independent replicates were performed per condition, and three representative different regions of
interest (ROIs) per condition and replicate were quantified. Values, ratios and statistical significance
were analysed using GraphPad Prism 7.03 (San Diego, CA, USA).
3. Results
3.1. Comparison of Transfection Efficiency of Standard Liposomes Versus DNA-Wrapped Gold NPs in
Differentiated ARPE-19 Cells
Differentiated cells are usually difficult to transfect by standard means even in in vitro cell cultures,
since lipofection, electroporation or calcium phosphate-mediated transfection strongly depend on
plasma and nuclear membrane composition and physicochemical characteristics, such as lability or
stiffness. As a first assay, we attempted to directly compare the transfection efficiency in differentiated
retinal pigment epithelium cells using GFP as a reporter gene. Dividing ARPE-19 cells (1.5 × 105 cells)
were seeded in 24-well plates. The shift to DMEM minimal medium without supplementation of FBS
together with cell confluence promotes differentiation to retinal pigment epithelium cells. Under those
conditions, ARPE-19 cells stop dividing and in 48 h produce one cilium per cell, demonstrative of
their differentiation state. At that stage, liposome-DNA complexes obtained following manufacturer’s
conditions (Lipotransfectine, 0.500 μg per well) and DNA-wrapped gold NPs (40 nm gold nanoparticles
from Sigma-Aldrich (St. Louis, MO, USA), wrapped with pEGFP plasmid DNA following the procedure
stated in [18]) (0.250 μg per well) were used to transfect ARPE-19 cells. The plasmon resonance of
DNA-gold NPs was activated by white light. After 16 h or 48 h post-transfection, fluorescence images
were obtained in a ZOE fluorescent cell imager using the same fluorescence settings (Figure 1A,B and
Figure S1). Several images were processed per well and condition and the number of green positive
cells was counted manually in a total of 1100–1600 cells.
The number of transfected cells, around 1.4%, was very similar using both methods after 48 h
(Figure 1C), even though the amount of DNA used was lower (half) for DNA-gold NP complexes.
These results indicated that DNA-gold NPs can be used to transfect differentiated cells with a similar
yield than other widely used transfection methods. Remarkably, when using DNA-gold NPs, the same
percentage of transfected cells (around 1.2%) was detectable at 16 h and at 48 h, which suggested that
the expression of the reporter gene was relatively fast (Figure 1C). Liposome-DNA complexes enter
through clathrin-coated vesicles and after trafficking through the endosomal pathway mainly end
up fusing to lysosomes (where DNA and lipids are degraded) [19–21]. Our results showing an early
reporter gene expression at 16 h indicated that at least a pool of DNA-gold NP complexes might enter
the cell through faster routes than clathrin-coated vesicles, thus escaping the endosomal-lysosomal
pathway and reaching the nucleus in less time.
3.2. DNA-Gold Nanoparticles Enter RPE Cells by Clathrin-Mediated Vesicles and Other Cellular
Uptake Routes
In order to assess whether the cellular uptake of DNA-wrapped gold NPs was clathrin-dependent or
independent, we performed colocalization assays of gold NPs and DNA-gold NPs with clathrin-coated
vesicles at 2 h post-transfection. Since clathrin internalization is dependent on dynamin activity
for closure of the forming vesicles at the membrane, we also treated cells with dynasore for 30 min
immediately before transfection. Dynasore is a strong and irreversible inhibitor of dynamin enzymatic
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activity and therefore, clathrin-coated vesicles can be neither closed up nor internalized. Dynasore also
affects the cell membrane stiffness and thus alters lipid raft-mediated processes [22,23].
Figure 1. Analysis of transfection efficiency of DNA-wrapped gold nanoparticles (40 nm) compared
to liposomes in differentiated ARPE-19 cells. Representative images of differentiated ARPE-19
cells transfected with the pEGFP reporter vector using either liposomes (LIPOTRANSFECTINE)
or nanoparticles at (A) 16 h and (B) 48 h (for wider field images with a lower amplification,
see Supplementary Materials, Figure S1). (C) Quantification of green fluorescent protein (GFP)-positive
cells showed similar levels of transfection efficiency by nanoparticles (1.4% positive cells using
0.25 μg/150,000 cells) compared to standard lipofection (1.31% positive cells using 0.5 μg/150,000 cells)
at 48 h. Remarkably, nanoparticles promoted GFP expression in transfected cells at an earlier
time after transfection compared to liposomes, since at 16 h, 1.2% cells were GFP-positive in
nanoparticle-transfected cells compared to 0.54% in those transfected with liposomes, thus suggesting
different cellular uptake and/or intracellular vesicular trafficking routes for the two transfection systems.
Quantification on 1100–1600 cells per condition.
Figure 2A shows representative images of the intracellular localization of clathrin vesicles
(immunodetected in red) and NPs (detected as black dots in optic tomography field, see zoom panels)
in differentiated ARPE-19 cells at 2 h post-transfection. Confocal image stacks were centred in the
subcellular localization where clathrin vesicles were more prominent (relatively close to the plasma
membrane). Several image masks were used to analyse the localization of NPs in the clathrin-coated
vesicles under control (panels at the left) and dynasore treatment (panels at the right) conditions.
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Inhibition of dynamin-mediated events by addition of dynasore was effective, since it significantly
reduced the number of clathrin-coated vesicles down to 60% in control untransfected cells (Figure 2A,B).
Figure 2. DNA-gold nanoparticles are uptaken by differentiated ARPE-19 cells through different
vesicular and/or non-vesicular routes. (A) After 2 h post-transfection, between 40 and 60% of pristine
gold NPs and DNA-wrapped gold NPs are detected in clathrin-coated vesicles. NPs are visualized as
black dots in the optic transmission microscopy channel (BF-bright field, see also zoom panels). DNA
nanoparticles appear in clusters compared to pristine 40 nm gold particles. Clathrin-coated vesicles
are immunodetected in red. Dynasore treatment inhibited the uptake by dynamin-mediated events.
Image analyses of colocalization were performed by using masks over different channels. (B) Treatment
with dynasore reduced down to 60% the number of clathrin-coated vesicles in untransfected cells,
after 2 h. Addition of DNA nanoparticles in either (C) control conditions or (D) with dynasore treatment
significantly reduced down to 55% the number of clathrin-coated particles. (E) At 2 h post-transfection,
the mean area of NPs/cell uptaken by differentiated RPE is reduced two-fold in dynasore-treated
cells, reflecting that at least half of the nanoparticles are internalized by dynamin-mediated events;
remarkably, the mean area of internal NPs is higher in cells transfected by DNA-wrapped NPs compared
to pristine NPs. (F) Percentage of NPs/cell in clathrin-coated vesicles is highly similar in all conditions,
ranging between 40 and 50%, indicating that a large pool of NPs was not uptaken by RPE cells using
this route. Representative images from three independent replicates (three images per replicate and
condition) were quantified. Statistical significance was analysed by the non-parametric Mann–Whitney
test (* indicates p < 0.05).
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Notably, the addition of pristine gold NPs, but particularly of DNA-gold NPs, also significantly
reduced the area of clathrin vesicles down to 55% compared to control untransfected cells, which were
considered the control reference (Figure 2A panels at the left, and Figure 2C), in a reduction effect
similar to that caused by dynasore treatment. This reduction in the area of clathrin vesicles in cells
transfected with DNA-gold NPs was also observed after treatment with dynasore (Figure 2A panels
at the right, and Figure 2D). This consistent reduction in clathrin area (in all cases after correction
per number of cells in each image) may reflect that at the cell–NP interface, surface properties of the
DNA-gold NPs, which also differ from those of pristine gold NPs, can alter the formation in number
and/or size of clathrin vesicles at the cell membrane of ARPE-19 cells.
Cell uptake of either pristine gold NPs or DNA-gold NPs (measured by the mean area covered by
black dots in each image corrected per cell) was reduced, but not abrogated, after dynamin-inhibition
in both cases (Figure 2E). However, the percentage of NPs colocalizing within clathrin-coated vesicles
was maintained in all conditions and for both types of NPs, with no statistically significant differences
(Figure 2F). Therefore, although dynasore treatment reduced the number of clathrin vesicles as well as
the total amount of internalized NPs per cell, the percentage of NP uptake via clathrin by ARPE-19
cells was maintained close to 50%.
Overall, these results showed that the presence of DNA-gold NPs (40 nm diameter) altered the
dynamics of the differentiated ARPE-19 plasma membrane since the area of clathrin-coated vesicles
was diminished at 2 h post-transfection. The percentage of gold NPs in clathrin-coated vesicles was
around 50% in all tested conditions, irrespective of the presence of the DNA wrapping and despite
inhibition of dynamin activity. Therefore, at least 50% of gold NPs (40 nm), with or without DNA,
could enter differentiating ARPE-19 cells through non-clathrin-mediated means.
3.3. Differences in the Intracellular Endosomal Trafficking of DNA-Wrapped Gold NPs Compared to Pristine
Gold NPs in RPE Cells
Once inside the cell, clathrin-coated and other endocytic vesicles (e.g., receptor- or
caveolin-mediated) enter into the dynamics of the endosomal pathway. The key internalization proteins
(clathrin, receptors, caveolin) are recycled and the vesicles fuse to endosomes. Early endosomes
mature into late endosomes, and this maturation process involves shifts in the protein epitopes of
the endosomal membranes. Late endosomes usually fuse to lysosomes, which degrade the engulfed
particles within. There are some exceptions to this endosomal trafficking pathway that leads to
degradation. For instance, caveolin-mediated vesicles fuse to neutral endosomes and particles within
can be liberated in the cytoplasm and bypass degradation [7,14]. Therefore, we decided to analyse the
colocalization of internalized gold NPs with endosomal markers, to assess whether NPs were localized
in early and/or late endosomes. After 2 h post-transfection with either pristine gold NPs or DNA-gold
NPs, under control and dynamin inhibition conditions, differentiated ARPE-19 were immunodetected
for EEA1 (in red) and RAB7 (in white), which are markers for early and late endosomes (Figure 3A).
Confocal image stacks were selected at the internal subcellular region with an optimum detection
of early and late endosomes. NPs were visualized as black dots in optic transmission microscopy.
Several masks were applied to quantify mean areas of NPs and colocalization of NPs within early or
late endosomes.
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Figure 3. A significant pool of DNA-wrapped gold NPs colocalized in early and late endosomes in
differentiated ARPE-19 cells. (A) After 2 h post-transfection, a significant pool of NPs colocalized
in early endosomes (early endosome marker EEA1, in red) and late endosomes (mature endosome
marker RAB7, in white). NPs are visualized as black dots in the optic transmission microscopy
channel (BF). Dynasore treatment (panels at the right) was also performed to inhibit dynamin-mediated
uptake events. The merge field is not shown since nanoparticles were not distinguishable on the dark
background of immunofluorescent images, but image analyses of colocalization were performed by
using masks over different channels. (B) The number of early and late endosomes was analysed as a
ratio (to normalize per cell and condition). After 2 h of transfection with NPs, the ratio EEA1/RAB7
was variable but not significantly different either between cells treated with dynasore compared
to controls or between control cells compared to cells transfected with pristine gold NPs or DNA
nanoparticles. (C) Percentage of pristine NPs and DNA–nanoparticle colocalization with early or
late endosomes/cell. At 2 h post-transfection, NPs showed a fluid trafficking between early and late
endosomal compartments, as detected by 35% localization in late (35%) versus 25% in early endosomes.
Instead, DNA NPs showed a higher localization in the endosomal compartment (close to 100%) but
with a similar distribution between early and late endosomes. The addition of dynasore changed
the proportion of NPs detected in early and late endosomes when analysing pristine NPs, but not
when analysing DNA NPs, indicating that internalization and intracellular trafficking routes differ
between pristine gold NPs and DNA NPs. Representative images from three independent replicates
(three images per replicate and condition) were quantified. Statistical significance was analysed by the
non-parametric Mann–Whitney test (* indicates p < 0.05).
First, we assessed that the ratio of early and late endosomes did not vary comparing control
cells with cells transfected with either pristine gold NPs or DNA-gold NPs after 2 h post-transfection,
in either normal conditions or post-treatment with dynasore (when applicable). No significant
differences between the ratio of areas of total early/late endosomes per cell were observed in any tested
condition and transfection, including cells treated with dynasore (Figure 3B). However, a more accurate
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quantification to assess the percentage of NPs within each endosomal compartment, whether in early
or in late endosomes, did show statistically significant differences (Figure 3C) when using different
NPs and conditions.
Concerning pristine gold NPs, 35% localized in late endosomes and only 25% within the early
endosome compartment (Figure 3C). Therefore, the amount of gold NPs that did not localize to
the endosomal pathway was close to 40%. In clear contrast, DNA-gold NPs showed an equivalent
distribution in both compartments, early and late, summing up to a total of 80% of NPs within the
analysed endosomal compartments and 20% outside endosomes. These difference in distribution
between pristine and DNA-gold NPs was statistically significant (Figure 3C).
On the other hand, the NPs trafficking through the endosomal pathway after inhibiting dynamin
was also divergent between the two types of NPs. After dynasore treatment, pristine gold NPs were
mainly found in the endosomal compartments (summing up to 100%), with a significant high increase
in the localization within the early endosomes compared to control conditions. Cells transfected
with DNA-gold NPs responded differently, since there was no significant variation between NPs
localizing at early or late endosomes, rendering similar values to untreated cells, overall indicating
that a pool of DNA-gold NPs did not enter through clathrin-coated vesicles. The high number of
early endosomes with DNA-wrapped NPs in treated and untreated cells suggest that these particles
promote an endocytosis route with a higher number of early endosomes that do not mature into
the late compartment. These endosomes might release the cargo into the cytoplasm (in this case,
the reporter plasmid pEGFP), which could reach the nucleus and be expressed much faster compared
to the early/late endosomal trafficking followed by liposomes, as observed by the early GFP detection
at 16 h when using DNA-gold NPs.
4. Discussion
Gene augmentation therapy in recessive mendelian disorders caused by loss of function mutations
is, in principle, a plausible option for treatment. Addition of a wild-type copy of the gene should be
effective, provided that the gene is delivered and correctly expressed at the target tissue. In IRDs, retinal
degeneration is caused by mutations in either genes expressed in photoreceptors or genes expressed
in the adjacent RPE, as it is the case with mutations in RPE65, MERTK or LRAT. AAV-based vectors
are being used for gene delivery to photoreceptors, but non-viral vectors based on NPs should be
concurrently explored for cases in which viral approaches may not be desirable [3,4,8]. Several reports
have shown that RPE is particularly amenable for transfection with NPs. This apparent feasibility
may be due to the phagocytic nature of RPE cells, which easily engulf and internalize photoreceptor
outer segments as well as other exogenous particles [4,9]. Phagocytosis involves the formation of large
vesicles, but most small particles enter the cell via pinocytosis, which involve internalization routes
mediated by different protein and lipid interactions, for example, clathrin- and caveolae-mediated
vesicles as well as clathrin- and caveolae-independent endocytosis [7,14]. The endocytic entry route
is key to the final outcome of the internalized particles, since cargo internalized via clathrin vesicles
mainly end up being degraded by the lysosome, whereas cargo internalized by caveolin-mediated
vesicles or clathrin-independent routes bypass lysosomal degradation. In this context, we have
explored the potential use of gold NPs to transfect RPE cells in culture, focusing on the uptake routes
and the intracellular endosomal trafficking pathways.
Several authors have reported that in vitro biocompatibility of gold nanoparticles largely depended
on their shape and size, and determined that sizes between 5 and 30 nm were more cytotoxic, even though
the rate of internalization was higher than that of the less toxic NPs of 50–100 nm (reviewed in [10]).
We have used NPs of 40 nm as a compromise between cytotoxicity and internalization. In addition,
surface chemical modification of NPs is a critical step that decreases toxicity, increases stability, reduces
aggregation and modulates cellular uptake. Most NPs use positive charges at the surface to facilitate the
entry at the negatively charged cell membranes, but positively charged NPs induce cell death, whereas
negatively charged surfaces induce internalization by clathrin/caveolae-independent endocytosis [7,14].
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In this context, we have used plasmid DNA wrapping over gold NPs for two different but relevant
reasons: as a means to stabilize gold NPs [8] and favour clathrin-independent cellular uptake, as well
as to provide the DNA molecule to be delivered.
In differentiated ARPE-19 cells, at least up to 48 h post-transfection, DNA-wrapped gold NPs did
not show any toxicity. DAPI staining did not detect any pyknotic cells, and the transfection efficiency
was equivalent for both systems (Figure 1 and Figure S1), even though NPs required half the amount
of DNA for the same rate of transfection, thus indicating that this point could be further optimized in
the future. Interestingly, in cells transfected with DNA-gold NPs, the same number of cells expressed
the reporter GFP gene at 16 h as at 48 h, which suggested that DNA-gold NPs might use a faster
uptake/internalization route than cationic liposome-DNA complexes, which are mostly internalized
via clathrin vesicles [14,19–21].
Our assays also determined that, in vitro, RPE cells responded differently to pristine gold NPs
and DNA-gold NPs, since the area of clathrin vesicles was reduced in the presence of DNA-gold NPs.
These differences might be due to changes in the membrane–NP interface. On the one hand, at least
50% of the pool of pristine gold NPs and DNA-gold NPs were internalized via clathrin-coated vesicles,
which most probably ended up in the endo-lysosomal degradation pathway (Figure 2). It is likely
that this 50% of 40 nm NPs internalized by clathrin-dependent endocytosis corresponded to soluble
NPs. On the other hand, the other half of the pool of pristine gold NPs and DNA-gold NPs uses
different alternative endocytic routes for internalization, as shown by different localization/trafficking
to endosomal compartments. At least 30% of pristine gold NPs are internalized by non-vesicular routes
and localized neither in early nor in late endosomes. Since after dynasore treatment this alternative entry
route was inhibited and all pristine NPs were detected in the endosomal pathway, the internalization
of a significant pool of gold NPs was through lipid rafts or diffusion by destabilization of the cell
membrane [22,23]. In contrast, the pool of DNA-gold NPs that was not detected in the endosomal
pathway was much lower. A preference for vesicular entry could be explained by the larger size of
the DNA-gold NP complexes. Interestingly, DNA-gold NPs are equivalently distributed in early and
late endosomes, irrespective of dynasore treatment, thus indicating that a pool of DNA-gold NPs
are found in early endosomes that will not mature into late endosome vesicles. These results are in
agreement with the earlier expression of the reporter gene detected at 16 h post-transfection, which
point to a pool of DNA-gold NPs being internalized by clathrin-independent endocytosis (for instance,
via caveolin-mediated vesicles [7,14]) and to cargo escaping lysosomal degradation. Nonetheless,
we cannot discard the result that DNA-gold NPs used alternative endosomal trafficking or recycling
routes [24].
Our results are but a first step towards the potential use of non-cytotoxic gold NPs for in vivo
gene therapy in retinal disorders. Indeed, several basic biological questions should be first addressed,
such as the internalization routes and their intracellular endosome trafficking. According to our initial
results, DNA-wrapped gold NPs might be considered for gene delivery in retinal tissues. However,
before considering this system for in vivo applications, further work is required to fully understand
the complexity of cell–NP interaction, which is crucial to increase their transfection efficiency, optimize
the cargo delivery by avoiding lysosomal, autophagic or other degradative pathways, and ensure
sustained expression of the therapeutic gene.
5. Patents
S.T. declares that the DNA wrapping protocol on NPs is unpublished and currently subject
to a patent (S. Trigueros Great Britain Patent GB201201207484A and United States Patent
Application 20180318424).
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/10/4/289/s1,
Figure S1. Wider field image of Figure 1, showing transfection efficiency of NPs in ARPE-19 cells.
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Abstract: Inherited retinal diseases (IRDs) are both genetically and clinically highly heterogeneous and
have long been considered incurable. Following the successful development of a gene augmentation
therapy for biallelic RPE65-associated IRD, this view has changed. As a result, many different
therapeutic approaches are currently being developed, in particular a large variety of molecular
therapies. These are depending on the severity of the retinal degeneration, knowledge of the
pathophysiological mechanism underlying each subtype of IRD, and the therapeutic target molecule.
DNA therapies include approaches such as gene augmentation therapy, genome editing and
optogenetics. For some genetic subtypes of IRD, RNA therapies and compound therapies have also
shown considerable therapeutic potential. In this review, we summarize the current state-of-the-art of
various therapeutic approaches, including the pros and cons of each strategy, and outline the future
challenges that lie ahead in the combat against IRDs.
Keywords: inherited retinal diseases; IRD; DNA therapies; RNA therapies; compound therapies;
clinical trials
1. Introduction
1.1. Inherited Retinal Diseases (IRDs)
Inherited retinal diseases (IRDs) are a rare and heterogeneous group of neurodegenerative disorders
that collectively result in progressive visual impairment. IRDs are estimated to affect around 1 in 2000
people worldwide [1]. Over 250 causative genes have been identified in which mutations can cause one
or more of the clinical subtypes of IRD (https://sph.uth.edu/retnet/). IRDs can be familial or sporadic,
isolated (non-syndromic) or syndromic and stationary or progressive. In terms of geographic distribution,
they could be diffused or localized. Most forms of IRD mainly affect photoreceptors but other forms
can also primarily affect the retinal pigment epithelium (RPE) or the inner retina. IRDs can propagate
through all modes of inheritance—autosomal dominant (AD), autosomal recessive (AR), X-linked (XL)
or mitochondrial, whilst digenic cases or uniparental disomy have also been described occasionally [2].
1.2. Present Treatment of IRD
The eye is an ideal target for molecular therapies, for various reasons. First, the tight junctions
of the blood-retina barrier (BRB) define the retina to be a relatively immune-privileged tissue [3].
In other words, the introduction of a foreign antigen (like a viral vector) is generally well tolerated
without evoking severe inflammatory responses [4,5]. The risk of widespread dissemination of the
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locally administered vector is low, preventing unwanted systemic effects. Furthermore, relatively small
amounts of the vector are needed to achieve a therapeutic response [6,7]. The eye is easily accessible
by surgery [8], which allows intravitreal and subretinal administration of vectors to the affected tissue.
As retinal cells are differentiated and non-dividing, there is no loss of the transgene even with the
use of non-integrating vectors [9]. Finally, there are many different non-invasive approaches that are
able to monitor disease progression [10]. Examples include fundus autofluorescence that provides
a topographical map of lipofuscin changes in the RPE cells, spectral domain OCT to assess retinal
thickness and photoreceptor layer architecture, as well as other known tests like visual acuity and
biomicroscopy [11–13].
Currently, there are various (overlapping) approaches to treat IRDs under development, including
molecular therapies but also stem cell-based therapies and retinal prostheses [14–18] (Figure 1). Despite
the promising results obtained with some of these approaches, there are still many challenges that must
be overcome in order to reach a broad implementation of treatment modalities for IRDs. The great
heterogeneity of these diseases [19] hampers the development of a common treatment for a large
number of patients [20]. In addition, a significant proportion of genes involved in IRDs has a cDNA
size that exceeds the cargo capacity of adeno-associated viral (AAV) vectors, generally considered
the most preferred viral vector for retinal delivery of therapeutic molecules [21]. Finally, the costs
of developing gene or even mutation-specific approaches are substantial, while often having only a
limited number of individuals that could potentially benefit from a given therapeutic molecule.
In this review, we summarize the current state-of-the-art of the therapeutic approaches for IRDs,
with a strong emphasis on molecular therapies.
2. Molecular therapies
Due to the severity and heterogeneity of IRDs, avid research is ongoing to identify therapeutic
strategies that could ameliorate symptoms and/or disease progression, including many that focus
on resolving the consequences of a particular genetic defect [22]. However, a good candidate for
molecular therapies requires—(i) a substantial disease burden and a favourable risk/benefit ratio
compared to another therapy, if any; (ii) the relevant gene/locus involved in the disease has already been
identified and there is ample knowledge of the molecular mechanism of disease and its progression;
(iii) the right target cell(s) can be reached, with or without using a therapeutic vehicle; (iv) phenotypic
improvement can preferably be achieved with limited expression levels of the therapeutic gene,
while its overexpression does not exert any toxic effect [23].
We can subdivide the molecular strategies into different groups—DNA, RNA and compound
therapies, as graphically depicted in Figures 1 and 2. Ongoing clinical trials for genetic subtypes of IRDs
are summarized in Table 1 (DNA therapies), Table 2 (RNA therapies) and Table 3 (Compound therapies).
2.1. DNA Therapies
2.1.1. Gene Augmentation
In gene augmentation therapy (also known as gene replacement therapy), a normal copy of the
mutated gene is inserted into the host cells using therapeutic vectors (for details on the various types
of vectors, see Section 3). To enable this, the gene of interest could be delivered as DNA, as messenger
RNA (mRNA) or as mRNA analogue. The big advantage of the mRNA platform is that it does not
require delivery into the nucleus and the risk of integration into the host genome is reduced [24,25].
Two of the main challenges of mRNA delivery however are immunogenicity and stability of the
RNA molecule [24,26]. Thus, since sustained production of the protein of interest is required for
continued improvement of visual function, the DNA platform is the preferred strategy for ocular gene
augmentation therapy [25]. With this, the gene of interest is introduced to the cell nucleus, where it
often remains in an episomal state while promoters and enhancers can facilitate its expression [25,27].
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Figure 1. Schematic representation of potential therapeutic approaches according to the retinal disease
progression and the knowledge of the genetic cause of the retinal disease. Genetic therapies (blue
boxes) are preferred in the first steps of the disease progression (retinal cells are still alive) and when
knowledge of the genetic causes of the diseases is present. As the disease progresses and the knowledge
of the pathogenesis decreases, other approaches such as cell therapies (pink box) or retinal prosthetic
implants (yellow box) can be used. Compound therapies (black box), based on pharmacological
treatments, could be used as an alternative approach when the genetic cause of the disease or the
pathway involved are either known or unknown. For late-stage diseases, optogenetics or retinal
prostheses may be the only option. Image sources—smart.servier.com and Doheny Retina Institute
(new.bbc.co.uk/2/hi/science/nature/6368089).
DNA can be delivered using one of several different vectors but in particular for IRDs,
adeno-associated viruses (AAVs) have been most commonly used due to their high tropism for
certain retinal cells and their low immunogenicity [14]. Other vectors under study are lentiviruses and
nanoparticles, which have larger cargo capacities [28].
Advanced stages of retinal degeneration are not compatible with the use of gene augmentation
therapy, since this approach requires the target cells to be alive [29]. Moreover, reaching substantial levels
of gene expression is crucial for a significant and strong rescue of the phenotype [30]. This requirement can
for instance be improved by varying the serotypes of AAVs that are used to deliver the transgene [31–33],
by varying the promoter sequence [30] or by producing codon-optimized cDNA versions of a given
gene [34,35].
For IRDs, gene augmentation is currently the most advanced therapeutic strategy, with market
approval for one gene (RPE65, LuxturnaTM), several ongoing clinical studies for other genes (Table 1)
and preclinical development for a plethora of genes mutated in these diseases [36]. Despite these
promising results, gene augmentation strategies may not be the best approach when treating dominant
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conditions [37], as the mutated allele underlying the disease most often first needs to be inactivated
such that it does not interfere with the normal allele [38]. Such an allele-specific inhibition of expression
can be achieved either at the DNA level (Section 2.1.2) or at the RNA level (Section 2.2) and, if needed,
can be combined with gene augmentation [39]. In addition, the cargo capacity of AAV remains a
challenge, since several of the recurrently mutated genes (e.g., USH2A, EYS, etc.) are by far exceeding
it. Several studies using dual or even triple AAVs [40–43], or microgenes (smaller versions of the
gene) [44] are ongoing.
2.1.2. Genome Editing
In addition to gene augmentation, precise editing of genomic DNA has gained an enormous
attention over the last five years. Currently, there are two main approaches in genome editing—an
in vivo approach, in which the disease-causing mutations are corrected inside the retina and an
ex vivo approach to first correct the mutation in patient-derived cells, which can be followed
by cell transplantation [45]. The editing itself can be achieved by different classes of molecules,
as outlined below.
ZFNs and TALENs: Zinc-finger nucleases (ZFNs) and transcription activator like effector nucleases
(TALENs) are molecules that pioneered genome editing. Both can induce a wide range of genetic
modifications by generating double-strand breaks (DSBs) in the DNA that subsequently stimulate one
of the DNA repair pathways of the cell—non-homologous end-joining (NHEJ), homology-directed
repair (HDR) or microhomology-mediated end joining [46,47]. To induce DSBs, either nuclease
needs to be guided to its target sequence by a DNA-binding protein domain. These approaches
are thus depending on the engineering of new proteins for each target, making them laborious and
challenging [48]. Nevertheless, ZFNs have been used as a proof-of-concept treatment in IRD. Human
embryonic cells carrying the c.68C>A; p.P23H mutation in RHO were targeted using ZFNs, which led to
an increase in homologous recombination events when the ZFNs were transfected with a homologous
donor template, compared to delivery in the absence of this template [49].
TALENs have been used in the correction of the Crbrd8 allele in C57BL/6N mice. HDR triggered
by a combination of TALEN and a single-stranded donor oligonucleotide repair template was observed
in 27% of the treated mouse embryos and resulted in an improvement of retinal function [50].
CRISPR/Cas system: The CRISPR/Cas system is considered a more advanced genome editing
tool compared to ZFNs and TALENs, as it presents many advantages including the simple design of
the target, its higher efficacy and its ability to introduce mutations in multiple genes at the same time
by using a combination of guide RNAs (gRNAs) [25]. The CRISPR/Cas system has been improved
to a simpler version, CRISPR/Cas9, which nowadays is commonly used for mammalian genome
editing [51–53]. The Cas9 endonuclease is delivered into a cell in conjunction with a gRNA, after which
it can cut the genome specifically at any desired location [52,54].
As for other genome-editing tools, its major limitation is the possibility of off-target effects [46].
To overcome this aspect, researchers have developed different strategies—(i) using ribonucleoproteins
(RNPs) as a form of delivery [55]; (ii) titrating the concentration of gRNA and Cas9 or using two
gRNAs flanking the target region [56]; (iii) adding two additional guanine bases at the 5’ end of the
gRNA sequence for Cas9 derived from Streptococcus pyogenes (SpCas9); interestingly, this modification
in the design did not reduce the on-target ratio both in vivo and in vitro [57]; (iv) selecting unique
DNA target sites with no homology to any other gene sequence [58]; (v) using paired Cas9 nickases,
modified Cas9 nucleases that cut only one strand of DNA and thus can produce DSBs with two times
more specificity [52,57,59], (vi) employing a high-fidelity version of Cas9 (SpCas9-HF1) [59] or (vii)
using the ‘enhanced specificity’ SpCas9, which is reported to not only decrease the off-target events
but also to obtain a higher on-target efficacy [60]. All these strategies have allowed researchers to yield
relatively high editing rates in vitro but these rates are generally lower in vivo, for instance in treated
retinas [52,61–72]. The first challenge is the delivery of the CRISPR system directly into the cells or tissue
of interest. As it was previously mentioned, AAV vectors are currently considered the most potent
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therapeutic vector for retinal delivery. However, its limited cargo capacity hampers an efficient delivery
of the complete CRISPR/Cas9 system [73]. One solution for this problem is the delivery of the SpCas9
and gRNA separated into two vectors, with which Hung and colleagues obtained an editing efficacy of
84% in the mouse retina [52]. Other studies using two AAV vectors have also obtained good results
over the last years, although it should be mentioned that these in vivo studies only used CRISPR/Cas9
technology to activate NHEJ, resulting in indels and subsequent gene inactivation [55,74–77]. A major
concern that remains to be solved is how to increase the efficacy of genome correction in the retina,
since photoreceptors are post-mitotic cells that to a large extent lack HDR mechanisms. Suzuki and
colleagues developed a strategy coined homology-independent targeted integration which allows
for targeted knock-in in non-dividing cells like photoreceptors [45,77]. This appears as a promising
approach, as it is based on the NHEJ mechanism, as opposed to HDR, for specific integration of a
desired DNA sequence [45,77].
Besides precise editing, the CRISPR/Cas9-system can also be used in other ways, such as the
invalidation of mutant alleles that underlie autosomal dominant IRD (reviewed by Diakatou et al.) [78],
or the removal of intronic sequences harbouring pathogenic pseudoexons. For the latter, Maeder
and colleagues recently developed a CRISPR/Cas9-based approach (EDIT-101) for the splice mutation
c.2991+1655A>G in CEP290. EDIT-101 promotes the deletion of part of intron 26 where the deep-intronic
variant is located. It was tested in a humanized Cep290 mouse model carrying the c.2991+1655A>G
variant [79] and a comparable surrogate non-human primate (NHP) vector also showed efficient
editing in photoreceptor and somatic primate cells [80].
Although several hurdles still need to be overcome, the development of the CRISPR/Cas9 system
has opened new avenues for the future treatment of various genetic subtypes of IRD.
2.1.3. Optogenetics
Although gene-specific augmentation therapy is a very attractive approach in patients with a
known genotype and at a relative early stage of the disease, it is not suitable for patients who present a
more advanced stage of the disease in which many of the photoreceptors have been lost (Figure 1).
Optogenetics is a technique used to monitor or control neural activity with light, which can
be achieved by the genetic introduction of light-sensitive proteins into retinal cells. This strategy is
often used to convert secondary or tertiary neurons into “photoreceptors” or, less often, to restore
sensitivity of degenerating photoreceptor cells [81–83]. One advantage of optogenetics is that it may
more precisely excite the neural pathway compared to for example, electronic retinal implants [82,84].
In addition, optogenetics can be used independent of the primary genetic defect.
Opsins represent the major optogenetic tool [85]. They function as sensory receptors or
light-responsive ion channels. Two types of opsin have been described—microbial opsins (type I) and
animal opsins (type II) [81,82]. Type-I opsins (channelrhodopsins, halorhodopsins and archaerhodopsins),
following light capture, result in a passive flow of ions across the cell membrane. When they are
introduced into non-light sensitive cells, microbial opsins can induce rapid optical control of specific
cellular processes. Type-I opsins allow high-speed neural activation and silencing, without requiring
any additional chemicals [86]. Type-II opsins (rhodopsin and melanopsin) are part of the large family of
naturally occurring light-sensitive G protein-coupled receptors (GPCRs). In contrast to microbial opsins,
animal opsins present a much higher light sensitivity, as the light signal is amplified by G-protein-coupled
signalling cascades [87]. Both types of opsins are small enough to be encapsidated in AAVs [81,82].
Experiments in animal models (mouse, rat and dog) revealed that expression of type-II opsins
resulted in increased light sensitivity, within 1–2 log units of the threshold for normal cone vision,
although this sensitivity may come at the cost of slower kinetics [88]. In contrast, the use of type-I
opsins is superior in terms of kinetics, yet its sensitivity is lower. Both types however are limited in their
operational range of light levels and will likely require modification of the incoming light signal [89].
Moreover, many questions still need to be addressed such as the identification of the best vector and
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surgical approach for delivery. Although a wide range of ubiquitous, photoreceptor-, bipolar- or
ganglion-cell specific promoters have been used, the ideal condition so far remains unclear [82].
Currently, there are two clinical trials ongoing that use optogenetics for vision restoration.
One comprises a phase I/II clinical trial (NCT02556736; Table 1) and a second trial is still in a recruiting
state (NCT03326336; Table 1), without any results reported yet for both trials.
2.2. RNA Therapies
2.2.1. Splicing Modulation
Antisense oligonucleotides (AONs): Around 15% of all IRD-causing mutations affect the splicing
process [90]. Currently, the most widely used genetic therapy to correct aberrant splicing employs
antisense oligonucleotides (AONs) [91], small DNA or RNA molecules that bind to their target
pre-mRNA in a complementary way [91,92]. Their ability to modulate splicing in fact offers several
advantages over gene replacement approaches, especially for IRDs [93]. Initially, AONs were simple
antisense RNA molecules but found to be rapidly degraded by nucleases [91]. Therefore, multiple
chemical modifications for the backbone or sugar groups were added to improve their target affinity
and resistance to nuclease activity [91,94]. These new AONs were classified as first or second generation
AONs, depending on their chemical modifications [94]. A third generation class of AONs consists
of analogues of nucleic acids. Due to their relatively small size, it has been shown that AONs can be
delivered to the eye either as naked molecules or in an AAV using a modified U7-snRNA system [95,96].
The first approved AON-based drug was Formivirsen, also known as Vitravene [97]. Vitravene
was used to treat cytomegalovirus retinitis in patients whose immune system was compromised [97,98].
In the last years, the number of IRD-causing mutations that affect pre-mRNA splicing has rapidly
increased. An example is a recurrent deep-intronic mutation in CEP290 (c.2991+1665A>G) underlying
congenital blindness [99]. For this mutation, the potential of AON-based therapy was demonstrated
first in in vitro and in vivo models [96,100–104] and later on, in a phase I/II clinical trial [105]. Promising
proof-of-concept studies employing AONs have also been developed for other mutations in CEP290 [106],
and for other genes mutated in IRD such as OPA1 [107], CHM [108], USH2A [109] and ABCA4 [110–113].
Besides the clinical trial for CEP290 (NCT03140969) there is also an ongoing clinical trial for USH2A
(Table 2). The results obtained so far indicate that AON-based therapy is a promising therapeutic
strategy, albeit only for a selected group of IRD-causing mutations. However, the use of whole genome
sequencing or targeted full-gene sequencing will likely identify more mutations amenable for this type
of therapy in the near future. Overall, the remaining challenges for AON-based splicing modulation
are mainly related to delivery, longevity and potential off-target effects.
U1 spliceosomal RNA: Many exonic splice donor site (SD) mutations have been identified in
the last nucleotide of an exon and over 95% of these are predicted to result in aberrant splicing [114].
The splicing process needs the recognition of splice sites and subsequent assembly of the spliceosome.
The latter is started by formation of stable complexes consisting of U1 small nuclear RNA (U1 snRNA),
pre-mRNA and splice factor proteins. Splice donor sites are recognized directly by the U1 complex
and are crucial for a proper splicing of exons. In case nucleotides within the splice donor site of an
exon are mutated, an attractive therapeutic approach is to use a modified U1 snRNA. Tanner and
colleagues demonstrated that a mutation that induces exon skipping in RHO (c.936G>A; p.Q311Q) can
be rescued by adapting the U1 snRNA to the mutation [114]. In the last years, this approach has also
been successfully employed in vitro, to rescue a mutation in exon 5 of the BBS1 gene that underlies
Bardet-Biedl syndrome [115], or a mutation in intron 10 causing RPGR-associated X-linked RP [116].
Thus, the U1 snRNA system definitely holds some therapeutic potential for mutations affecting the
splice donor site. However, possible off-target effects caused by the delivery of an exogenous modified
U1 snRNA are still poorly studied [117,118].
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SAR422459 NCT01736592 Enrolling by invitation
CHM
AAV2-hCHM NCT02341807 Active, not recruiting
AAV2-REP1 NCT03496012 Recruiting
AAV2-REP1 NCT03507686 Recruiting
AAV2-REP1 NCT02407678 Active, not recruiting
rAAV2.REP1 NCT02671539 Active, not recruiting
rAAV2.REP1 NCT02077361 Completed
rAAV2.REP1 NCT01461213 Completed










MERTK rAAV2-VMD2-hMERTK NCT01482195 Recruiting
MYO7A UshStat NCT02065011 Enrolling by invitation
PDE6B AAV2/5-hPDE6B NCT03328130 Recruiting
RPE65
AAV OPTIREP NCT02946879 Recruiting
rAAV2-CBSB-hRPE65 NCT00481546 Active, not recruiting
AAV2-hRPE65v2- NCT00516477 Active, not recruiting
AAV2-hRPE65v2 NCT00999609 Active, not recruiting
AAV2-hRPE65v2 NCT01208389 Active, not recruiting






AAV RPE65 NCT02781480 Completed







rAAV2tYF-CB-hRS1 NCT02416622 Active, not recruiting
Genome editing
CEP290 EDIT-101 (AGN-151587) NCT03872479 Recruiting
Optogenetics
Advanced RP RST-001 NCT02556736 Recruiting
Non-syndromic RP
Retinitis Pigmentosa GS030-DP NCT03326336 Recruiting
Black and gray are just used to indicate the different sectiond and can be considered as headers. Gene or disease
condition (first column), therapeutic molecule (second column), clinical trial identifier (third column) and the
current status of the trial (last column) are indicated. Completed trials are highlighted in bold. Data obtained from
https://clinicaltrials.gov/. RP: retinitis pigmentosa.
Trans-splicing: Trans-splicing is a naturally occurring process that results in an alternative processing
of the pre-mRNA and was first reported in plants and bacteria [119,120]. Unlike in cis-splicing, trans-splicing
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takes place between two independent RNA molecules [93,119,120]. In vertebrates, these trans-splicing
events occur in some key physiological processes, for example, the regulation of gene expression [121–123].
In humans, trans-splicing has also been reported in some diseases such as cancer [120].
Therapeutic trans-splicing offers an intriguing strategy to remove mutations from the mRNA.
Only the introduction of an exogenous RNA molecule can be sufficient to activate the trans-splicing
process. This exogenous RNA, also called PTM (pre-mRNA trans-splicing molecule), is constituted by a
binding domain that specifically targets the molecule towards a specific region within the endogenous
pre-mRNA, an artificial intron sequence harbouring all the elements required for splicing and the
sequence that needs to be replaced [93,119]. For a 5′ PTM, the partial coding sequence has to end
at the 3′ end of an exon to allow for a 5′ splice site and vice versa for a 3′ splice site [124]. In the
last years, trans-splicing has revealed promising results for the correction of mutations in RHO and
CEP290. In the first example, Berger and collaborators were able to correct RHO mutations located in
exons 2 through 5 by delivering the correct sequence of those exons in an AAV. This led to successful
trans-splicing events, both in vivo and in vitro [119]. Dooley and colleagues delivered a part of the
CEP290 gene in an AAV and thereby could successfully replace the aforementioned c.2991+1655A>G
mutation using the trans-splicing approach [124]. These data support the usefulness of trans-splicing
as a therapeutic tool in IRDs.
2.2.2. Post-transcriptional Gene Silencing
iRNA and Ribozymes: Both Hammerhead ribozymes (hhRz) and (short) interference RNA
((s)iRNA) catalyse the sequence-specific cleavage of target mRNAs. iRNA molecules are double-stranded
RNAs that are able to inhibit gene expression by binding to specific mRNAs (cellular or viral) [93,125].
Despite their affordability and speed, the effect of iRNA is often incomplete and temporary, with potential
off-target effects [126]. In addition, variations between experiments and laboratories often occur. These
variations limit the broad application of iRNA technology in many diseases including IRDs [46], although
promising results have been obtained in age-related macular degeneration, a multifactorial subtype of
retinal disease. Specifically, Ryoo and colleagues used a novel siRNA-based anti-VEGF nanoball that,
upon intravitreal administration in mice, showed therapeutic effects for at least two weeks [127].
HhRzs are small RNA molecules causing enzymatic cleavage of polyribonucleotides [128].
The hhRz consists of three helixes surrounding an evolutionary conserved catalytic core. This gives rise
to an antisense complementary region that provides the unimolecular RNA the capacity to recognize
and subsequently enzymatically cleave its target mRNA [128].
Both types of molecules (iRNA and hhRz) have been successfully used to degrade an incorrect
RHO transcript responsible for dominant retinitis pigmentosa, a common subtype of IRD [128]. Another
alternative is employing microRNAs (miRNAs), which act at the post-transcriptional level to regulate
gene expression in the retina. miRNAs generally bind to mRNA and cause a reduction of translated
products. Some miRNAs are commonly expressed in all retinal cell types while others are specifically
expressed in one or the other [5,129], suggesting that there are possibilities to employ these molecules
therapeutically. However, more studies are needed before miRNAs can actually be used [130]. Overall,
post-transcriptional gene silencing mediated by iRNA and ribozymes are believed to be a promising
strategy for treating dominant-negative mutations.
RNAse H-dependent AONs: Besides redirecting splicing, AONs can also be used to specifically
degrade transcripts, even in an allele-specific manner. Some oligonucleotide modifications combine
AON segments with conformationally restricted residues that affect cleavage of their intended
targets [131]. With this, catalytic activation of RNase H, a ubiquitous enzyme cleaving the RNA part of
DNA/RNA hybrid duplexes, can be induced. The big advantage of these hybrid duplexes is that only
a low amount of AON is sufficient to induce catalytic turnover. Furthermore, this catalytic turnover
provides enough time for AONs to act as a potential drug due to their stability in blood serum, that is,
a few days [132]. Murray and colleagues used rodent models genetically modified for RHO (p.P23H) to
test RNAse H-activating AONs in vivo. They observed that the AON-mediated knockdown of mutant
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p.P23H rhodopsin expression reduced photoreceptor degradation, thereby preserving the function of
photoreceptors in the transgenic rats [133]. Recently, AON-mediated transcript downregulation has
also been assessed in vitro for a NR2E3 variant underlying autosomal dominant RP [134], underscoring
the usefulness of this approach for some (dominant) mutations.
Cas13: The editing system based on Cas13 can reduce off-target effect rates shown by other
systems as explained previously [135]. RNA-guided RNA-targeting CRISPR-Cas effector Cas13
(previously named C2c2) can be engineered to bind and subsequently knockdown mammalian
RNA [136]. Abudayyeh and colleagues verified that, for endogenous genes, the knockdown efficiency
is transcript-dependent. Despite, the efficacy was comparable to that shown by iRNA, thus the
substantially lower off-target ratio makes this approach well-suited for therapeutic applications [137].
2.2.3. RNA Editing (dCas13 and ADAR)
The ADAR (adenosine deaminase acting on RNA) family of proteins can mediate endogenous
editing of transcripts via the deamination of adenosine to inosine, a nucleobase that is functionally
equivalent to guanosine both in splicing and in translation [135]. Cox and colleagues designed a
catalytically inactivated Cas13 (dCas13) that is able to retain its RNA-binding capacity, to direct an
ADAR towards the RNA transcript of interest and to perform its adenosine-to-inosine deaminase
function [135]. This demonstrated the flexibility of Cas13 to be adapted as a tool for nucleic acid
modification. The system that was created is called REPAIRv2 and generates a higher specificity
compared to other RNA-editing platforms reported so far [138,139] with high levels of on-target activity.
Other advantages include—(i) Cas13 has no targeting sequence constraints and does not present any
preferential motif surrounding the target adenosine, allowing any adenosine in the transcriptome to
be potentially targeted; (ii) the REPAIRv2 system directly deaminates target adenosines to inosines
and does not depend on endogenous repair pathways, thereby enabling RNA editing in post-mitotic
cells like neurons and photoreceptors and, (iii) RNA editing, contrary to DNA editing, is transient and
thus can be more readily reversed, allowing temporal control over editing events [135]. These features
make RNA editing an interesting strategy to be used in future therapeutic studies in IRDs.
Table 2. List of clinical trials for IRDs using RNA therapies.
Gene Therapeutic Molecule Clinical Trial Identifier Status
CEP290
QR-110 NCT03140969 Active, not recruiting
QR-110 NCT03913130 Recruiting
QR-110 NCT03913143 Recruiting
USH2A QR-421a NCT03780257 Recruiting
Black is just used to indicate the different sectiond and can be considered as headers. Gene (first column), therapeutic
molecule (second column), clinical trial identifier (third column) and current status of the trial (last column) are
indicated. Data obtained from https://clinicaltrials.gov/.
2.3. Compound Therapies
As happens in other types of diseases, pharmacological development can offer an entirely
different approach to the treatment of IRD. However, the great heterogeneity observed in IRDs and the
access-limiting BRB present major challenges towards an effective compound therapy [140]. In this
section, we focus our attention on some promising drugs for the treatment of IRDs.
2.3.1. Translational Read-Through
Translational read-through (TR) therapy is based on small molecules, also known as TR-inducing
drugs (TRIDs), that allow the translation machinery to bypass a premature termination codon (PTC)
during translation [141]. In addition, PTCs can induce mRNA degradation through nonsense-mediated
decay and thereby also inhibit full-length protein expression [141,142]. The incorporation of an amino
acid at the site of the premature stop codon can increase the expression of the full-length protein as
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well as the reduction of nonsense-mediated decay [142]. Until now, the detailed mechanisms by which
TRIDs induce their therapeutic effect are not completely understood. However, it is known that TR
efficiency depends on the competition between decoding of the stop codon by a near-cognate tRNA
and stop codon recognition by eRF1 [141]. There are two main classes of TRIDs—aminoglycoside
and non-aminoglycoside TRIDs. From the first group, gentamicin has been most widely used to
analyse TR in different disease models, including those affected with IRD. The efficacy of gentamicin
was studied in different rat and mouse models—(i) the S334ter rat model that carries a nonsense
mutation (c.1002T>A; p.S334*) in the gene encoding the visual pigment rhodopsin (Rho) and (ii) the
rd12 mouse, a model for retinal degeneration caused by a nonsense mutation in Rpe65. Systematic
gentamicin treatment showed different results between the two models. In S334ter rats, a partial
rescue of photoreceptor survival was noticed however, no rescue was observed in rd12 mice [143].
Studies on genes mutated in Usher syndrome (a syndromic form of IRD accompanied by hearing
impairment) demonstrated that aminoglycosides and derivatives thereof can mediate TR of different
disease-causing PTCs in the PCDH15 and USH1C genes, in in vitro translation assays as well as in cell
culture experiments [144–149].
The non-aminoglycoside TRID PTC124 (also known as Ataluren) is used in a wide range of
diseases including Duchenne muscular dystrophy and cystic fibrosis [150–153], with several clinical
studies having been performed or ongoing. For IRDs, promising results using PTC124 have been
reported by the restoration of full-length RP2 protein, the encoding gene of which is mutated in
X-linked RP, as well as for the REP1 protein, encoded by the CHM gene that is mutated in choroideremia.
In X-linked RP, rod photoreceptors mainly suffer from the loss of RP2, although the effect on cone
photoreceptors and RPE cells should not be neglected. Schwarz and colleagues used TRIDs (both the
aminoglycoside G418 as well as PTC124) to successfully increase full-length RP2 protein levels in the
presence of the p.R120ter (c.358C>T; p.R120 *) mutation. In choroideremia, many nonsense mutations
in CHM have been described. Several studies attempted to use TRIDs, including PTC124 or its analogue
PTC-414, to increase REP1 protein levels, either in cellular (human fibroblasts, iPSC-derived RPE)
or animal (zebrafish) models [154–156]. The efficacy of read-through was found to be considerably
variable, not only depending on the type of nonsense codon and its surrounding sequence but also
on the remaining transcript levels that can differ significantly between patients [142]. Another study,
based on topical administration of PTC124 to the eye, demonstrated functional restoration of the
harmonin protein in a mouse model for Usher syndrome type 1c (USH1C) [141,145].
One of the disadvantages of the systemic use of TRIDs is that for many diseases, drugs need to go
through physical barriers (such as the blood-brain barrier or BRB). These barriers can reduce compound
availability in the targeted organ after treatment, illustrating the need to increment the dosage
administered to the patients or to change the delivery method of TRIDs (commonly intraperitoneal)
towards local administration [141]. One strategy to overcome this is the encapsulation of drugs into
tissue-specific liposomes [157]. In particular for IRDs, topical applications or intraocular injections
should be considered in the future.
2.3.2. Restoring Proteostasis (Protein Therapies)
Photoreceptor cells require a rigorous regulation of proteostasis (maintaining a healthy protein
balance) to ensure their correct function and viability. As a result, certain genetic changes in specific
genes with an essential function in the photoreceptor cell can have dramatic effects. One example is
the dominant-negative effect of mutations in RHO, which leads to the disruption of outer segments
in the photoreceptor cell [158]. The manipulation of proteostasis mechanisms such as the heat-shock
response (HSR) or unfolded protein response could be a good therapeutic target in order to alleviate
misfolding diseases (e.g., targeted up-regulation of these pathways to reduce aggregation of proteins
such as rhodopsin) [159]. This could be achieved either by the administration of drugs that restore
proteostasis (e.g., pharmacological chaperones, kosmotropes, molecular chaperones or autophagy
inducers) or by targeting key molecules in the photoreceptor proteostasis network [160,161].
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So far, “proteostasis” therapies are mainly focused on rhodopsin, as RHO is one of the most
frequently mutated genes in autosomal dominant RP. One of the most common mutations in this
gene is the p.P23H mutation, which acts in a dominant-negative fashion on wild-type rhodopsin by
inducing misfolding [160]. Intriguingly, it was reported that misfolded proteins could be rescued by a
ligand that works as a chaperone [161].
Pharmacological chaperones are small, substrate-specific molecules that are able to directly target
the protein structure and shift the protein folding equilibrium towards its native state [158,162]. Studies
using this kind of chaperones suggested that correction of mutant rhodopsin folding, without improving
its stability, could further compromise the outer segments and increase rod cell death. Thus, these data
underscore the necessity to ensure opsin stability using parallel treatment strategies [163,164].
Kosmotropes are small, low molecular weight compounds that can enhance the stability of proteins
in their native conformation and decrease aggregation. Kosmotropes bind to proteins non-specifically
and thus have the potential to be used in a wide range of protein-misfolding diseases [161]. The chemical
chaperone tauroursodeoxycholic acid (TUDCA) has been studied in several retinal degeneration
models [165–167], although its efficacy was found to vary between different studies, even in the
presence of the same IRD-causing mutation, namely p.P23H, in the gene encoding rhodopsin. It has
been hypothesized that activation of PERK, one of the receptors responsible for UPR [168] differs
between models, thereby explaining the ineffectiveness of TUDCA in some of them [161,165].
Finally, another alternative to restore proteostasis is through the control of the adaptative machinery
that is responsible for its maintenance via HSR and UPR [158]. Inhibition of molecular chaperones can
activate the HSR by releasing HSF1 and inducing cell stress, which triggers the production of molecular
chaperones. The Hsp90 inhibitors and HSR inducers geldanamycin, radicicol and 17-AAG reduced
P23H aggregation and cell death in vitro [162]. Hsp90 works as a crucial chaperone in the maturation
of many proteins. Targeting Hsp90 directly however could affect normal vision, suggesting that an
alternative therapeutic approach could include the stimulation of both the HSR and UPR pathways with
arimoclomol (a heat shock protein inducer). In rat models carrying the p.P23H rhodopsin mutation,
it has been demonstrated that administering arimoclonol via intraperitoneal injection reduced mutant
rhodopsin aggregation and ameliorated photoreceptor degeneration [160,161].
2.3.3. Pathway-Specific Therapies
Cyclic guanosine-monophosphate (cGMP) is a crucial molecule for photoreceptor signal
transduction and has two main cellular effectors—cyclic nucleotide gated ion channels (CNGCs)
and cGMP-dependent protein kinase G (PKG) [169]. It has been reported that over-activation of PKG
can be enough to cause photoreceptor cell death and that its activation levels are higher in mutant
photoreceptors. Knowing that CNGCs play an important role in driving phototransduction, some
interesting observations have been made. The deletion of CNGC beta subunits protects photoreceptors
in rd1 mice that harbour a defect in the Pde6b gene, which encodes the phosphodiesterase protein
involved in the phototransduction cascade. Therefore, either PKG or CNGCs can be considered as
critical disease drivers; consequently, both of them are therapeutic targets for prevention of (further)
retinal degeneration [140]. As mentioned above, the BRB can prevent the access of therapeutic agents
to the retina. Vighi and colleagues overcame this problem using a liposomal drug delivery method,
the liposomal cGMP analogue formulation LP-CN03, and demonstrated improved visual function
as well as reduced photoreceptor degeneration in mouse models harbouring mutations in different
IRD gene orthologues [140]. Together, these data suggest that cGMP signalling could be a common
pathway to target for the treatment of genetically and phenotypically divergent kinds of retinal
degeneration [140,169].
Another drug previously tested in clinical trials is an orally delivered synthetic cis-retinoid also
known as QLT091001. This drug triggered visual restoration in transgenic and naturally occurring
mouse and dog models mutant for Rpe65 [170]. The results of the clinical trial NCT01014052 (Table 3)
showed that QLT091001 did improve visual function in subjects with IRD due to LRAT or RPE65
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mutations. Mutations in these genes can cause different subtypes of IRD, usually classified as LCA
or RP. Despite this, the exact genetic defect apparently did not affect the drug response in both LCA
and RP patients [171]. Upon oral administration of QLT091001, patients showed beneficial effects in
the remaining photoreceptors of the retina in both eyes, although it did not stop the progression of
photoreceptor degradation completely. The safety profile of this drug showed transient adverse effects
such as headaches or nausea [171]. In theory, QLT091001 could be combined with gene augmentation
therapy, although the combination of treatments, in particular for orphan diseases, poses additional
challenges on drug development.
Table 3. Summary of clinical trials for IRDs using compound therapies.
Gene Therapeutic Molecule Clinical Trial Identifier Status
ABCA4
ALK-001 NCT02402660 Recruiting






QLT091001 NCT01543906 * Completed
RS1 Dorzolamide 2% TID orbrinzolamide 1% TID NCT02331173 Completed
Black is just used to indicate the different sectiond and can be considered as headers. Gene (first column), therapeutic
molecule (second column), clinical trial identifier (third column) and current status of the trial (last column) are
indicated. Completed trials are highlighted in bold. Data obtained from https://clinicaltrials.gov/. * Of note, Trial
NCT01543906 describes the use of QLT091001 in patients with a dominant RPE65 mutation (unlike most RPE65
mutations inherited in an autosomal recessive manner).
3. Delivery of Therapeutic Molecules
3.1. Methods of Ocular Delivery
Despite its small size, the eye contains several cell and tissue types that can be targeted by
therapeutic agents [172]. Local tolerability of vector administration in IRDs has been reported in
various studies and no serious systemic problems have been indicated so far [23]. Commonly, we can
identify two main potential delivery methods—subretinal and intravitreal injections. Subretinal
injections are considered to be more prone towards complications (e.g., retinal detachment), especially
in patients with affected retinal integrity, compared to intravitreal injection. Despite, the vector is
delivered much closer to its target cells/region, allowing an efficient vector transduction in RPE cells
and/or photoreceptors [173]. In contrast, intravitreal injections allow an easier targeting of the optic
nerve, lens or inner retina and less often the outer retina or the anterior chamber. It also shows fewer
procedure-related complications but the transduction of the viral vector into photoreceptors and RPE
cells is less efficient when compared with subretinal injections [23,174]. Apart from these two methods,
there is an alternative system—Suprachoroidal delivery. With this, therapeutic agents are delivered
directly to the suprachoroidal space located between the sclera and choroid [175,176]. Preclinical
animal studies showed that suprachoroidal drug delivery has the same safety profile as intravitreal
injections [177–179]. Results from completed clinical trials (e.g., NCT01789320) have also showed
encouraging safety profiles [180], although potential spreading of therapeutic vectors into the systemic
circulation needs to be considered.
226
Genes 2019, 10, 654
Figure 2. Schematic and simplified representation of the several types of molecular therapies.
(A) DNA therapies are represented by gene augmentation, genome editing and optogenetics. In gene
augmentation, the entire coding sequence of the gene of interest (GOI) is delivered using different
vectors. Genome editing employs nucleases able to edit the DNA at a specific position; CRISPR/Cas9 is
depicted in green, guide RNA in dark yellow and ZFN and TALEN in blue. Mutations are depicted in
red. In optogenetics, a light-sensitive molecule is delivered to the eye to give photosensitive properties
to remaining retinal neurons. (B) RNA therapies; splicing modulation can be achieved using AONs
(in dark blue) for (pseudo)exon skipping or modified U1 snRNA (in black) to favour exon inclusion
in cases where mutations (in red) are found in the donor splice site. Trans-splicing occurs between
two independent RNA molecules—The original transcript and the exogenous molecule without the
mutation. In all cases, splicing is modulated to obtain a transcript with full or residual function.
Post-translational gene silencing can be achieved by degrading the RNA transcript using AONs (dark
blue), Cas13 (green) with a guide RNA (dark yellow) or (s)iRNA and hhRz (in green). These approaches
can be used for dominant-negative mutations by promoting allele-specific degradation. Mutations are
indicated in red. With RNA editing using CRISPR/Cas technology, dead Cas13 (in green) is conjugated
with an adenosine deaminase (dark yellow) acting at the RNA level (ADAR, in light red). This molecule
is guided to the mutation using a guide RNA binding on top of the mutation (in red) to induce a G-to-A
transversion. (C) Representative examples of compound therapies. Translational read-through allows
the ribosome to continue protein synthesis despite a premature stop codon (in red) in the presence of
the translational read-through-inducing drugs (TRIDs). Restoring proteostasis can be accomplished by
using chaperones to properly fold proteins. QLT091001 is a pathway-specific therapy that acts in the
visual cycle and can be used when for example, RPE65 or LRAT are mutated.
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Finally, there is the possibility of topical delivery by the use of eye drops. However, this approach
can result in lower bioavailability and increased clearance in comparison to the different types of
injections. In addition, ocular barriers decrease the bioavailability of topically applied therapeutic
agents to less than 5% [181]. Therefore, the effectiveness of this method is less than those reported with
the systems previously described.
3.2. Vectors
Besides the routes of administration, a wide range of viral and non-viral gene delivery approaches
has been developed over the last twenty years, in order to allow an efficient transfer of therapeutic
molecules to the right target cell. Choosing one over another depends on the cell or tissue type to be
targeted, the cloning capacity of each of the vectors and safety concerns [23].
3.2.1. Viral Vectors
Adeno-associated viruses (AAVs): Most commonly but not exclusively, therapeutic genes are
delivered to their target cells by viral vectors. AAVs are the most common viral vectors used for
gene therapy in IRDs, mainly due to their low immunogenicity and toxicity, and allow for long-term
transgene expression [182,183].
Recombinant AAV (rAAV) is the most popular viral vector for delivery in IRDs. Its tropism
for different types of retinal cells allows efficient transduction of these cells and relatively fast and
stable transgene expression [184]. rAAV is available in two forms, single-stranded AAV (ssAAV) and
self-complimentary AAV (scAAV). Once a cell is transduced with ssAAV, the single-stranded DNA
of the virus needs to be converted into the double-stranded form; this is a rate-limiting step that can
be circumvented with scAAVs [25]. The scAAVs are engineered in a way that upon infection two
complementary halves will generate a double-stranded DNA, promoting faster and increased transgene
expression [185]. However, the main disadvantage of scAAVs is their reduced cargo capacity (2.4 kb),
compared to ssAAV (4.8 kb) which limits its transgene selection. scAAV vectors have been demonstrated
to transduce retinal ganglion cells, photoreceptors and RPE cells, and can lead to transgene expression
within two days after injection in mice while ssAAV requires several weeks [186]; this rapid and increased
transgene expression was independent of the AAV serotype tested (i.e. -1, -2 or -5) [25].
Despite its numerous advantages, AAV presents a limited packaging capacity (4.8 kb) [22,25,45].
To overcome this, various strategies have been developed. For instance, with the use of dual AAV
vectors, a cDNA can be split in two separate fragments, after which the two parts recombine inside
the cells using HDR, trans-splicing or both [41,187]. With this, the capacity can be increased up to
9 kb [41,43,187]. The dual AAV system has been used in preclinical studies to deliver some genes
mutated in IRD such as ABCA4 [188] and MYO7A [189], with promising results. However, dual AAVs
may still not be sufficient for several other genes mutated in IRD. The use of triple AAV approaches
allows to increase the cargo capacity to 14 kb [43,189,190], enabling the development of gene therapies
for IRDs caused by mutations in even larger genes. Maddalena and colleagues demonstrated the
potential of this system to restore CDH23 (cDNA size 11.1 kB, mutated in Usher syndrome type 1D) and
ALMS1 (cDNA size 12.9 kb, mutated in Almstrom syndrome) gene expression. Certainly, the enclosed
and small subretinal space may facilitate co-infection of the same cell by three independent AAV
vectors [43].
To date, up to 12 AAV serotypes and more than 100 variants have been identified in humans and
NHPs [25]. From these, AAV2, AAV5 and AAV8 have been most extensively studied, being used as
delivery vector in several clinical and preclinical studies for different genes such as RPE65, CNGB3,
RS1 or PDE6B (Table 1) [25]. AAV serotypes 2, 5, 7, 8 and 9 are able to transduce photoreceptors,
while virtually every AAV serotype is capable of efficiently infecting RPE cells [23]. So far, AAV2
is the only vector described to transduce retinal ganglion cells upon intravitreal delivery [191,192].
However, alternative serotypes of AAV have also been developed. Some examples are the serotypes
AAV7m8 [193] and AAV8BP2 [194]. Both of them were designed to alter AAV capsids aiming to improve
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uptake into the retina and be able to target photoreceptors following intravitreal injection [193,194].
AAV7m8 serotype was generated by in vivo directed evolution in the mouse retina by Dalkara and
collaborators [193,195]. They reported that the intravitreal delivery of AAV7m8 resulted in effective
pan-retinal photoreceptor and RPE cell transduction in mice. This serotype was also tested in NHP
retinas via intravitreal administration. The results indicated a higher transduction rate of foveal
and extrafoveal photoreceptors in comparison with the parental serotype AAV2. However, authors
also noted toxicity in an NHP injected with a high titre of AAV7m8 [193]. Therefore, a study of
safety and efficiency of transduction using lower doses of this serotype is required if this capsid is
planned to be used in primates, including humans. The AAV8BP2 serotype was generated in vivo by
Cronin and colleagues, it targets ON-bipolar cells and cone photoreceptors efficiently following both
intravitreal and subretinal injections in mouse [194]. This research group performed a comparative
study between these two novel serotypes. Both vectors showed promising results in mice but in
NHPs, either subretinal or intravitreal delivery did not allow to transduce all target cells within
the retina. Specifically, AAV7m8 showed some toxicity effects (as previously reported) as well as
severe inflammation when using a high titre [195]. For AAV8BP2, a lower transduction of bipolar
cells was observed, even at high doses. Taken together, the results of both serotypes indicate that
studies in rodents might not provide sufficient information to understand the cellular transduction and
pharmacological properties of these engineered AAVs and further studies in for example NHPs are
needed before using them in humans. Carvalho and collaborators characterized an in silico designed
serotype named Anc80 for retinal gene transfer [196]. Three Anc80 variants were evaluated, Anc80L27,
Anc80L65 and Anc80L12, in mice and NHP. All of them were capable of efficiently targeting retinal
cells following subretinal delivery, although Anc80L65 showed a higher efficiency for targeting retinal
cells as well as higher expression levels compared to AAV8. These data support the use of Anc80L65
for gene delivery to the retina. Taken together, all these studies characterizing novel serotypes have
illustrated the impact of minimal changes in capsid composition on aspects relevant to experimental
and clinical gene transfer applications. This will prove useful for improving delivery to the retina and
thus for their use in developing new treatments for IRDs.
Lentiviral vectors: Lentiviruses (LV) are RNA viruses of the retrovirus family. In IRDs, the
retroviral variant of human immunodeficiency virus type 1 (HIV-1) or the equine infectious anaemia
virus (EIAV) have been tested. LVs have the ability to pass through the cells’ intact nuclear membrane
and infect both dividing and non-dividing cells [197]. Moreover, LVs efficiently integrate their genome
into that of the host-cell, leading to stable expression. LVs are modified to stop replication, so these
vectors are not pathogenic after initial gene delivery. LVs present a transgene capacity cargo of
~8–10 kb and, in terms of IRD, are capable of infecting RPE cells and to a lesser extent of differentiated
photoreceptors [23,25]. EIAVs have been used for ABCA4, as its cDNA size (6.8 kb) outplaced the cargo
capacity of AAV but not that of lentiviruses [198]. To assess this strategy in human subjects, a clinical
trial (NCT01367444) has been ongoing for several years (Table 1), whilst no clear efficacy data have
been reported.
Adenoviruses and helper-dependent adenoviruses: In comparison to the previously mentioned
viral vectors, adenoviruses (AdVs) have a cargo capacity of about 8 kb, while its ‘gutted’
helper-dependent adenovirus (HDAd) has an extremely large capacity of up to 36 kb. It is demonstrated
that adenoviral vectors infect RPE cells efficiently but because the coxsackie-AdV receptor is presumed
to be absent on the cell membrane of photoreceptors [199,200], these vectors do not efficiently transduce
photoreceptor cells [201]. Overall, AdVs have been only sparsely used in the treatment of IRDs [202,203].
3.2.2. Non-Viral Vectors
Although various viral vectors have demonstrated their potential in the treatment of IRDs, there
is a continuing need for refinement delivery vectors for the eye. Therefore, research efforts have also
been directed towards the development of non-viral delivery systems, such as nanoparticles (NPs),
naked DNA or liposomes [174].
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Naked DNA is the most elementary form of non-viral gene therapy [204]. As naked DNA does
typically not enter into the cells, it is not considered as a suitable therapy for the eye. Different studies
have used electroporation or iontophoresis to obtain a significant uptake and expression in the target
cells, however both delivery ways presented significant challenges. The side effects of electroporation
make it an unlikely method to be clinically feasible, whilst iontophoresis so far presents conflicting
information about the real effectiveness of this method [174,204].
In contrast, NPs are well capable of delivering plasmid DNA containing a functional copy of a
gene into the retina [205]. The three determinants of the effectiveness of gene delivery using this kind
of vectors are cellular uptake, endosomal escape and transfer of the plasmid DNA into the nucleus.
All forms of NPs-(metal, lipid or polymers) have some capability to pass through the cell membrane,
avoid endosomal trapping and deliver the plasmid DNA into the nucleus. Lipid-based NPs are
biocompatible and stable particles; furthermore, there is no inflammatory response to these NPs when
injected into the eye. However, there are also some disadvantages, such as lower gene expression when
compared to the same transgenes delivered by viral vectors [174]. A new type of delivery system was
recently developed by Trigueros and colleagues using gold nanoparticles (DNA-gold NPs), as these are
relatively easy to generate and can be adapted to different shapes and sizes [206]. Gold is well-tolerated
inside an organism and presents low rates of toxicity. However, they present a low clearance rate,
thereby hampering their uptake in specific cells or tissues [207]. Therefore, Trigueros et al. further
optimized this system for IRDs. In this study, they compared this new system with DNA-liposome
complexes and demonstrated higher expression of a reporter gene. Their results showed that RPE cells
responded differently to pristine-gold NPs and DNA-gold NPs, probably because of changes in the
membrane-NP interface. Moreover, both types of NPs used different alternative endocytic ways for
internalization, as indicated by their detection in different endosomal compartments. DNA-gold NPs
were located in early endosomes that later will not mature into late endosome vesicles, resulting in an
earlier expression of the reporter gene compared to pristine-gold NPs. This study was the first step
to use non-cytotoxic gold NPs for an in vivo gene therapy to treat IRDs. However, some biological
questions are still unclear, such as the internalization routes that are used and the exact nature of
intracellular endosome trafficking. Furthermore, before using these particles as a delivery method
in the retina, it is necessary to understand the complexity of cell–NP interaction, enhance the cargo
delivery by avoiding degradative pathways (such as the lysosomal pathway) and ensure a constant
expression of the therapeutic gene [206].
Finally, cationic lipids (liposomes) offer an alternative way to deliver DNA into the eye. In addition
to the two most common ways of retinal delivery (see above), other delivery methods such as
topical or intravenous administration have already reported positive results in eye diseases [174].
Liposomes however also present some limitations such as retinal toxicity and aggregation following
administration [208]. Consequently, researchers developed a new type of liposome-PEGylated with
perfluoropropane gas-that appears to be safer and more efficient for transfection but, as happened with
other lipid-based vectors, presented a drop in gene expression four days after administration [174].
4. Other IRD Treatments
While gene-based therapies may stop or at least delay, the progression of the disease, other
promising approaches that are less dependent of the genetic cause of the disease are also gaining
momentum. This is for instance the case for stem cell-derived retinal cell transplantation (cell therapy)
or the use of prosthetic implants.
4.1. Cell Therapy
Retinal cells, like other cells within the central nervous system, present a low regeneration potential.
Therefore, cell therapies could be applied in those IRDs that present an advanced degeneration stage.
The use of this type of therapy aims to result in an integration of exogenously delivered cells and
subsequent re-activation of visual function [45]. Patient-derived somatic cells could be used to
230
Genes 2019, 10, 654
reprogram induced pluripotent stem cells (iPSCs) that subsequently could be differentiated to retinal
precursor cells and introduced into the eye to replace either photoreceptors or supporting cells (e.g.,
RPE) that provide trophic and metabolic maintenance to prevent further degeneration of the remaining
photoreceptors [209]. Genome editing tools (such as those described in Section 2.1.2) can be used to
repair patient-specific mutations, to eventually transplant the corrected cells back to the patient [210].
The use of embryonic stem cells (ESCs) would not require this genetic modification and it has been
demonstrated that these cells also have a high capacity to differentiate into retinal precursors [45,211].
However, the use of ESC is associated with ethical considerations not present with the use of iPSCs
generated from the patients. Moreover, the transplantation of iPSC-derived retinal cells would avoid
the risk of immune rejection after surgery [45].
Following up on the promising advances that demonstrated that stem cell-derived photoreceptor
transplantation can restore rod- and cone-mediated vision [211–214], recent studies showed that
these transplanted cells are not able to integrate well into non-degenerative host retinas. Instead,
it seems that post-mitotic donor and host photoreceptors can exchange RNA and proteins, including
rhodopsin [215,216]. The visual improvements measured after stem cell-derived photoreceptor
transplantation could thus also be the result of endogenous photoreceptors that have taken up donor
cell-derived proteins. Recently, it was demonstrated that cell integration as well as cytoplasmic
transfer can occur but the relative contributions of each depend on the environment within the host
retina [45,216].
Some cell therapies that are already tested in the clinic use hESC or hiPSC-derived RPE, for
treating diseases such as AMD or Stardgardt disease [217–220]. For the study employing iPSC-derived
RPE transplantation, a one-year follow-up analysis indicated that the transplantation did not generate
any adverse effect and no immune response was induced, even in the absence of immunosuppression.
One of the studies using hESC-derived RPE also reported an improvement of vision in patients
with age-related macular degeneration as well as those with Stargardt disease [218]. Nevertheless,
more studies are needed to provide reproducible protocols to generate iPSC-derived photoreceptor
precursor cells. In addition, if such cells are transplanted after gene mutation repair, stringent quality
controls of the iPSCs before and after genome editing are extremely important [45].
4.2. Retinal Prosthetic Implants
Inner retinal neurons largely retain their capability of signal transmission and are still present
in advanced stages of retinal degradation. This fact encouraged the use of a stimulation mechanism
(prosthetic implants) that is able to restore vision to some extent. Such a device would bypass the
degraded photoreceptor layer and directly interact with the still functioning inner retinal neurons [84].
Retinal prostheses work as an integral system that contain an image acquisition device (which is
integrated by thousands of light-sensitive microphotodies), an image processor, a stimulator chip and
an electrode array [84,221]. In this system, light emanating from visible objects is converted by the
microphotodies into little currents of hundreds of microelectrodes, which are directed onto remaining
neurons within the neuronal network, the middle and the inner retina [221]. These systems have
demonstrated a partial visual restoration, presenting the first evidence of this strategy in the field
of vision [222]. To date, several stimulation modalities have been built [84] and four of them have
obtained market approval for use in Europe and/or United States (Argus II, IRIS, IMS and AMS) [222].
These devices are classified according to their anatomical placement.
Epiretinal prostheses (Argus II, IRIS and EPI-IRET3) are implanted on the surface of the
neurosensory retina, adjacent to nerve fibre and ganglion cell layers. Its location ensures certain
advantages such as easy surgical delivery and safe heat dispersion [84,222]. Functionally, the stimulation
is directly applied to the retinal ganglion cells, bypassing the residual intraretinal processing system,
thereby inhibiting the capacity to mimic the physiological topographic organization. Besides this, as the
epiretinal prostheses are close to passing axonal nerve fibres, ectopic visual perceptions from axonal
stimulation can occur, thereby decreasing spatial resolution and confusing the intended stimulation
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pattern. As a note, the epiretinal prostheses have an external camera positioned outside the eye that
provides power induction and a data signal that is transmitted to the intraocular simulator [84,221,222].
From these prostheses, Argus II is the most widely-used and it has been implanted in more than 250
patients to date, reporting encouraging results [223].
Subretinal prostheses (ASR, IMS/AMS, PRIMA and BSI) are placed between the degenerated
photoreceptor layer and the RPE, such that the intrinsic signal processing capability of the retinal
interneurons can be used optimally, generating vision similar to the one that is physiologically generated
in the eye [84,222]. Moreover, the device is placed closer to the retina and is therefore favoured over
the natural retinal signal amplification, requiring lower stimulation intensities. Unless the system has
intrinsic photosensitivity and amplification capacity, it, like the epiretinal devices, requires a power
source and a connection serving the delivery of data. Surgically, some studies have indicated that
positioning these devices could be technically complicated because of the RPE adhesion caused by the
retinal degeneration. Moreover, this surgical approach is less known and practiced outside routine
retinal surgery [222]. To date, there are two methods to subretinal stimulation—one that employs a
standard electrode array and another that uses a microphotodiode array (MPDA) that is present in
all devices with exception of BSI (Boston retinal implant). This last one itself is able to capture light,
allowing to avoid the use of cameras, while the visual scene is perceived by the lens on the array [84].
Suprachoroidal prostheses (STS and BVA) are located in the suprachoroidal space. This space
is highly vascular and therefore there is a high risk of haemorrhage and fibrosis post-implantation.
In comparison with the other two counterparts mentioned above, suprachoroidal devices are relatively
far away from the retina. This implies that the design requires greater stimulation power to elicit
visual perception [84,222]. Larger numbers are needed to establish solid conclusions about the efficacy
of both suprachoroidal and transscleral implants in their present formats; however, results to date
suggest greater limitations to these approaches compared to epiretinal or subretinal implants [84].
5. Concluding Remarks
The approval of LuxturnaTM as the first approved gene augmentation therapy for an ocular disease
has provided an enormous impulse to the development of retinal therapeutics, both in academic
centres as well as in industry. As summarized in this review, current developments range from
gene augmentation, splice modulation, genome editing, optogenetics and compound therapies to cell
replacement strategies and retinal prostheses. Patients with progressive vision loss are in need of
treatment, to improve their quality of life by (partially) restoring vision or at least slow down or halt
the progression of their diseases. Which strategy has the highest chance of being safe and efficacious
depends on many factors, including the person’s genetic defect(s) and the stage of disease accompanied
by the appearance of the retina. However, therapeutic development also requires appropriate cellular
and/or animal models to test the efficacy of a given approach, as well as clinical endpoints to determine
whether an improvement of therapeutic intervention can be measured. Only when fundamental and
translational scientists, clinicians, funding agencies, patient organizations, industry and regulatory
bodies join forces, we can fight these devastating conditions and provide hope and vision, for thousands
of visually impaired individuals worldwide.
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Abstract: The Foundation Fighting Blindness leads a collaborative effort among patients and families,
scientists, and the commercial sector to drive the development of preventions, treatments, and cures
for inherited retinal diseases (IRDs). When the nonprofit was established in 1971, it sought the
knowledge and insights of leaders in the retinal research field to guide its research funding decisions.
While the Foundation’s early investments focused on gaining a better understanding of the genetic
causes of IRDs, its portfolio of projects would come to include some of the most innovative approaches
to saving and restoring vision, including gene replacement/augmentation therapies, gene editing,
RNA modulation, optogenetics, and gene-based neuroprotection. In recent years, the Foundation
invested in resources such as its patient registry, natural history studies, and genetic testing program
to bolster clinical development and trials for emerging genetic therapies. Though the number of
clinical trials for such therapies has surged over the last decade, the Foundation remains steadfast
in its commitment to funding the initiatives that hold the most potential for eradicating the entire
spectrum of IRDs.
Keywords: retinitis pigmentosa; Usher syndrome; Stargardt disease; Leber congenital amaurosis;
RPE65; nonprofit; patient registry; translational
1. Introduction
The founders of the Foundation Fighting Blindness had no idea how challenging the development
of treatments and cures for inherited retinal diseases (IRDs) would be. Little did they know, it would
take nearly two decades for Foundation-funded researchers to find the first IRD gene and more than
35 years to advance a gene therapy into a human study.
The nonprofit was established in 1971, when Eliot Berson, MD, brought together Gordon and
Lulie Gund and Ben and Beverly Berman to create the first IRD research center: the Berman–Gund
Laboratory for the Study of Retinal Degenerations at Massachusetts Eye and Ear Infirmary.
At the time, Dr. Berson had recently diagnosed the Berman’s young daughters, Mindy and Joanne,
with retinitis pigmentosa (RP). Gordon had recently lost all of his vision to RP after he and Lulie
had completed an exhaustive search for something—anything—to save his vision. The Gund’s quest
for a cure, which included a harrowing journey to a clinic in Russia at the height of the Cold War,
came up empty.
It was obvious to the Foundation’s founders that virtually nothing was known about the conditions.
Furthermore, they understood that no other entity—public or private—would fund research for rare
retinal conditions. There was simply no commercial incentive for anyone to do so at the time. Driven
by passion and a personal commitment, the small group of families took it upon themselves to get the
research off the ground. Their goal was clear and singular: find preventions, treatments, and cures for
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everyone affected. The Berman–Gund lab was their first step forward, but little did they know how
difficult the path forward would be.
“If you put your shoulder to the grindstone, we’d find an answer in five or six years,” said Lulie,
reflecting on her expectations for conquering RP. “It just never occurred to me it could go on so long.”
Today, nearly 50 years later, the Foundation is the world’s largest private funding source for
research to find preventions, treatments, and cures for the entire spectrum of IRDs. The nonprofit has
raised more than $750 million toward its focused mission. Throughout its history, the Foundation has
been led by a board and trustees comprised of families and individuals with IRDs. Likewise, it has
been largely funded by grassroots donors who are also affected. Its urgent mission has been driven by
those who have the greatest stake in its success.
Excitingly, there has been a tremendous surge in human research for treatments over the past
10–15 years. Nearly three dozen clinical trials for IRD therapies are underway. The US Food and Drug
Administration’s (FDA’s) approval of LUXTURNA™ (Voretigene neparvovec)—the first gene therapy
for the eye or an inherited condition to receive regulatory marketing approval—was a historical moment
for the Foundation, which funded preclinical studies that made the sight-restoring treatment possible.
The Foundation’s leadership and supporters were ebullient about the advent of the life-changing gene
therapy. Finally, something made it across the finish line. Something worked, and it worked well.
However, the Foundation recognized it must optimally leverage the LUXTURNA™ approval and
clinical research momentum to save the vision for the millions who still do not have any therapies.
The Foundation’s funding strategy has therefore evolved from only funding basic lab research to better
understand IRDs to also getting treatments across the translational chasm known as “the valley of
death”—that is, to the point where biotechnology and pharmaceutical companies would invest in their
clinical and commercial development.
A little de-risking from the Foundation has gone a long way. Looking at the current IRD
gene therapy and genetic treatment landscape, the Foundation’s footprint is virtually everywhere.
Most current and emerging genetics-based treatments were made possible by lab, translational, and/or
early clinical research funded in part by the Foundation.
In 2018, the Foundation launched its venture philanthropy fund, known as the Retinal Degeneration
Fund (RD Fund), with initial capital of $70 million. Its charter is not only to fund translational and
early stage clinical projects, but to attract more venture capital into the IRD space and re-invest returns
back into research.
“Yes, we are a nonprofit, but that doesn’t mean we shouldn’t realize and re-invest returns for
projects we are funding”, said Benjamin Yerxa, PhD, the Foundation’s chief executive officer. “The IRD
gene therapy business is burgeoning, and we owe it to patients and families to leverage that momentum
as much as possible to accelerate and expand therapy development.”
While the Foundation has traditionally emphasized research to identify treatment targets and
develop therapies for these genetic retinal conditions, its project portfolio has recently expanded
to include natural history studies—ProgStar, for people with Stargardt disease, and RUSH2A,
for those with USH2A mutations—as well as the global patient registry at www.MyRetinaTracker.org.
An ancillary study of My Retina Tracker has thus far provided diagnostic genetic testing to approximately
4,000 IRD patients, at no cost to them. The overarching goal for these new initiatives is to gain a better
understanding of how these genetic diseases affect vision, share de-identified patient data for disease
progression, genetically diagnose more patients, and facilitate recruitment for clinical trials.
Data from both My Retina Tracker and the natural history studies can accelerate clinical
development by helping researchers identify more powerful and sensitive clinical endpoints.
2. Patient Perspectives on the Progress of Genetic Research
As mentioned, the FDA’s approval of LUXTURNA™ in December 2017 created tremendous
excitement and hope for patients and families with IRDs. The success of the gene therapy program
provided proof that a genetic treatment could, in fact, save and restore vision and be made
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commercially available to the people who need it. For the thousands of constituents affiliated
with the Foundation—many of whom had been part of the organization for several decades—this was
the most important and encouraging advancement in their journey. Also, the advent of additional
gene therapy clinical trials in recent years—for several other IRDs, including choroideremia, X-linked
RP, Stargardt disease, and Usher syndrome type 1B—boosted optimism for the potential for genetic
research to halt and reverse vision loss. The Foundation’s constituents are also eager to learn about other
genetic therapies, such as clustered regularly interspaced short palindromic repeats/CRISPR-associated
protein 9 (CRISPR/Cas9) and antisense oligonucleotides, especially as these approaches begin to move
into human studies.
With all the enthusiasm for the current progress in research, those affected are keenly aware that
only one treatment has made it through the pipeline thus far. Furthermore, LUXTURNA™ can only
help a small fraction of those affected. Much more work needs to be done to address the overall need.
Ultimately, sustained hope and excitement about genetic research for each patient is often predicated
on the advancement of research directed toward the mutated gene causing their (or a loved one’s) IRD.
Jen Walker, a woman with moderate vision loss from RP (PDE6A mutations), is excited about the
LUXTURNA™milestone, but recognizes well the unmet need and the urgency to meet it. “Hearing
about LUXTURNA™was life changing. It was astounding to see so many young people with visual
impairments regain sight. The feeling of putting away a white cane for good is immeasurable,” she said,
“but more work needs to be done. This is only one gene, when there are hundreds more. We need
a cure quickly, as it’s going to be harder to regain sight as we lose more and more photoreceptors. I am
hopeful that doctors and researchers are noticing that gene therapy for vision is an up and coming
science movement, and I hope everyone gets on board sooner than later.”
John Corneille, who has advanced vision loss from RP (PDE6B mutations), shares Jen’s urgency
for answers, but maintains an overall positive outlook. He said, “There are days, for sure, when I get
discouraged thinking, at age 59, a treatment will not be found in time to enable me to see the faces of
my children and grandchildren again. Most days, however, I remain very optimistic, given how far
we have come in the last couple of decades. It was very exciting to learn that a company in France
is engaged in a clinical trial for my gene! I try not to think about the complexity of gene studies,
replacement, and editing. But it is very reassuring to know that there are countless incredibly talented
researchers working hard, each day, to find breakthrough treatments for us.”
Though gene-specific therapies are often at the top of patients’ minds, more are beginning to
appreciate the potential of emerging, cross-cutting genetic treatment approaches, such as optogenetics.
“Perhaps most exciting is the diversity of research approaches that seem likely to eventually address
any stage of these progressive and devastating diseases,” said Martha Steele, who has Usher syndrome
type 2A. “As someone with advanced vision loss, I realize that not all treatments under investigation
will likely work for me, but some, such as optogenetics, may well be in my future.”
Thanks to the advanced power and increasing affordability of gene-sequencing panels, more people
are getting genetically tested and having their IRD gene mutation(s) identified. A genetic diagnosis
can have a big impact on the patient and their family. Of course, the genetic diagnosis can put people
on the path toward a clinical trial or future treatment.
But for many patients, the identification of their gene mutation can also be cathartic. It’s a step
forward in unravelling the mystery of a disease that has been progressively robbing them of their
vision. For parents, the identification of their gene mutation gives them answers about the risk of
passing the IRD on to their kids. Depending on the result, the knowledge can be a relief or it can raise
new questions and emotions.
For Michelle Glaze, a woman with moderate vision loss from mutations in RP1, getting a definitive
genetic diagnosis took some time, but the result helped ease her mind about her son’s risk of inheriting
her IRD. “I had genetic testing done about six years ago. The initial diagnosis helped me to understand
what was causing my vision loss. However, there were some missing pieces, which left some things
unclear. I was not sure if my son was at risk. Thanks to additional investigation by a genetic counselor,
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I learned he was not at risk. Thanks to advances in genetics, and the increased ability to identify
pathogenic mutations, I am now able to rest well knowing that my son will not be affected by RP.
This was always a fear, always a concern in my mind, until now. As a patient and mother, I am extremely
grateful for advances in research, clinical developments, and genetic testing. I have an increased hope
that I may be able to see my son’s sweet face clearly one day.”
Michelle’s story underscores how critical a genetic counselor can be to the patient’s and family’s
understanding and journey in managing an IRD, especially when results are inconclusive or additional
testing may be advised.
3. In the Beginning: The Foundation’s Early Focus on Genetics
When the Foundation began funding research in the early 1970s, one of the few clues scientists
had about IRDs was that they ran in families; the conditions were clearly genetic. The nonprofit and
its scientific advisors—including prominent visionaries in the retinal research community, such as
John Dowling, PhD, Morton Goldberg, MD, and Alan Laties, MD—understood that identifying the
genetic causes would be critical to: 1) diagnosing patients, 2) elucidating disease pathways, and 3) the
development of therapies.
As a result, throughout its early years and for decades to come, the Foundation aggressively
funded (and continues to fund) the leading IRD genetic research labs around the world.
Despite its early and substantial investments in genetic research, it took nearly two decades for
Foundation-funded investigators to find the first gene associated with RP (or any IRD). That gene was
RHO, which was identified in 1989 by a team at Trinity College Dublin [1].
The landmark genetic breakthrough brought momentum to the search for more IRD genes, but the
magnitude of the challenge was not well understood. To date, more than 270 genes have been associated
with IRDs.
“In the 1980s, we expected there would only be a handful of RP genes. We now know there are
more than 80 and still counting. The effort started with a small group of scientists, across the world,
working together and sharing ideas, patient samples, and lab reagents,” said Stephen Daiger, PhD,
a world leader in IRD genetic research at The University of Texas Health Science Center in Houston,
who has been funded by the Foundation for genetic research and discovery since 1986. “With the
identification of RHO in 1989, the field took off. As the Human Genome Project got underway, the first
useful byproduct was a much better map of human chromosomes. Because of this improved map,
many more RP genes were mapped by 1995.”
While most IRD genes have been identified, diagnostic gaps remain. Today, about two out of
every three people with an IRD will have their gene mutation(s) identified when they undergo genetic
diagnostic testing using a comprehensive gene panel. To address the need to genetically diagnose
more patients, the Foundation is funding a five-year, $2.5 million project to find elusive IRD genes and
mutations, including those in non-coding regions. The collaborative effort is being led by Dr. Daiger,
Dr. Ayyagari, and Kinga Bujakowska, PhD, at Massachusetts Eye and Ear, and will include more than
140 families and an additional 400 individuals.
4. The Trajectory for Gene Therapy Development
With the discovery of the first genes associated with IRDs in the 1990s, the idea of developing
gene replacement therapies—using viral vectors to replace mutated copies of an IRD gene with
healthy copies—was tantalizingly attractive to the Foundation and its scientific advisors. After all,
IRDs were caused by mutations in single genes and the retina was a clear and accessible target for such
an approach. So, Foundation funding for IRD gene therapy, and relevant animal models for testing,
began in earnest.
However, for Jean Bennett, MD, PhD, and Albert Maguire, MD, the visionaries for what eventually
became LUXTURNA™, the idea of gene therapy for a condition like RP came to them in medical
school, well before the first IRD gene had been discovered.
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“I remember in 1985, my husband, Albert Maguire, asked me if I thought we could do a gene
therapy for retinitis pigmentosa. I said, sure. But what I didn’t tell him is that we didn’t know the
genes, we didn’t have any animal models, and we didn’t know how to deliver DNA to the target cells,”
recalled Dr. Bennett. “But that planted a seed and I started researching the state of the art. A few
years later, I applied for a career development award from what was then the Retinitis Pigmentosa
Foundation, now the Foundation Fighting Blindness, and got it. And that launched my whole career
developing gene therapy for retinal degenerations.”
The Foundation invested approximately $10 million in RPE65 gene therapy lab studies to enable
the launch of the clinical trial in 2007 at the Children’s Hospital of Philadelphia (CHOP), which brought
to fruition the vision of Drs. Bennett and Maguire. It was the first clinical trial of a gene therapy for
an IRD. The company Spark Therapeutics was spun out of CHOP in 2013 to raise the money needed to
get the treatment across the regulatory finish line and out to the patients who needed it. In early 2019,
Spark was acquired by Roche for nearly $5 billion.
“The Foundation’s goal has been, and always will be, to get vision-saving treatments out to the
people who need them. LUXTURNA™was an important first step in achieving that goal, and we will be
in business until all inherited retinal diseases are eradicated,” said Dr. Yerxa. “We are also delighted that
our projects are attracting such large commercial investments, including Roche’s potential acquisition
of Spark. It affirms we are on the right track with the right science, the right strategies, and the right
investments.”
Several other clinical trials for IRD gene therapies were made possible by earlier Foundation
funding. Take, for example, Nightstar Therapeutics’ Phase 3 clinical trial for its choroideremia
gene therapy, which has preserved or improved vision for 90 percent of patients in a Phase 1/2
study. That study would not have been possible without earlier lab research by Miguel Seabra, PhD,
who received more than $1.5 million from the Foundation for his efforts to characterize the CHM gene,
develop a rodent model of choroideremia, and evaluate early versions of the CHM gene therapy in lab
studies. Nightstar was recently acquired by Biogen for approximately $800 million.
Large animal models and related safety and efficacy studies have been invaluable to the
advancement of IRD gene therapies, and perhaps no other Foundation-funded lab has been more
productive in IRD large animal research than the University of Pennsylvania School of Veterinary
Medicine. Its successful studies in canines have led to gene therapy clinical trials for: Leber congenital
amaurosis (RPE65 mutations), X-linked RP (RPGR mutations), and achromatopsia (CNGA3 and CNGB3
mutations). Human trials resulting from its Best disease and RP (RHO mutations) gene therapy canine
studies are currently being planned.
5. Beyond Gene Replacement
While momentum for the clinical development of gene replacement therapies for IRDs is strong,
the approach has its limitations.
For example, the cargo capacity of the adeno-associated viruses (AAVs) commonly (and
successfully) used for gene delivery in LUXTURNA™ and most ongoing clinical trials is limited to
about 4.7 kb. Several genes, including ABCA4 (Stargardt disease), USH2A (RP and Usher syndrome),
and CEP290 (LCA) exceed the AAV’s capacity.
Also, for autosomal dominant IRDs, such as RP caused by mutations in RHO, the delivery of
a replacement gene will not be sufficient; a therapy will need to silence the mutated allele encoding the
toxic protein or the allele acting in a dominant-negative fashion.
In recent years, the Foundation’s research portfolio has expanded to include gene-editing treatment
approaches such as CRISPR/Cas9 for autosomal dominant RP caused by mutations in RHO (Johns
Hopkins and Columbia) and RP1 (Massachusetts Eye and Ear), as well as Usher syndrome type 1B
caused by mutations in MYO7A (UCLA).
In February 2018, the Foundation Fighting Blindness, through its RD Fund, announced funding
of up to $7.5 million for the development of ProQR’s QR-421a, an antisense oligonucleotide (AON)
249
Genes 2019, 10, 511
designed to block mutations in RNA caused by defects in exon 13 of USH2A. ProQR announced in
March 2019 that it had dosed the first patient in its Phase 1/2 clinical trial for QR-421a. Excitingly,
the company reported vision improvements for 60 percent of participants in its Phase 1/2 targeting
a recurrent mutation in CEP290, which causes LCA10. A Phase 2/3 trial for the LCA10 AON is
now underway.
6. Cross-Cutting Gene Therapies
Even before the first gene replacement therapy clinical trial got off the ground (the RPE65 trial
at CHOP) in 2007, Foundation-funded scientists were envisioning neuroprotective gene-therapy
paradigms that could help people regardless of the mutated gene causing their disease. That is,
delivering a gene to express proteins that would slow photoreceptor degeneration.
Neuroprotection became attractive to Foundation leadership and scientific advisors because of
the technical and financial infeasibility of developing a gene replacement therapy for the hundreds of
mutated genes that cause IRDs. According to RetNet (https://sph.uth.edu/retnet/) there are more than
270 genes associated with IRDs. Furthermore, approximately one third of patients will not have their
mutation(s) identified when genetically tested.
In 2005, José Sahel, MD, and Thierry Léveillard, PhD, at the Institut de la Vision, received the
Foundation’s Board of Director’s Award for identifying a protein produced and secreted by rod
photoreceptors that prevented cones from degenerating in models of RP. Aptly named the rod-derived
cone-viability factor (RdCVF), the protein was an intriguing approach for saving cone-mediated vision
in people with RP and related conditions. Perhaps most appealing was that RdCVF had the potential
to work independent of the patient’s mutated gene—an approach that would be desirable for those
whose gene mutation could not be identified, or those for whom gene replacement or editing wasn’t
technically desirable.
The newly-formed French company SparingVision plans to advance RdCVF into a clinical trial
soon, thanks to the culmination of many years of lab funding from the Foundation and its recent
commitment of up to €7 million.
The Foundation is also funding optogenetic therapies—the delivery of a gene to retinal ganglion
or bipolar cells to express a light-sensitive protein in a retina that has lost all its photoreceptors due to
an advanced IRD. In fact, the Foundation funded preclinical research for retinal optogenetic approaches
currently in clinical trials—studies sponsored by Allergan and GenSight. The Foundation is also
funding John Flannery, PhD, UC Berkeley, who is developing optogenetic alternatives designed to
work in more natural lighting conditions.
While still in early clinical trials, optogenetic therapies hold promise for restoring meaningful
vision to people who have lost all of their photoreceptors, regardless of the mutated gene causing
their blindness.
7. Natural History Studies: Learning about Disease Progression and Genotype–Phenotype
Correlations
The successful development of any new therapy requires a thorough understanding of the
disease—in the absence of treatment—ideally from the time of diagnosis to its end stages. Understanding
this natural history of disease enables clinical researchers to describe the clinical manifestations of
disease (the phenotype) and its association with the genotype, estimate how quickly the disease
progresses over time, identify patient characteristics that predict slower or faster disease progression,
and study which clinical assessments are most appropriate to measure a treatment’s benefit. Addressing
these objectives is particularly important for IRDs because they are highly variable in their clinical
manifestations, they may progress over decades, and because they are rare diseases about which little
may be known. Ultimately, the knowledge gained from natural history studies will provide a number
of key insights. This fundamental work will inform the designs of clinical trials of new treatments,
250
Genes 2019, 10, 511
the patient population most likely to benefit, the length of follow-up required to demonstrate a benefit,
and the outcomes that are most sensitive to change [2].
The Foundation funds and conducts natural history studies of IRDs through its Clinical Consortium,
a coordinating center and an international group of over 25 leading research centers which are experts
in IRDs. The Clinical Consortium’s mission is to accelerate the development of treatments for IRDs
through collaborative and transparent clinical research. These objectives are met by ensuring the
studies are designed, led, and reported by participating investigators and by making the study datasets
publicly available for wider use. Because the studies are conducted using industry standards for
quality—including good clinical practice (GCP) and site certification for retinal imaging modalities—the
Foundation has designed the studies so the data will have broad utility, including, in some situations,
to serve as a historical control.
Currently, the Foundation’s Clinical Consortium is conducting RUSH2A, a prospective, four-year,
natural history study of approximately 100 patients with an IRD associated with mutations in the
USH2A gene, the most common mutated gene in Usher syndrome type 2 and a frequent cause of
non-syndromic RP. The primary objectives of the RUSH2A study are to characterize the progression of
the disease with respect to functional outcome measures (e.g., visual acuity and static perimetry) and
structural outcome measures (e.g., the area of the ellipsoid zone measured by SD-OCT), to investigate
the relationships between structure and function, and to assess whether there are genotypic or
phenotypic predictors of progression at four years.
By the end of 2019, the Clinical Consortium plans to initiate a natural history study of retinal
dystrophy associated with the EYS gene, PRO-EYS. The PRO-EYS study has similar objectives to
RUSH2A and will follow approximately 100 patients for four years. A key feature of PRO-EYS is
that the patient population will be stratified by the severity of disease at study entry. Thus, the study
will provide valuable information that can be used to design trials for treatments at various stages of
disease progression.
Natural history studies of IRDs and their associated pathogenic genes will continue to be a major
activity of the Foundation’s Clinical Consortium. These studies have broad applicability; they therefore
represent an ideal partnership opportunity for industry sponsors, who can save time and effort by
leveraging the network’s existing research infrastructure and access to IRD patients around the world.
8. My Retina Tracker: The Foundation’s Global Patient Registry
Patient data for IRDs—both genetic and phenotypic information—is rare. Furthermore, IRD patient
data collected by academic research centers is usually not shared widely and often limited to the
conditions studied by the institution.
However, the need for comprehensive IRD patient data has become paramount with the surge
in clinical trials for emerging therapies. The success of these human studies depends greatly on
a sponsor’s ability to recruit enough genotypically and phenotypically well-characterized patients.
In 2014, the Foundation launched its secure global patient registry, My Retina Tracker (www.
MyRetinaTracker.org), to provide pre-screened researchers and companies with de-identified patient
and disease data for relevant studies, including IRD clinical trials and natural history studies.
The registry is patient controlled; the patient uploads and maintains their own record.
When a company or researcher searches the registry for potential clinical trial participants, they never
receive patient names or personal information. Instead, they are sent an alphanumeric identifier,
which Foundation administrators use to identify and notify the patient who matched the search criteria.
It is then up to the patient to contact the clinical trial coordinator about possible participation in the
trial or study.
As of June 2019, more than 12,260 patients (with an informative profile of their disease) were
registered in My Retina Tracker. Approximately 400 new patients register every month.
The Foundation Fighting Blindness has been conducting a genetic testing study for patients
registered in My Retina Tracker. Through the study, registrants obtain genetic testing, at no cost to them.
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A 266 IRD gene panel (includes copy number variation testing) is being used to screen DNA samples.
No cost genetic counseling is provided for those patients who don’t receive genetic counseling from
their clinic or physician.
“Genetically characterizing IRD patients and making their de-identified molecular and disease
information available to the research community is critical for advancing human disease and therapy
studies,” said Brian Mansfield, PhD, the Foundation’s executive vice president research and interim
chief scientific officer. “Dozens of therapy developers and investigators from around the world have
used data from My Retina Tracker to advance their lab and clinical research. With approximately
200,000 IRD patients in the United States alone, we still have a lot of work to do, but we are building
momentum as more patients learn about My Retina Tracker and the genetic testing study.”
9. Conclusion: Filling the Gaps to Advance the Field
The Foundation’s role in driving genetic research for IRDs has evolved and expanded as a result
of advancement in biological sciences, the development of powerful gene sequencing technologies,
the mapping of the human genome, and the growth in its own revenues and membership base.
Of course, success in gene therapy development—including the regulatory approval of LUXTURNA™
and the impressive results from preclinical research that propelled the RPE65 gene therapy toward the
clinic—has also brought accelerating momentum to clinical development in the field.
However, the Foundation has always maintained (and continues to maintain) a commitment to
funding projects that would fill critical gaps in research that were not addressed by commercial or
government sectors, especially when doing so advanced the entire IRD field.
Today, the My Retina Tracker patient registry, genetic testing study, and Stargardt disease and
USH2A natural history studies are all prime examples of significant Foundation investments that are
having a wide-reaching impact in the advancement of research, especially when it comes to the clinical
development of sight-saving and -restoring therapies. In most cases, these are major investments,
each costing several millions of dollars, which other organizations haven’t been able or willing to make.
The Foundation’s long-standing, guiding imperative—whatever the investment—is to ensure
that it is based on good science and it will get more preventions, treatments, and cures for IRDs across
the finish line for everyone affected.
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